Sustainability
Report 
2021

Editorial Policy .............................................................. 2
Sustainability ................................................................ 4
Message from Chief Strategy Officer ............................. 6
Olympus Group ESG .................................................... 7
Value Creation Model .................................................... 9
Environment
Environmental Policy and Strategy .............................. 10
Reduce Environmental Impact .................................... 18
Environmental Communication ................................... 24
Environmental Data .................................................... 26
Society
Human Rights ............................................................ 36
Product Responsibility ................................................ 38
Procurement ............................................................... 43
Employment ............................................................... 45
Labor Relations .......................................................... 51
Occupational Safety and Health .................................. 52
Occupational Safety and Health,
Health Management ................................................... 59
Training and Education ............................................... 65
Diversity and Equal Opportunity .................................. 67
Physician Training in Developing Countries ................. 72
Participating in the Medical Industry Organizations ..... 73
Social Impact Assessment (Cancer Awareness) .......... 74
Governance
Corporate Philosophy ................................................. 81
Framework of Corporate Philosophy ........................... 82
Corporate Governance ............................................... 83
Communication with Stakeholders............................ 125
Compliance .............................................................. 127
Tax ........................................................................... 131
Anti-Corruption ......................................................... 133
Disclosure of Medical Business Information .............. 135
Information Security .................................................. 136
Risk Management System ........................................ 139
Policies - Environment
Environmental Health and Safety Policy .................... 141
Control of Chemical Substances Used in Products ... 142
Plans for Global Warming Countermeasures
 (Only in Japanese) ................................................... 200
Status of Acquiring ISO14001 Certification 
in Olympus Group .................................................... 209
Green Procurement .................................................. 211
Policies - Society
Human Rights Policy ................................................ 218
Olympus Group Quality Policy .................................. 220
Supply Chain Policy of Olympus Group .................... 221
Request to Suppliers ................................................ 222
General Employer Action Plan based on the Act 
on Promotion of Women's Participation 
and Advancement in the Workplace ......................... 232
General Employer Action Plan based on the Act 
on Advancement of Measures 
to Support Raising Next-Generation Children ........... 234
Promoting Work-Life Integration ............................... 236
Corporate Citizenship Policy ..................................... 238
Charitable Donations and Grants Policy .................... 240
Charitable Donation Initiatives ................................... 241
Policies - Governance
Basic Policy on Corporate Governance .................... 242
Because What We Do Matters:
Olympus Global Code of Conduct ............................ 248
Whistleblowing System ............................................. 249
Global Standards:
What Olympus Expects of Third Parties .................... 250
Olympus Group Tax Policy ........................................ 251
Olympus Group guidelines covering 
the prevention of bribery ........................................... 253
Disclosure Policy ...................................................... 256
The Ethics Committee .............................................. 257
Payments to Healthcare Professionals 
and Healthcare Organizations ................................... 258
Olympus Group Information Security Policy .............. 260
Internal Control System ............................................ 261
Olympus Group Risk Management 
and Crisis Response Policy ...................................... 267
Global Privacy Notice ............................................... 268
The Olympus Group Personal Information 
Protection Policy 
(Translation) .............................................................. 280
External Evaluation ................................................... 282
Participating in External Initiatives ............................. 283
Independent Assurance Statement related 
to Environmental and Social Data ............................. 284
GRI Content Index .................................................... 286
CONTENTS

Editorial Policy
Editorial Policy
The Olympus Group Sustainability Website provides detailed data on our governance, and social and environmental efforts. (Details of our corporate
governance are available in the Integrated Report.)
From July 2021, utilizing the flexible nature of website publishing, we intend to publish the above data, previously released annually, in a timely manner.
We also plan to compile the information published on this Sustainability Website as of October every year, as a PDF version of the Olympus Group
Sustainability Report for the corresponding fiscal year.
Olympus Group Sustainability Report 2021
Organizations Covered by the Report
Taking the Olympus Group as its basis, any references in this report that fall outside that basis are identified separately.
* Data for the imaging business, which was transferred in January 1, 2021, are not included unless otherwise specified.
Period Covered by the Report
[FY2020: April 1, 2019-March 31, 2020]
The report contains some information outside this period.
Reporting cycle, date of most recent report
Once a year, October 30, 2020 (in Japanese and English)
Reference Guidelines
Social aspects:
Some part of information such as human resources, etc. covers Olympus Corporation or Olympus Japan subsidiaries
Environmental aspects:
Small businesses are excluded.
As the environmental performance data has been revised due to expansion of the coverage of information disclosure, the data values may differ from past
disclosed environmental performance.

The descriptions used herein denote the following.
Olympus Group: Olympus Corporation and subsidiaries (global)
Olympus: Olympus Corporation
Japan subsidiaries: Major subsidiaries in Japan
Subsidiaries outside Japan: Major subsidiaries outside Japan
GRI, Sustainability Reporting Standard
The report does not, however, address all of the requirements of the "comprehensive" and "core" level options of the guidelines.
Environmental Reporting Guidelines (2018) of the Ministry of the Environment, Japan
Task Force on Climate-related Financial Disclosures (TCFD)
2

The ISO 26000 guidelines and the 10 Principles of the United Nations Global Compact were also used as reference when selecting items for inclusion in the
report.
External Assurance
Contact
The Olympus Group actively discloses and publishes corporate information to ensure that our stakeholders have a complete understanding of the Group.
Our major publication and communication tools, excluding the Integrated Report and the Sustainability Report, are as follows.
Environmental Data
Scope of external assurance
The amounts of CO2 emissions in Scope 1, Scope 2 (locationbased and market-based methods), and Scope 3: Categories 2 to 8, 12, and 15; and energy
consumption, water usage, and waste discharged.
External Assurance Organization
Lloyd's Register Quality Assurance Limited (LRQA)
Occupational Safety and Health Data
Scope of external assurance
Lost Time Injuries Frequency Rate (LTIFR), Occupational Illness Frequency Rate (OIFR), Number of Industrial Accidents, Number of Fatal Industrial
Accidents (Fiscal 2021)
External Assurance Organization
Lloyd's Register Quality Assurance Limited (LRQA)
Principal corporate information disclosure and distribution media
Financial information disclosure and distribution media
Sustainability Contact Form 
3

Sustainability
Sustainability
Based on our Corporate Philosophy, the Olympus Group identifies the important ESG areas and initiatives (materiality items) on which we should focus and
strives to resolve various social issues through our business. Aiming to transform into a Truly Global MedTech Company, the Olympus Group continues its
endeavors to both realize sustainable growth and develop a sustainable society.
Message from Chief Strategy Officer
Olympus Group ESG
Environment
Social
Sustainability Library
GRI Content Index
ESG Initiatives
Environment
Social
Governance
Environmental Policy and Strategy
Reduce Environmental Impact
Environmental Communication
Environmental Data
Independent Assurance Statement Related to Environmental
Data (PDF: 609.1KB)
Human Rights
Product Responsibility
Procurement
Employment
4

Governance
Labor Relations
Occupational Safety and Health
Independent Assurance Statement related to the
occupational health and safety (PDF: 609.1KB)
Occupational Safety and Health, Health Management
Training and Education
Diversity and Equal Opportunity
Diversity and Inclusion in the Americas
General Employer Action Plan based on the Act on
Promotion of Women’s Participation and Advancement in
the Workplace
General Employer Action Plan based on the Act on
Advancement of Measures to Support Raising Next-
Generation Children
Promoting Work-Life Integration
Contributing to Society through Medical Business
Corporate citizenship activities
Charitable Donations and Grants
Corporate Philosophy
Framework of Corporate Philosophy
Corporate Governance
Communication with Stakeholders
Compliance
Tax
Anti-Corruption
Information Disclosure (PDF: 35.2KB)
Disclosure of Medical Business Information
Information Security
Risk Management System
Related Information
Related Information
Sustainability Library
Integrated Report
GRI Content Index
List of Policies
General Meeting of Shareholders
External Evaluation
Participating in External Initiatives
Editorial Policy
5

Message from Chief Strategy Officer
As a leading global business, Olympus is committed to nurturing world-class corporate responsibility.
We are proud to have provided significant value to society for more than 100 years, making people’s
lives healthier, safer and more fulfilling around the world through our innovative range of products and
services. In particular, we have delivered benefits to the global healthcare community with solutions
that have improved clinical outcomes for patients, boosted the quality of life and patient experience,
and created economic value throughout the medical and scientific communities. By taking a proactive
approach to Environmental, Social, and Governance (ESG) perspective, we believe we can play an
essential role in helping to create a sustainable society.
In doing so, we will also improve our economic value and fuel sustainable growth.
Corporate Officer, Chief Strategy Officer,
Tetsuo Kobayashi
6

Olympus Group ESG
Basic Approach and Policy
All the activities undertaken by the Olympus Group are to respond to requests and expectations from society and to fulfill our duties and responsibilities
under our Corporate Philosophy. We understand that Olympus as a corporation deserves to continue to exist only when we fulfill our responsibilities through
dialogs with stakeholders-including customers, suppliers, shareholders, investors, employees and their families, local communities, and international society.
We extracted six important ESG areas and defined five materiality items. These five materiality items reflect our corporate strategy, benchmarks by
stakeholders and an external ESG evaluation organization’s opinions, and have been established by the Group Executive Committee and the Board of
Directors. The five materiality items show that we contribute to solving social issues through our business, and are in a mutually complimentary and solid
relationship. We consider ESG to be a crucial component as we grow to become a globally leading medtech company and contribute to the creation of a
sustainable society. The distinct materiality items can vary depending on social and business changes and we continue to revise them as required.
Promotion Structure
To reinforce the implementation of the ESG measures, in April 2021, we designated an ESG Head to be responsible for our ESG initiatives and established
the KPIs to be specified in our medium- to long-term business plan. The ESG Head comprehensively manages ESG initiatives while monitoring the
implementation progress of ESG measures. The ESG Head also reports the status of that progress to the Group Executive Committee and the Board of
Directors for deliberation. From FY2021, 10% of the executive officers' performance share unit (PSU), a part of our long-term incentive compensation, was
linked to the results of an evaluation by an external ESG evaluation organization. In FY2022, the percentage is being increased from 10% to 20% to
Procedure to Establish ESG Enhancement Measures
Six Important ESG Areas:
Five Materiality Items
Healthcare access and outcomes
Compliance, product quality and safety
Responsible supply chain
Diversity and inclusion
Carbon Neutral Society and Circular Economy
7

reinforce the commitment of management. We adopt the Dow Jones Sustainability Indices (DJSI) as its benchmarks, which are reputed to be more reliable
and have a wider coverage than other external ESG criteria. We have been listed in the DJSI Asia/Pacific Index for two consecutive years.
Value Creation Model
Value Creation Model (PDF: 139.4KB)
8

OUR PURPOSE
Making people’s lives healthier, safer  
and more fulfilling
Dominant position built on basis of  
relationships of trust with customers
	Dominating global market share for gastrointestinal 
endoscopes approximately 70%
	Training for doctors conducted around the world
	Entered emerging markets ahead of other companies  
and built relationships of trust with doctors
	
	 Have built relationships of trust in Chinese market for about  
50 years, since normalization of diplomatic relations between  
Japan and China in 1972
	
	 Established representative office in Singapore in 1975
Global and robust management foundation
	Approximately 17 training centers with the aim of  
providing training opportunities for healthcare professionals
	Build an industry-leading service network among  
the world's medical device companies
	Established a global headquarters for the Therapeutic 
Solutions Division in the U.S.
	Credit ratings: A (R&I), BBB + (S&P)
	Approximately 900 dialogues with institutional investors  
and securities analysts*1 
Technological capabilities that produce 
high-quality and advanced products
	Selected as one of the top 100 most innovative companies 
in the world for ten consecutive years
	Approximately 17,000 patents*2 held to maintain an 
overwhelming market share and acquire further technology
	Strong know-how and optical technology built up since  
the Company’s founding
	Manufacturing techniques that realize high-mix,  
low-volume production
Diverse human resources that possess  
high expertise
	Aiming to become a global medtech company, hiring  
highly specialized and talented people for global positions
	
	 To further grow mainly in the Therapeutic Solutions Division,  
set up a specialized business development team in the U.S.,  
hired talented people, and carried out four M&As*1
	
	 Percentage of foreign management roles globally:  
approximately 37%*3
	To strengthen implementation skills, approximately 2,600 
employees participated in training, and approximately 3,000 
people participated in a program to strengthen global 
communications
Strength
Olympus’ Value Creation Model
Financial KPI
Social Outcome
Providing value to patients, countries, and  
society through our customers
*1	 Fiscal year 2021
*2	 As of March 2021
*3	 The percentage within global senior management as of July 1, 2021
*4	 Numbers come from the Company’s research. Numbers for the U.S., Canada, Germany, France, Italy, Spain, the UK, Japan, China, South Korea, Australia and India. As of 
2018 or 2019 depending on the region
*5	 Olympus has versatile medical devices with the ability to treat approximately 100 diseases or conditions as of March 2021.
*6	 Adjusted for extraordinary items 
> 20%
Operating margin*6
5-6 %
Annual average revenue 
growth rate
Relationships  
of trust built by 
collaborating 
with customers
 Feedback on  
product improvements 
and requests
 Providing products that 
meet abundant needs
 Support for procedure 
development
Strategy
Corporate Strategy
1. Corporate governance
2. Economic sustainability
3. Product sustainability
4. Environment
5. People
6. Society
Six Important ESG Areas
 Healthcare access and outcomes
 Compliance, product quality and safety
 Responsible supply chain
 Diversity and inclusion
 Carbon neutral society and circular economy
Our Materiality
Fo
cu
si
ng
 o
n 
th
e 
cu
st
o
m
er
 a
nd
 v
al
ue
Transforming into a Truly Global  
Medtech Company
Realization of corporate culture and structure  
that enables sustainable growth
 Contributing to limiting medical expenses through early 
diagnosis and minimally invasive treatments
 Contributing to the future of medicine
 Contributing to safety and security in everyday lives
Countries/Society
 Contributing to improvements in efficiency of medical care and  
its economic outcomes through early diagnosis and  
minimally invasive treatments
 Contributing to biological/medical research as well as pathology research
 Contributing to industrial efficiency and improvements in inspection quality
Customers
(Medical institutions, research institutions, manufacturing industry, etc.)
 100
Diseases or  
conditions treated*5
50million
Colonoscopies  
performed worldwide*4
 Contributing to the health of  
people around the world
 Improving patients’ QOL through 
early diagnosis and minimally 
invasive treatments
Patients
Olympus Integrated Report 2021
12
13
Chapter 01  
  Our Company
Value Creation Model
9

Environmental Policy and Strategy
Basic Approach and Policy
The Olympus Group's environmental initiatives are founded on its Corporate Philosophy, the Olympus Global Code of Conduct and the Environmental Health
and Safety Policy. The Olympus Global Code of Conduct sets out our policy on the environment and the actions required. The objectives are described with
clarity and detail in the Environmental Health and Safety Policy.
* In May 2015, we published the Olympus Group Environmental Policy. This was based on the Olympus Group Environmental Charter adopted in August 1992, to which we added
aspects on both environmental protection and economic growth. This Environment Policy was then converted into the Environmental Health and Safety Policy in April 2021, by
incorporating environmental health and safety policies to comprehensively manage our EHS activities.
Promotion Structure
In the Olympus Group, the CEO and the CAO are appointed as the top executive officers for the environment. Also, the Human Resources Head, who
manages human resource development and general affairs including matters related to the environment, health and safety (EHS), serves as the top
management for environmental affairs for the entire Group. Under the leadership of the Human Resources Head, the EHS division is responsible for
developing Environmental Health and Safety Policy for the entire Group, as well as planning and promoting environmental measures. The division also
monitors environmental initiatives across the entire Group, such as the progress of energy reduction targets and implementation status of environmental
measures.
We have environmental management divisions for each business division and Group company. The EHS division is responsible for environmental
management for the entire Group. Since FY2015, the EHS division has created an information platform for the entire Group to enable efficient gathering of
information on environmental initiatives at various global sites that are essential to environmental management, as well as environment-related data and the
status of these sites in complying with laws and regulations. In FY2021, the Olympus Group obtained ISO 14001 multi-site certification, which covers 12
group companies in Japan and Asia, including the EHS division, to reinforce the group's environmental governance and streamline the environmental
management. 
To address environmental issues promptly and appropriately, we aim to globally expand the scope of this ISO 14001 multi-site certification.
(Name of sites and offices are as they were at time of the certification.)
Basic Approach and Policy
Promotion Structure
Mechanisms and Initiatives
Environmental Education and Awareness Activities
Environmental Health and Safety Policy
Environmental Management Structure
Status of Acquiring ISO14001 Certification in Olympus Group (As of July 2021)
10

Sites/Office
Date of Certification
Sites/Office
Date of Certification
Japan
Olympus*4
Headquarters (Shinjuku)*1
August 2020
Sasazuka Facility*2
August 2020
Technology Research Center (Ishikawa)
March 2000
Technology Research Center (Utsugi)
March 2000
Technology Research Center (Takakura)
February 2018
Nagano Facility (Tatsuno)
February 1998
Nagano Facility (Ina)
May 2014
Shirakawa Facility
October 1998
Olympus Medical Systems*4
Technology Research Center (Ishikawa)
March 2000*3
Technology Research Center (Utsugi)
March 2000*3
Hinode Plant
July 1998
Nagano Olympus*4
February 1998
Aizu Olympus*4
October 1998
Shirakawa Olympus*4
October 1998
Aomori Olympus*4
November 1998
Olympus Terumo Biomaterials*4
Mishima Plant
August 2020
R&D Center
August 2020
Olympus Logitex*4
Distribution Center in Sagamihara
November 2003
Olympus Medical Science Sales*4
March 2004
Americas
Olympus Surgical Technologies America National Service Center
December 2005
Olympus Scientific Solutions Americas Corp.
July 2010
Olympus Scientific Solutions Technologies Inc.
July 2010
Olympus NDT Canada Inc.
July 2010
Olympus Corporation of the Americas
September 2019
Olympus Surgical Technologies America
September 2019
Olympus Respiratory America
September 2019
Center Valley Pennsylvania Regional Headquarters
Breinigsville Pennsylvania Distribution Center
Bartlett Tennessee Manufacturing Facility
Brooklyn Park Minnesota Manufacturing Facility
Norwalk Ohio Manufacturing Facility
Redmond Washington Manufacturing Facility
11

Sites/Office
Date of Certification
Europe/Middle East
Olympus Winter & Ibe GmbH
May 2001
KeyMed (Medical & Industrial Equipment) Ltd.
March 2002
KeyMed (Ireland) Ltd.
March 2002
Algram Group Ltd.
January 2007
Medical Physics International Limited
October 2012
Olympus Iberia S.A.U.
September 2018
Asia Pacific
Olympus (GuangZhou) Industrial Co., Ltd.*4
October 2004
Olympus Trading (Shanghai) Limited*4
February 2012
Olympus Vietnam Co.,Ltd.*4
April 2013
Olympus Australia Pty Ltd
August 2017
Olympus New Zealand Limited
August 2017
*1 The scope of certification includes the EHS division for Olympus Group and headquarters, and its medical business management functions.
*2 The scope of certification includes the administrative functions at Sasazuka Facility in Tokyo and the customer support for the medical products.
*3 It had been included in the scope of the ISO 14001 certification of Olympus Corporation until March 2020.
*4 It is included in the scope of the ISO 14001 multi-site certification of the Olympus Group.
Mechanisms and Initiatives
Recognition of Environmental Issues
When establishing its Corporate Strategy and Business Plan, the Olympus Group identifies potential risks that could impact on our business operations. The
high risks are then extracted, and their risk levels are assessed. Such high risks include business transition risks to keep up with changes in environmental
regulations and technologies to adapt climate change, as well as physical risks associated with natural disasters.
Risk evaluation and prioritization are carried out in each organization assuming the impact on the business should the risk become reality, and the likelihood
of such. According to the results of such evaluation and prioritization, business plans for the following year or multiple years are established to manage such
risks. As for risks related to environmental regulations, the Quality Management function monitors the regulation trends concerning our products, and the
EHS division of each company monitors the regulation trends concerning the business site. The state of compliance is regularly assessed while changes are
implemented as required.
The management status of those risks posing a high impact on business operations are regularly monitored in each organization and monitoring results are
reported to the Group Executive Committee and the Board of Directors. In response to the monitoring results, the CEO may revise the plan details if
management efficacy is insufficient.
Olympus continuously develops and maintains internal rules and regulations adapted to statutory requirements, and trains environmental managers and
related personnel, as well as monitoring and improving on-site management.
In FY2021, there were no violations or incidents related to environmental laws and regulations, excluding relatively minor issues. Also, there were no claims,
penalties or fines.
Status of Acquiring ISO14001 Certification in Olympus Group
Compliance with Environmental Laws and Regulations (FY2021)
12

The Olympus Group is fully aware that the recent climate change and ecosystem deterioration, brought about by excessive environmental impact and
pollution, is the issue we need to address promptly. In May 2021, we added "carbon neutral society and circular economy" to the materiality items. The target
of achieving carbon neutrality was set as reaching net zero CO2 emissions from our entire business operations by 2030. To achieve this target, we continue
to improve production efficiency and implement further energy-saving measures, as well as gradually replacing the energy used in all of our business sites*
with renewable energy sources by 2030. We also recognize the importance of environmental impact reduction across the supply chain and continue the
transportation modal shift, logistical efficiency improvement, reduction in energy consumption and weight of products, and green procurement.
* Excluding rental properties, such as sales sites.
Primary Policy
Target
Measures
Achievements and
Results in FY2021
FY2022 Target
Promotion of
environmental
management
Enhancement of
environmental
governance
system
Improve effectiveness
and efficiency of the
Environmental
Management System
Development of the
action plan toward
carbon neutral
Ensure appropriate
response to indicated
points in internal
environmental audit
and ISO14001
certification external
audit
Ensure appropriate
response to indicated
points in internal
environmental audit,
and ISO 14001 multi-
site certification
external audit
Long-term targets and measures
Major Environmental Activity Results in Fiscal 2021
Development of
long-term
environmental
targets
Setting the goal of
long-term net zero
CO2 emissions by
2030
Maintenance of
ISO 14001
certification
Maintenance of
ISO 14001
certification for
global major
manufacturing
sites (Europe,
Americas,
Australia)
Provided training
for newly
appointed
environmental
managers, and
training to improve
skills and
compliance training
for the
Environmental
Secretariat in
Japanese sites (6
persons)
Activities aimed at
ISO 14001 multi-
site certification
ISO 14001 multi-
site certification
external audit of 10
sites in Japan and
three sites in Asia
13

Primary Policy
Target
Measures
Achievements and
Results in FY2021
FY2022 Target
Environmental
risk reduction
activities
Continue to improve
the process to comply
with environmental
laws and regulations
Expand target sites
for the
Environmental/health
and safety risk
assessment
Continue to improve
the environmental
regulatory compliance
process for products
and facilities
Environmental
initiative
throughout
product life
cycles
Product-related
initiatives
Create Olympus Eco-
Products
Continue to create
products that are
environmentally
conscious and
tailored to business
characteristics
Facilities-related
initiatives
CO2 emission: reduce
by 15% compared to
FY2018
Energy consumption
intensity: improve by
7.73% compared to
FY2013
Renewable energy
rate: more than 10%
Emission intensity:
improve by 6%
compared to FY2018
Water use intensity:
improve by 6%
compared to FY2018
CO2 emission: reduce
by 25.4%
Energy consumption
intensity: improve by
12.3%
Renewable energy
rate: 12.7%
Emission intensity:
improve by 16.1%
Water use intensity:
improve by 14.1%
CO2 emission: reduce
by 21% compared to
FY2018
Renewable energy
rate: improve
compared to FY2021
Emission intensity:
improve by 7%
compared to FY2018
Water use intensity:
improve by 7%
compared to FY2018
The Olympus Group recognizes that climate change is a serious issue that threatens the global environment, as well as having grave implications for the
group's business activities. Based on this awareness, we announced our endorsement of the Recommendations of the Task Force on Climate-Related
Financial Disclosures (TCFD) in May 2021, as a part of our contribution to building a carbon neutral society-one of the materiality items in our Corporate
Strategy. According to the TCFD's recommendations, the Olympus Group will disclose its climate-related financial information in a timely manner.
Enhance
inspection for
compliance status
with environmental
laws and
regulations
Education for
environmental laws
and regulations
Inspection on the
waste
management
process and
operational
improvements at
each site in Japan
Education on
Waste
Management and
Public Cleansing
Act by external
experts in Japan
(36 persons)
Education on
waste and
chemical
substance
management at
Olympus Surgical
Technologies
America (101
persons)
Continue to
improve the related
internal rules for
products and
facilities
Create products
that are
environmentally
conscious and
tailored to business
characteristics
Created new Eco-
Products in all
business units (9
new, bringing total
to 664)
Continue to
implement
improvements
such as improving
manufacturing
processes, saving
of energy and
material resources
and introduction of
renewable energy,
etc., in accordance
to local
characteristics
Response to Climate Change
Governance
14

The Olympus Group endeavors to reduce the environmental impact from the entire value chain, including product development, procurement, manufacture,
logistics, sales, and repair. Under the CEO and CAO, who are the highest environmental responsible officers, the Human Resources Head, who manages
human resource development and general affairs, oversees matters related to the environment, health and safety (EHS) for the entire Group.
The EHS functional division creates an environmental action plan, including the reduction target of CO2 emissions, as well as monitoring the progress of
action plan implementation across the entire Group. In response to the progress report, the highest environmental responsible officers (CEO and CAO) give
instructions for any improvement required. The Board of Directors continues to monitor the status of the implemented climate change measures while
receiving the related reports at least once a year. Also, to reinforce the commitment of management to the ESGs and climate change initiatives, 20% of the
executive officers' performance-based stock remuneration, a part of our long-term incentive remuneration, is linked to the evaluation results of an external
ESG evaluation organization.
The Olympus Group identifies risks and opportunities related to climate change for the short-term, medium-term, and long-term periods by using scenario
analysis. The influence of climate change on our business activities is analyzed based on the 2-degree scenario (holding the increase in the global average
temperature to below 2℃ above pre-industrial levels) and the 4-degree scenario (where the increase is assumed to be up to 4℃ above pre-industrial levels),
both of which were presented by the International Energy Agency (IEA). We identified that the major risks within the short-term period (one to five years)
would be the suspension of factory operations or breakdown of the supply chain due to natural disasters; and the risks within the medium- to long-term
period (10 to 20 years) would be an increase in business costs due to the introduction of carbon taxes and further tightening of CO2 emissions regulations.
Although such climate change risks could affect our corporate strategy and financial plan, we assume that the scope of influence would be limited. For
example, the geographical location of our factories in terms of natural disasters, such as typhoons, can be classed as a physical risk. We confirmed that our
factories are at low-risk locations and a business continuation plan for each site was created in case of emergency. As a supply chain risk, we have
experienced closures of sales sites due to typhoons and flooding across the world. Still, the influence was limited. We also expect an increase in operational
costs due to carbon taxes etc. as a transition risk. However, the percentage of energy costs in the factories among overall business costs is small, and,
therefore, the impact on our business will be limited.
As a climate change opportunity, we will continue development of environmentally conscious products with energy-saving functions, taking the rising
requirement for such products-which contribute to CO2 emissions reduction-as a business opportunity. However, we estimate the impact from this
opportunity on our business will not be so large because the majority of our products are already small with low energy consumption, and the nature of our
products and services are relatively independent from any impact from climate change.
Environmental
Changes
Risks
Opportunities
Measures
2℃ scenario
Stronger regulatory
action for a low carbon
society
<Transition risks>
4℃ scenario
Rise in temperature &
increased extreme
weather events
<Physical risks>
* The calculated financial influence was approx. 600 million yen/year based on the carbon tax figures in the World Energy Outlook 2020 by the IEA (2020).
Environmental Health and Safety Policy
Strategy
Increase in business
costs due to carbon tax,
carbon emissions trading
and stronger regulatory
action on CO2 emission
by various countries
Reduction of business
costs by energy-saving
measures
Improvements in market
competitiveness by
development of
environmentally
conscious products
Improvements in
evaluation by
stakeholders
Improvements in energy
efficiency
Wider use of renewable
energy
Diversification of
suppliers
Environmentally
conscious design in the
product/service design &
development stage
Development and
provision of
products/services that
contribute to resolving
environmental issues in
society
Supply chain disruption
caused by growing scale
of natural disasters, such
as typhoons, floods, etc.
Risk Management
15

The Olympus Group identifies, assesses, and manages climate change and other environmental risks within the group-wide risk management system that
covers all the risks that could affect our business. For more details, see Recognition of Environmental Issues.
The Olympus Group set two targets in 2021. One is net zero CO2 emissions from its business activities by 2030, and the other is switching electricity
procurement for all of its business activities to renewable energy sources also by 2030.
The results in FY2021 were a 25.4% reduction in CO2 emissions (compared to FY2019) and the percentage of renewable energy usage reached 12.7%. We
continue our production efficiency improvements, energy-saving activities, and introduction of renewable energy in business sites across the world. We also
pursue the development of environmentally conscious products, green procurement, and improvement of logistical efficiency in order to reduce CO2
emissions across the life cycles of our products.
Regarding our water risk management, an issue in which the world is taking a great interest, we confirmed that none of our major development and
production sites are located in areas where the water risk is extremely high. For this analysis, we used a water risk assessment tool created by the World
Resources Institute (WRI)-the Aqueduct Water Risk Atlas, which covers various aspects such as physical water stress and regulatory risk. Although the
influence of water risks on our business is low, we are adopting various measures, such as choosing low water risk locations for business sites, reducing
water usage in our business activities, appointing drainage system managers, and regular inspections of drainage water.
Low
Low - Medium
Medium - High
High
Extremely High
2
16
2
1
0
Biodiversity Conservation
There is a concern that the loss of biodiversity will have a serious impact on the global environment and our lives.
The Olympus Group is working to conserve biodiversity, including the management of water use and wastewater and the maintenance of green spaces,
through cleanup and forest conservation activities in areas surrounding its facilities.
Recognition of Environmental Issues
Indexes and Targets
Long-term Targets and Measures
Results
Response to Water Risk
Number of Major Sites in Different Risk Levels as Defined by the Aqueduct Water Risk Atlas
Total Water Usage by the Result of Water Risk Evaluation
16

Green Procurement
Olympus published the "Olympus Group Green Procurement Standard" in 2001.
The Green Procurement Standard, which is also posted on our website, explains the Olympus Group's approach to its environmental activities to all
suppliers.
In addition, in our corporate survey that we conduct once a year targeting major suppliers around the world with whom we have ongoing business, we verify
whether the suppliers have acquired ISO 14001 certification, reduced CO2 emissions, water use and waste, and what measures they have taken against
chemical substances.
In this way, we are working to raise the level of our environmental activities with suppliers.
Environmental Education and Awareness Activities
The Olympus Group recognizes the importance of greater environmental awareness by each and every employee and full participation in environmental
activities under the Environmental Health and Safety Policy. We are running more environmental awareness activities such as the Olympus Environment
Month, a global group-wide event. In FY2021, an environmental e-learning program was conducted involving all Group employees, to promote group-wide
awareness of important environmental issues, such as climate change and marine plastic pollution, and the state of environmental activities throughout the
Group. We held events adapted to regional characteristics to promote environmental awareness in our major sites with COVID-19 countermeasures
implemented.
We have also introduced special training programs to improve our environmental management system and implement it effectively. These include programs
on compliance with environmental laws and regulations, and ISO 14001 internal audits at facilities around the world.
Target
Purpose/Description
Number of
Participants
Environmental managers
Understanding the responsibilities and roles of environmental managers (key points in
compliance with environmental laws and regulations, and development of an effective
EMS)
5
Environmental Secretariat staff
at facilities
Training to improve skills for environmental officers (Understanding new developments
in environmental laws and regulations, and practical application of the Revised Energy
Conservation Act)
1
Waste management officers
Training on the Waste Management and Public Cleansing Act (Understanding of the Act
and practical application of waste management)
36
New employees
Environmental education for new employees (Understanding environmental issues and
corporate responsibility, as well as the environmental initiatives by Olympus Group)
58
Olympus Group Green Procurement Standard
Major Environmental Education Programs
(Olympus and its Japan subsidiaries/FY2021)
17

Reduce Environmental Impact
Basic Approach
The Olympus Group is implementing a variety of environmental activities while assessing the environmental impact of its business activities with precision
and with awareness of the scale of the impact on and risk to the environment. Also, following the diversification in our suppliers and with an awareness of
climate change as a major environmental issue impacting our business activities, we continue to implement measures to assess information on energy
conservation and regulations on reducing CO2 emissions and responding to sudden flooding.
At the same time, we actively develop and market environmentally conscious products that contribute to resolving issues with climate change and water risk
and products designed to resolve environmental issues
Initiatives
Energy/Atmospheric Release
FY2021 Targets
FY2021Results
Main Measures
FY2022 Targets
CO2 emissions: reduced by 15%
(compared to FY2018)
Energy consumption intensity:
improved by: 7.73%
(compared to FY2013)
Energy consumption intensity:
improved by: 10%
(compared to FY2020)
CO2 emissions: reduced by 25.4%
(compared to FY2018)
Energy consumption intensity:
improved by 12.3% 
(compared to FY2013)
Renewable energy rate : more than
12.7%
CO2 emissions: reduced by: 21%
(compared to FY2018)
Renewable energy rate: more than
the previous year
The Olympus Group supports KEIDANREN's Commitment to a Low Carbon Society initiative and has set a target to reduce its energy consumption in
FY2021 by 7.73% or more compared with FY2013. Among its energy-reduction activities is reducing its CO2 emissions. We arrange positions of experts and
promote initiatives through our structure to promote energy saving at sites where energy consumption is high. In FY2021, continual improvements in
manufacturing, energy-saving measures, updates company cars to environmentally conscious cars and the use of renewable energy were considered at its
sites around the world. At the Hachioji Facility, lighting was upgraded to use LEDs and the temperature setting for the indoor storage of chemicals was
reviewed to reduce energy consumption. The Hinode Facility updated its central air conditioning to use highly efficient equipment.
We have also been focusing on the construction and renovation of facilities. At Olympus Europa SE & Co. KG and Olympus Winter & Ibe GmbH,
construction and renovation of facilities are underway with German Sustainable Building Council certification (DGNB certification*). 
For wider use of renewable energy, studies are focusing on dissemination, economic feasibility and other factors in each country. The renewable energy use
rate vis-á-vis the total electric power consumption has risen to 12.7% (compared to 11.7% in the previous year). 
Energy/Atmospheric Release
Water/Emission
Product Life Cycle Assessments
Examples of Environmentally Conscious Products
Products that Contribute to Solving Environmental Issues
Internal (Scope 1, 2) Results
Ongoing implementation of
manufacturing improvement
activities
Introduction of energy saving
equipment
Ongoing implementation of
energy-saving activities on a
daily basis, including switching
off lights and adjusting air-
conditioning temperatures
Introduction of environmentally
conscious cars
Effective use of renewable
energy
18

Olympus Corporation participates in the Carbon Neutral LNG Buyers Alliance as a part of new initiatives to reduce CO2 emissions, and has started to
introduce carbon neutral LNG* to the Hachioji Facility.
*1 DGNB certification: Environmental certification for architectural structures issued by the German Sustainable Building Council to reduce the environmental impact of structures.
Certification is given after assessment of the environmental performance of the building and confirmation that the structure satisfies certain criteria.
*2 Carbon neutral LNG: A type of LNG that offsets greenhouse gases generated in the processes from the extraction to the burning of natural gas with carbon credits created by
environmental conservation projects.

Olympus Surgical Technologies America (Gyrus
ACMI, Inc.) (U.S.A.)

Olympus Europa SE & Co. KG (Germany)

KeyMed (Medical & Industrial Equipment) Ltd. (U.K.)
FY2021 Results
Main Measures
CO2 emissions: reduced by: 30.7%
(compared to FY2013)
The Olympus Group is engaged in reducing logistics-related CO2 emissions at each of its sites. We continue with improvements, including optimizing the
loading efficiency of transportation containers by products type and shape, consolidating logistics sites for transportation efficiency and direct shipping by
reviewing logistics routes. In FY2021, CO2 emissions were reduced in a proactive modal shift from aircraft to ships for medical product transportation from
Japan to the Americas and Australia.
Carbon Neutral LNG (Only in Japanese) 
Green Energy Certificates
Logo for the Carbon Neutral LNG
External (Scope 3 [Category 4 Upstream transportation and distribution]) Results
Enhanced loading efficiency by improving packaging size and strength
Reduced transportation weights by improving packing and packaging methods
Shortened lead times and transportation distances by improving logistics routes
19

Medical product transportation by ship (from Tokyo to the Americas, from Tokyo to Australia)
Water/Emission
FY2021 Targets
FY2021 Results
Main Measures
FY2022 Targets
Water use intensity:improve by
6% compared to FY2018
Water use intensity:improved by
14.1% compared to FY2018
Water use intensity: improve by
7% compared to FY2018
The Olympus Group uses water mainly in production processes, such as for cleaning components and cooling, as well as in its dining halls. We implement
thorough wastewater control by adopting stricter standards than the legal requirements in each region, and we continue to reduce water consumption and
wastewater emissions by setting targets in those sites that have high water consumption. We are also acting to conserve water resources under
collaborations with local communities at each site.
In FY2021, we reassessed the water risks at each of our sites using water risk assessment tools (e.g. Aqueduct), hazard maps, and their water usage. In
Japan, Olympus Terumo Biomaterials started using the residue from generating RO-purified water*1 for toilets and sprinklers, and Aizu Olympus reduced
water usage by shortening the time taken to wash parts. To conserve regional water resources, the Nagano Facility discharges wastewater into the nearby
Tenryu River with the approval of the local fisheries cooperative association. The wastewater discharge is strictly controlled and regularly monitored by the
facility to minimize any impact on the river habitat. The Nagano Facility also helps maintain the local forest that serves as a water source for the area under a
Forest Fostering Agreement concluded with the Monzen Forest Association and Tatsuno Town in Nagano Prefecture. Olympus Surgical Technologies
America (formerly Gyrus ACMI, Inc.) in the U.S. received a Commitment-to-Compliance Award*2 for two consecutive years in recognition of long-time efforts
to maintain compliance with the industrial wastewater discharge permit requirements set by King County, Washington.
*1 Nearly 100% pure water filtered using a reverse osmosis (RO) membrane.
*2 Presented to companies that have received a Gold Award for five consecutive years in the recognition program in King County, Washington, to meet or exceed wastewater
discharge permit requirements.
Water Use/Wastewater Results
Improvements in water use
processes
Implementation of secondary
use of water
Commitment-to-Compliance Award 
Water Use
Environmental Data
Wastewater Results
Environmental Data
Emission Results
20

FY2021 Targets
FY2021 Results
Main Measures
FY2022 Targets
FY2021 Targets
FY2021 Results
Main Measures
FY2022 Targets
Emission intensity : improve by
6% compared to FY2018
Emission intensity : improved by
16.1% compared to FY2018
Emission intensity: improve by
7% compared to FY2018
The Olympus Group is working continually on reducing losses in manufacturing processes by making improvements to them and efficient use of resources,
including thorough waste separation to reduce waste discharge, extract valuable materials and promote recycling.
In FY2021, paper usage was significantly reduced in our development sites and offices due to digitalization associated with increased remote working
progressed by our Work Style Reform. In Japan, Shirakawa Olympus extracted valuable materials from waste organic solvents and components. Olympus
Logitex reduced waste packaging by expanding the use of returnable containers and reuse of cushioning materials, and by replacing disposable stretch film
to prevent load shifting with recyclable packaging bands. In the U.S. Olympus Surgical Technologies America Inc. provided an intra-company awareness
raising program to help employees increase the recycling rate. The company's Bartlett office signed up to the Tennessee Recycling Coalition*1 and
Tennessee Materials Marketplace*2 to explore new ways of recycling, and open and expand the reuse and recycling market.
Our hazardous waste emissions have been reduced compared to FY2020 by reinforcing waste management and replacing certain chemical substances with
safer ones.
*1 Tennessee Recycling Coalition: A non-profit organization dedicated to promoting recycling and sustainable materials management practices in Tennessee, U.S.
*2 Tennessee Materials Marketplace: A corporate consortium to create and expand the reuse and recycle market in Tennessee, U.S.
FY2021 Results
Main Measures
Emissions and Movements of PRTR Class 1-Designated 
Chemical Substances: Reduced by 25.6%
(compared to FY2013)
The Olympus Group is striving for appropriate management and emissions reduction of chemical substances subject to the PRTR regulations in order to
minimize the impact on people and the environment. In FY2021, we continuously reduced the use of organic solvents through improvements to the cleaning
process of component, etc. at each manufacturing site.
FY2013
(Base year)
FY2017
FY2018
FY2019
FY2020
FY2021
Emissions and
Movements of PRTR
Class 1-Designated
Chemical Substances
20.7
18.0
17.7
18.8
19.3
15.4
Reduction of process
defects
Promotion of recycling by
thorough separation
Promotion of reusing
package materials
Extracting valuable
materials from wastes
Emission/Landfill
Environmental Data
Hazardous waste discharged
Environmental Data
Chemical Substance Safety and Control
Substitution of PRTR-designated chemicals with other substances
through material developments
Reduced usage of PRTR-designated chemical substances
Emissions and Movements of PRTR Class 1-Designated Chemical Substances
21

Video Gastroscope GIF-XZ1200
* Scope: Manufacturing and development sites in Japan
Product Life Cycle Assessments
The Olympus Group works to develop products and production technologies that show consideration for safety and for the environment. Having in FY2004
established its Eco-Products Administration Rules, a voluntary standard relating to the environmental considerations of our products, we continue to certify
our products as Olympus Eco-Products.
In addition, a life cycle assessment (LCA) is performed at each stage of a product's life cycle to assess its impact on the environment at the product
development stage and from procurement through manufacture, distribution, use and final disposal. Clarifying the environmentally conscious aspects that
differ for each product, we have set them as items for the environmental consideration standard.
We are working to reduce the use of containers and packaging materials, and promoting effective use of resources.
Examples of Environmentally Conscious Products
The Olympus Group works to show consideration for the environment through the products in each of its business fields.
< Main Product Features >
1. Maximum 125 times magnification and superior image quality using a high-sensitivity CMOS
image sensor.
2. High-speed sequential color imaging delivers an image with higher resolution and minimum
chromatic aberration.
3. New ErgoGrip improves usability for operators.
< Environmentally Conscious Aspects >
< Main Product Features >
1. Autopopulates data to your experiment plan metrix, reducing the chance of input errors
2. Clear data trend visualization tools
3. Renowned Olympus optics reduce aberration to capture the correct shape of your sample
throughout the entire field of view.
< Environmentally Conscious Aspects >
Products that Contribute to Solving Environmental Issues
Utilized even at the forefront of automobile and aircraft development with the aim of improving the efficient use of energy and the recycling facilities, Olympus
products contribute to solving environmental issues.
Medical Business
Video Gastroscopes GIF-XZ1200
Reduction in product weight.
Scientific Solutions Business
LEXT™ OLS5100 3D Laser Scanning Microscope
Use of lead-free optics and high recyclability
22

Assisting in hazardous substance analysis and resource
recycling.
Contributing to the realization of a society that emits
only small amounts of CO2
< Main Product Features >
1. Nondestructive measurement of substances (elements) in the target object by type and content.
2. Durability and toughness for use under rigorous conditions.
3. Use for quality inspections at production sites, selecting recycled raw materials, inspecting
hazardous metals, etc.
< Main Product Features >
1. Used in the inspection and diagnosis of the internal parts of machinery.
2. Reproduces even the slightest defect in a sharp, clear image.
3. Used for inspections of wind power generation facilities and of automobiles competing on low fuel
consumption as well as of aircraft engines.
X-ray Fluorescence (XRF) Analyzers
Industrial Videoscope
23

Environmental Communication
Initiatives
The Olympus Group is disseminating environmental information through smooth communication with its stakeholders so that they can have a fuller
understanding of the environmental conservation activities conducted by its employees in local communities.
Environmental conservation activities
The Olympus Group is involved in continuous environmental conservation activities in the local communities where its business sites are located, including
cleanup programs, tree planting and recycling.
Tokyo Metropolitan Government ordinances
Ishikawa Facility's plans for global warming countermeasures are being disclosed in response to the Tokyo
Metropolitan Government's program on global warming countermeasures.
The Hachioji Facility, which is covered by the Tokyo Metropolitan Government Cap & Trade System*, donated to the
metropolitan government carbon credits worth 15,033 tons of CO2 resulting from it overachieving its compulsory
reduction volume between FY2010 and FY2014.
* Tokyo Metropolitan Government Cap & Trade System: A program that requires large-scale business facilities (where consumption of
fuel, heat and electricity in the previous fiscal year exceeds 1500 kL of crude oil per year) to comply with CO2 emissions reduction
requirements.
Olympus Environment Month
June 5 is designated by the United Nations as World Environment Day. For more than 40 years, Olympus has been
fostering greater environmental awareness every June, which it has designated as Olympus Environment Month.
Although the June Environment Month events organized by all Group companies were canceled in FY2021 to
prevent the spread of COVID-19, we started to hold environmental e-learning and other activities globally in
December to promote employee awareness of the environment.
In the past, during Environment Month our business sites in Japan have organized collections of used books, CDs,
DVDs, etc., sold them to external dealers and used the proceeds to aid environmental conservation activities by
NGOs and NPOs. This scheme was expanded in December 2020, and now collections are organized throughout the
year.
Corporate Citizenship Activities' Newsroom(environment)
Plans for global warming countermeasures (Only in Japanese) 
FY2020 Olympus CSR Environment Month
FY2019 Olympus CSR Environment Month
24

Participation in the Ministry of the Environment's Environmental Reporting Platform
Development Pilot Project
Olympus participates in the ESG Dialogue Platform verification project of the Ministry of the Environment, which serves as a foundation for environmental
information and dialogue among businesses and investors.
Related link
Secretariat of Environmental Reporting Platform Development Pilot Project 
Olympus Corporate Citizenship Activities
25

Environmental Data
Initiatives
Material Balance (FY2021)
Resource and Energy Input
Energy (total)
296,521MWh(-10%)*1
Electric power
142,232MWh(-13%)*1
Gasoline
3,864kL(-15%)*1
City gas
3,826 thousand m3(-4%)*1
Hot water
2,110GJ(14%)*1
LPG
1,560t(9%)*1
District heat
1,954MWh(-2%)*1
LNG
804t(-1%)*1
Green electricity
19,114MWh(-6%)*1
Heavy fuel oil
206kL(-1%)*1
Solar power (internal)
518MWh(-3%)*1
Kerosene
59KL(-2%)*1
Solar heat (internal)
483GJ(0%)*1
Diesel fuel
897kL(-23%)*1
Chemical Substances
(PRTR Substances Handled) *Production sites in Japan only
40.4t(-5%)
Water(Total)
1,055 thousand m3(-11%)*1
Piped water
382 thousand m3(-27%)*1
Ground water
673 thousand m3(2%)*1
Raw Materials and Sub-Materials *Production sites in Japan only
Metals: Steel, aluminum, brass
Plastics: Optical plastics, ABS, PC, polyethylene, polypropylene
Office Supplies
Copy paper
167t(-21%)
Material Balance (FY2021)
Internal Energy Consumption
Renewable Energy Consumption
Breakdown of Internal Energy Consumption
CO2 Emissions/Basic Unit (Scope 1, 2)
CO2 Emissions (Scope 3 [Category 4 Upstream transportation and distribution])
CO2 Emissions for the Entire Supply Chain
NOx Emissions
SOx Emissions
Water Use
Wastewater
Emission/Landfill
Hazardous waste discharged
Emissions and Movements of PRTR Class 1-Designated Chemical Substances
Olympus Group Site Data
Environmental Conservation Costs
Environmental Conservation Effects
INPUT
26

Transportation Fuel
Transportation: Gasoline, diesel fuel, etc.
Packaging Materials (Total)
1,039t(-18%)
Cardboard
613t(-16%)
Paper
217t(-21%)
Plastic
180t(-20%)
Metal
0t(0%)
Glass
0t(0%)
Other
29t(-17%)
*1 Indexes certified by the Assurance Statement.
* Percentage change from previous year in brackets
Greenhouse Gases (Total)
90,656t-CO2e(-11%)*1
CO2 generated from energy
90,650t-CO2e(-11%)*1
CO2 not generated from energy
６t-CO2e(50%)*1
Substances Emitted
NOx
55t(-8%)
SOx
0.3t(0%)
Chemical Substances (PRTR substances emitted and transferred)*Production sites in Japan only
15.4t(-20%)
Discharge to Water Systems (Total)
1,055 thousand m3(-12%)
Water discharged (public waters)
547 thousand m3(11%)
Water discharged (sewage)
508 thousand m3(-26%)
BOD
1.6t(21%)
Discharge(Total)
5,647t(-19%)*1
Amount recycled
4,654t(-14%)*1
Other waste
993t(-38%)*1
Landfill
63t(-41%)*1
Hazardous waste
288t(-7%)*1
CO2 Emissions during Transportation(Total)
38,649t-CO2e(-17%)
Product Shipments
OUTPUT
27

Medical Business (Total)
2,253t(-19%)
Medical Business(Endoscopes)
1,243t(-12%)
Scientific Solutions Business(Microscopes)
792t(-6%)
Imaging Business(Digital cameras, Recorder)
218t(-60%)
*1 Indexes certified by the Assurance Statement.
* Percentage change from previous year in brackets
Internal Energy Consumption
FY2013
FY2017
FY2018
FY2019
FY2020
FY2021
Consumption(MWh)
338,854
328,197
348,925
328,371
328,974
296,521 *1
*1 Indexes certified by external assurance.
* Scope: The Olympus Group. However, small businesses are excluded. Conversion coefficient based on Enforcement Regulation for the Act on the Rational Use of Energy
Renewable Energy Consumption
FY2013
FY2017
FY2018
FY2019
FY2020
FY2021
Consumption(MWh)
9,369
15,705
16,110
17,882
21,754
20,612 *1
*1 Indexes certified by external assurance.
* Scope: The Olympus Group. However, small businesses are excluded. Conversion coefficient based on Enforcement Regulation for the Act on the Rational Use of Energy
* Renewable energy includes green electricity, solar power (internal), solar heat (internal) and hot water.
Breakdown of Internal Energy Consumption
(MWh)
FY2013
FY2017
FY2018
FY2019
FY2020
FY2021
Direct
City gas
42,816
45,375
52,437
51,776
50,009
48,155 *1
LPG
10,086
19,928
19,708
19,467
20,140
22,008 *1
LNG
15,655
13,127
12,627
11,707
12,305
12,190 *1
Heavy fuel oil
4,163
2,492
2,072
2,183
2,252
2,234 *1
Kerosene
505
574
548
612
614
601 *1
Diesel fuel
56,221
13,512
13,089
12,392
12,234
9,396 *1
Gasoline
17,720
33,213
42,844
45,899
43,814
37,139 *1
Subtotal
147,166
128,221
143,325
144,036
141,368
131,723 *1
Indirect
Electricity
180,051
182,165
187,345
164,458
163,852
142,232 *1
28

FY2013
FY2017
FY2018
FY2019
FY2020
FY2021
Hot water
324
687
682
597
701
797 *1
District heat
2,268
2,106
2,145
1,995
2,000
1,954 *1
Green electricity
8,700
14,423
14,763
16,576
20,338
19,114 *1
Solar power (internal)
168
479
497
536
533
518 *1
Solar power (internal)
177
116
168
173
182
183 *1
Subtotal
191,688
199,976
205,600
184,335
187,606
164,798 *1
Total
338,854
328,197
348,925
328,371
328,974
296,521 *1
*1 Indexes certified by external assurance.
CO2 Emissions/Basic Unit (Scope 1, 2)
FY2013
FY2017
FY2018
FY2019
FY2020
FY2021
Scope 1 (t-CO2e)
31,972
26,851
30,091
30,365
29,770
27,495 *1
Scope 2 (t-CO2e)
91,418
93,325
91,490
75,150
72,356
63,161 *1
Scope1+2 (t-CO2e)
123,390
120,176
121,581
105,515
102,126
90,656 *1
Basic unit of consolidated sale
(t-CO2e/¥100 million)
19.6
16.1
15.5
13.3
12.8
12.1
*1 Indexes certified by external assurance.
* Scope: The Olympus Group. However, small businesses are excluded.
* Reporting based on the following GHG Protocol scopes.
Scope 1: Greenhouse gas emission from direct use of fossil fuels.
Scope 2: Greenhouse gas emission from secondary use, such as electric power purchase.
CO2 Emissions (Scope 3 [Category 4 Upstream transportation and distribution])
29

FY2013
FY2017
FY2018
FY2019
FY2020
FY2021
Logistics (t-CO2e)
55,758
51,125
50,779
52,486
46,415
38,642 *1
*1 Indexes certified by external assurance.
CO2 Emissions for the Entire Supply Chain
Category
CO2 Emissions(t-CO2e)
FY2019
FY2020
FY2021
Scope 1
30,365
29,770
27,495 *1
Scope 2
Market-based method
75,150
72,356
63,161 *1
Location-based method
80,358
79,959
70,119 *1
Total
Scope 1+2 (Market-based method)
105,515
102,126
90,656
Scope 3
484,130
437,309
481,735
Total
Scope 1+2+3
589,645
539,435
572,391
Scope 3
CO2 Emissions(t-CO2e)
FY2019
FY2020
FY2021
1. Purchased goods and services
83,019
75,040
56,242
2. Capital goods
199,918
184,026
274,407 *1
3. Fuel- and energyrelated activities (not included in Scope 1, Scope 2)
10,819
10,760
16,214 *1
4. Upstream transportation and distribution
52,486
46,415
38,642 *1
5. Waste generated in operations
5,063
5,398
4,233 *1
6. Business travel
19,588
16,601
4,708 *1
7. Employees' commuting
13,811
13,867
12,480 *1
8. Leased assets (upstream)
-
-
-
9. Downstream transportation and distribution
-
-
-
10. Processing of sold products
-
-
-
11. Use of sold products
93,398
80,738
71,073
12. End-of-life treatment of sold products
2,057
2,889
2,265 *1
13. Leased assets (downstream)
-
-
-
14. Franchises
-
-
-
30

Scope 3
CO2 Emissions(t-CO2e)
FY2019
FY2020
FY2021
15. Investments
3,971
1,575
1,471 *1
*1 Indexes certified by external assurance.
NOx Emissions
FY2017
FY2018
FY2019
FY2020
FY2021
NOx Emissions (t)
64
67
60
60
55
* Scope: The Olympus Group. However, small businesses are excluded.
SOx Emissions
FY2017
FY2018
FY2019
FY2020
FY2021
SOx Emissions (t)
0.3
0.2
0.3
0.3
0.3
* Scope: The Olympus Group. However, small businesses are excluded.
Water Use
FY2017
FY2018
FY2019
FY2020
FY2021
Groundwater (thousand m3)
680
656
675
660
673 *1
Piped water (thousand m3)
589
623
518
522
382 *1
Total (thousand m3)
1,269
1,279
1,193
1,182
1,055 *1
Basic unit of consolidated sales (thousand m3/¥100 million)
0.17
0.16
0.15
0.15
0.14
*1 Indexes certified by external assurance.
* Scope: The Olympus Group. However, small businesses are excluded.
31

Wastewater
FY2017
FY2018
FY2019
FY2020
FY2021
Public water areas (thousand m3)
530
499
519
493
547
Sewage systems (thousand m3)
739
780
674
689
508
Total (thousand m3)
1,269
1,279
1,193
1,182
1,055
* Scope: The Olympus Group. However, small businesses are excluded.
Emission/Landfill
FY2017
FY2018
FY2019
FY2020
FY2021
Emission (t)
6,584
6,995
6,793
6,993
5,647 *1
Amount recycled (t)
5,475
5,681
5,439
5,390
4,654 *1
Other waste (t)
1,109
1,314
1,354
1,603
993 *1
Landfill (t)
129
150
100
107
63 *1
Basic unit of consolidated sales (t/¥100 million)
0.88
0.89
0.86
0.88
0.75
*1 Indexes certified by external assurance.
* Scope: The Olympus Group. However, small businesses are excluded.
Hazardous waste discharged
FY2017
FY2018
FY2019
FY2020
FY2021
Hazardous waste discharged (t)
263
273
317
311
288 *1
*1 Indexes certified by external assurance.
* Scope: The Olympus Group. However, small businesses are excluded.
32

Emissions and Movements of PRTR Class 1-Designated Chemical Substances
FY2013
(Base year)
FY2017
FY2018
FY2019
FY2020
FY2021
Chemical Substances (PRTR
substances) (t)
20.7
18
17.7
18.8
19.3
15.8
* Scope: Manufacturing and development sites in Japan
Olympus Group Site Data
Company/Facility
Location
CO2Location
Water used
Emission
Amount
recycled
(t-CO2e)
(thousand m3)
(t)
(t)
Japan
Olympus
Technology
Development
Center, Ishikawa
Facility
Hachioji-shi,
Tokyo
7,806
74
255
255
Technology
Development
Center, Utsugi
Facility
Hachioji-shi,
Tokyo
2,640
22
335
335
Technology
Development
Center, Takakura
Facility
Hachioji-shi,
Tokyo
344
3
6
6
Nagano Facility
Tatsuno
Tatsuno-machi,
Kamiinagun,
Nagano
16,039
367
465
461
Nagano Facility
Ina
Ina-shi, Nagano
2,019
16
82
78
Olympus
Medical
Systems
Hinode Plant
Hinode-cho,
Nishitama-gun,
Tokyo
1,118
5
49
49
Aizu Olympus
Aizu-Wakamatsu-
shi, Fukushima
14,112
228
452
420
Aomori Olympus
Kuroishi-shi,
Aomori
4,404
29
245
242
Shirakawa Olympus
Nishigo-mura,
Nishishirakawa-
gun, Fukushima
4,164
41
409
335
Olympus
Terumo
Biomaterials
Mishima Plant
Nagaizumi-cho,
Suntogun,
Shizuoka
1,319
7
13
8
33

Company/Facility
Location
CO2Location
Water used
Emission
Amount
recycled
(t-CO2e)
(thousand m3)
(t)
(t)
Research and
development
Center
Nagaizumi-cho,
Suntogun,
Shizuoka
24
0.03
2
1
Olympus Logitex
Sagamihara-shi,
Kanagawa
680
-
393
393
Americas
Olympus Corporation of the
Americas
Pennsylvania,
U.S.A.
10,310
1
314
314
Olympus Scientific Solutions
Americas Corp.
Massachusetts,
U.S.A.
947
15
199
81
Gyrus ACMI, Inc.
Massachusetts,
U.S.A.
2,796
17
478
265
Olympus
Surgical
Technologies
America
National Service
Center
California, U.S.A.
554
18
205
205
Europe/
Middle East
Olympus Winter & Ibe GmbH
Hamburg,
Germany
746
15
319
319
Olympus Medical Products Czech
spol s.r.o.
Olomouc, Czech
Republic
836
1
15
0
KeyMed (Medical & Industrial
Equipment) Ltd.
Essex, U.K.
912
25
324
273
Algram Group Ltd.
Devon, U.K.
42
2
106
74
Asia/
Oceania
Olympus (GuangZhou) Industrial
Co., Ltd
Guangzhou,
China
327
3
79
75
Olympus Trading (Shanghai) Limited
Shanghai, China
286
1
14
4
Olympus Vietnam Co.,Ltd.
Dong Nai Province,
Vietnam
11,329
140
738
385
Olympus Australia Pty Ltd
Victoria, Australia
294
1
45
18
Including Olympus Medical Systems
Environmental Conservation Costs
(Millions of yen)
Grouping
FY2019
FY2020
FY2021
Investment
Cost
Investment
Cost
Investment
Cost
Costs inside Business Area
104
236
292
376
244
368
Content
Prevention of Public Nuisance Cost
31
113
22
184
22
219
34

Grouping
FY2019
FY2020
FY2021
Investment
Cost
Investment
Cost
Investment
Cost
Global Environmental Conservation
Cost
73
3
240
40
213
37
Resource Circulation Cost
0
120
30
152
9
112
In Upstream Costs
0
109
0
149
0
230
In Downstream Costs
0
5
0
1
0
1
Environmental Management Activity Costs
0
355
0
345
4
308
R&D Costs
0
468
0
62
0
35
Costs of Social Activities
0
6
0
1
0
0
Costs for Damaged Environment
0
0
0
0
0
0
Total
104
1179
292
934
248
942
Target period: April 1, 2018-March 31, 2021
Scope: Head office functions, manufacturing companies and distribution companies in Japan
Note: 1) Tabulation based on "Environmental Accounting Guideline 2005." 2) Cost and depreciation that cannot be separated clearly in environmental management are not divided
proportionately. Bull amount has been excluded from the calculations.
Environmental Conservation Effects
Quantitative Effects of Environment Preservation
FY2019
FY2020
FY2021
Effects Inside Business Area
CO2 Emissions (t-CO2e)
57,021
55,949
54,691
Waste Discharged (t)
2,827
2,977
2,705
Water Usage (thousand m3)
819
804
792
Chemical Substances Transferred/Discharged (t)
19
19
16
Economic Benefits of Environmental Protection
Change from Previous Fiscal
Year
Revenue Benefits
Revenues from Sales of Valuable
Recycled Substances
0
Cost Savings
Energy Costs
-251
Costs of Water Usage
-8
Disposal Contracting Costs
-4
Target period: April 1, 2018-March 31, 2021
Scope: Head office functions, manufacturing companies and distribution companies in Japan
Note: 1) Tabulation based on "Environmental Accounting Guideline 2005." 2) Cost and depreciation that cannot be separated clearly in environmental management are not divided
proportionately. Bull amount has been excluded from the calculations.
35

Human Rights
Basic Approach and Policy
Olympus supports the United Nations Declaration of Human Rights, the ILO Declaration on Fundamental Principles and Rights at Work, UN Guiding
Principles on Business and Human Rights, and the 10 Principles of the United Nations Global Compact. To put international initiatives into practice in our
business activities, we have also clearly spelled out the respect for human rights in the Olympus Global Code of Conduct. In addition, we have formulated
the Olympus Group Human Rights Policy that stated implementation of human rights due diligence based on the UN Guiding Principles. We strive to respect
human rights in the management of our businesses. We also urge our customers and third parties which are promoting business activities with Olympus to
comply with the protection of human rights.
Initiatives
Initiatives with Suppliers
Olympus publishes "Global Standards: What Olympus Expects of Third Parties" to show its basic requirements to all the third-parties that support its
business activities. Olympus has also adopted the "Request to Suppliers," a document defining its expectations toward suppliers in such areas as respect for
human rights, compliance with laws, regulations and social norms, including the laws concerning the exclusion of antisocial elements, the prohibition of
corruption, bribery and similar behavior, the promotion of fair and equitable trading, and consideration for the environment. Once each year, we use a Web-
based system to conduct a corporate survey in this regard targeting major suppliers all over the world, and the survey results are utilized for work procedure
improvement to avoid problematic incidents (see page 43). There have been zero incidents so far. In cases where we find problems related not only to
compliance with local regulations and social norms but also respect for human rights in our on-site audits and if the supplier does not comply with Olympus's
request to make improvements, we may terminate our business with them.
Human Rights Due Diligence
Olympus participates in various research groups to verify and strengthen initiatives that target human rights issues within the Olympus Group.
Since 2017, we have been a co-managing member of the Human Rights Education Subcommittee of Global Compact Network Japan (GCNJ), whose
headquarters are at the United Nations Information Center (UNIC). Research has been conducted on themes aimed at a greater understanding of the UN
Guiding Principles on Business and Human Rights and a wider awareness among businesses, with the aim of developing a human rights educational tool
regarding the rights of women, persons with disabilities, LGBT and other gender minorities, child labor and foreigner in Japan that can be employed internally
by participating companies. In FY2020, we participated in the training program organized by GCNJ's Human Rights Due Diligence Subcommittee and is
using what was learned to reinforce our human rights due diligence activities described below.
In FY2021 we became a member of Business for Social Responsibility (BSR), a global organization offering support to businesses in the field of human
rights and sustainability, and we are reinforcing our global activities in the area of human rights due diligence in compliance with the principles set out by the
United Nations. In January 2021, a human rights impact assessment was conducted with support from BSR for the entire Olympus Group, including our
regional headquarters (for the Americas, Europe/Middle East/Africa, China and Asia-Pacific). The assessment was participated in by the senior management
in each region, including the managers of the business divisions and functions. Prior to the assessment, all members who participated in the human rights
impact assessment underwent training related to global trends in business and human rights. In FY2022, we plan to use the assessment findings to identify
the most important risks that affect our business activities and implement concrete measures to prevent and reduce risks. Employee training on human rights
and business will be organized concurrently, along with upgrading and expanding the scope of human rights due diligence for our suppliers and other third
parties.
Human Rights Policy
Request to Suppliers (PDF: 248.1KB)
Global Standards: What Olympus Expects of Third Parties
36

Preventing Harassing Behavior and Promoting DEI
The Olympus Global Code of Conduct states that "Our Behaviors" are the expression of "Our Core Values" through our day-to-day activities. The Code of
Conduct places the highest value on "Respectful Behavior." Olympus Group does not tolerate harassment or discrimination based on personal
characteristics such as gender, age, nationality, ethnicity, skin color, political views, sexual orientation, religious beliefs, social background, or disability.
Olympus makes every effort to prevent workplace harassment by itemizing concrete prohibitions on sexual and other types of harassment in the employment
regulations.
The Olympus Group has created an organization structure that includes its worksites outside Japan to prevent harassment of any kind and to resolve any
incidents that may occur swiftly and completely. Olympus and its Japan subsidiaries have also established a Harassment Hotline in each business site and
subsidiary as a preventive means and to provide a prompt and pertinent solution if a problem arises. Our Hotline officers are trained with the skills and
knowledge to handle complaints appropriately, which include the protection of the privacy of the consulter or harassment victim, ensuring consultation
confidentiality, and preventing any adverse consequences from the consultation. Since FY2019, we have delivered the Harassment Prevention Guidebook to
all employees of the Japan subsidiaries. In this guidebook, a description of gender minorities, such as LGBT, was also included. We keep up-to-date with the
expanding scope of harassment, which covers power harassment and gender harassment, including maternity, paternity, and LGBT issues. Accordingly, the
coverage of our internal consultation manual has been revised and enhanced. In June 2020, the so called "Power Harassment Prevention Act," which
stipulates that companies must take preventative measures regarding harassment, was enforced. In preparation for this and to avoid potential incidents we
provide an e-learning course to help employees to understand the key points of the law and what could be seen as power harassment.
We also hold regular harassment prevention training programs for managers (with 730 participants in FY2020—a 79% participation rate), who are
responsible for creating a culture of respect in the workplace, to widen their understanding and to ensure harassment-free offices.
To promote diversity, equity and inclusion (DEI), we have been organizing activities to support the empowerment of women, widen the employment of
persons with disabilities and to bring greater understanding and support for sexual minorities. A training system has been organized to improve the
empowerment of women, and several training programs have been organized to increase the appointment of women to managerial posts.
In Japan and the USA, on International Women's Day in March 2021 we held internal events that included lectures on women's career development by
internal and external experts and leaders (Participants: 604 in Japan, around 80 in the USA).
The group of eight special-purpose subsidiaries for the employment of people with disabilities achieved an employment rate of 2.6%, exceeding the statutory
employment rate of 2.3% raised in March 2021. In Japan subsidiaries, we also held training programs for officers involved in employing people with
disabilities to improve the number of people with disabilities we employ and to support their work.
We conducted a range of activities to widen the understanding of sexual minorities and provide support. Such activities included establishing a dedicated
consultation office, providing seminars to promote awareness, hosting an LGBT Week (an awareness-raising campaign through e-learning and videos) and
establishing a voluntary group called "LGBT ALLY." As a result of our efforts, we received a Bronze rating in PRIDE Index 2020, a Japanese index of a
corporation's performance in LGBTQ inclusion.
Response to the UK Modern Slavery Act
Olympus KeyMed, the Olympus Group company in the UK, has issued the statement in accordance with the provisions of Article 54, Clause 1, of the 2015
Modern Slavery Act in the UK.
Olympus UK and Ireland: Modern Slavery Statement (In English only) 
37

Product Responsibility
Basic Approach and Policy
In response to the growing social demand for high-quality and safe products and services, the Olympus Group is working to improve the quality and safety of
its products and services and provide reliable services that satisfy our customers.
Quality Assurance
The Olympus Group has established the Olympus Group Quality Policy based on its corporate philosophy. We continue to implement measures to instill
quality policy standards in our daily operations for all members to foster a mindset that emphasizes safety and quality.
Initiatives
Creating a Safety-and Quality-Oriented Corporate Culture
QARA function believes that it is essential for Olympus members to act with a mindset to always prioritize customers and patient's safety and security by
implementing activities to foster an organizational culture where it emphasizes safety and security of our customers and patients. One example is to provide
seminars to share case studies for both R&D and manufacturing members to let them realize that their daily work directs to the customers and patient's
safety.
Quality Management System
The Olympus Group has established the Olympus Group Quality Policy based on its corporate philosophy. We continue to implement measures to instill
quality policy standards in our daily operations for all members to foster a mindset that emphasizes safety and quality. The Olympus Group, with its Chief
Quality Officer (CQO) and QARA members of each region, review and improve their worldwide work processes. As a result, the Olympus Group business
divisions and subsidiaries have actively been obtaining and maintaining ISO 9001 or ISO 13485 certifications, the international quality control standards.
Based on the global management rules revised in fiscal year 2021, QARA members regularly report to executive officers and CQO who are top of quality
and regulatory functions, to clarify companywide issues. In addition, we conduct group internal quality audits aimed at monitoring the status of each quality
management system from an objective perspective to get hold of the status of each organization to promote improvement.
Appropriate Communication
In order to comply with the Laws concerning environmentally related substances for Olympus Group Products and to reduce environmental impact, we
collect information on handling of environmentally related substances and trends in laws and regulations in each country, As a consequence, we have
established the "Standards for management of environmentally related substances" in our group products, and publish them on the website.
Quality Assurance
Creating a Safety-and Quality-Oriented Corporate Culture
Quality Management System
Appropriate Communication
Valuing Bioethics in Evaluating Product Efficacy and Safety
Improvement of Sales/After-Sales Service Quality, Basic Approach
Promotion Structure and Initiatives in the Medical Business
Promotion Structure and Initiatives in Scientific Solutions Business
Olympus Group Quality Policy
(Case 1)
38

Olympus offers advanced information on endoscopes, and diagnostic test using endoscopes and techniques through a membership website for medical
professionals. Medical safety information, such as corrective actions, recall letters regarding Olympus equipment and warnings are available to non-
members to ensure greater transparency.
Valuing Bioethics in Evaluating Product Efficacy and Safety
Olympus and its Japan subsidiaries may conduct animal research to develop medical equipment, assess product efficacy and safety, and promote the
correct usage of the products. We are keen to ensure that the research we carry out is ethical from both the scientific and animal welfare viewpoints,
because we value the lives of animals.
Olympus and its Japan subsidiaries introduced their animal research corporate rules based on the Act on Welfare and Management of Animals, Basic
Guidelines for Animal Research in Institutions under Management of the Ministry of Health, Labour and Welfare and other related laws and guidelines. We
established the Institutional Animal Care and Use Committee (IACUC) based on the animal research corporate rules to rigorously review all our animal
research plans and ensure that they are based on the 3Rs of animal testing —Replacement (of animal testing with alternative methods), Reduction (of the
number of animals to be used), and Refinement (of the testing method to minimize animals' suffering).
We are committed to the ethical and humane handling of the animals used in our research, paying extra attention to their physical and psychological
wellbeing. Self-inspections are also conducted, verifying our compliance with the research corporate rules for animal research. Our practice is accredited
under the Accreditation of Laboratory Animal Care and Use by the Japan Pharmaceutical Information Center.
Improvement of Sales/After-Sales Service Quality, Basic Approach
To implement a customer-centric approach and a constant quest for quality under the Olympus Group Quality Policy, the Olympus Group regularly monitors
customer satisfaction in each of our activities, from sales to after-sales service, and provides feedback on our activities during and after sales to improve the
quality of our operations. Especially in the medical area, we are working to provide a safe and reliable healthcare environment for our customers.
Specifically, we are contributing to greater efficiency in medical care at medical institutions, including communicating important information to customers,
providing training on the appropriate use of our products, maintenance services and prompt recovery and repair services for our products.
Promotion Structure and Initiatives in the Medical Business
Olympus seeks to improve the customer experience of doing business with Olympus, while also improving our commercial efficiency and meeting operating
income goals. Olympus' Vision is to evolve our customer engagement model in a comprehensive manner to respond to rising expectations in the medical
device industry.
Global
Call centers located in major cities are set up with dedicated teams to handle medical equipment and troubleshoot, providing a
detailed response suited to each region. (Japan, United States, China, etc.).
Major medical devices are installed in the call centers so we can provide accurate support for inquiries (Japan, United States,
China, etc.).
(Case 2)
"Medical Town," a membership website for medical professionals in Japan (Only in Japanese)
Control of Chemical Substances Used in Products
Medical safety information in Japan (Only in Japanese) 
Important Customer Information in the USA 
Initiatives to improve sales activities
Customer Response
Call centers
39

Japan
Global
The "Olympus Continuum," a comprehensive training platform providing medical professionals with training in medical products
and skills, has been introduced to provide training adapted to the skill level of the medical professional and to further enhance
patient value. In addition to the existing hands-on group training programs that have been organized for medical professionals,
we provide integrated online training and programs that combine preliminary study and post-training study effectively.
Japan
Running Medical Town, a membership website that offers up-to-date information on medical endoscopes and related medical
treatment for healthcare professionals.
Response to
COVID-19
pandemic
USA
Holding webinars covering infection prevention measures during endoscopy cases, contact information for
relevant authorities, customer letters, COVID-19 Q&As etc. Customers can also register themselves to receive
updates by following a link on the website.
Europe
Publishing information about infection prevention measures, endoscope reprocessing procedures, equipment
handling cautions against COVID-19 (tutorial videos), etc. The website also offers PDF files in 10 different
languages that show the above information and a list of relevant contacts for our customers.
Japan
Publishing COVID-19 FAQs and other related information through our membership website, Medical Town
We offer a prompt repair service at each of our repair service centers. To minimize downtime at customers' site, we handle repair service orders as quickly
as possible and also respond to customers' requests for loaners during repairs appropriately.
Repair service network
Running Endoscopes Customer Support Center, a call center dedicated to providing an information service for healthcare
professionals.
The call center operations are continuing during the COVID-19 pandemic through remote working to support healthcare
professionals. The immediate telephone connection rate has stayed at 95% or more, which is the same level as pre-COVID-
19 .
Introducing advanced technologies such as AI to improve quality of response.
Immediate hybrid response system based on coordination and interaction between call centers and Olympus sales/service
personnel or authorized distributors in various areas.
Initiatives to share the content of call center inquiries inside the company for the purpose of product and service
improvements.
Our innovative initiatives have won the recognition of the call center industry and led to us winning the Operation Category
Award in Center of Excellence 2020 sponsored by a monthly magazine called Call Center Japan.
Enhanced information on the corporate website
Safe handling of our devices
Training
Lectures on how to use, maintain and manage our products.
Training on how to prevent problems offered to customers who have service contracts, tailored to their actual situation and the types of problems that
have occurred.
Customer support by field service staff
Engineers and technical staff with specialized skills are deployed to enable prompt response to problems and maintenance requests.
Providing preventive maintenance to ensure that equipment stays in good condition.
In case of a problem, dedicated technical staff respond promptly for troubleshooting and quick recovery.
Repair service
40

Major repairs* (Repairs in need
of overhaul)
Overseas
Service centers in the United States, Germany, France, Czech, Portugal, United
Kingdom, Russia, China, Singapore, India, etc.
Japan
Medical Equipment Service Operation Centers located in Shirakawa and Nagano
Minor repairs (to endoscopes and peripherals)
Available through a worldwide network of approx. 150 repair sites
Response in case of a natural disaster
Multiple service centers are operated in each region, in order to be able to offer
uninterrupted repair service even in case of an earthquake or other natural disasters.
* Repairs in need of overhaul
Offering multiple maintenance contracts globally in accordance with the product characteristics or the regional situations and demands.
Promotion Structure and Initiatives in Scientific Solutions Business
Global
New customer support through websites and blogs
In response to the spread of COVID-19, we started customer
support activities through websites and blogs. We set up specific
COVID-19 pages, and started offering a range of information
and services, including virtual demonstrations through a video
conferencing system and webinars.
Japan
Call Center
Running Customer Support Center to solve customers' problems
in using our products
Technical assistance
USA
Expanding training opportunities
In addition to training programs for customers in the safe use of
Olympus products, a program has been created to train
nondestructive inspection engineers. In 2019, we donated
Olympus nondestructive inspection devices to a university in
Pasadena, Texas, known prominently for its ties with the
petroleum industry and provided trainings for their use because
these products are widely used in the inspection of petroleum
pipelines, etc.
Europe
Olympus Academy activities
Manned by specialist staff, the Olympus Academy provides
training in products and applications for subsidiaries and sales
distributors in various countries. Product and application
seminars are then held for customers by the subsidiaries and
sales distributors that have undergone such training themselves.
Providing repair services at the same high level at service sites across the world.
The following services are provided at manufacturing sites, service sites, sales subsidiaries and contracted agents around the world.
Microscopes
Back-to-base repairs, on-site repair services, function inspections, calibration, service contracts, delivery
installation
Industrial endoscopes
Back-to-base repairs, function inspections, service contracts
Service contracts
Customer Response
Running the Olympus Techno Lab for customers to
experience our products and evaluate their performance
Holding Microscope Training Program for customers to learn
how to use the product correctly
Repair system
41

Non-destructive testing
devices
Back-to-base repairs, on-site repair services, function inspections, precision calibration
X-ray analytical systems
Back-to-base repairs, function inspections
Back-to-base repair
services
Transportable products and those that may require extensive repairs are shipped to and repaired at service sites
across the world.
On-site repair services
For installation-type products, technical staff is dispatched to provide on-site services, including repairs, calibration and
maintenance inspections.
Service contracts
Offering multiple maintenance contracts depending on the product.
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
Medical business
142,279
138,878
124,736
140,074
129,079
115,027
Scientific Solutions business
18,127
17,733
17,864
16,604
18,276
14,740
* In Medical Business, the number of calls only by telephone until FY2018 and includes inquiries through website in/after FY2019.
Main service contents
Reference Information
Calls Received at Customer Support Centers (Japan)
42

Procurement
Basic Approach and Policy
The Olympus Group aims to strengthen supply chain management (SCM) within the context of business continuity and sustainable value creation. In June
2021, we replaced our procurement policy with a supply chain policy in line with our ESG (the environment, society and governance) initiatives to contribute
to sound and fair transactions and the sustainable development of society. In addition, we formulated the Olympus Group Green Procurement Standards,
which set out our basic environmentally conscious approach to procurement. Since then, the Olympus Group has disclosed its basic stance on supply chain
both internally and externally through its website and training sessions, while strengthening compliance with laws, regulations and social norms. We have
also established the "Request to Suppliers" as a concrete guideline for complying with laws, regulations and social norms, including respect for human rights
and the elimination of antisocial forces, prohibiting corruption and bribes, promoting fair and lawful transactions, and taking the environment into
consideration. When selecting new suppliers, we review their current response to compliance with social norms and environmental issues as one of our
screening criteria.
Based on these principles for procurement activities, the Olympus Group strives to create and strengthen good relationships with its suppliers through fair,
just, and transparent transactions.
System, Mechanisms and Initiatives
Sharing Business Strategies and Supply Chain Policy
Olympus is sharing the business strategies and procurement policy of the Olympus Group with our suppliers. Once a year, we hold the Supply Chain Policy
Meeting with key suppliers extracted from our business condition, etc. among approximately 1,000 suppliers for each business in Japan.
In FY2021, we canceled onsite meetings with suppliers due to the circumstances around COVID-19 and are planning to hold online meetings in future.
Supplier Survey and Improvement Activities
Once a year, Olympus conducts a web-based survey of its major suppliers around the world with whom we have ongoing business in Japan. The survey
covers 121 questions, of which 24 are related to CSR, related to management information, CSR initiatives, and business continuity plans (BCPs).
In FY2021, survey was conducted on 826 companies, including overseas suppliers. Responses were received from about 87% of companies. If the survey
results show that a supplier does not satisfactorily comply with legal and social norms as well as environmental protection and needs to improve, an onsite
audit is conducted, and they must implement corrective actions in order to meet the points listed in our Request to Suppliers. At the same time, wherever
possible, we recommend self-improvement actions to prevent the risk of incidents. We conduct studies for risk assessment in collaboration with concerned
divisions within the Group.
Evaluation
Criteria Details
Management information
Corporate information, Financial condition
CSR
Compliance with laws, regulations and social norms
Protection of human rights (child labor, forced labor, inappropriate low-wage labor)
Protection of worker rights (labor standards, occupational safety and health)
Protection of the environment (CO2 emissions, waste discharged, water usage, environment-related chemical
substances)
Personal and confidential information protection, Intellectual property protection
Procurement
Key Evaluation Items in Supplier Survey for Initiatives with Suppliers
43

BCP
Business continuity strategy, Manufacturing site information,
Contact information during emergencies and disasters,
Confirmation of supply chain, Confirmation of employee safety
Environment and quality
Acquisition of ISO 14001, ISO9001 and ISO 13485
Procurement and process management (5Ms (materials, methods, measurement, machinery, manpower), change
information, noncompliant treatments)
Delivery/Cost
Production plans, Progress and distribution management, cost reduction activities
System
Computer security
Response to Conflict Minerals
One of the effects of the continuing civil war in the Democratic Republic of the Congo (DRC) has been the use of minerals, including tantalum, tin, tungsten
and gold, mined in the DRC and neighboring countries to raise funds for armed groups. For many years, this practice has resulted in human rights violations,
including child labor, sexual violence and environmental damage. In July 2010 the United States sought to cut off this supply of funds to armed groups by
introducing an amendment to its financial regulation law defining these four substances as conflict minerals. Companies listed in the United States that use
conflict minerals are now required to submit reports to the U.S. Securities and Exchange Commission (SEC). Other moves by international organizations,
governments, NGOs and industry organizations to solve this problem include the publication of the Due Diligence Guidance for Responsible Supply Chains
of Minerals from Conflict-Affected and High-Risk Areas by the Organization for Economic Cooperation and Development (OECD). 
The Olympus Group upholds international efforts to resolve the problem of conflict minerals. On behalf of the Olympus Group, Olympus participates in a
committee established by the Responsible Minerals Trade Working Group of the Japan Electronics and Information Technology Industries Association
(JEITA). Working together with suppliers, such as by discussing the conflict minerals at procurement policy meetings, we ensure transparency in our supply
chains and continue the procurement of parts and materials that does not cause human rights violations.
Education for Adhering to the Subcontract Act
The Subcontract Act is regarded as one of the important applicable laws by Olympus, and Olympus engages in a wide range of activities to ensure
compliance. The participation rate for the Subcontract Act e-learning programs for all employees of Olympus and its Japan subsidiaries has reached 99.5%.
Following the establishment of the Subcontractor Act Promotion Committee in FY2020, we are reinforcing the Olympus Group's compliance with the act and
are providing internal workshops as a part of such efforts. Due to the COVID-19 pandemic, we moved from the conventional group workshops for
manufacturing divisions to an online program in FY2021. A total of 504 employees participated in the program to deepen their understanding of the
Subcontractor Act.
We will continue to confirm group-wide compliance and organize training programs to enhance our observation of the Subcontract Act.
44

Employment
Basic Approach and Policy
The Olympus Group published the Olympus Global Code of Conduct to define the ethical standards for the actions that all group members always act in a
manner. We place the highest value on "Respectful Behavior." Under the Code of Conduct, we clearly declare that we do not allow harassing behavior or
discrimination based on personal characteristics like gender, age, nationality, ethnicity, skin color, political views, sexual orientation, religious beliefs, social
background or disability. "Show appreciation for diversity of people, views, and work styles" and "Never discriminate against job candidates or employees"
are two examples of "What we do". With these basic codes of conduct fully implemented, we provide all employees with equal opportunities to fulfill their
potential and improve their abilities as well as opportunities to work, develop their abilities and gain promotion according to their level of competency.
In April 2019 we introduced a corporate transformation plan Transform Olympus, a global-scale human resources development system that serves as the
basis for our global employees to follow our Corporate Philosophy (Our Purpose and Our Core Values), and to encourage each employee to take on
ambitious challenges for personal growth. Under our transformation plan, we will assign employees in the most efficient way without regard to nationality or
gender to encourage our diverse human resources to work effectively. Especially in Japan, we plan to expand the use of our "job-based" personnel system,
starting from Olympus. This allows the company to assess individual employee's performance and reward their achievements in a fairer manner with the
conventional Japanese style "membership" personnel system, in which the employee's years of service and age are given greater account in their career
assessment. The job-based system should also provide a way for employees to pursue their expertise and aim at further career advancement.
Promotion Structure
In the Olympus Group, the President is ultimately responsible for our strategy for human resources including human resource development and labor
management, while the senior executive officer in charge of employment and labor issues implements our group-wide human resource strategy through the
functions of the HR division at the headquarters.
We are implementing measures to ensure that we follow labor-related regulations in the various countries in which each subsidiary and division operate in
compliance with the Group's human resource strategy to ensure diversity in human resources for optimal business management.
Olympus and its Japan subsidiaries are sometimes located in one facility. Each facility has its own general manager to ensure comprehensive
implementation of policies and measures involving personnel and labor issues.
Basic Approach and Policy
Promotion Structure
Initiatives
Employee-Related Data
Human Rights Policy
Organization of Human Resource Strategy Promotion (Olympus and its Japan subsidiaries)
45

Initiatives
Recruitment in FY2021
Olympus hired 90 employees (only full-time employees) in FY2021, down by 73% over the previous year. Of these, mid-career employees accounted for
37% of the total.
Also, the hiring of women was actively promoted in line with the Act on Promotion of Women's Participation and Advancement in the Workplace, and the
percentage of female employees increased by 7.9% to 36.6%.
Employment of People with Disabilities
Olympus proactively works to employ people with disabilities (physical, mental, and intellectual), and after recruitment, they work in a wide range of fields,
including general administration and engineering fields that include manufacturing technology and IT development. Established in April 2009, our special-
purpose subsidiary* Olympus Support Mate is now in its twelfth year of the foundation and hires essentially persons with intellectual disabilities. We have
created working environments and working conditions that are appropriate both for the nature of each individual's disabilities and the operational
requirements required to ensure that they can continue to work there. Following Aomori Olympus and Aizu Olympus, Shirakawa Olympus created a cleaning
service group of Olympus Support Mates in April 2021, to provide jobs and fulfilling lives for persons with disabilities in the local communities. We also
started an office chair cleaning business to maintain comfortable working environments in our business sites. As of April 2021, eight companies in the
Olympus Group achieved a combined employment rate of 2.6%, exceeding the statutory rate of 2.2%. Olympus Terumo Biomaterials employs an athlete who
aspire to participate in the Paralympic Games and actively supports their activities.
* Special-purpose subsidiary
A subsidiary approved by the Minister of Health, Labour and Welfare under the provisions of Article 44 of the Act on Employment Promotion, etc., of Persons with Disabilities as
an organization that gives special consideration to the employment of people with disabilities and is deemed as one of the business offices of its parent company.
Employment of the Elderly
Olympus and its Japan subsidiaries have a system to continue employing employees who want to work for the Company after reaching the retirement age of
60 until they become 65 years old.
In FY2021, 113 people qualified for the system, and 100% of the employees requesting continued employment were hired accordingly.
Employee-Related Data
Consolidated companies
(As of March 31, 2021)
Name of segment
Number of employees (persons)
Endoscopic Solutions Business
14,243 (389)
Therapeutic Solutions Business
7,269 (179)
Scientific Solutions Business
3,551 (169)
Others
608 (30)
Headquarters Administration Department
5,982 (368)
Total
31,653 (1,135)
46

*1 The number of employees indicates the number of people who are currently employed.
*2 It does not include the number of the employees seconded to a non-group company but contains the number of the employees seconded to a group company. The yearly
average number of temporary employees is recorded in parentheses ( ), which is excluded from the number of employees.
*3 Since the Company has transferred the Imaging Business in the fiscal year under review, it is excluded from the segments above.
*4 Since the fiscal year under review, the calculation method of the Headquarters Administration Department has been changed.
*5 The number of employees includes the retirees who utilize career support for external opportunity.
Olympus and its Japan subsidiaries
Olympus
Corporation
Overall Japan
Subsidiaries *1
Number of employees (As of the end of March 2021) (persons)
4,775
8,792
Breakdown
Full-time employees
Total*5
4,232
6,808
Men
Men's total
3,473
4,866
20s and younger
390
1,169
30s
800
1,455
40s
1,025
1,264
50s or older
1,258
978
Women
Women's total
759
1,942
20s and younger
132
729
30s
254
632
40s
272
435
50s or older
101
146
Excluding full-time employees
Total
543
1,984
Men
Men's total
252
1,176
20s and younger
38
229
30s
58
339
40s
73
289
50s or older
83
319
Women
Women's total
291
808
20s and younger
31
146
30s
58
280
40s
107
266
50s or older
95
116
Number of employees
47

Olympus
Corporation
Overall Japan
Subsidiaries*1
Number of senior management Total(persons)
193
141
Breakdown
Men
189
141
Women
4
0
Rate of women in senior management for direct divisions(%)
4.3
-
Number of junior management Total(persons)
896
454
Breakdown
Men
844
440
Women
52
14
Number of foreign employees Total(persons)
35
17
Breakdown
Men
17
10
Women
18
7
Olympus
Corporation
Overall Japan
Subsidiaries*1
Number of newly employed (FY2021) (persons)
53
460
Men
30s and younger
20
233
40s and older
9
11
Women
30s and younger
12
167
40s and older
12
49
Rate of newly employed*2 (%)
1.11
5.23
Breakdown
Men
30s and younger
1.56
7.30
40s and older
0.37
0.39
Women
30s and younger
2.53
9.35
40s and older
2.09
5.09
Number of new graduates (persons)
35
-
Percentage of employees with disabilities (As of the end of March 2021)*6
2.63
-
Number of employees with disabilities (persons)
106
187
Number of reemployed retired workers*7 (persons)
289
165
Employee composition
Recruitment
48

Olympus
Corporation
Overall Japan
Subsidiaries*1
Job retention rate (Only full-time employees)*3
87.02
89.31
Breakdown
Men
88.54
90.86
Women
82.35
87.50
Job retention rate for new graduates*4 (%)
95.63
90.78
Breakdown
Number of new graduates (FY2019) (persons)
252
206
Number of those who remain the company as of March 2021. (persons)
241
187
Number of staff leaving (FY2021) (persons)
628
294
Breakdown
Of which number of voluntary leavers
275
223
Men
30s and younger
41
84
40s and older
203
75
Women
30s and younger
6
44
40s and older
25
20
Olympus
Corporation
Overall Japan
Subsidiaries*1
Number of employees taking childcare leaves*8 (persons)
124
237
Breakdown
Men
29
35
Women
95
202
Work-at-home system users*9 (persons)
4,775
6,007
Breakdown
Men
3,725
4,537
Women
1,050
1,470
Average overtime hours (hours/fiscal year)
78.9
71.9
Average number of paid holidays actually taken (days/fiscal year)
11.4
10.4
*1 The following 14 companies: Olympus Medical Science Sales, Nagano Olympus, Aizu Olympus, Aomori Olympus, Shirakawa Olympus, TmediX, Olympus Digital System
Design, Olympus Terumo Biomaterials, Olympus Memory Works, Olympus Logitex, Olympus-Supportmate, AVS, Olympus Systems, and Olympus RMS.
*2 Includes both new graduates and midcareer employment.
*3 The percentage of those who remain in the company as of March 31, 2021, out of those employed in FY2019 (including new graduates and mid-career employment).
*4 The percentage of those who remains in the company at March 31, 2021 out of those employed as new graduates in April 2018.
*5 Including on-loan in the Group.
*6 Eight special-purpose subsidiaries (Olympus, Olympus Medical Systems, Olympus Medical Science Sales, Nagano Olympus, Aomori Olympus, Shirakawa Olympus, Aizu
Olympus, Olympus- Supportmate)
Job retention rate and Number of staff leaving
Work-Life Integration
49

*7 Number of reemployed retirees.
*8 Taken in FY2021.
*9 Measures to prevent the spread of COVID-19 and work restriction were implemented this fiscal year, and so many employees used the work-at-home system temporarily.
* Figures are for full-time employees unless otherwise stated.
50

Labor Relations
Basic Approach
The Olympus Group values protection of the rights of individual employees in order to offer better value to society. We implement appropriate measures
based on human rights viewpoints and the labor-related laws of each country.
The Olympus Group Human Rights Policy supports respect for the rights of the worker as set out in the ILO Declaration of Human Principles and Rights in
Labor and the Group pledges to implement these principles in its companywide management and daily business activities.
Initiatives
Global Employee Survey for the Improvement of Employee Engagement
We conduct an employee survey called the Core Values Survey for about 35,000 Olympus Group employees in 43 countries biannually and use the results
to improve our corporate culture and workplace environment. The findings are shared by top management and regional management officers and reflected in
various measures and policies. In particular, we are taking action to develop an open corporate culture, reform working styles and improve operational
efficiency. We have also introduced systems that allow leave for volunteer activities and permission for side jobs.
Labor-Management Consultations (Japan)
The Olympus top management provides regular opportunities to engage in labor management consultations, both centrally and at individual facilities, such
as during its twice-annual Central Labor-Management Council with the Olympus Labor Union. Such councils serve as a forum for discussing improvements
in labor conditions and corporate culture reforms. 
In the FY2021, labor-management talks confirmed that we would continue discussions on working styles in place during the COVID-19 pandemic and on
human resource management systems in general. We also postponed an increase to the basic salary of union members.
As of April 1, 2021, 5,385 employees (other than management) were members of the labor union, which covers 76% of all employees.
Human Rights Policy
51

Occupational Safety and Health
Occupational Safety and Health
The Olympus Group has stated its policies on occupational safety and health and its basic approach to employee health management and the actions
necessary to achieve them in the Olympus Global Code of Conduct.
Under the Code of Conduct, we are developing working environments that ensure safety and health for our employees.
Occupational health and safety is a major priority. We take proactive steps to prevent accidents and occupational illnesses at work. We want our employees
to work in an ergonomic and work-friendly environment. At Olympus, we promote good health and wellness.
Establishing the Environmental Health and Safety Policy to practice the Code of Conduct, we are developing working environments that ensure safety and
health for our employees.
Promotion Structure and Initiatives
Global Safety and Health Organization
The Olympus Group is promoting a global safety and health organization led by top management, as shown below. Based on the Environmental Health and
Safety Policy, we set out an annual EHS action plan and disseminated it throughout our global sites. We keep up on the safety and health activities and the
status of industrial accidents in each region through regular assessments to ensure group-wide implementation of safety and health activities and the risk
reduction structure.
Occupational Safety and Health
Global Safety and Health Organization
Industrial Accident Data
Regional Activities
Olympus Global Code of Conduct　
Safe and Healthy Workplace
What We Do:
Use good judgment and act in a manner that is safe for you and others.
Report safety concerns and work-related injuries or illnesses.
Never joke about violence and report any violent threats or warning signs from others.
Comply with applicable health and safety regulations.
Environmental Health and Safety Policy　
52

For the maintenance and continual improvement of our occupational safety and health management systems and to retain the trust of our customers and
stakeholders, we are acquiring certification for our occupational safety and health management systems. Shirakawa Olympus (Japan), KeyMed (Medical &
Industrial Equipment) Ltd. (UK) acquired ISO 45001 certification in FY2021.
Sites
Certification
Year of Certification
Aizu Olympus
JISHA OSHMS Standards*1
2011
Shirakawa Olympus
ISO 45001
2020
Aomori Olympus
JISHA OSHMS Standards*1
2009
Olympus Scientific Solutions Americas Corp.
OHSAS 18001
-
KeyMed (Medical & Industrial Equipment) Ltd.
ISO 45001
2020
Olympus Iberia S.A.U.
OHSAS 18001
-
*1 ISHA OSHMS Standards Certification: Certification bodies certify sites that comply with the JISHA OSHMS Standards certification conducted by the Japan Industrial Safety &
Health Association.
Industrial Accident Data
Starting in FY2020, the tabulation and analysis of data on industrial accidents has been expanded to cover major sites in the Olympus Group (North America
& manufacturing sites and repair bases; regional headquarters in Europe and its manufacturing and repair bases; and manufacturing sites and repair bases
in Asia).
The scope of the data on industrial accidents is as follows.
Japan: FY2017 & FY2018 for Olympus Corporation and its 11 major Japan subsidiaries
FY2019, FY2020 & FY2021 for Olympus Corporation and its 14 major Japan subsidiaries
Americas: Olympus Corporation of the Americas (regional headquarters) and its major subsidiaries
Europe: Olympus Europa SC & Co. KG (regional headquarters) and its major subsidiaries
Asia/Oceania: Major manufacturing sites
External Certification (Occupational Safety and Health Management Systems)
Number of Industrial Accidents
53

FY2017
FY2018
FY2019
FY2020
FY2021
Japan
55
64
50
56
35★
Americas
-
-
-
55
26★
Europe
-
-
-
20
47★
Asia/Oceania
-
-
-
10
13★
Total
-
-
-
141
121★
★Indexes certified by external assurance.
FY2017
FY2018
FY2019
FY2020
FY2021
Japan
11
10
6
4
2★
Americas
-
-
-
20
4★
Europe
-
-
-
6
16★
Asia/Oceania
-
-
-
8
6★
Total
-
-
-
38
28★
★Indexes certified by external assurance.
FY2017
FY2018
FY2019
FY2020
FY2021
Japan
0.39
0.34
0.20
0.13
0.08★
Americas
-
-
-
1.93
0.39★
Europe
-
-
-
1.07
2.04★
Asia/Oceania
-
-
-
0.77
0.62★
Overall
-
-
-
0.66
0.52★
All industries (Japan)*3
1.63
1.66
1.83
1.80
1.95
Manufacturing industry (Japan)*3
1.15
1.02
1.20
1.20
1.21
★Indexes certified by external assurance.
*2 Lost time injury frequency rate = number of lost time accidents ÷ (average number of employees for that fiscal term × work hours) × 1,000,000
*3 Survey on Industrial Accidents, Ministry of Health, Labour and Welfare
Number of Lost Time Injuries
Lost Time Injuries (of one day or more) Frequency Rate*2 (LTIFR)
Occupational Illness Frequency Rate*4 (OIFR)
54

FY2017
FY2018
FY2019
FY2020
FY2021
Japan
0.07
0.07
0.07
0
0★
★Indexes certified by external assurance.
*4 Occupational illness frequency rate = number of cases of occupational illness that result in lost time*5 ÷ (average number of employees for that fiscal term × work hours) ×
1,000,000
*5 Industrial accidents found in the list of occupational diseases of the Ministry of Health, Labour and Welfare (Appended Table 1-2 of the Ordinance for Enforcement of the Labor
Standards Act (Ordinance of the Ministry of Health and Welfare No. 23 of August 30, 1947))
FY2017
FY2018
FY2019
FY2020
FY2021
Japan
0
0
1
0
0★
Americas
-
-
-
0
0★
Europe
-
-
-
0
0★
Asia/Oceania
-
-
-
0
0★
Total
-
-
-
0
0★
★Indexes certified by external assurance.
To raise employee awareness of safety and health, the Olympus Group implements a variety of safety and health training programs, led by the safety and
health officers at each facility.
Region
Contents
Japan
Americas
Europe
Mental health workshop (October 2020, and February and March 2021)
China
Number of Fatal Industrial Accidents
Employee Training
Basic training (for all employees)
1.
Group-wide training
Safety and health e-learning training (12,692 in July 2020)
(1)
Infectious disease e-learning training (12,659 in October 2020)
(2)
Mental health training
(3)
Training at each facility and subsidiary
Basic safety and health training for new employees (58 in April 2020)
(1)
Safety awareness refresher training
(2)
Firefighting & evacuation training
(3)
Specialized training (for employees in designated workplaces)
2.
Hazard awareness (near-miss) training: Safety Dojo (Training Center)
(1)
Risk assessment workshop for safety and health promoter (101 participants)
(2)
Safety and health online training program (monthly, 2,187 participants)
1.
Environment health and safety training session (October 2020)
2.
Safety and health online education program (August, October, and December 2020)
1.
Chemical leakage emergency drill (June 2020)
2.
Fire evacuation route instruction and evacuation training (November and December 2020)
3.
55

Region
Contents
Asia/Oceania
Regional Activities
In line with our Occupational Safety and Health Management Rules, we have established a Safety & Health Promotion Committee in Japan. The Committee
consists of representatives of the safety & health promotion committees at each business site and plans activities that help to achieve our safety and health
activity plan. We are working on initiatives to improve our current safety and health management system, establish a risk management based on risk
assessment and introduce more employee training and education to raise awareness.
Shirakawa Olympus Co., Ltd. and the Shirakawa Facility of Olympus Corporation have been operating their occupational safety and health system under the
OHSAS 18001 standard. 
With ISO 45001 coming into effect, we have clarified our management's commitment to the health and safety system and are working to make it into a
system in which all employees can participate. We acquired ISO 45001 certification in December 2020 after an audit conducted online due to the impact of
COVID-19. We are introducing initiatives to create a workplace environment where all employees can work with safety through continuous improvements in
safety and health.
Industrial accidents occur when unsafe conditions in the workplace coincide with unsafe human behavior. Until now, the Olympus Group has focused on
reducing hazards that were founded on unsafe conditions in the workplace. Our current training focuses on unsafe human behavior, a characteristic of our
manufacturing sites at Aizu Olympus, Aomori Olympus, Shirakawa Olympus and Nagano Olympus. We provide training programs that use simulation. The
simulation programs enable employees to experience "entanglement"—the hazard of getting their fingers or clothing entangled in a machine, and "stabbing"
using a simulated hand—the danger of a screwdriver slipping when components are not fixed in place.
Health and safety special education (total 644 participants)
1.
Fire drill for dormitory residents (Approx. 600 participants)
2.
Chemical or radiation leakage emergency drill
3.
Workshop on mental health and flexible working in the COVID-19 pandemic
4.
Online education on safety and health in remote working
5.
Activities in Japan
Shirakawa Facility
Transition from OHSAS 18001 to ISO 45001
Hazard Awareness Training
56

We consider risk assessment to be one of the most important initiatives in promoting safety and health. To improve the effectiveness of our risk assessment,
we invited an external expert to give an online training program for officers responsible for safety and health, and 101 people participated. We conducted
interactive role-playing sessions on how to identify sources of danger and how to carry out a risk assessment.
At Olympus Corporation of the Americas, all the employees and locations are encouraged to report all incidents where an injury or illness could have
occurred but fortunately did not result in injury or illness. The corrective actions resulting from these incidents will assist in preventing an injury or illness to
other employees.
Olympus Europa SE & Co. KG (OEKG) has a support system for employees on business trips to inform them about possible risks, health hazards and
possible special conditions of the countries to be travelled through. OEKG especially prepares for business trips to countries with difficult political situations,
problematic medical care and infrastructure, or the effects of natural disasters. ISOS provides daily updated information on its homepage on all important
questions concerning the trip and the countries involved. In addition, it provides support before and during the business trips such as medical emergencies,
searches for Western standard hospitals, evacuation in the event of unrest, and advice on unusual incidents such as theft. The assistance centers are open
24/7.
KeyMed (Medical & Industrial Equipment) Ltd. had formerly managed health and safety in the workplace
under OHSAS 18001 certification. The company completed the transition from OHSAS to ISO 45001
certification in all KeyMed sites in January 2021. We maintain this certified status by receiving regular external
audits for compliance with each item specified in the standards.
Risk assessment training for officers responsible for safety and health
Activities in Americas
Employee Near-Miss Reporting
(Olympus Corporation of the Americas)
Activities in Europe
International SOS
(Olympus Europa SE & Co. KG)
Transition to ISO 45001
(KeyMed (Medical & Industrial Equipment) Ltd.)
Activities in China
57

A letter of appreciation from the Shanghai
Emergency Management Bureau
Olympus Trading (Shanghai) Limited has developed a safety production management system that includes
manufacturing safety, industrial health and workplace environment evaluations in compliance with the basic
requirements of corporate safety production standards mandated by the Shanghai Emergency Management
Bureau. The company has established a policy and targets for manufacturing safety, set up a committee,
assigned detailed responsibilities and produced an emergency response manual, all aimed at putting top priority
on safety, prevention and total management. It also organizes annual emergency response drills.
The company received a letter of certification as a manufacturing safety standardization company for the first
time in June 2015. In addition, further improvements in manufacturing safety led to an award from the Shanghai
Free-Trade Zone in FY2019.
The company analyzes the risks and looks at case studies of manufacturing safety on a regular basis, at the same time working to improve employee
awareness of manufacturing safety through a range of training programs.
Olympus (GuangZhou) Industrial Co., Ltd. conducts a safety check twice a day to maintain a safe and healthy workplace. In addition, an extensive health
and safety patrol takes place before holiday periods, such as for the foundation anniversary. The Company organizes annual firefighting & evacuation drills
as part of its efforts to raise employee awareness of safety. This is aimed at raising coordination among firefighting organizations, upgrading leadership
capabilities, improving the capabilities of firefighting team in evacuation, rescue and firefighting, as well as in improving employee awareness of firefighting
and safety.
Olympus Vietnam Co., Ltd. (OVNC) provides labor safety training at least once a year based on Vietnamese regulations. 
Since OVNC has a large number of employees, up to about 5,000, it uses internal and external venues to hold trainings.
OVNC is committed to training and improving knowledge on occupational safety and sanitation for employees to ensure compliance with the principles and
rules of labor safety in the factory. To all people—support the criteria: "Safety comes first."
Olympus Australia Pty Ltd. has newly established internal safe driving rules for its field staff to help reduce traffic accidents.
Award Received from Shanghai Free-Trade Zone
(Olympus Trading (Shanghai) Limited)
Health and Safety Patrols & Firefighting & Evacuation Drills
(Olympus (Guangzhou) Industrial Co., Ltd.)
Activities in Asia/Oceania
Labor Safety Training
(Olympus Vietnam Co., Ltd.)
Promotion of safe driving
(Olympus Australia Pty Ltd.)
58

Occupational Safety and Health, Health Management
Basic Approach and Policy
Introduction of Olympus Health Declaration
The Olympus Global Code of Conduct states that "Safe and healthy workplace is a major priority. We take proactive steps to prevent accidents and
occupational illnesses at work and promote good health and wellness as well as work-friendly environment."
In Olympus and its Japan subsidiaries, we established the Olympus Health Declaration to help maintain and improve the health of employees and their
families.
In line with the announcement of the Health Declaration, action to prevent passive smoking is to be made a priority. At the same time, we are introducing
measures to help employees to become healthy and stay healthy, including advice with lifestyle improvements, recommendations and financial assistance
with screenings to catch cancer at an early stage, and how to avoid mental health problems.
In this way, the Olympus Group wants to create a corporate culture that encourages employees to be healthy, both physically and mentally and for everyone
to lead healthy and happy lives.
Olympus Health Declaration
Our corporate philosophy is to contribute to society by "Making people's lives healthier, safer and more fulfilling." We believe this is possible with the
support of healthy employees and their families with vitality.
Olympus places top priority on the health of its employees and their facilities through the following activities.
1. Olympus regards employee health as an important management issue and is committed to a corporate culture that places top priority on
employee safety and health.
2. Olympus will continue to create a workplace environment where employees are able to work with vitality and good physical and mental health.
3. Olympus cooperates with the Health Insurance Association to support better health to each and every employee and their families.
In addition to the health management activities that form part of its industrial health and welfare program, Olympus and its Japan subsidiaries work with its
Health Insurance Association to enable collaboration and coordinated action between the company and the Health Insurance Association. As an industrial
health and welfare organization, we have maintained and strengthened our health management system by appointing dedicated industrial physicians, health
care workers and health supporters proportionate to the scale of the facilities. Specifically, monthly meetings are organized for dedicated industrial
physicians, at which they discuss the health conditions of employees, conduct reviews to share health condition and address problems together with
healthcare workers and health supporters. In addition, industrial physicians and health supporters are working to upgrade their competences as specialists
through the specialist qualification program for physicians under the Japan Society for Occupational Health. Four of our specialists presented case studies
and researched presentations given at the Society (FY2021) to improve their skills. In addition to internal training programs for specialists, we accept
university students studying medicine and nursing as trainees each year (six medical university students and nine nursing students in FY2021), to support
the development of the next generation of specialists in industrial health and welfare.
Initiatives
Basic Approach and Policy
Health Improvement Activities (Japan)
Health Improvement Activities (Outside Japan)
Realization of a Better Livelihood and Happiness
Health Management System
59

Health Improvement Activities (Japan)
Olympus's activities in employee health management, implemented strategically from a management point of view, have won five-year consecutive
recognition since 2017 from White 500*, the Certified Health and Productivity Management Organization Recognition Program. In 2021, Aizu Olympus
Corporation was listed in the Certified Health and Productivity Management Organization Recognition Program, and Olympus Medical Science Sales Co.,
Ltd. was listed in the White 500 of the Program.
Our health management is actively promoted through a combination of industrial health activities, which include health guidance based on health
examinations results and a range of mental health services, and activities led by our health insurance association, such as awareness-raising about lifestyle
disease prevention and promotion of cancer screening tests using endoscopes.
We plan to continue to work in cooperation with the Health Insurance Association, for continuing effort in building a better working environment and good
health for both the employees and their families. We intend to work actively in promoting health among employees of the Japan subsidiaries and to
contribute to society through promotion of health among its customers through our business activities.
Olympus Corporation
Olympus Medical Science Sales Corp.
Aizu Olympus Co., Ltd.
* White 500 organized jointly by the Ministry of Economy, Trade and Industry and Nippon Kenko Kaigi, is a certification program to highlight outstanding large enterprises engaging
in efforts to advance health and productivity management.
Olympus and its Japan subsidiaries cooperate with the Health Insurance Association regularly to upgrade their lineup of health examinations.
To contribute to the prevention of lifestyle diseases, we hold various events such as exercise seminars and quit smoking programs. We also provide physical
and mental health counseling services through cooperation with external organizations.
* Most events are currently provided online due to the COVID-19 pandemic.
* Health counseling services are accessible by both employees and their families.
Olympus is also enhancing its cancer screening program of endoscopic screenings for the early detection of cancer. Such promotion includes full financial
assistance of cancer screening by the Health Insurance Association for employees and their families; maintaining a high screening rate for endoscopic
examinations (71% for gastrointestinal endoscopy and more than 61% for colonoscopy); and not setting age limitations for gynecological examinations for
employees and families for the early detection of cancer.
We utilize a cancer screening call/recall program*, in which examinees for the current fiscal year are encouraged to take screenings following a certain set of
criteria based on previous examinations. Further, we provide a Cancer Education E-learning program for employees each year to raise cancer awareness
and encourage cancer screening.
* Call/recall system: A system to automatically send emails to examinees selected based on previous screening data to advise on taking a further cancer screening.
Examination 
Item
Gastrointestinal
endoscopy
Colonos
copy
Lung cancer
screening
(CT)
Breast cancer 
screening
(breast 
ultrasonography)
Breast cancer 
screening
(mammography)
Cervical
cancer
screening
(cervical
cytology)
Abdominal
ultrasonograph
y
Recognized under White 500, the 2021 Certified Health and Productivity Management Organization
Recognition Program
Health Examinations, Health Promotion, and Health Counseling
Cancer Screening
Cancer Screening (screening rates*)
60

Screening 
rate (%)
71.1
61.5
33.7
56.7
26.6
65.5
84.8
* Screening rate: Number of people who actually take an examination within the encouraged yearly interval set for a specific cancer divided by the total number of examinee
candidates.
* Data for the imaging business, which was transferred in January 1, 2021, are not included.
Examination Item
Target
Health Insurance
Cost Subsidy
Years Consultation
Encouraged*
Stomach cancer
(endoscope)
35 years and older
100% coverage
Once every two years
Stomach cancer
(pepsinogen examination)
35 years and older
100% coverage
Year that Gastrointestinal
endoscopy is not undertaken
Colorectal cancer
(endoscope)
35 years and older
100% coverage
Once every three years
(40 years and older)
Colorectal cancer
(fecal occult blood test)
35 years and older
100% coverage
Year that Colonoscopy is not undertaken
Breast cancer/Cervical cancer
Women of all ages
100% coverage
Once every two years
Prostate cancer
(PSA marker)
Men 50 years and older
100% coverage
Once every two years
Abdominal ultrasonography
40 years and older
100% coverage
Once every two years
Lung cancer
(lung helical CT)
40 years and older
50% (Limit of ¥5,000 including tax)
Individual decides whether
to receive health exam
* Consultation encouraged: For those who have not yet taken the exam for certain period from the target age (those who have not yet taken an exam within the encouraged yearly
interval).
Self-care
Mental health training such as e-learning programs, mental toughness seminars, etc., for employees.
Interviews for all new employees and midcareer employees
Line care
Activities to support employees in the workplace, such as mental health seminars for managers.
Care by industrial
health care personnel at
business sites
Consultation and daily care service provided by industrial doctors and other health staff. Activities organized by
industrial healthcare workers in cooperation with the Human Resources Division for the returning to work program for
those with health problems.
Care provided by
resources outside the
business site
Consultation service and seminars provided by external psychologists
In addition, we are holding training workshops conducted by psychiatrists and other specialists in clinical practice for healthcare workers and nurses to
support mental health care for employees.
We conduct the statutory stress checks all together in Olympus and its Japan subsidiaries. In fiscal 2021, the participation rate was 95%, with appropriated
interviews and personalized follow-up provided according to results for early response if necessary. We continue to review its effective application, as part of
our mental health program.
Cancer Screening Test Support System
Preventing Mental Health Problems
61

As a part of passive smoking prevention, ban on smoking inside all buildings and structures at business sites belonging to Olympus and its Japan
subsidiaries was accomplished by the end of March 2020, and smoking was also prohibited within all premises by the end of March 2021. We also run the
Quit-Smoking Marathon program, through which the health care personnel support those employees wanting to quit smoking. Also, the Health Insurance
Association provides an online quit smoking program, covering expenses in full. Thanks to these efforts, the smoking rate decreased to 16.9% as of the end
of March 2021.
Smoking Rate (average in Japan)*
End of March 2018 (at the start of activities)
22.0%
End of March 2019
20.0%
End of March 2020
18.4%
End of March 2021
16.9%
* Data for the imaging business, which was transferred in January 1, 2021, are not included.
The following activities are being conducted to prevent infectious diseases.
Activities under the Specific Health Guidance program are being conducted to prevent lifestyle diseases. Specific health
guidance for Olympus and its Japan subsidiaries is provided by healthcare workers and nurses working in the health
management offices of each company, through counseling and guidance. In the past, we have provided personalized exercise
guidance to employees, but we now share online videos to promote exercising. The scope of this online exercise was widened
to include all employees and due to these efforts, we were selected as a Sports Yell Company 2021* certified by the Japan
Sports Agency.
In addition, some facilities introduced healthy cuisine created by healthcare workers and nurses at employee dining halls.
Healthy dishes have been developed and are provided on request to employees in the Specific Health Guidance program.
* The Japan Sports Agency certifies companies that proactively encourage their employees to participate in sports for health promotion as
"Sports Yell Companies." Olympus Terumo Biomaterials Corp. and Olympus Medical Science Sales Co., Ltd. were each certified as a Sports
Yell Company 2021.
Activities to Quit Smoking
Action on Infectious Diseases
Hepatitis B antigen/antibody tests and vaccination to medical professionals
Education programs on infection prevention to all employees who visit medical institutions
Vaccination of employees traveling overseas on business assignments and accompanying family members (vaccines recommended for the destination
region)
Examples: Hepatitis A, hepatitis B, tetanus or DTP vaccination
Partial coverage of expenses for influenza vaccination
Starting in FY2020, rubella antibody test conducted with the health examination (in response to additional action on rubella announced by the Ministry of
Health, Labour and Welfare for men born between 1962 and 1978)
Olympus's Response to COVID-19 (including safety and health)
Preventing Lifestyle Diseases
Health Promotion Activities and Campaigns
62

To foster greater awareness and provide support for employees to manage their health, the portal site WellsPort Navi was introduced under the initiative of
the Health Insurance Association to promote health management for individual employees in Olympus and its Japan subsidiaries. In this portal site, various
health campaigns have been actively organized, including campaigns for walking, weight control during new year holiday, stopping smoking and dental
health.
Effective activities are being introduced, such as the formation of groups at some facilities run by employees who have participated in internal exercise
seminars and plan to continue exercising.
To help employees who are undergoing treatment to retain financial stability and continue their outpatient treatment and to raise employee incentive, various
support programs have been introduced, including paid leave, flexible working hours and work-at-home system. To provide greater employee assistance, a
special leave program was introduced in April 2020 for employees suffering from a disease for which the Ministry of Health, Labour and Welfare
recommends support.
In addition to the statutory health examinations for expatriate employees required on departure and return to Japan, employees can have a health
examination (for the items in the complete medical examination) during a temporary return to Japan. Health management is provided not only for the
employee but also for their family members.
Industrial physicians, healthcare workers and nurses are assigned to provide everyday health counseling before departure and on returned to Japan. A
health counseling service is offered not only to expatriate employees but also to their families.
Also, industrial physicians are dispatched on a regular basis to overseas subsidiaries to upgrade the quality of health management for expatriate employees.
Health Improvement Activities (Outside Japan)
The Cigna Mental Health First Aid training is designed to teach participants how to identify, understand and respond to signs of mental illness and substance
use disorders. This training provides the skills needed to reach out and provide initial support to someone who may be developing a mental health or
substance use problem and help connect them with appropriate care.
We aim to be an employer that is True to Your Life, and that means prioritizing your wellness. Our walking challenges focus on and support a culture of
healthy living, and employees are encouraged to stay true to their health and wellbeing throughout the year. The New Year's Commit to Be Fit Walking
Challenge ran for 35 days from January 18 – February 21. This 5-week challenge averaged out to 8,000 steps per day.
Olympus Europa SE & Co. KG (OEKG) provides employees with the opportunity to a fecal occult blood test for colorectal cancer where early detection and
early treatment are important. In cooperation with a local NPO, an event was organized for employees to promote greater awareness of colorectal cancer.
Support for Treatment and Continuing to Work
Health Management for Expatriate Employees
Activities in North America
Cigna - Mental Health First Aid Training program
(Olympus Corporation of the Americas U.S.A)
New Year's Commit to Be Fit Walking Challenge
(Olympus Corporation of the Americas U.S.A)
Activities in Europe
Colorectal Cancer Awareness
(Olympus Europa SE & Co. KG Germany)
63

Employee health is a top priority for Olympus. This is why the company supports all Olympus Europa SE & Co. KG and Olympus Deutschland GmbH
colleagues throughout Germany in quitting smoking. This also applies to users of e-cigarettes and so-called heets. If interested and requested, the employer
pays the costs for different seminar and therapy formats that are offered by external Olympus partners
In step with the arrival of the influenza season, we carried out a full influenza vaccination program again this year, in recognition of the importance of
employee health management. Employees who were vaccinated by their local doctor or clinic were reimbursed on submitting an expense claim form.
Over the years various health and wellbeing initiatives have been organized by HR and Corporate Communications. However, at the beginning of FY2021,
OAZ identified a need to not only improve the current offerings, but also to promote and maintain the wellbeing of our employees in more structured way. The
COVID-19 pandemic highlighted just how important it was to ensure the total wellbeing of our employees are strongly supported. Therefore, a cross-
functional committee was formed, comprising of employees across various departments and locations, who are all passionate about ensuring health and
wellbeing is made an organization-wide priority. The committee created a vision, mission, purpose and strategy.
Due to the COVID-19 pandemic, for most of 2020 the majority of OAZ employees worked from home. This presented both physical and social connection
challenges given most staff members did not spend as much time being active by walking around the office, and from a social perspective were also isolated
from their colleagues. Local COVID-19 restrictions were also in place, meaning many employees were not permitted to do the physical exercises they would
normally do, such as going to the gym. The Health & Wellbeing Committee decided to run a company-wide tournament whereby over a four week period,
teams would aim to walk 10,000 steps per person per day, from Perth to Broome in Western Australia, with the ultimate goal of being the first team to reach
the final destination. This initiative encouraged employees to increase their steps around their home or walk outdoors (which was permitted during COVID-19
lockdowns), in addition to some friendly competition which contributed to positive social connection.
With COVID-19 spreading through India at a spectacular speed, OMSI provided support to the Haryana state government where Gurgaon is located for the
prevention and control of COVID-19. The specific support activities were as follows.
1- Antigen Test Kit
2- Viral Transport Medium Kit
3- 12 numbers of canopy Tent for putting up Covid-19 Testing camps
4- 3 Rental minivan Eeco required for three months (January, February, March 2021) for Covid-19 Samples transportation and Lab Technician pick up and
drop from various Gurgaon Camps
Quit smoking program
(Olympus Europa SE & Co. KG Germany)
Activities in China
Injection of influenza vaccine
(Olympus(Beijing) Sales & Service Co.,Ltd.)
Activities in Asia/Oceania
Health & Wellbeing Committee
(Olympus Australia & New Zealand)
Olympus Western Seaboard 10,000 Steps Tournament
(Olympus Australia & New Zealand)
Supporting Government to control COVID-19 spread
(Olympus Medical Systems India Private Limited)
64

Training and Education
Basic Approach
Basic Approach to Human Resource Development
The Olympus Group regards its employees as its most important management resource from a long-term perspective. By treating every employee with
respect, sincerity and empathy, we aspire to become an organization capable of working globally with speed and solidarity in the face of changes in the
business environment. To achieve this goal, every employee needs to gain a deep understanding of the principles and values shared by the entire Group
and the skills to conduct business on a global scale, along with leadership and a high level of expertise. We believe it is important to trust in the incentive and
enthusiasm shown by our employees and to assign each person to a job that matches their capabilities so that they can apply their own individual skills and
competences.
For this reason, we have introduced activities to disseminate and energize these principles and values, including organization of a Core Value Week, which
is held simultaneously worldwide, skills training programs held internally in the Global Group and foreign language learning programs for employees who
work in non-English-speaking regions. In addition, the Olympus Global Talent Management System has been introduced for job definitions that require the
implementation of management strategies. We are starting succession planning (planning to train successors for various job functions) for important
positions and working to make effective use of human resources regardless of nationality so that we can maintain our advanced levels of expertise.
Other activities include the establishment of a globally unified leadership competency model, Leadership Academy, to train employees to exercise leadership
and one-on-one support and onboarding programs in an effort to create a corporate culture that enables employees to continue to demonstrate outstanding
performances in their jobs and a study of how to upgrade our human resources development.
Promotion Structure and Systems
Promotional Structure in Human Resources Development
In addition to the human resources development systems that operate in each region, to ensure optimal development of human resources on a global scale,
the Olympus Group has improved its coordination between human resources development systems at the global and regional levels by organizing them into
mirror organizations. Coordination among leaders of business and functional organizations has been improved by appointing human resources officers
responsible for business and functional organizations known as HR Business Partners. This scheme is designed not only to assure consistency throughout
our global organization, but also to maximize the efficiency and effectiveness of human resources development measures adapted to conditions specific to
each region and business.
Human resources coordination between global and regional operations has proven effective in bringing greater efficiency to worldwide programs from the
aspects of better multilingual responses, better coordination among existing regional programs and more effective resolution of business and organizational
issues through closer coordination among business and leaders of functional organizations.
Training and Education System
The Olympus Group has started succession planning for important positions under the title "Leaders Developing Leaders," established a global leadership
competency model for promising leadership candidates and activities aimed at the exercise of leadership and rendered assistance with skills development.
Additionally, the globally unified skills training program that was started in 2019 is progressing as planned and training for all managerial employees was
completed in March 2020. We are preparing to further develop the program and establish it as part of our corporate culture.
At present, Olympus and Olympus Medical Science Sales provide learning opportunities for their employees, with several hundred course titles made
available each year. They include e-learning programs based on the Olympus College Plus educational management system and group specialized skills
training and compliance training programs. With advances in the online environment in recent years, we are working to develop more effective and efficient
skills development systems. Specifically, we have reduced travel costs by conducting online group training programs, created new internal studios, improved
65

the program participation rate with on-demand videos for existing programs and improved the learning effect through combining these programs with flipped
learning. By thus consolidating our human resources systems on a global scale, we hope to achieve greater improvements in the training content, learning
effect and participation efficiency.
Manufacturing Technicians Training Program
The Olympus Group regards its manufacturing technicians as an important source of added value.
The manufacturing sites in Japan provide them with functional training through the Manufacturing Technicians Training Program. In the Manufacturing
Technicians Training Program, we classify skills of manufacturing technicians into 6 stages, aiming at a planned level-up. Level 1 to 3 new employees are
"general technicians," Level 4 and above are certified as "advanced technicians" with high technical skills. Level 4 employees are referred to as
Manufacturing Advisors (MA), Level 5 as Manufacturing Supervisors (MS), and the highest level 6 as Manufacturing Masters (MM). From new recruits to
MMs, we nurture our employees in a planned manner according to their level. As of April 1, 2020, the cumulative number of advanced technicians reached
150.
We provide training programs oriented toward certification and programs that allow higher ranking certified technicians to provide assistance to raise the
motivation of each employee.
At Olympus Vietnam Co., Ltd., where medical products are manufactured, a certification system for bonding and soldering work has been introduced. This is
designed to upgrade the training and education programs and contribute to the creation of a global manufacturing system.
Skill level of Manufacturing Technicians Training Program (Manufacturing sites in Japan)
66

Diversity and Equal Opportunity
Basic Approach
For the Olympus Group, which is propelling its business globally, utilization of diverse human resources has a significant influence in our business. We
believe that maintaining an awareness of the importance of diverse human resources in progressing every aspect of our human resource strategy provides
work satisfaction to each employee.
In addition to the promotion of female workers, which we have been working on over the years, we are building a working environment where people in
different situations—including people with disabilities or long-term illnesses, nursing caregivers, and those of a sexual minority (LGBT etc.)—can work fully.
Systems and Mechanisms
Work-Life Integration
In 2011, the Olympus Group introduced the concept of Work-Life Integration to help our diverse employees progress their careers regardless of the life
events they are facing. We also implemented a range of activities under this concept among Olympus and its Japan subsidiaries, and are aiming to further
enhance these measures, which we believe can lead to synergetic fulfillment in both work and life. The measures are being implemented under four themes:
(1) Promotion of diversity, (2) Nurturing the next generation, (3) Enhancing work productivity and (4) Promoting health (Occupational Safety and Health).
We also started Work-Life Integration training for managers on a regular basis in FY2016 in order to disseminate an understanding of the importance of a
management approach that will empower a diverse range of human resources. In FY2018, we published a booklet describing our systems concerning Work-
Life Integration and case studies, to promote usage of such systems, as well as providing know-how about achieving a good work-life balance.
Basic Approach
Work-Life Integration
Workstyle Reform
Effects of Workstyle Reform
Personnel Evaluation System
Welfare System
Promoting the Advancement of Women
Employer Action Plan Based on the Next-Generation Act
Support for Childcare and Work
Employer Action Plan Based on the Act on the Promotion of Women
The Olympus Group's Approach on the Human Resources Utilization toward Sustainable Growth
67

Workstyle Reform
Olympus and its Japan subsidiaries embarked on the Business Process Reengineering (BPR) Project in July 2016 to strengthen our business and
management foundation and to make best use of our organizational strengths. In 2020, the Human Resources Division established a project to review
working styles to address and control the spread of COVID-19. We developed a basic policy on new working styles at Olympus. We then conducted studies
on our teleworking scheme, policy on commutation allowance, approach to office design, application of IT, etc., in coordination with the IT, security and other
relevant divisions. We are promoting initiatives on working styles and developing a working environment founded on a self-reliant approach to work, to build
a corporate culture that delivers high performance through the application of advanced specialized skills by each employee and a company that offers a
sense of fulfillment at work and opportunities for growth.
Effects of Workstyle Reform
Starting in June 2020, we removed the requirements to qualify for our teleworking scheme to enable more employees to participate, expanding its use to all
full-time employees by lifting the restrictions on use of our childcare and nursing care schemes. When all employees started using the scheme for COVID-19
countermeasures from March 2020, because application of the system had been expanding gradually while monitoring any issues, it was implemented
without major confusion. At the same time, we deployed Office 365 as a communication tool in April 2020, earlier than planned. In addition to promoting a
hybrid work scheme combining work in the office and work at home, the teleworking scheme was revised in April 2021. We reviewed the ceiling on the
number of workdays and working venues of our previous teleworking scheme, making it into a new teleworking scheme. 
In addition, we created a work environment that offers versatile working styles and that is not restricted by time or location by introducing paid annual leave
that is granted in units of hours, introducing satellite offices and other measures.
We have also introduced a flextime work system*, which allows employees to decide freely when to start and finish work during core time, to create a
workplace culture that values their initiative, to improve their working efficiency and increase their mental and physical motivation. In June 2020, we revised
our core time to 11:15-13:30, which was shorter than before.
* Employees who are involved in work that requires regular working hours may not be eligible.
Personnel Evaluation System
Olympus and its Japan subsidiaries manage their own goal management and evaluation system, to allow employees to proactively pursue their business
themes and develop their abilities to grow towards their goals. Employees have regular individual interviews with their line managers to confirm the degree to
68

which they have achieved their quantitative and qualitative targets and to set goals for the next term.
Repeatedly attending interviews and improving their abilities not only allows employees to make temporary improvements in performance, but also allows
them and their company to pursue mid- to long-term growth.
Furthermore, some senior management are to set and evaluate goals on a global scale to strengthen and promote integrated group management.
Welfare System
The Olympus Group implements welfare systems suited to different countries and regions.
Olympus and its Japan subsidiaries provide employees with a welfare system to share the healthcare, childcare/nursing care and self-enlightenment
expenses they have to pay. Specifically, we give priority to implementing measures to support employees who in need of support for home nursing care,
home bathing services, babysitting, childcare facilities and language learning, including employees who are strongly committed to self-development.
System
Description
Coverage
Pension
Legally designated system
Olympus Group
Childcare leave
Longer than legally specified number of days
Olympus Group
Promotion Structure and Initiatives
At Olympus and its Japan subsidiaries, the Human Resources Division serves as the center for dialogue with employees and the labor union, providing
systems to support an active role for diverse human resources and appropriately drafting and implementing measures. In FY2018, we established a
dedicated organization to reinforce our diversity promotion structure. To further develop a corporate culture and environment in which diversity is valued, we
assigned the role of diversity promotion to the departments responsible for organizational development in April 2021. We are committed to continuing
working on this issue.
We conducted a range of activities to promote understanding and support for sexual minorities. Such activities include establishing a dedicated consultation
office, providing seminars to promote awareness, hosting an LGBT Week (an awareness-raising campaign through e-learning and videos) and establishing a
voluntary group called "LGBT ALLY." As a result of such efforts, we received the Bronze rating under the PRIDE Index 2020, a Japanese index to evaluate a
corporation’s performance in LGBTQ inclusion.
Promoting the Advancement of Women
Olympus adopts gender equality in employment opportunities, employee promotions, and salary increases. We also actively appoint highly skilled and ethical
people to appropriate positions. The advancement of women is in progress. At Olympus, as of the end of April 2021, 75 women were in managerial positions
and the female candidates for managerial positions increased to 252. As well as establishing these welfare systems that support career progression
irrespective of different major life events, we are also actively promoting the usage of such systems by publishing and distributing the leaflet concerning
balancing work and child/elderly caring. We also hold related workshops in each department.
In FY2020, we have established a new common employer action plan based on the Act on Promotion of Women’s Participation and Advancement in the
Workplace. Because measures implemented under the action plan established in 2016 were found to be effective in improving the empowerment of women,
the 2019 plan strengthened measures aimed at further career advancement for women to promote this empowerment, while maintaining the basic
framework for the plan’s goals. We will continue Work-Life Integration (WLI) training for managers to learn a management approach that will empower a
diverse range of human resources, and training of managerial candidates to encourage the appointment of female managers, a mentoring system for female
workers, and post-childcare training for early return to work. 
In FY2021, we created online networking opportunities for employees on childcare leave to communicate with each other.
Since April 2020, we started a special leave scheme through which employees can continue working while receiving treatment for cancer, long-term
Major Welfare System
Diversity and Inclusion in the Americas
Diversity & Inclusion (Olympus Corporation of the Americas) 
69

illnesses, fertility, etc. to optimize their work-life integration (WLI).
In March 2021, we held an internal event on International Women’s Day. The event was opened with a message from the President and followed by an
online town hall meeting presented by the CAO and the HR Executive Officer, lectures by external experts and role models from within our Companies. The
event succeeded in promoting a culture that embraces diverse human resources.
We support the career development of women by taking the "feed forward" approach through which we offer opportunities to plan goals and work tasks in
advance of assumed future life events.
Employer Action Plan Based on the Next-Generation Act
Olympus has formulated a general business operator action plan based on the Act on Advancement of Measures to Support Raising Next- Generation
Children (Next-Generation Act). We revised the Plan in April 2021. 
We are building a working environment that supports employees’ child caring by expanding eligibility for the work-at-home system to all full-time employees
and establishing childcare facilities in our business sites. Our nursery established in Shirakawa Facility in September 2018 was the first of its kind built in a
production site in Japan. In June 2020, we built another nursery in Hachioji Facility, in which the highest number of our employees are working. In this way,
we proactively provide work-life integration support to enable our employees to fulfill both work and child caring commitments.
We also offer the same type of support to working parents in subsidiaries outside Japan, such as through the Olympus America Child Care Center in
Pennsylvania, U.S.
Fukushima Prefecture in Japan hosts the Ikuboss Declaration program, to which companies can register themselves to encourage their managers to pay
attention to the work-life balance of their staff members. Aizu Olympus and Shirakawa Olympus, both located in the prefecture, are registered with the
program.
* Ikuboss refers to a manager who considers their staff members' work-life balance and provides the necessary support, playing the role as a model work-life balancer while at the
same time generating successful business results in the organization.
Support for Childcare and Work
At Olympus, employees can take maternity and childcare leave and nursing care leave (by the day and hour) and be exempt from overtime work as laid
down by the law. Shorter working hours also apply to employees with a child older than three years, which is for longer than the law specifies. A lump-sum
allowance for childbirth is provided by the Health Insurance Association for female employees who give birth and male employees whose spouses give birth
and who are dependents on their health insurance.
We are working to support the balance between work and child care in the following ways.
Of the companies that formulate action plans under the Act on Advancement of Measures to Support Raising Next-Generation Children (Next-Generation
Act), those that achieve the targets specified in those action plans and meet certain standards may apply to be recognized as companies that support the
raising of children and receive Kurumin certification from the Minister of Health, Labour and Welfare.
To date, Olympus and its Japan subsidiaries has developed action plans to implement the Act on Advancement of Measures to Support Raising Next-
Concept of Feedforward
General Business Operator Action Plan Based on the Act on Advancement of Measures to Support Raising Next-Generation Children (Only in Japanese) 
Kurumin
70

Generation Children. Olympus obtained Kurumin certification in 2016 and 2019 from the Minister of Health, Labour and
Welfare. Olympus Terumo Biomaterials Corporation got Kurumin certification in 2018, and Olympus Medical Science Sales got
it in 2020.
Of the companies that formulate action plans under the Act on the Promotion and Advancement of Women, those that
achieve the targets specified in those action plans and meet certain standards may apply to be recognized as good
companies that implement measures for promotion and advancement of women and receive Eruboshi certification from the
Minister of Health, Labour and Welfare.
In 2019, Olympus received Eruboshi certification at the highest grade 3 from the Minister of Health, Labour and Welfare.
Employer Action Plan Based on the Act on the Promotion of Women
Olympus and its Japan subsidiaries have formulated a general business operator action plan based on the Act on the Promotion of Women's Participation
and Advancement in the Workplace (Act on the Promotion and Advancement of Women), which was adopted in August 2015.
The number of female managers is increasing thanks to the expanding a mentor program for female workers and continuing provision of training programs to
develop female leaders. To date, our efforts to promote women include introducing nurseries in the Shirakawa and Hachioji Facilities, expansion of the scope
for teleworking and shorter working hours for childcare, and the introduction of a special leave scheme in April 2020 for long-term medical treatment,
including fertility treatment. Implementation of the work-life balance systems are also steadily progressing through the creation of a database to exchange
company information to retain their career connections while on childcare leave and so on.
The female employment rate is also increasing by focusing on women candidates in our recruitment campaigns and by holding job fair presentations for
women candidates.
Eruboshi
General Business Operator Action Plan Based on the Act on the Promotion and Advancement of Women (Only in Japanese) 
71

Contributing to Medical Development
Physician Training in Developing Countries
Olympus endoscopes for diagnosis and treatment are contributing to the health and well-being
of people in regions such as developing countries in Asia, where cancer and other lifestyle
diseases due to rapid economic growth are raising the need for urgent measures.
Olympus is demonstrating its corporate citizenship activities by working with Japanese
international-cooperation organizations and academic societies to help train doctors in
endoscopy and related medical technologies and services from Japan.
Olympus-supported training in Thailand, Indonesia, Vietnam and other countries is raising
health standards and contributing to healthier and more fulfilling lives.
72

Contributing to Medical Development
Participating in the Medical Industry Organizations
As a global medtech company, Olympus participates in medical industry groups in each country and region and contributes to the development of the
medical industry. Membership fees are set for each group according to the company size and the business scale.
Name of the organization
Membership fee payment
FY2019
FY2020
FY2021
Medical Excellence JAPAN
¥1,500,000
¥1,500,000
¥1,500,000
Advanced Medical Technology Association (AdvaMed)
US$566,595
US$591,440
US$590,262
Medical Alley Association
US$7,500
US$7,500
US$8,000
Medtech Europe
134,354 €
119,533 €
122,000 €
The Asia Pacific Medical Technology Association (APACMed)
US$40,000
US$50,000
US$50,000
Japan Electronics and Information Technology Industries Association
*Total delivery from company-wide
¥9,396,000
¥8,004,960
¥9,694,300
Japan Medical-Optical Equipment Industrial Association
¥3,575,550
¥3,575,550
¥3,650,350
Medical Technology Association of Japan
¥1,200,000
¥1,200,000
¥1,700,000
Japan Association for the Advancement of Medical Equipment
¥444,000
¥444,000
¥444,000
Japan Association of Medical Devices Industries
¥400,000
¥400,000
¥410,000
The Japan Federation of Medical Devices Associations
¥300,000
¥300,000
¥300,000
73

Social Impact Assessment (Cancer Awareness)
Olympus group global cancer awareness activity
As a leading global medical technology company with key products in the field of gastric and colorectal cancer screening, detection and treatment, the
Olympus Group bears a great social responsibility. It takes more than our innovative products to fulfill our Purpose to make people's lives healthier and more
fulfilling.
At the Olympus Group, we address relevant social issues by promoting impactful cancer awareness activities that generate outcomes for beneficiaries such
as public citizen like potential cancer patient and nonprofit partners on a global scale.
We, the Olympus Group, also conduct internal awareness campaigns for employees. 
Accordingly, our cancer awareness activities contribute to a positive social change in the area of healthcare with the aim of improving the awareness and
knowledge of prevention and early detection of cancer amongst our communities and employees. 
In addition to raising awareness about cancer, we also focus on wellness activities that comfort cancer patients and their families during the healing process.
Introduction of logic model (Cancer Awareness)
The Olympus Group Cancer Awareness activity is implemented in accordance with the following logic model, which would give the maximum benefits to
stakeholders.
FY2021 result
The Olympus Group conducted following activities in FY2021, under the newly developing situations by COVID-19, which restricted its capacity and
opportunity world widely.
Region
Cancer Awareness
Youth Education
Japan
3
5
Americas
8
1
EMEA
4
-
China
2
2
Korea
7
-
Introduction of logic model (Cancer Awareness) (PDF: 586.4KB)
Japan
Americas
EMEA (Europe, Middle East & Africa)
China
Australia & New Zealand
Korea
74

Japan
Promoting cancer awareness activities to improve the rate of gastric and colorectal
cancer screenings in collaboration with health administration and NPOs
The Olympus Group supports the improvement of the rate of gastric cancer screening and colorectal cancer screening to reduce the number of people who
lose their lives from cancer by early detection and treatment of cancer. Our goal is to have many citizens have the right knowledge of cancer, get many
people to check for cancer on a regular basis for early detection and treatment of cancer, and have people with suspected cancer have a detailed cancer
examination. In Japan, public health care administrations conduct public cancer screening for citizens. We enclose a leaflet prepared by the Olympus Group
to educate the public about endoscopic examinations, when the medical administrations send a guidance on cancer screening to citizens. To raise
awareness of colorectal cancer screening, we support activities conducted by the Brave Circle Steering Committee, an NPO, and sponsor the Colorectal
Cancer Awareness Campaign. To understand why the general public receives cancer screening and detailed examinations, and why they do not, we conduct
an awareness survey throughout Japan. The cancer prevention awareness website "Onaka-Kenko.com" is used to educate people about the importance of
early detection and treatment of cancer. By publishing the results of the analysis of the survey, we are implementing initiatives to make them useful to people
involved in cancer countermeasures.
Colon Cave
Endoscope Hands-on
75

Americas
Promoting colorectal cancer awareness activities across the Americas
Olympus Corporation of the Americas (OCA) implements activities during National Colorectal Cancer Awareness Month in March and throughout the year
that are dedicated to raising awareness internally and externally about colorectal cancer and the Olympus Group's commitment to prevention detection and
treatment. Our goal is for employees to understand the Olympus Group's role in combating colorectal cancer and drive awareness amongst the public to
understand the importance of early detection and know the national recommended screening age. We are dedicated to raising awareness about colorectal
cancer and promoting prevention, detection, and treatment. We provide our employees and the public with education about preventative measures,
diagnostic screenings, and life-saving procedures. Through key partnerships, we support organizations that are on the frontline of combating colorectal
cancer and providing access to underserved communities. Our objectives consist of three impact goals; reduce the number of colorectal cancer deaths, raise
general awareness about colorectal cancer and screening and increase employee engagement in support of this cause.

Dress in Blue
TdT Group 2019
76

EMEA (Europe, Middle East & Africa)
Colorectal cancer prevention initiatives
Within the EMEA region, the Olympus Group supports various initiatives to raise awareness about colorectal cancer prevention. 
By doing so, the purpose of our initiatives are to raise awareness and draw attention to the importance of information and knowledge on screening and early
detection amongst employees. Therefore, OEKG (Olympus Europe SE & Co. KG) regularly provides educational communication and activities for employees
as well as invites external keynote speakers to inform and empower employees to actively take care about their own prevention measures. In addition, we
offer direct prevention measures to employees as part of our ongoing stool test campaign. 
Within our activities we strive for maximal impact for beneficiaries and the society, which is why we cooperate, and support selected Non-Profit-Organizations
in order to make a meaningful and effective contribution to beneficiaries, such as young patients affected and suffering by cancer.
Leaflet for employees
Leaflet for employees
77

China
Stomach Care Month -- the cancer awareness project in China
The purpose of the project is to raise the public awareness of early gastrointestinal cancer screening, and to increase the endoscopy rate in China. 
The Stomach Care Month campaign was started in 2010 and held from November to January, annually. We have carried out various activities to promote the
knowledge of early gastrointestinal cancer prevention and treatment to the public and reduce their fear of endoscopy. Activities include lectures (online and
offline), roadshow, media promotion, materials, etc. 
Those activities intend to provide knowledge and information to people. To make them understand the importance of early cancer screening and let them go
for endoscopy actually. 
The target groups we want to promote are divided as internal and external: employees and the public. Different approaches are adopted to reach the internal
and external outcomes.

Launching event
Educational video
78

Australia & New Zealand
Various cancer awareness activities
OAZ (Olympus Australia Pty Ltd. and Olympus New Zealand Limited) has undertaken several varying activities in an effort to raise awareness pertaining to
cancer. By partnering with established NGOs including not-for-profit organizations, OAZ has four key initiatives.
The first is to increase community awareness. The second initiative is to provide aid - financially or equipment to aid NGO's campaigns. The third is to
provide professional education opportunities to developing countries by supporting with the Australia & New Zealand Gastroenterology International Training
Association (ANZGITA ). And the last one is to create public education opportunities.
By partaking in these activities, OAZ hopes that there will be three broader outcomes:
We feel that these outcomes will naturally lead to future positive impacts in our greater community.
Evelyn's Morning Tea
Operation Ouch 2020
An increase in Cancer Recognition
1.
Improved interaction with local communities
2.
Improvement in patient care in developing countries
3.
79

Korea
Running the 'going on' campaign to support cancer patients
Despite the increase of the cancer survival rate (70.4%, domestic cancer survival rate) with an early cancer screening and development of treatment
technology, our society has not yet embraced cancer patients and survivors. OKR (Olympus Korea Co. Ltd.) developed and runs the ‘Going-on' campaign
which is designed to support their successful return to society. The campaign name implies that their beautiful lives will continue even after cancer diagnosis.
There are several programs to support cancer survivors in the ‘Going-on' campaign. 
For example, ‘Going-on Studio' is a video content training program which is conducted for cancer patients, provides educational opportunity to learn video
planning, filming and editing skills. 
‘OLYM# Concert' is a special concert to improve emotional stability and quality of life of cancer survivors and their families by providing opportunities for
enjoying culture and arts. 
‘Going-on' campaign consists of many other programs, such as ‘Going-on Talk', ‘Going-on Harmony', ‘Going-on Diary' and ‘Going-on Walk', which is an
employee participation program. 
The purpose of the ‘Going-on' campaign is to improve the mental health and quality of life of cancer survivors through meaningful CSR activities. As time
progresses, we will look to implement additional programs to further support those diagnosed with cancer.
Going-on Studio
Going-on YouTube
80

Corporate Philosophy
All of our activities are based on our corporate philosophy, which consists of Our Purpose and Our Core Values.
Our Purpose
Making people's lives healthier, safer and more fulfilling
Supporting cutting-edge medical procedures and scientific discoveries. Helping make people feel safer and more secure. Through our business activities, we
aim to contribute to global society by making these things happen. This is the purpose of our existence.
Our Core Values
Integrity, Empathy, Long-term View, Agility, and Unity
These values are shared among all global Olympus employees and are reflected in everything we do at Olympus. They are the very values that will let us
realize Our Purpose.
81

Framework of Corporate Philosophy
The Olympus Group specifies the Basic Management Policies within the Framework of Corporate Philosophy, positioning its Corporate Philosophy at the top.
The concrete guidelines for business execution are then compiled into two structures: Planning and Global Rules.
Related link
Corporate Philosophy
Corporate Strategy
Olympus Global Code of Conduct
Basic Policy on Corporate Governance (PDF: 82.8KB)
Basic Policy on the Internal Control System
82

Corporate Governance
Basic Policy for Corporate
Governance (PDF: 82.8KB)
The Olympus Group has created the
basic policy for Corporate Governance
based on the principals of Japan's
Corporate Governance Code.
Corporate Governance
Report (As of June 24, 2021)
(PDF: 1.4MB)
The Olympus Group submits a
compilation of our corporate
governance situation the "Corporate
Governance Report" to the Tokyo Stock
Exchange.
Corporate Governance
Structure
Find out our Corporate Governance
Structure to ensure sound management
including the makeup of the board and
the roles of outside directors
Board of Directors
Find out the reasons for appointments
of outside directors, as well as the
efforts to ensure robust audit and
supervisory functions and the overview
of the results of the evaluation of the
Board Effectiveness.
Internal Control System
Read our basic policy for internal
controls which enhances effectiveness
and efficiency of operations and the
reliability of financial reporting by the
company and its subsidiaries.
Olympus Group Tax Policy
Find out our Group Tax Policy based on
the principles of how Olympus people
are expected to operate with respect to
tax matters.
83

1 
CORPORATE GOVERNANCE REPORT 
OLYMPUS CORPORATION 
Last updated: June 24, 2021 
Olympus Corporation 
Director, Representative Executive Officer, President and CEO, Yasuo Takeuchi 
Contact for inquiries: Investor Relations, Vice President, Takaaki Sakurai 
Securities Code: 7733 
https://www.olympus-global.com/ 
The status of corporate governance of the Company is as set out below. 
I Basic concepts of corporate governance, capital structure, corporate attributes, and other 
basic information 
1. Basic concepts
The Company has formulated basic concepts and policies concerning corporate governance in the “Basic Policy on Corporate
Governance” set forth below.
[Basic Policy on Corporate Governance]
Our Corporate Philosophy
All our activities are based on our Corporate Philosophy, “Making people’s lives healthier, safer and more fulfilling.” Following this 
philosophy, we aim to improve our company’s continuous development and mid- and long-term corporate value for all stakeholders,
including shareholders.
Basic Concepts Regarding Corporate Governance
Based on our fiduciary responsibility to shareholders and our responsibility to stakeholders including clients, employees and local
communities, etc. as well as the above Corporate Philosophy, our company has implemented basically the principles of the Corporate 
Governance Code and developed this policy with the aim of realizing effective corporate governance.
1. Securing Shareholders’ Rights and Equality
(1)
Our company respects shareholders’ rights and secures their substantial equality.
(2)
Our company takes appropriate steps to improve the environment pertaining to the exercise of rights at the general meeting
of shareholders.
(3)
If it is judged that listed shares will contribute to the improvement of our group’s corporate value in the mid- to long-term,
then, upon verifying the economic rationality and the future prospects for the mid- to long-term, our company will hold the listed 
shares. Every year, the Board of Directors will verify the suitability of ownership considering comprehensively the purpose of
holding, the benefits associated with holding and the risks, and gradually reduce shares that we judged not to be suitable for
possession. In order to exercise shareholders’ rights regarding policy shareholdings, our company will exercise its voting rights
on all agenda items, and from the viewpoint of improving the mid- to long-term corporate value of an enterprise issuing such
shares, will consider said enterprise’s financial condition and decide appropriately about whether to approve or disapprove each
agenda item.
(4)
In the case of conducting related party transactions, our company and its subsidiaries are required to obtain the approval of 
the Board of Directors of each company in accordance with the “Job Authority Rules” and any other related rules. Its subsidiaries
are required to report to our company after obtaining approval from the regional headquarters.
2. Cooperation with Stakeholders other than Shareholders
Under our Corporate Philosophy, “Making people’s lives healthier, safer and more fulfilling.” our company endeavors to cooperate 
as appropriate with various stakeholders including employees, clients, business connections, creditors and local communities.
Our company will present its values regarding appropriate cooperation with stakeholders, respect for their interests, and ethics for 
sound business activities, and stipulate and implement a code of conduct to be complied with by such members. Specifically, we
have formulated the “Corporate Philosophy” , “Our Behaviors” and the “Olympus Global Code of Conduct” as a code of conduct
for all groups, and have widely disseminated them among all officers and employees who belong to our company groups.
As a supervisor responsible for compliance-related matters, we have appointed a Chief Compliance Officer (CCO). Furthermore,
we have established a global contact desk which can be available 24 hours a day in multiple languages for any employees and
external stakeholders in addition to local internal compliance-related reporting system in each region,  We reports the status of
use thereof to the Audit Committee regularly and to the Board of Directors as necessary.
This document has been translated from the Japanese original (as submitted to the Tokyo Stock Exchange) for reference purposes only.  
Olympus Corporation assumes no responsibility for direct, indirect or any other forms of damages caused by misunderstanding from the translation. 
84

2 
3. Complete Information Disclosure and Secured Transparency 
Under the basic concept for all corporate activities, our Corporate Philosophy, “Making people’s lives healthier, safer and more 
fulfilling,” our company will disclose corporate information, such as management policy, financial condition, status of business 
activities and CSR activities in a fair, timely, appropriate and active manner for the purpose of obtaining all stakeholders’ correct 
understanding and trust. 
 
4. Responsibility of the Board of Directors, etc. 
(1) Role of the Board of Directors 
The Board of Directors determines basic management policy, matters related to the internal control system, and other important 
matters, and supervises directors and executive officers, in the execution of their duties. 
 
(2) Qualification of Directors  
Having high ethical standards as well as the experience, knowledge and ability required to create mid- to long-term corporate 
value, our directors spend a sufficient amount of time for the Board of Directors in order to fulfill their own obligations and 
responsibilities. 
 
(3) Diversity of the Board of Directors  
Our company considers the diversity of the composition of the Board of Directors in terms of experience, knowledge and ability, 
etc. regardless of nationality, race, and gender. 
 
(4) Scale of the Board of Directors 
Based on our group’s scale and business lines, we maintain an appropriate number of members, 15 or fewer persons, as stipulated 
in the Articles of Incorporation, in order to effectively and efficiently exercise the functions of the Board of Directors. 
 
(5) Independent Outside Director 
From the viewpoint of increasing the supervisory functions of the Board of Directors, more than half of the directors are 
independent outside directors. The independence standards are set forth by the Nominating Committee. 
 
(6) Chairman of the Board of Directors 
For the purpose of securing the separation of executive and supervisory function, an independent outside director serves as the 
chairman of the Board of Directors. 
 
(7) Committees for Nomination, Compensation and Audit 
The Board of Directors shall set up a Nominating Committee, Compensation Committee and Audit Committee. 
 
[Nominating Committee] 
• 
The Nominating Committee shall deliberate matters related to human resources at the director and executive officer level, 
and shall determine the content of proposals submitted to the general meeting of shareholders in relation to the appointment and 
dismissal of directors. 
• 
The Nominating Committee consists of three or more committee members selected from among the directors by the Board 
of Directors, and independent outside directors constitute the absolute majority thereof. An independent outside director serves 
as the chairman. 
 
[Compensation Committee] 
• 
The Compensation Committee shall deliberate matters related to compensation of directors and executive officers, and 
prescribe policy in relation to determining the details of compensation, etc. for individuals, and in accordance with the policy, 
determine the contents of compensation, etc. for individuals. 
• 
The Compensation Committee consists of three or more committee members selected from among the directors by the Board 
of Directors, and independent outside directors constitute the absolute majority thereof. An independent outside director serves 
as the chairman. 
 
[Audit Committee] 
• 
The Audit Committee shall carry out the following duties. 
1) Auditing the execution of duties by executive officers and directors, and creating audit reports 
2) Determining the content of proposals relating to the appointment, dismissal and non-reappointment of accounting auditors 
3) Other duties prescribed by law or by the Articles of Incorporation, and other matters recognized as necessary by the Audit 
Committee 
• 
The Audit Committee shall consist of at least three individuals selected from among the directors by the Board of Directors, 
of whom more than half shall be independent outside directors. The chairman of the committee shall be an independent outside 
director. Moreover, at least one member shall be an individual who possesses extensive knowledge related to financial and 
accounting. 
 
(8) Appointment Process of the Directors 
The Nominating Committee shall deliberate director candidates while making reference to the selection criteria, hold interviews, 
and determine the content of proposals submitted to the general meeting of shareholders in relation to the appointment and 
dismissal of directors. 
 
85

3 
(9) Fostering and Deciding the CEO’s Successor 
The Nominating Committee establishes a succession plan for the CEO, and reviews it periodically. 
As for determining the successor, the Nominating Committee discusses whether the candidates, including outside candidates, 
have qualifications that are suitable for the President, and provides opinions and advice to the Board of Directors. Thereafter, the 
successor is decided by the Board of Directors. 
 
(10) Compensation System 
Regarding officers’ compensation (directors and executive officers), the basic policy is to provide compensation that is suited to 
their duties, and to increase the awareness among the officers in order to: “Meet expectations of various stakeholders including 
shareholders by aiming to maximize corporate values.” Based on said policy, the Compensation Committee focuses on 
appropriately setting the compensation ratio linked to short and mid- and long-term performance, and decides officers’ 
compensation. 
 
(11) Management of the Board of Directors Meeting 
For the purpose of deciding on important matters and supervising business operations, agenda items for, time of, and the frequency 
of holding the Board of Directors meeting are set in order to facilitate necessary and sufficient discussion. In order to facilitate 
constructive discussions and the exchange of opinions at the Board of Directors meeting, materials are previously sent regarding 
matters to be discussed and matters to be reported at the Board of Directors meeting in consideration of the time required for the 
attendees to prepare for the Board of Directors meeting. Moreover, the Board of Directors meeting schedule and expected agenda 
items are prepared in advance. 
 
(12) Assembly for Outside Directors Only  
Aiming at information exchange and knowledge sharing, our company will hold an assembly for only outside directors as needed. 
 
(13) Evaluation of the Board of Directors Meeting 
Every year, the effectiveness of the Board of Directors is analyzed and evaluated including a third party’s perspectives, and an 
overview of the evaluation result is released. 
 
(14) Information Acquisition and Support System 
• Our company endeavors to actively provide the directors with information helpful for effectively fulfilling their roles and duties. 
• The outside directors of the Company may, whenever deemed necessary or appropriate, request an explanation or report from 
internal directors, executive officers or employees, or request the submission of internal materials. 
• Our company shall set up an office provided with suitable personnel, etc., so that the Nominating Committee, Compensation 
Committee, Audit Committee and any other committees can execute their duties appropriately. 
 
(15) Improvement through Study of the Directors 
The directors endeavor to improve themselves including by acquiring and updating, etc. their knowledge in order to fulfill their 
roles and duties. Our company provides newly-appointed outside directors with various programs for acquiring knowledge 
concerning our company, including tours to our company’ business office and factory, as well as study groups on our business, 
etc. 
 
5. Interaction with Shareholders 
For the purpose of our company’s continuous development and improvement of mid- to long-term corporate value, the Board of 
Directors have stipulated and announced the Policy for Improving the System and Initiatives for Promoting Constructive 
Interactions with Shareholders. 
 
Policy for Improving the System and Initiatives for Promoting Constructive Interactions with Shareholders 
 
1) 
Basic Policy 
For the purpose of our company’s continuous development and improvement of mid- to long-term corporate value, our company, 
centering on the CEO and the CFO, actively conducts constructive interactions with shareholders. The IR function assists such 
initiatives through internal information exchange and improving the system for providing shareholders’ opinions as feedback, etc. 
to the upper management team. 
 
2) 
Policy for Interactions by the CEO and CFO 
The President and the financial officer play a central role in conducting overall interactions with shareholders toward the 
realization of constructive interactions. Specifically, the CEO and the CFO will proactively establish opportunities for direct 
interactions with shareholders by conducting the following in addition to individual interviews with shareholders: briefing 
sessions for every quarterly settlement, small meetings, telephone conferences with overseas investors, domestic and international 
road shows on a regular basis, and participation in conferences held by securities firms, etc. 
 
3) 
Policy for IR Activities by the IR Function 
By putting the IR function in charge of IR activities, our company actively implements IR activities toward solid interactions with 
shareholders. Specifically, in addition to conducting individual interviews at any time as requested by shareholders, our company 
will regularly implement IR events, such as briefing sessions for individual investors and facility tours. Moreover, we will actively 
provide information to shareholders through the website, integrated reports, business reports for shareholders and the Convocation 
of the General Meeting of Shareholders, etc. 
 
86

4 
4) 
 Policy for Internal Information Exchange by the IR Function 
The IR function, as needed, exchanges information with the Corporate Strategy and Planning, Internal Control, the Treasury, the 
Accounting, and the Legal Affairs functions etc. on a daily basis, and establishes a project team if necessary, in order to build a 
coordinated collaboration system. Moreover, the IR function reports shareholders’ opinions and concerns obtained from 
interactions with shareholders centering on institutional investors at the Group Executive Committee as well as the Board of 
Directors meeting, if necessary. Thereafter, the contents of such opinions and concerns will be discussed. 
 
5) 
Policy for Insider Information Management when Interacting with Shareholders 
In accordance with the “Regulations for Insider Trading Prevention,” insider information is strictly managed. When interacting 
with shareholders, the IR function issues a reminder to the person in charge of the interaction, thereby preventing the divulgence 
of insider information. 
 
6) 
Revision and Abolition of this Policy 
Revision and abolition of this Policy shall be subject to a resolution of the Board of Directors. 
 [Disclosure based on the principles of the Corporate Governance Code] 
 
[Principle 1-4 Policy shareholdings] 
• In line with the Company’s “Basic Policy on Corporate Governance,” the Board of Directors specifically gives comprehensive 
consideration to the benefits and risks of its holdings, verifying the necessity of holdings for each individual issue, and sells shares 
which are not reasonable to hold. As of the end of March 2016 the Company held 64 issues worth 68 billion yen. This was reduced 
to 57 issues worth 27.9 billion yen at the end of March 2017, 48 issues worth 26.9 billion yen by the end of March 2018, 37 issues 
worth 18.9 billion yen at the end of March 2019, 29 issues worth 14.5 billion yen at the end of March 2020 and further decreased to 
18 issues worth 10.4 billion yen at the end of March 2021. 
• Details of shares held by the Company have been disclosed in annual securities reports, for your reference. 
Annual Securities Report For the Fiscal Year Ended March 31, 2021 (from April 1, 2020 to March 31, 2021) 
https://www.olympus.co.jp/ir/data/pdf/annual153PA.pdf 
• If a company that holds the Company’s shares as policy shareholdings other than pure investment makes an offer to sell, etc., the 
sale cannot be prohibited. 
• The Company’s policy regarding possession of listed shares as a policy measure and the criteria for exercise of voting rights for 
such policy shareholdings is stated in 1.-(3) of the “Basic Policy on Corporate Governance,” for your reference. 
 
[Principle 1-7 Related party transactions] 
Information concerning the framework of procedures when the Company and the Company’s subsidiaries conduct transactions with 
related parties is stated in 1.-(4) of the “Basic Policy on Corporate Governance,” for your reference. 
 
[Principle 2-6 Exercising the functions of corporate pension asset owners] 
Regarding the corporate pension fund of the Company, the Asset Management Committee, which is charged with deliberations and 
proposals concerning the investment management of pension assets, submits proposal to various conference bodies, such as the 
Governing Board and the Representatives Committee, where proposals are deliberated upon and after verification of the 
appropriateness thereof executed by the Olympus corporate pension fund.  
The Olympus corporate pension fund is subject to investment trust and pension insurance arrangements in accordance with policies 
and portfolios approved by the Asset Management Committee and the Representatives Committee. The actual fund management is 
mandated to a financial institution, with the investment status including stewardship activities being subject to quarterly monitoring 
in regular operations briefing sessions. The Asset Management Committee and the Representatives Committee consist of persons 
from the fields of human resources, accounting, and finance who have specialist expertise in the subject functions, as well as 
employee representatives, forming a framework capable of verifying the sound operations of the pension funds from the perspectives 
of professional expertise and beneficiary protection. 
 
[Principle 3-1 Complete information disclosure] 
In addition to appropriate disclosure based on laws and regulations, the Company voluntarily disseminates the following information 
in order to ensure transparency and fairness in decision-making and to realize effective corporate governance. 
(1) Corporate Philosophy and Corporate Strategy 
• Corporate Philosophy 
Employing the concept of responding to fundamental requests for health, safety and fulfillment from people around the world and 
society and widely contributing to society through its business activities as “Meaning of our existence,” its Corporate Philosophy, 
the Group restates the concept as “Making people’s lives healthier, safer and more fulfilling,” and all its activities are based on this 
philosophy. 
 
• Corporate Strategy 
As announced in January 2019, aiming to develop itself as a truly global medtech company while reaching a milestone of the 
centennial anniversary of the foundation, the Company developed a transformation plan “Transform Olympus,” and has striven to 
establish a foundation that ensures sustainable growth of the Group as a truly global medtech company by carrying out activities 
such as 1. establishing centralized global group management, 2. globally integrating human resources management, 3. optimizing 
and simplifying medical device business “Transform Medical,” 4. diversifying the Board of Directors, and 5. migrating to a 
company with Nominating Committee, etc. In November 2019, the Company also developed a medium- to long-term Corporate 
Strategy as the first step of developing itself as a truly global medtech company and for the purposes of fostering a more competitive 
corporate culture that encourages high performance and creating value for customers under the Company’s Corporate Philosophy 
Updated 
87

5 
“Making people’s lives healthier, safer and more fulfilling.” 
The Company’s strategic aspiration in this Corporate Strategy is to “become a globally-leading medtech company contributing to 
people’s health around the world through innovative value that benefits customers, such as patients and healthcare professionals, 
medical institutions and the medical economy,” and the Company has stipulated the core components for business growth and 
enhanced profitability as follows. 
1. Selection of and concentration on the corporate portfolio, 2. Strengthening our overwhelming position in Endoscopic Solutions 
Business, 3. Focus and scale the Therapeutic Solutions Business, 4. Leading the next-generation minimally invasive surgery market 
• The Company’s Corporate Philosophy and Corporate Strategy are published on the Company’s website and in integrated reports 
available for reference. 
(2) Basic concepts concerning corporate governance of the Company 
• As set out in the above section 1 “Basic concepts,” based on the respective principles of the Corporate Governance Code, the 
Company has formulated as its “Basic Policy on Corporate Governance” basic concepts and basic policies concerning corporate 
governance, which are available for reference. 
(3) Compensation of directors and executive officers 
• At the Company, the compensation of directors is determined by the Compensation Committee, which is chaired by an independent 
outside director and whose members consist in the majority of independent outside directors. The Compensation Committee holds 
deliberations on the linkage with short-term and medium-term business results in relation to the performance-linked compensation 
element, including the composition of bonuses and compensation in stocks, and conducts reviews each time the Corporate Strategy 
is rolled forward. 
The compensations of senior management members (meaning executive officers concurrently serving as directors; the same applies 
in the following.) are as stated above. 
(4) Election of directors and executive officers 
• At the Company, proposals for director candidate elections and dismissals are determined by the Nominating Committee, which is 
chaired by an independent outside director and whose members consist in the majority of independent outside directors, after it is 
discussed whether the candidate has experience, insight, etc. appropriate for directors. In addition, elections of executive corporate 
officers are determined by the Board of Directors after the Nominating Committee discusses whether the candidate has experience, 
insight, etc. appropriate for executive officers and develops proposals for elections. Elections of senior corporate officers are 
determined through interviews attended by the president and outside directors of the Nominating Committee. 
(5) The reasons for the election of each director 
• The reasons for the election of each director and skill matrix are described in the reference documentation to proposals for the 
election of directors, which is part of the convocation notice of the general meeting of shareholders and this report (II. Business 
management organization and other corporate governance structures related to business decisions, execution, and supervision, 1. 
Matters pertaining to organ structure and organization management, etc. and Directors Skills Matrix). 
Notice Regarding the Convocation of the General Meeting of Shareholders For the Fiscal Year Ended March 31, 2021 (from 
April 1, 2020 to March 31, 2021) 
https://www.olympus-global.com/ir/stock/pdf/meeting153p_02.pdf 
 
 
[Supplementary principle 4-1-1 Scope of delegation to the management team] 
Based on the Company’s policy of segregation of business execution and supervision, matters to be referred to the Board of Directors 
are set forth in the Board of Directors Regulations and the Standards for Referrals and Reports to the Board of Directors, respectively 
determined by the Board of Directors. These matters consist of basic policies of management, including statutory matters and matters 
set out in the Articles of Incorporation, etc., as well as important matters related to management, such as the Corporate Strategy. The 
management board executes business operations in accordance with the basic management policies and the Corporate Strategy 
determined by the Board of Directors. 
 
[Principle 4-9 Qualifications and standards for independent judgments by independent outside directors] 
The Board of Directors determines criteria for ensuring the independence of independent outside directors, which are detailed in this 
report, section II. 1. “Matters pertaining to organ structure and organization management, etc.,” sub-section “Independent officers.” 
The Nominating Committee, which consists in the majority of independent outside directors, assesses the independence of candidates, 
thereby ensuring practical effectiveness, and at the same time verifies that the selected candidates can be expected to contribute to 
the Board of Directors. 
 
[Supplementary principle 4-11-1 Balance, diversity and scale for the Board of Directors, and policies and procedures for election of 
the Directors] 
Balance and diversity for the Board of Directors, and policies and procedures for election of the Directors are stated in the section 
on “Basic Policy on Corporate Governance,” sub-section “4. Responsibility of the Board of Directors, etc.” 
As for the current composition, of 11 directors, eight are independent outside directors. In addition, of 11 directors, three have a 
citizenship other than Japanese nationality, and one is female. With multiple human resources equipped with abundant experience 
and insight in corporate management, finance and international business deployment, the board has a composition with consideration 
for internationality and gender as well. 
 
[Supplementary principle 4-11-2 Situation of concurrent posts for directors and audit & supervisory board members] 
Directors’ status as concurrently serving officers of other listed companies is disclosed annually as reference document to the notices 
regarding the convocation of the general meeting of shareholders, in business reports and in annual securities reports. 
Notice Regarding the Convocation of the General Meeting of Shareholders For the Fiscal Year Ended March 31, 2021 (from 
April 1, 2020 to March 31, 2021) 
https://www.olympus-global.com/ir/stock/pdf/meeting153p_02.pdf 
88

6 
Annual Securities Report For the Fiscal Year Ended March 31, 2021 (from April 1, 2020 to March 31, 2021) 
https://www.olympus.co.jp/ir/data/pdf/annual153PA.pdf 
 
[Supplementary principle 4-11-3 Self-evaluation for the Board of Directors] 
At the Board of Directors of the Company, an analysis and evaluation of the effectiveness of the Board of Directors overall is annually 
conducted, including from a third-party perspective. Since 2015, the Company has continuously implemented evaluations, primarily 
with self-evaluations through a questionnaire, and is sharing problems and promoting improvement to enhance effectiveness. After 
the transition to a company with Nominating Committee, etc. in 2019, the Company has understood matters for improvement, etc. 
to further increase the effectiveness of the Board of Directors and individual committees (Nominating Committee, Compensation 
Committee, and Audit Committee) and been promoting improvement. 
 
[Major initiatives for issues extracted in the effectiveness evaluation of the Board of Directors during the term of office of directors 
in FY2019] 
Initiatives for the Board of Directors and individual committees to further contribute to sustainable growth and increase in medium- 
to long-term corporate value in order for the Company to develop itself as a truly global medtech company have been complied as 
follows: 
1. Work to further increase the quality of management, and improve the speed of management. 
(i) Focus on monitoring important strategic issues 
(ii) To increase effectiveness of the Board of Directors, review how to operate the Board of Directors, selection of issues, and ideal 
ways and methods of information provision, and promote improvement 
(iii) Clarify responsibilities and roles of directors and executive officers 
2. Realize the optimal composition of directors for the Board of Directors from the standpoints of diversity and continuity. 
Develop a necessary matrix of candidates for directors from the viewpoint of “experience,” “insight” and “attributes,” and examine 
proposals for planned election and dismissal of directors as succession plans. 
3. Continuously make operational efforts to realize the best decision making and the further enhancement of Board of Directors’ 
deliberations. 
(i) Further strengthen the internal control structure 
(ii) Implement improvement of the risk management structure and process contributing to monitoring, and progress report 
 
[Overview of the evaluation regarding the effectiveness of the Board of Directors during the term of office of directors in FY2020] 
In this effectiveness evaluation, the evaluation of the Board of Directors was made for two main purposes of (a) confirming the 
direction of improvement of issues in the previous effectiveness evaluation and firmly establishing improvement activities, and (b) 
reaching an agreement in the Board of Directors on responsibilities to be carried out by the Board of Directors and how to fulfill a 
monitoring function more effectively for further strengthening of the supervisory function of the Board of Directors based on the 
Corporate Strategy aiming for continuous development as a global medtech company. 
• Evaluation method 
The evaluation was conducted for directors and executive officers through a questionnaire concerning the Board of Directors and 
each committee. Discussions were also held between all directors, and based on the opinions of directors during these discussions, 
the evaluations were discussed at the Board of Directors. The questionnaire was conducted based on the knowledge of external 
consultants in order to objectively measure the effects of improvements identified in the previous evaluation of the Board of Directors 
and to understand how the Board of Directors should monitor those improvements. Based on the results of the questionnaire, 
discussions were held several times to obtain the frank opinions of each director on the effective monitoring function of the Board 
of Directors of the Company. External consultants facilitated the discussion to objectively organize the issues and support the 
discussion. Subsequently, the Board of Directors discussed measures to improve the effectiveness of the Board of Directors based 
on the analysis results based on the discussions. 
 
• Summary of evaluation results 
As a result of the analysis and evaluation, we have confirmed that trust in the execution of the Board of Directors has been fostered 
and a common understanding has been formed in which the Board of Directors should appropriately expand the delegation of 
authority to executive officers and further accelerate management decision-making. 
Furthermore, the systemic foundation to support effective corporate governance has been secured for the Board of Directors of the 
Company as a company with Nominating Committee, etc. In addition, in terms of operations, we have also confirmed that substantial 
efforts have been continuously made to improve the effectiveness of the Board of Directors, such as through prior explanations to 
outside directors and information sharing and mutual exchange of opinions through meetings of outside directors, and such efforts 
have been well established. We identified the following responsibilities of the Board of Directors of the Company. “In order to 
contribute to the enhancement of Olympus’ corporate value through cooperation with the executives, the Board of Directors will: (i) 
deepen the recognition and insight of the business environment and management issues through constructive discussions with the 
executive officers; (ii) effectively supervise management decision-making and execution from a strategic and broad perspective; and 
(iii) support the promotion of strategy for the growth of Olympus as a truly global medtech company.” 
 
• Future initiatives 
Based on the aforementioned responsibilities of the Board of Directors and the confirmation on the common recognition of directors 
in discussions, the Board of Directors of the Company will promote the following initiatives in order to further improve the 
effectiveness of these initiatives. 
I. Going forward, in the execution of the Company’s Corporate Strategy to become a global medtech company, the Company will 
regard the proposals for product quality, research and development, etc., as a major important issue for the Board of Directors, and 
continue to promote initiatives to further deepen discussions on such proposals. 
II. In light of the fact that it is important for the Board of Directors to understand the reality of the Company’s management, including 
89

7 
the issues of execution, their historic background, and corporate culture, in supervising management, the Board of Directors will 
strive to organize and present specific issues in relevant agenda items and share the importance, complexity, and broad significance 
of such issues in order to promote overall understanding, which includes a sensible understanding among the members of the Board 
of Directors. 
III. We will ensure the effective operation of the three committees (Nominating, Compensation and Audit Committees) and 
strengthen cooperation between the three committees and the entire Board of Directors. 
IV. In order to ensure the sustainable operation of the “Board Succession Plan,” the Board of Directors shall clarify the optimum 
composition (skill matrix) to effectively fulfill its duties, taking into account the management strategy and management issues of the 
time, and the Nominating Committee shall evaluate and appoint directors in a systematic manner for its realization. 
 
An overview of the evaluation of the Board of Directors is published on the website of the Company. 
Board of Directors: https://www.olympus-global.com/company/governance/board.html 
 
[Supplementary principle 4-14-2 Training policy for directors and audit & supervisory board members] 
With regard to training for directors, the Company’s policy is to support the acquisition of knowledge about the Company by carrying 
out visits to the Company’s major business bases such as business offices and factories, etc., briefing sessions, and business study 
sessions in addition to providing opportunities to acquire knowledge about the Company’s Corporate Strategy and corporate 
governance structure for newly inaugurated directors including outside directors. Additionally, it is a policy of the Company to 
arrange for, and cover the cost of, external training sessions for directors to acquire basic knowledge necessary for the performance 
of directors’ duties with a view to deepening directors’ understanding of their roles and responsibilities. 
 
[Principle 5-1 Policy concerning constructive interaction with shareholders] 
Policies concerning the creation of frameworks and efforts to promote the constructive interaction with shareholders are described 
in the section “Basic Policy on Corporate Governance,” sub-section “5. Interaction with Shareholders.” 
 
2. Capital structure 
Foreign shareholder ratio 
30% or more 
 
[Main shareholders] 
 
Name 
Number of shares held (shares) 
Ratio (%) 
The Master Trust Bank of Japan, Ltd. (trust accounts) 
169,323,100 
13.17 
JP MORGAN CHASE BANK 385632 
92,419,874 
7.19 
Custody Bank of Japan, Ltd. (trust accounts) 
73,115,000 
5.69 
Nippon Life Insurance Company 
53,146,472 
4.13 
SMBC Trust Bank Ltd. (Sumitomo Mitsui Banking Corporation 
Pension Trust) 
45,616,000 
3.55 
MUFG Bank, Ltd. 
43,522,344 
3.39 
STATE STREET BANK AND TRUST COMPANY 505010 
42,787,084 
3.33 
SSBTC CLIENT OMNIBUS ACCOUNT 
33,854,835 
2.63 
MSCO CUSTOMER SECURITIES 
23,495,015 
1.83 
STATE STREET BANK WEST CLIENT - TREATY 505234 
18,376,712 
1.43 
 
Controlling shareholders (excluding parent company) 
――― 
Parent company 
None 
 
Supplementary information 
 
――― 
 
Updated 
90

8 
3. Corporate attributes 
Listed Stock Market and Market Section 
Tokyo Stock Exchange First Section 
Fiscal Year-End 
March 
Industry type 
Precision instruments 
Number of group employees at the end of the previous 
fiscal year 
1,000 or more 
Consolidated sales in the previous fiscal year 
100 billion yen to under 1 trillion yen 
Number of consolidated subsidiaries at the end of the 
previous fiscal year
 
100 to 299 
 
4. Guidance on measures to protect minority shareholders when conducting transactions with controlling 
shareholders 
――― 
 
5. Other special circumstances that may have significant impact on corporate governance 
――― 
 
Updated 
91

9 
II Business management organization and other corporate governance structures related to 
business decisions, execution, and supervision 
1. Matters pertaining to organ structure and organization management, etc. 
Organizational form 
A company with Nominating Committee, etc. 
[Directors] 
Number of directors pursuant to the Articles of 
Incorporation 
15 
Tenures of directors pursuant to the Articles of 
Incorporation 
1 year 
Chairman of the Board of Directors 
Outside directors 
Number of directors 
 
11 
[Outside Directors] 
Number of outside directors 
 
8 
Number of outside directors designated independent 
officers
 
8 
 
Company relationships (1) 
 
 
Name 
Attribute 
Relationship with the Company* 
a 
b 
c 
d 
e 
f 
g 
h 
i 
j 
k 
Sumitaka Fujita 
From another company 
 
 
 
 
 
 
 
 
 
 
 
Susumu Kaminaga 
From another company 
 
 
 
 
 
 
 
 
 
 
 
Tetsuo Iwamura 
From another company 
 
 
 
 
 
 
 
 
 
 
 
Yasumasa Masuda 
From another company 
 
 
 
 
 
 
 
 
 
 
 
Atsushi Iwasaki 
From another company 
 
 
 
 
 
 
 
 
 
 
 
David Robert Hale 
From another company 
 
 
 
 
 
 
△ 
 
 
 
 
Jimmy C. Beasley 
From another company 
 
 
 
 
 
 
 
 
 
 
 
Sachiko Ichikawa 
From another company 
 
 
 
 
 
 
 
 
 
 
 
* Item selection concerning relationship with the Company 
* Marked “○” if recently or currently applicable to the person in question and marked “△” if previously applicable. 
* Marked “●” if recently or currently applicable to a relative in question and marked “▲” if previously applicable. 
a 
Business executive of a listed company or its subsidiary 
b 
Business executive or non-executive director of a listed company’s parent 
c 
Business executive of a listed company’s affiliate or subsidiary 
d 
Person whose main transaction counterparty is a listed company or a business executive thereof 
e 
Main transaction counterparty of a listed company or a business executive thereof 
f 
Consultant, accounting expert, or legal expert deriving from a listed company large financial gains or other property (other than 
officers’ remuneration)  
g 
Main shareholder of a listed company (if that shareholder is a corporation, a business executive thereof) 
h 
Business executive (only the person in question) of a transaction counterparty of a listed company (other than items d, e, and f) 
i 
Business executive of an entity in a relationship of mutual employment as outside officers (only the person in question) 
j 
Business executive of a recipient of a donation from a listed company (only the person in question) 
k 
Other 
Updated 
Updated 
Updated 
Updated 
92

10 
Company relationships (2) 
 
 
Name 
Committee affiliation 
Indepen-
dent 
officer 
Supplementary 
explanation concerning 
applicable items 
Reasons for appointment 
Nominating 
Committee 
Compensation 
Committee 
Audit 
Committee 
Sumitaka 
Fujita 
○ 
 
 
○ 
There is no fact that falls 
under attribute 
information. 
Mr. Sumitaka Fujita has extensive experience and 
diverse knowledge as a business manager at 
ITOCHU Corporation. He also possesses a high 
level of insight, expertise, and capabilities that are 
expected of an Outside Director of the Company 
through his experience as an Outside Director and 
Outside Auditor at other companies and his 
experience as the Chairman of the Japan 
Association for Chief Finance Officers. Since Mr. 
Fujita took the post of Outside Director of the 
Company in April 2012, he has been giving 
guidance/advice to the business management of 
the Company at the Board of Directors. In 
addition, he contributed to the development of a 
transparent director compensation system as the 
Chairman of the Compensation Committee which 
was established voluntarily. Since June 2018, he 
has been leading the Board of Directors as the 
Chairman of the Board of Directors of the 
Company. Furthermore, after the transition to a 
company with Nominating Committee, etc., in 
June 2019, he facilitated decisions of contents of 
an agenda item to elect directors as the Chairman 
of the Nominating Committee in addition to the 
supervision of the business execution of the 
Company at the Board of Directors. The 
Company expects that Outside Directors will 
supervise management from the perspective of 
achieving sustainable growth of the Company and 
enhancing corporate value over the medium to 
long term as entrusted by shareholders, and will 
provide advice based on their own knowledge. 
Based on this, the Company has determined that 
he is an indispensable person for the composition 
of the Board of Directors and nominated him. 
The appointed person meets the independence 
criteria and is therefore designated as an 
independent officer. 
Susumu 
Kaminaga 
 
○ 
 
○ 
There is no fact that falls 
under attribute 
information. 
Mr. Susumu Kaminaga has extensive experience 
and diverse knowledge as a business manager at 
Sumitomo Precision Products, Co., Ltd. in 
addition to his long experience in global business 
development in advanced technology fields. In 
addition, through his experience as an Outside 
Director at other companies, he possesses a high 
level of insight, expertise, and capabilities that are 
expected of an Outside Director of the Company. 
Since Mr. Kaminaga took the post of Outside 
Director of the Company in June 2016, he has 
been giving guidance/advice to the business 
management of the Company at the Board of 
Directors and the Compliance Committee 
voluntarily established. In addition, he has been 
serving as a member of the Compensation 
Committee since June 2017. Since the transition 
to a Company with Nominating Committee, etc., 
in June 2019, he has been taking charge of the 
operation of the Compensation Committee as the 
Chairman since February 2020 in addition to the 
supervision of the business execution of the 
Company at the Board of Directors. The 
Company expects that Outside Directors will 
Updated 
93

11 
Name 
Committee affiliation 
Indepen-
dent 
officer 
Supplementary 
explanation concerning 
applicable items 
Reasons for appointment 
Nominating 
Committee 
Compensation 
Committee 
Audit 
Committee 
supervise management from the perspective of 
achieving sustainable growth of the Company and 
enhancing corporate value over the medium to 
long term as entrusted by shareholders, and will 
provide advice based on their own knowledge. 
Based on this, the Company has been determined 
that he is an indispensable person for the 
composition of the Board of Directors and 
nominated him. 
The appointed person meets the independence 
criteria and is therefore designated as an 
independent officer. 
Tetsuo 
Iwamura 
○ 
○ 
 
○ 
There is no fact that falls 
under attribute 
information. 
Mr. Tetsuo Iwamura has an extensive experience 
and diverse knowledge as a business manager at 
Honda Motor Co., Ltd. In addition, through his 
long experience in global expansion in the sales 
marketing, manufacturing and development field 
at Honda Motor Co., Ltd., he has a high level of 
insight, expertise, and capabilities that are 
expected of an Outside Director of the Company. 
Since Mr. Iwamura took the post of Outside 
Director of the Company in June 2017, he has 
been giving guidance/advice to the business 
management of the Company at the Board of 
Directors and the Nominating Committee and 
Compliance Committee voluntarily established. 
After the transition to a company with 
Nominating Committee, etc., in June 2019, he 
facilitated decisions of contents of an agenda item 
to elect directors as a member of the Nominating 
Committee in addition to the supervision of the 
business execution of the Company at the Board 
of Directors. In addition, since July 2020, he has 
facilitated decisions regarding executive 
compensation as a member of the Compensation 
Committee. The Company expects that Outside 
Directors will supervise management from the 
perspective of achieving sustainable growth of 
the Company and enhancing corporate value over 
the medium to long term as entrusted by 
shareholders, and will provide advice based on 
their own knowledge. Based on this, the 
Company has determined that he is an 
indispensable person for the composition of the 
Board of Directors and nominated him. 
The appointed person meets the independence 
criteria and is therefore designated as an 
independent officer. 
Yasumasa 
Masuda 
 
 
○ 
○ 
There is no fact that falls 
under attribute 
information. 
Mr. Yasumasa Masuda has extensive experience 
and diverse knowledge as a business manager in 
the healthcare industry at Astellas Pharma Inc. In 
addition, through his experience as an 
independent non-executive officer at the Deloitte 
Tohmatsu Group, he possesses a high level of 
insight, expertise, and capabilities that are 
expected of an Outside Director of the Company. 
Since Mr. Masuda took the post of Outside 
Director of the Company in June 2018, he has 
been giving guidance/advice to the business 
management of the Company at the Board of 
Directors and the Nominating Committee 
established voluntarily. After the transition to a 
company with Nominating Committee, etc., in 
June 2019, he facilitated decisions of contents of 
94

12 
Name 
Committee affiliation 
Indepen-
dent 
officer 
Supplementary 
explanation concerning 
applicable items 
Reasons for appointment 
Nominating 
Committee 
Compensation 
Committee 
Audit 
Committee 
an agenda item to elect directors, and decided 
directors’ compensations as a member of the 
Nominating Committee and the Compensation 
Committee in addition to the supervision of the 
business execution of the Company at the Board 
of Directors. The Company expects that Outside 
Directors will supervise management from the 
perspective of achieving sustainable growth of 
the Company and enhancing corporate value over 
the medium to long term as entrusted by 
shareholders, and will provide advice based on 
their own knowledge. Based on this, the 
Company has determined that he is an 
indispensable person for the composition of the 
Board of Directors and nominated him. 
The appointed person meets the independence 
criteria and is therefore designated as an 
independent officer. 
Atsushi 
Iwasaki 
 
 
○ 
○ 
There is no fact that falls 
under attribute 
information. 
Mr. Atsushi Iwasaki has extensive experience and 
diverse knowledge as a certified public 
accountant. In addition, through his experience as 
an Outside Director and Outside Audit & 
Supervisory Board Member at other companies, 
he possesses a high level of insight, expertise, and 
capabilities that are expected of an Outside 
Director of the Company. Since Mr. Iwasaki took 
the post of Audit & Supervisory Board Member 
of the Company in June 2016, he has been 
auditing/supervising the business execution of the 
Company at the Audit & Supervisory Board and 
the Board of Directors. In addition, after the 
transition to a company with Nominating 
Committee, etc., in June 2019, he conducted an 
audit on the execution of duties of the Directors 
and the Executive Officers of the Company as a 
member of the Audit Committee in addition to the 
supervision of the business execution of the 
Company at the Board of Directors. The 
Company expects that Outside Directors will 
supervise management from the perspective of 
achieving sustainable growth of the Company and 
enhancing corporate value over the medium to 
long term as entrusted by shareholders, and will 
provide advice based on their own knowledge. 
Based on this, the Company has determined that 
he is an indispensable person for the composition 
of the Board of Directors and nominated him. 
The appointed person meets the independence 
criteria and is therefore designated as an 
independent officer. 
95

13 
Name 
Committee affiliation 
Indepen-
dent 
officer 
Supplementary 
explanation concerning 
applicable items 
Reasons for appointment 
Nominating 
Committee 
Compensation 
Committee 
Audit 
Committee 
David 
Robert 
Hale 
○ 
 
 
○ 
Mr. David Robert Hale 
is a Partner of Value Act 
Capital Management 
L.P. Previously, Value 
Act Capital Master 
Fund, L.P. controlled by 
Value Act Capital 
Management L.P. held 
more than 5% of the 
total number of voting 
rights of the Company 
and the Company 
deemed Mr. David 
Robert Hale not an 
independent officer 
considering the 
Company’s criteria for 
independence of Outside 
Officers. However, as pf 
March 31, 2021, the 
voting rights of the 
Company held by the 
said company consist of 
less than 5% of the total 
number of voting rights 
of the Company and the 
Company’s 
independence criteria is 
satisfied, and therefore 
the Company designates 
him as independent 
officer. 
Mr. David Robert Hale is a Partner of Value Act 
Capital Management L.P. (hereinafter called 
“VAC”), one of the Company’s shareholders. He 
has a track record of helping global companies 
transform themselves with his knowledge of the 
global capital markets and the healthcare industry 
as a business management consultant and investor 
with experience in diverse industries, and he 
possesses a high level of insight, expertise, and 
capabilities that are expected of an Outside 
Director of the Company. Since Mr. Hale took the 
post of Outside Director of the Company in June 
2019, he has been giving guidance/advice to the 
business management of the Company at the 
Board of Directors. In addition, he has 
participated in decisions on the evolution of the 
board as a member of the Nominating 
Committee. The Company expects that Outside 
Directors will supervise management from the 
perspective of achieving sustainable growth of 
the Company and enhancing corporate value over 
the medium to long term as entrusted by 
shareholders, and will provide advice based on 
their own knowledge. Based on this, the 
Company has determined that he is an 
indispensable person for the composition of the 
Board of Directors and nominated him as a 
candidate for Outside Director again. Since he 
serves as a partner at VAC, which is one of the 
Company’s shareholders, the Company believes 
that he will contribute to the enhancement of the 
Company’s corporate value by reflecting 
shareholders’ voices into the business 
management of the Company. 
The appointed person meets the independence 
criteria and is therefore designated as an 
independent officer. 
Jimmy C. 
Beasley 
 
○ 
 
○ 
There is no fact that falls 
under attribute 
information. 
Through his 30 years of global business 
experience and extensive management experience 
in the C. R. Bard Group, one of the world’s 
leading companies in the healthcare industry, Mr. 
Jimmy C. Beasley possesses a high level of 
insight, expertise, and capabilities that are 
expected of an Outside Director of the Company. 
Since Mr. Beasley took the post of Outside 
Director of the Company in June 2019, he has 
been giving guidance/advice to the business 
management of the Company at the Board of 
Directors. In addition, he facilitated decisions of 
directors’ compensations as a member of the 
Compensation Committee. The Company expects 
that Outside Directors will supervise management 
from the perspective of achieving sustainable 
growth of the Company and enhancing corporate 
value over the medium to long term as entrusted 
by shareholders, and will provide advice based on 
their own knowledge. Based on this, the 
Company has determined that he is an 
indispensable person for the composition of the 
Board of Directors and nominated him. 
The appointed person meets the independence 
criteria and is therefore designated as an 
independent officer. 
96

14 
Name 
Committee affiliation 
Indepen-
dent 
officer 
Supplementary 
explanation concerning 
applicable items 
Reasons for appointment 
Nominating 
Committee 
Compensation 
Committee 
Audit 
Committee 
Sachiko 
Ichikawa 
 
 
○ 
○ 
There is no fact that falls 
under attribute 
information. 
Ms. Sachiko Ichikawa has extensive experience, 
broad knowledge and a global perspective as an 
attorney (in Japan and New York, U.S.A.) and a 
certified public accountant in the U.S. In addition, 
through her experience as an Outside Director 
and Outside Audit & Supervisory Board Member 
at other companies and as a Director of The 
Board Director Training Institute of Japan, she 
possesses a high level of insight, expertise, and 
capabilities that are expected of an Outside 
Director of the Company. The Company expects 
that Outside Directors will supervise management 
from the perspective of achieving sustainable 
growth of the Company and enhancing corporate 
value over the medium to long term as entrusted 
by shareholders, and will provide advice based on 
their own knowledge. Based on this, the 
Company has determined that she is an 
indispensable person for the composition of the 
Board of Directors and nominated her. 
The appointed person meets the independence 
criteria and is therefore designated as an 
independent officer. 
[Committees] 
Committee compositions and chairman attributes 
 
 
 
 
Total number of 
members 
Number of full-
time members 
Number of  
internal directors 
Number of  
outside directors 
Chairman 
Nominating 
Committee 
4 
0 
1 
3 
Outside director 
Compensation 
Committee 
3 
0 
0 
3 
Outside director 
Audit Committee 
4 
1 
1 
3 
Outside director 
[Executive officers] 
Number of executive officers 
5 
 
Concurrently held positions 
 
Name 
Representative 
authority 
Concurrent position as director 
Concurrent  
position as  
employee 
 
Nominating 
Committee 
member 
Compensation 
Committee 
member 
Yasuo Takeuchi 
Yes 
Yes 
○ 
× 
No 
Akihiro Taguchi 
No 
No 
× 
× 
No 
Nacho Abia 
No 
No 
× 
× 
No 
Chikashi Takeda 
No 
No 
× 
× 
No 
Stefan Kaufmann 
No 
Yes 
× 
× 
No 
[Audit framework] 
Directors and employees assigned to assist with the 
duties of the Audit Committee 
Yes 
Updated 
97

15 
Matters concerning relevant directors’ and employees’ independence from executive officers 
The Company shall allocate a dedicated employee who will assist with the Audit Committee’s duties. Employees can be deployed 
in dual roles as needed. In addition, the Company shall set forth internal corporate regulations to ensure independence from 
execution as stated below, and ensure effectiveness of directions from the Audit Committee to such employees. 
1) While employees who have been assigned to assist in the duties of the Audit Committee assist in those duties, directors
(excluding Audit Committee members), executive officers and employees, etc. shall not give them commands or instructions.
2) The appointment, dismissal, transfer, wage or personnel evaluation of employees who are assisting the Audit Committee with
their duties shall be decided only after obtaining the approval of the Audit Committee.
Cooperation of Audit Committee, accounting auditor, and internal audit department 
The Audit Committee members have, at the Audit Committee meetings, received reports from the internal audit function and the 
accounting auditor, respectively, and engaged in cooperation, such as by exchanging opinions with the internal audit function and 
the accounting auditor. Moreover, outside directors receive through the meetings of the Board of Directors regular reports from 
the Audit Committee. 
[Independent officers] 
Number of independent officers 
8 
Other matters concerning independent officers 
The Company designated eight outside directors as independent officers. No special interest relation exists between outside 
directors and the Company. 
[Concepts concerning the independence of outside officers] 
The Company has established the following “Criteria concerning the independence of outside officers” to clarify the concepts of 
outside officers’ independence. 
[Criteria concerning the independence of outside officers] 
1)
No remuneration (excluding officer remunerations from the Company) or other property was directly received from 
the Company or an affiliate of the Company in any of the last 10 years (collectively, the “Group”) in an amount 
exceeding 10 million yen. If the person in question is a consultant, accounting professional, or legal specialist, no affiliated 
organization of the person in question has received from the Group a remuneration or other payment in an amount exceeding 
10 million yen.
2)
In the last 10 years, the person in question has held no position as executive director, executive officer, corporate officer, or 
as employee in a position as general manager or higher in a company that meets any of the following conditions.
(1) In any fiscal year of the past 10 years, the transaction amount with the Group exceeds 2% of consolidated revenue 
on either side.
(2) A large shareholder of the Company (directly or indirectly holding more than 5% of the total voting rights of the 
Company. The same applies in the following.).
(3) The Group is a large shareholder.
(4) Effectively an interested party in relation to the Group (main bank, consultant, etc.).
(5) The Group and the relevant company have a relationship in which they mutually dispatch and appoint directors.
3)
The livelihood of the person in question is not predicated on a person corresponding to items 1) or 2) above.
4)
The person in question is not the spouse or a relative up to the third degree of a director, executive director, corporate officer, 
or of an employee holding a position at the Group as general manager or higher.
5)
The person in question does not belong to an audit firm that conducts statutory audits of the Group.
6)
Further to the foregoing items, the person in question has no relationship of significant interest that renders independence 
doubtful. 
Updated 
Updated 
98

16 
[Incentives] 
Implementation status of incentives for directors and 
executive officers  
Introduction of a performance linked compensation system 
 
Supplementary explanation of relevant items 
 
 
Details on the Company’s compensation system are provided in the section “Disclosure content of policy for determining 
compensation amount or the calculation method.” 
 
Stock option awardees 
 
 
Supplementary explanation of relevant items 
――― 
[Compensations of directors and executive officers] 
Disclosure status (compensation of individual  
director) 
Individual compensation is partially disclosed 
Disclosure status (compensation of individual  
executive officer) 
 
Individual compensation is partially disclosed 
 
Supplementary explanation of relevant items 
 
 
The Company has disclosed the below compensation results for directors and executive officers for the fiscal year ended March 31, 
2021 in its business report and annual securities report. 
 
＜Compensation for the fiscal year ended March 31, 2021＞ 
 
(1) Total amount by type of compensation, etc., and the number of officers subject to compensation, etc. 
Officer classification 
Total amount of 
compensation, etc. 
(in millions of yen) 
Total compensation by type (in millions of yen) 
Number of subject 
officers (persons) 
Basic 
compensation 
Performance-
linked 
compensation, 
etc. 
Non-monetary 
compensation, 
etc. 
Director 
Inside 
717 
450 
182 
86 
5 
Outside 
149 
129 
– 
20 
10 
Total 
866 
578 
182 
106 
15 
Executive Officer 
431 
191 
173 
67 
3 
Notes: 
1. Basic compensation shows the amount paid for the fiscal year ended March 31, 2021. Performance-linked compensation, etc. 
show the amounts of short-term incentive compensation for the applicable period, the fiscal year ended March 31, 2021 (to be paid 
in July 2021), and non-monetary compensation, etc. shows the amount of long-term incentive compensation to be recorded as 
expenses for the fiscal year ended March 31, 2021. Performance-linked stock compensation (PSU) of 87 million yen is only 
recorded in non-monetary compensation, etc. and is not recorded in performance-linked compensation, etc. 
2. There are two other executive officers (who double as director) in addition to the three executive officers mentioned above, 
compensation, etc. of the two are included in compensation for directors. 
3. The Company does not pay performance-linked compensation, etc. to directors who do not double as an executive officer. 
4. The aforementioned inside directors include the two inside directors who retired at the close of the General Meeting of 
Shareholders for the fiscal year ended March 31, 2020 held on July 30, 2020. Outside directors include the one outside director 
who retired at the close of the same General Meeting of Shareholders. 
5. One outside director has requested to decline his compensation and the Compensation Committee has decided to not pay the 
compensation to him. However, he is included in the number of outside directors mentioned above. 
 
(2) Total amount of consolidated remuneration, etc. for each officer of the submitting company whose total amount of consolidated 
remuneration, etc. is 100 million yen or more. 
Updated 
Updated 
Updated 
99

17 
(i) The total amount of consolidated compensation, etc. for the fiscal year ended March 31, 2021 for each officer is as follows. 
Name 
Officer 
classification 
Total amount of  
compensation, etc. 
(in millions of yen) 
Total compensation by type (in millions of yen) 
Basic  
compensation 
Performance-
linked 
compensation, 
etc. 
Non-monetary 
compensation, 
etc. 
Yasuo Takeuchi 
Director, 
Executive Officer 
234 
91 
87 
57 
Stefan Kaufmann 
Director, 
Executive Officer 
425 
302 
95 
28 
Akihiro Taguchi 
Executive Officer 
115 
42 
47 
26 
Nacho Abia 
Executive Officer 
239 
118 
91 
30 
 
Note: 
This table shows the amounts of compensation paid in the current fiscal year (the fiscal year ended March 31, 2021) and includes 
amounts equivalent to housing and pensions based on tax adjustments for compensation outside of the country of origin and 
individual agreements. Performance-linked compensation, etc. lists the amount of short-term incentive remuneration with the 
applicable period of the current fiscal year (the fiscal year ended March 31, 2021, schedule to be paid in July 2021), and non-
monetary compensation, etc. lists the amount of long-term incentive remuneration to be recorded as expenses in the current fiscal 
year (the fiscal year ended March 31, 2021). Furthermore, performance-linked stock compensation (PSU) is recorded only in non-
monetary compensation, etc., and is not recorded in performance-linked compensation, etc. 
 
(3) Target and actual values related to performance-linked compensation 
(i) Short-term incentive compensation (STI) 
 
 For short-term incentive compensation (STIs) for executive officer with the applicable period of the fiscal year ended March 31, 
2021, the target and actual values of the respective performance indicators are as follows. 
Performance evaluation 
index 
Target value 
Actual value 
Achievement rate 
Payment rate 
Revenue (20%) 
¥669.5 billion 
¥715.4 billion 
107% 
21.4% 
General and 
administrative expenses 
(20%) 
¥384.2 billion 
¥358.9 billion 
120% 
24% 
Strategic goals (60%) 
– 
– 
111% 
66.6% 
Notes: 
1. The contents and target values related to the strategic goals in the performance evaluation index have been set mainly in 
the “Measures to Be Implemented in Fiscal Year 2021” disclosed in June 2020. 
2. Revenue: Forex-adjusted and excluding the Imaging Products Business, which was transferred during the fiscal year. 
3. General and administrative expenses: Forex-adjusted and excluding the Imaging Products Business, which was transferred 
during the fiscal year. Excluding other gains and losses. 
 
1.The upper limit of payments is set at 131.5 % based on the average share price in the most recent 30 business days of the previous 
fiscal year and the current fiscal year. 
 
2.As a result of the above, the payment rate is 112% for the total payment rate of each performance evaluation index. In addition, 
the payment amount was determined by multiplying this payment rate by the standard amount of performance-linked compensation 
(STI). 
 
(ii) Long-term incentive compensation (LTI): Performance-linked stock compensation (PSU), which is non-monetary 
compensation, etc. 
 
For executive directors through the fiscal year ended March 31, 2019 and for executive officers through the fiscal year ended 
March 31, 2021 after the transition to a company with a Nominating Committee, etc., we have listed the performance-linked stock 
compensation (18PSU) as non-monetary compensation with the applicable period of the fiscal year ended March 31, 2021 as the 
final fiscal year of the assessment period. 
 
1. Performance-linked stock compensation (18PSU) is intended to stimulate motivation to increase medium- to long-term business 
growth and profitability and to reward the results of such efforts, and with an applicable period of three fiscal years, has adopted a 
performance evaluation index of (i) the average rate of revenue growth over the applicable period and (ii) the total profit attributable 
to owners of parent (hereinafter “Profit”) for the applicable period. In addition, the PSU has been set to grant a number of common 
shares of the Company equivalent to an amount adjusted within the range of 0 to 150% according to the achievement rate of the 
targets at the end of the applicable period. 
 
 
 
100

18 
2. Target and actual values of each performance indicator for 18PSU are as follows. 
Performance 
evaluation index 
Target value 
Minimum value 
Actual value 
Payment rate 
Total Profit for 
applicable period 
¥291.9 billion 
¥145.9 billion 
¥72.7 billion 
0% 
Average rate of 
revenue growth over 
applicable period 
6.4% 
3.2% 
0.2% 
0% 
Notes: 
1. Total Profit includes the Imaging Business for the fiscal year ended March 31, 2019 and the fiscal year ended March 31, 
2020, and does not include the Imaging Business for the fiscal year ended March 31, 2021. 
2. The actual value for the average rate of revenue growth does not include the Imaging Business for the entire period. 
 
3. The payment rate is 0% as the actual value fell below the target value. 
 
<Other decisions regarding compensation for the fiscal year ended March 31, 2021 term> 
In order to improve corporate value, we examined the improvement of the system to further strengthen compensation governance 
and decided to apply the following from compensation for the fiscal year ending March 31, 2022. 
[Compensation risk management] The RSU’s rights will be defined after six months following the time of retirement of an 
executive officer. 
 
Availability of policy for determining compensation 
amount or the calculation method 
 
Available 
 
 
Disclosure content of policy for determining compensation amount or the calculation method 
(1) Basic policy 
Our basic policy regarding officer compensation is to make officers have a strong sense of awareness that maximize the corporate 
value and meet expectations of various stakeholders, and reward their responsibilities with suitable and appropriate treatments. 
 
(2) Structure of the Compensation Committee and reporting to the Board of Directors 
The policy to determine the compensation of directors and executive officers and the details of individual compensation are 
discussed and determined by the Compensation Committee, which consists of at least three members, the majority of whom are 
independent outside directors. The Compensation Committee reports the determined policy and compensation details to the Board 
of Directors. 
 
(3) Details of policy to determine the amount of compensation, etc. for officers or the calculation method thereof and how the 
policy is determined 
(i) At the Company as a company with nominating committee, etc., the Compensation Committee the majority members of which 
are occupied by independent outside directors discusses/determines policy to determine compensations, etc., of the Company’s 
directors and executive officers on an individual basis, details of compensation, etc. and compensation rules. The Compensation 
Committee determined the details of compensations, etc. for the fiscal year ended March 31, 2021 after discussing matters 
concerning the determination of compensations, etc., including the consistency of the policy to determine compensations, etc., of 
directors and executive officers on an individual basis with how the details and amounts of compensations, etc., are determined, 
and the rationality of the process of deriving the details and amounts of compensations, etc., by applying numerical values and 
other relevant factors to the way they are determined, and the Company has decided that this is in accordance with said policy for 
determination. 
(ii) The Compensation Committee retained “Pay Governance,” an international independent compensation consultant, to provide 
objective and professional advice and information, and to support investigations. They attended 12 of 14 meetings of the 
Compensation Committee. 
 
< Compensation of directors for the fiscal year ended March 31, 2021> 
(1) Level of compensation for directors for the fiscal year ended March 31, 2021 
(i) In order to set the directors’ compensation at competitive compensation levels for securing and retaining talented personnel, the 
compensation level shall be 50-75% compared with the peer group in the role responsibilities and each residence. 
1. Full-time non-executive director (Resident in Japan) 1 person 
2. Part-time non-executive director (Residents in Japan) 7 people 
3. Part-time non-executive director (Non-residents in Japan) 2 persons 
4. Executive officers who double as director 2 persons 
(ii) Compensation levels for each peer group are confirmed using objective compensation survey data from external specialist 
organizations. 
(iii) If a director requests to decline compensation, the Compensation Committee will confirm and decide on the response. 
 
(2) Compensation composition of directors for the fiscal year ended March 31, 2021 
Updated 
101

19 
(i) Non-executive directors perform supervisory functions at various points of contact with the Board of Directors meeting, 
managements, and executive officers, and contribute to the creation of corporate value. Therefore, in addition to monetary 
compensation (basic compensation) for supervisory functions, non-performance-linked stock compensation (non-monetary 
compensation) is granted as compensation for the creation of corporate value. 
(ii) Stock compensation for non-executive directors shall be subsequent grant-type restricted stock compensation (RSU: Restricted 
Stock Unit), and the right will be defined at retirement for those directors who live in Japan. The right will be defined on an 
individual basis in accordance with a general method of stock compensation in each region for those directors who do not live in 
Japan. 
(iii) Stock compensation will be set at 3 million yen for both Japanese and non-Japanese residents. The number of shares to be 
given will be calculated based on the share price at the time of assumption of office at the general meeting of shareholders, and the 
number of shares will be given after vesting. In addition, the following shareholding guidelines are established. 
a. Residents in Japan: Shareholding guidelines will not be established because they will vest upon their retirement 
b. Non-residents in Japan: 0.5 times or more of basic compensation 
(iv) Chairman of the Board of Directors receives a Chairman allowance in addition to the basic compensation. 
(v) For those who double as executive officer, monetary compensation paid for management and supervisory functions performed 
as director is separate from compensation of executive officer for those who are natives of Japan. For those who are not natives of 
Japan, monetary compensation paid for management and supervisory functions performed as director is included in compensation 
of executive officer. 
 
< Compensation of executive officers for the fiscal year ended March 31, 2021> 
Executive officers in this section include those who double as directors. 
(1) History overview 
(i) In the management strategy published in November 2019, we defined “the meaning of our existence (Corporate Philosophy)” 
as “Making people’s lives healthier, safer and more fulfilling,” and announced the strategic aspiration and performance metrics of 
“become a globally-leading medtech company contributing to people’s lives by delivering innovative solutions that benefit patients, 
healthcare professionals, payors and providers.” The Company transitioned to a company with nominating committees, etc. in the 
fiscal year ended March 31, 2020, and the position of the compensation committee was changed from a voluntary committee to a 
statutory committee. In accordance with the management strategy of aiming to become a global medtech company, based on the 
direction of greater emphasis on long-term incentive compensation (LTIs), which was discussed by the Compensation Committee 
in the fiscal year ended March 31, 2019, we further deepened discussions and conducted numerous discussions about the new 
officer compensation system. As a result, we have established a new compensation system and described it in annual securities 
report for the fiscal year ended March 31, 2020. 
(ii) However, with the spread of COVID-19, as the business environment in the fiscal year ended March 31, 2021 has changed 
significantly, the Compensation Committee determined that the reward content of the fiscal year ended March 31, 2020, originally 
set, is not suitable for “enhance the motivation of executive officers by setting challenging and achievable targets,” which is one 
of the philosophies of compensation, and it does not lead to creating corporate value and enhancing the shareholder value. As a 
result the Company reviewed the compensation for the fiscal year ended March 31, 2021. 
 
(2) Details of policy to determine the amount of compensation, etc. for officers or the calculation method thereof and how the 
policy is determined 
(i) Philosophy on compensation 
In order to achieve our management strategy and to create corporate value, it is essential that we have a compensation system that 
ensures that we have capable management personnel and that they can fully demonstrate their abilities. To this end, we have 
decided on a compensation system based on the following concepts. 
a. Establish a more powerful incentive program which can compete with global med-tech companies. 
b. Establish an incentive program which is consistent with the management strategy. 
c. Establish a program with focuses on value creation and performance evaluation utilizing long-term incentive compensation, 
which is non-monetary compensation, etc. 
d. Pay a competitive basic compensation compared to leading Japanese global companies. 
e. Ensure a sound management of incentives by putting claw-back clauses and shareholding guidelines in place. 
f. Enhance the motivation of executive officers by setting challenging and achievable targets. 
 
(ii) Level of compensation for executive officers for the fiscal year ended March 31, 2021 
1. While a standardized, global compensation system is desirable for compensation design for executive officers who are 
responsible for global management, differences in compensation levels by region make it difficult to attract and retain talented 
executives by pay levels of Japan. As such all executive officers are compensated within a standard structure and set of ratios for 
basic compensation (BS: Base Salary), short-term incentive compensation (STI: Short Term Incentive), which is performance-
linked compensation, etc., and long-term incentive compensation (LTI: Long Term Incentive), which is non-monetary 
compensation, etc. However, actual compensation levels are determined by considering differences in pay levels in the country of 
origin of the executive officer. Basic compensation for executive officers from Japan was set by comparing with basic 
compensation of companies included in TOPIX500 in the medical or life science field (peer groups). The total compensation also 
considers the pay ratio (the ratio of the median between CEO compensation and employee salary). A similar approach is used for 
executive officers whose country of origin is outside of Japan using appropriate local and regional benchmarks. 
2. Compensation levels for the peer group are verified using objective compensation survey data from external specialist 
organizations. 
 
(iii) Compensation composition of executive officer for the fiscal year ended March 31, 2021 
102

20 
1. Compensation for executive officer is a combination of fixed base compensation (BS), short-term incentive compensation (STI), 
which is performance-linked compensation, etc., and long-term incentive compensation (LTI), which is non-monetary 
compensation, etc. 
2. For executive officers who are not from Japan, time-sum payments and Severance Pay, as well as housing allowances and 
pensions, are established to make adjustments to the previous compensation agreements on an individual basis. The Compensation 
Committee decides on the amount and terms that are set individually. The payment of Severance Pay at the time of retirement and 
the amount of the allowance are determined based on multiple conditions such as the term of office. 
3. Focusing on achieving management strategies aimed at enhancing medium-to long-term corporate value and shareholder value, 
the ratio of Performance-linked compensation, particularly long-term incentive compensation, was raised for the CEO, and the 
ratio of short-term incentive compensation (STI), and long-term incentive compensation (LTI) against basic compensation (BS) 
was set as follows. 
BS:STI:LTI=1 (25%) :1 (25%) : 2 (50%) 
4. With respect to executive officers other than the CEO, the following ratios were adopted based on the same concept. 
BS:STI:LTI=1 (28.5%) :1 (28.5%) :1.5 (43%) 
 
(iv) Short-term incentive compensation, which is performance-linked compensation, etc., for the fiscal year ended March 31, 2021 
(FY2021-STI) 
While taking into account the status of the spread of COVID-19, the Compensation Committee ultimately decided the details of 
FY2021-STI as follows. 
a. Upper limit of payment 
In order to share value with our shareholders, we calculated the Total Shareholders Return (TSR) using the average share price 
in the most recent 30 business days of the previous fiscal year (the fiscal year ended March 31, 2020) and the current fiscal 
year (the fiscal year ended March 31, 2021) and set the upper limit of payment. 
b. Due to the spread of COVID-19, it was difficult to establish targets for the initial financial indicators that were set, so the 
Company increased the ratio of strategic goals, which are non-financial indicators. In addition, since operating profit, which 
was set as a financial indicator, is an index that is greatly affected by the external environment, the Company has determined 
that it is appropriate to set general and administrative expenses, which are closely related to operating profit, as an index. 
c. The composition ratio of revenue, general and administrative expenses, and strategic goals was set as follows. 
Revenue 
General and administrative 
expenses 
Strategic goals 
20% 
20% 
60% 
Note: 
The composition ratio of indices under the new compensation system set in the fiscal year ended March 31, 2020 was revenue 
30%, operating profit 50% and strategic goals 20%. 
 
(i) Revenue: 20% 
 
Even in a business environment where COVID-19 continues to spread, revenue growth is essential to achieve medium-
to long-term management strategy targets and was set as an indicator. 
 
Evaluation table 
 
The achievement rate for the management-base plan as of the first quarter equals the payment rate. 
 
With 100% achievement of targets equaling 100% payment and achievement rate equaling payment rate, we have set 
a payment curve with a lower limit of 70% and an upper limit of 130%. 
 
(ii) General and administrative expense: 20% 
 
General and administrative expenses is set as an indicator because it is closely related to operating profit and is essential 
for implementing investments for future growth. 
 
Evaluation table 
 
It is assessed using the consumption rate for general and administrative expenses versus the management-base plan as 
of the first quarter. 
 
An incremental evaluation table for general and administrative expenses has been established in which actual results 
in the range of 105 to 92% provide a payment rate of 70 to 130% and actual results of 100% provide 100% payment. 
In addition, the lower limit of 0% is provided if actual results are over 105%, and the upper limit of 130% is provided 
if actual results are less than 92%. 
 
(iii) Strategic goals: 60% 
 
The following “Measures to Be Implemented in Fiscal Year 2021” disclosed in June 2020 are set as the main targets. 
 
Focus our corporate portfolio 
 
Structural reform of fixed costs 
 
Successful launch of next-generation GI endoscopy system EVIS X1 
 
Continued steady investment in product development for future growth 
 
Driving efficiency in our R&D operations 
 
Evaluation table 
 
The payment curve is set at between 0% and 200% by individual policy. 
 
103

21 
(v) Long-term incentive compensation, which is non-monetary compensation, etc., for the fiscal year ended March 31, 2021 
(FY2021-LTI) 
1. The business environment has been greatly affected by the spread of COVID-19). However, we have decided not to change the 
compensation composition for subsequent grant-type restricted stock compensation (RSU) or performance-linked stock 
compensation (PSU=Performance Share Unit) (RSU=25%, PSU=75%), the evaluation indicators or ratios (operating margin: 40%, 
ROIC=15%, EPS growth rate=15%, relative TSR=20%, ESG=10%) for performance-linked stock compensation (PSU), or the 
target values. 
2. Subsequent grant-type restricted stock compensation (RSU) has a transfer restriction period of three years, and a number of 
shares equivalent to 25% of the standard amount for long-term incentive compensation (LTI) (basic compensation multiplied by a 
factor of 2 for the representative executive officer and 1.5 for executive officers) is determined at the beginning of the transfer 
restriction period. This number of shares is provided after three years have passed. 
3. Reasons for selecting evaluation indicators, target values, and evaluation tables of performance-linked stock compensation 
(PSU) are as follows. 
a. Operating margin: 40% 
 
Operating margin, a financial guidance on management strategy was set as an indicator of performance evaluation. 
 
100% will be paid to achieve the operating margin target of the financial guidance of the management strategy. The 
evaluation table of 0% to 200% payment is calculated based on the reasonably set logic by relative comparison with the 
peer group. 
b. ROIC: 15% 
 
ROIC, a financial guidance for management strategy, is used as an indicator for performance evaluation. 
 
100% will be paid to achieve the ROIC target of the financial guidance of the management strategy. 
 
The evaluation table of 0 to 200% payment is calculated based on the logic reasonably consistent with the evaluation 
table of operating margin. 
c. EPS growth rate: 15% 
 
The EPS growth rate, a financial guidance for management strategy, is used as an indicator of performance evaluation. 
 
100% will be paid to achieve the EPS growth rate target in the financial guidance of the management strategy. 
 
The evaluation table of 0 to 200% payment is calculated based on the logic reasonably consistent with the evaluation 
table of operating margin. 
d. Relative TSR: 20% 
 
Relative TSR is set as an indicator of performance evaluation. It is an important standard which makes long-term 
performance and pay align from the viewpoints of both shareholders and the executive management. 
 
Twenty global medtech companies (companies with medical or life science related businesses) are set as a peer group, 
and 100% will be paid if the rank of our TSR is located at 50%. The evaluation table of 0 to 200% payment is calculated 
based on the logic reasonably set by relative comparison with the peer group. 
e. Strategic target (ESG): 10% 
 
Strategic goals are used as an indicator for ESG, which is announced to be reinforced in its management strategy. 
 
The index of DJSI (Dow Jones Sustainability Index) is set as an evaluation index for the following reasons. 
 
It is a highly reliable external evaluation organization and ensures transparency and fairness. 
 
The breadth of coverage in the evaluation area contrasts with the expectations of a broad range of stakeholders. 
 
There is completeness of corporate activities as a whole. 
 
DJSI ratings are “World Index (W),” “Asia Pacific Index (AP),” and “Non-Index (N)” from the top ranks. In the fiscal 
year ended March 31, 2019, the Company won Asia Pacific Index. Establish an assessment table that emphasizes Index 
to be acquired in the third year, considering the outcome in the first and second years, and set payment rates of 200%, 
150%, 100%, 50%, and 0%. 
 
(3) Compensation risk management 
(i) Shareholding guidelines 
1. Shareholding guidelines are established to share interests between investors and management (executive officers). 
2. Shareholding guidelines shall be as follows. 
a. The CEO shall hold a number of the Company’s shares that is three times the amount of basic compensation or more. 
b. Other executive officers shall hold a number of the Company’s shares that is one times the amount of basic compensation or 
more. 
3. The shareholding guidelines will depend on the achievement of the targets but will be achieved in approximately three to five 
years after taking role. We will review the ratio of long-term incentive compensation (LTI), which is non-monetary compensation, 
etc., and consider the necessity of reviewing the holding guidelines when changing the composition of compensation. 
(ii) Clawback clause 
1. A clawback clause has been set up to deter the management (executive officers) from reckless investments and improper 
accounting. 
2. Clawback is subject to short-term incentive compensation (STI), which is performance-linked compensation, etc., and long-
term incentive compensation (LTI), which is non-monetary compensation, etc., for executive officer. The clawback will be turned 
on if the following event occurs. 
a. An event that requires the refund of the difference between the amount of compensation that have been paid and the amount 
of compensation that should have been paid caused by a revelation that the information prerequisites for compensation is 
incorrect or different. 
b. An event requiring the return of the amount of compensation already paid as a kind of sanctions in the event of a violation 
of obligation, etc. 
104

22 
3. The final decision on the application of clawback to individual events is made by the Compensation Committee and reported to 
the Board of Directors 
 
<Compensation of directors for the fiscal year ending March 31, 2022> 
Compensation of director will be paid in the following manner. 
(1) Level of compensation for directors 
(i) In order to set the directors’ compensation at competitive compensation levels for securing and retaining talented personnel, the 
compensation level shall be 50-75% compared with the peer group in the role responsibilities and each residence. 
(ii) Compensation levels for each peer group are confirmed using objective compensation survey data from external specialist 
organizations. 
(iii) If a director requests to decline compensation, the Compensation Committee will confirm and decide on the response. 
 
(2) Compensation composition of directors for the fiscal year ending March 31, 2022 
(i) Non-executive directors perform supervisory functions at various points of contact with the Board of Directors meeting, 
managements, and executive officers, and contribute to the creation of corporate value. Therefore, in addition to monetary 
compensation (basic compensation) for supervisory functions, non-performance-linked stock compensation (non-monetary 
compensation) is granted as compensation for the creation of corporate value. 
(ii) Stock compensation for non-executive directors shall be subsequent grant-type restricted stock compensation (RSU), and the 
right will be defined at retirement for those directors who live in Japan. The right will be defined on an individual basis in 
accordance with a general method of stock compensation in each region for those directors who do not live in Japan. 
(iii) Stock compensation will be set at 3 million yen for both Japanese and non-Japanese residents. The number of shares to be 
given will be calculated based on the share price at the time of assumption of office at the general meeting of shareholders, and the 
number of shares will be given after vesting. In addition, the following vesting and shareholding guidelines have been established. 
a. Residents in Japan: Vested upon their retirement 
b. Non-residents in Japan: Shareholding guidelines of 0.5 times or more of basic compensation 
(iv) Chairman of the Board of Directors receives a Chairman allowance in addition to the basic compensation. 
(3) For those who double as executive officer, monetary compensation paid for management and supervisory functions performed 
as director is separate from compensation of executive officer for those who are natives of Japan. For those who are not natives of 
Japan, monetary compensation paid for management and supervisory functions performed as director is included in compensation 
of executive officer. 
 
<Compensation of executive officers for the fiscal year ending March 31, 2022> 
Executive officers in this section include those who double as directors. 
 
(1) Type of executive officer compensation 
The following compensation will be paid to each target person. 
1. Basic compensation 
2. Short-term incentive compensation, which is performance-linked compensation, etc. 
3. Long-term incentive compensation, which is non-monetary compensation, etc. 
a. Subsequent grant-type restricted stock compensation: FY2022-RSU 
b. Performance-linked stock compensation: FY2022-PSU 
4. Transformational FY22-RSU 
 
(2) Level of compensation for the fiscal year ending March 31, 2022 
Similar to the fiscal year ended March 31, 2021, the composition level for the fiscal year ending March 31, 2022 has been set based 
on the following concept. 
1. While a standardized, global compensation system is desirable for compensation design for executive officers who are 
responsible for global management, differences in compensation levels by region make it difficult to attract and retain talented 
executives by pay levels of Japan. As such all executive officers will be compensated within a standard structure and set of ratios 
for basic compensation (BS: Base Salary), short-term incentive compensation (STI: Short Term Incentive), which is performance-
linked compensation, etc., and long-term incentive compensation (LTI: Long Term Incentive), which is non-monetary 
compensation, etc. However, actual compensation levels are determined by considering differences in pay levels in the country of 
origin of the executive officer. Basic compensation for executive officers from Japan was set by comparing with basic 
compensation of companies included in TOPIX500 in the medical or life science field (peer groups). The total compensation will 
also consider the pay ratio (the ratio of the median between CEO compensation and employee salary). A similar approach will be 
used for executive officers whose country of origin is outside of Japan using appropriate local and regional benchmarks. 
2. Compensation levels for the peer group will be verified using objective compensation survey data from external specialist 
organizations. 
 
(3) Compensation composition for the fiscal year ending March 31, 2022 
Similar to the fiscal year ended March 31, 2021, the fiscal year ending March 31, 2022 has been set based on the following concept. 
1. Compensation for executive officer is a combination of fixed base compensation (BS), short-term incentive compensation (STI), 
which is performance-linked compensation, etc., and long-term incentive compensation (LTI), which is non-monetary 
compensation, etc. 
2. For executive officers who are not from Japan, time-sum payments and Severance Pay, as well as housing allowances and 
pensions, are established to make adjustments to the previous compensation agreements on an individual basis. The Compensation 
Committee decides on the amount and terms that are set individually. The payment of Severance Pay at the time of retirement and 
the amount of the allowance are determined based on multiple conditions such as the term of office. 
105

23 
3. Focusing on achieving management strategies to improve medium- to long-term corporate value and shareholder value, the 
Company has set the ratio of short-term incentive compensation (STI) and long-term incentive compensation (LTI) to the base 
salary (BS) in the case of the CEO as follows. 
a. BS:STI:LTI=1 (25%) : 1 (25%) : 2 (50%) 
4. With respect to executive officers other than the CEO, the following ratios were adopted based on the same concept. 
a. BS:STI:LTI=1 (28.5%) : 1 (28.5%) :1.5 (43%) 
 
(4) Short-term incentive compensation, which is performance-linked compensation, etc. (FY2022 STI) 
(i) Target composition 
Since it is important to steadily implement long-term and strategic efforts within each fiscal year, the Compensation Committee 
has decided to increase the composition ratio of strategic goals among FY2022-STI targets to the following ratios. 
 
Revenue 
Operating profit 
Strategic goals 
30% 
40% 
30% 
 
(ii) Upper and lower limit on the evaluation table 
Upper limit is set as 200% and lower limit 0% at each evaluation index. 
 
(iii) Evaluation table of revenue 
1. The target is revenue in the “Forecast for the Fiscal Year Ending March 31, 2022” stated in the Consolidated Financial Results 
for the Fiscal Year Ended March 31, 2021. 100% will be paid for achieving 100% of the target. When evaluating the results, the 
exchange rate will be the exchange rate of the “Forecast for the Fiscal Year Ending March 31, 2022” in the Consolidated Financial 
Results for the Fiscal Year Ended March 31, 2021. Furthermore, if the target values change greatly in the future, we will hold new 
discussions and decide at the Compensation Committee, including the payment curve shown below. 
2. 200% payment is paid when 107% of the amount of sales is achieved for 100% payment. The payment table between 100% and 
200% payments is a straight line connecting the respective sales. 
3. The 50% payment will be the same amount of sales as the actual sales for the fiscal year ended March 31, 2020. The payment 
table between 50% payment and 100% payment shall be a straight line connecting the respective sales. 
4. If the sales amount for the fiscal year ending March 31, 2022 is less than the actual sales for the fiscal year ended March 31, 
2020, the payment rate will be 0%. 
5. The payment rate is rounded to the first decimal place. 
(iv) Evaluation table of operating profit 
1. The target is the amount of operating profit in the “Forecast for the Fiscal Year Ending March 31, 2022” of the Consolidated 
Financial Results for the Fiscal Year Ended March 31, 2021. 100% will be paid for achieving 100% of the target amount. When 
evaluating the results, the amount of operating profit after deducting other income and other expenses will be used, and the actual 
exchange rate will be used. In the event that target amounts are changed significantly going forward, the target amounts, including 
the payment curve presented below, will again be discussed and determined by the Compensation Committee. 
2. If the operating margin reaches 20% of the sales at the time of 200% payment in the preceding paragraph, 200% will be paid. 
The payment table between 100% payment and 200% payment is a straight line connecting the respective operating profit amounts. 
3. The 50% payment shall be the same amount of operating profit as the operating profit of the fiscal year ended March 31, 2020 
after deducting other expenses and other income. The payment table between 50% payment and 100% payment shall be a straight 
line connecting the respective operating profit amounts. 
4. If the operating income for the fiscal year ending March 31, 2022 is less than the actual operating income for the fiscal year 
ended March 31, 2020, the payment rate will be 0%. 
5. The payment rate is rounded to the first decimal place. 
 
(v) Strategic goals 
Target items are set on important company-wide issues in the fiscal year ending March 31, 2022 explained at the financial results 
meeting for the fiscal year ended March 31, 2021 held on May 7, 2021 and set them as common goals for all executive officers. 
The payment curve between 0% and 200% in the evaluation table is set for each item. 
 
Deepening profitable growth strategy in Medical business 
 
Further improvement of efficiency and effectiveness through Transform Olympus 
 
Continued steady investment in product development for future growth 
 
ESG initiatives that contribute to a sustainable society 
 
(5) Long-term incentive compensation, which is non-monetary compensation, etc. (FY2022 LTI) 
This section describes long-term incentive compensation, which is non-monetary compensation, etc. (FY2022-LTI) starting in the 
fiscal year ending March 31, 2022 and ending in the fiscal year ending March 31, 2024. 
Long-term incentive compensation (LTI), which is non-monetary compensation, etc., in the new compensation system established 
in the fiscal year ended March 31, 2021 consisted of 25% stock compensation (RSU: Restricted Stock Unit) and 75% performance-
linked stock compensation (PSU: Performance Share Unit). Every assessment period is three years. However, the spread of 
COVID-19 significantly affected the initiatives in the first year (the fiscal year ended March 31, 2021) of the management strategy 
announced in November 2019, and increased uncertainty in the business environment in the second year (the fiscal year ending 
March 31, 2022). As a result of discussions on the ratio of RSUs and PSUs of FY2022-LTI at the Compensation Committee, we 
set 40% of RSU and 60% of PSU. 
106

24 
RSU 
PSU 
40% 
60% 
 
 
(i) Subsequent grant-type restricted stock compensation: FY2022-RSU 
1. Vesting 
a. Three years after the payment, the rights will be vested after confirmation by the Compensation Committee. 
b. When retiring as an executive officer, the rights shall be vested after confirmation by the Compensation Committee six 
months after the retirement. 
2. Grant date and number of units provided 
a. The grant date shall be April 1, 2021. 
b. The calculated stock price shall be the closing price of the Company’s common shares on the First Section of the Tokyo 
Stock Exchange on the business day prior to the grant date. 
c. For foreign exchange, apply TTM on the business day before the grant date. 
d. The total basic salary of executive officers, which is the basis for granting, is 324,983,375 yen, and the total number of units 
paid is 91,866 units. 
 
(ii) Performance-linked stock compensation: FY2022-PSU 
1. The PSU will be decided based on the philosophy of compensation, which is to make the incentive program consistent with the 
management strategy, and also in consideration of the business environment. 
2. PSU metrics consist of operating profit, relative TSR, and ESG metrics. 
Operating profit 
Relative TSR 
ESG 
40% 
40% 
20% 
 
Increased corporate value is equally assessed from both a financial perspective (operating profit) and a shareholder 
perspective (relative TSR) 
 
We are focused on increasing corporate value from an ESG perspective, and the ESG metrics are 50% of the financial 
perspective / shareholder perspective 
 
3. The target values and evaluation table for each metric are set as follows. 
a. Operating profit: 40% 
 
Going forward, we will continuously promote reforms to increase corporate value, and the Compensation Committee has 
decided that the below method is suitable to assess operating profit. 
 
At the start of each fiscal year during the assessment period of PSU, operating profit targets and a 0 to 200% payment 
curve are decided, and after the end of each fiscal year, the payment rate for each fiscal year is calculated from results. 
The average payment rate for the three fiscal years is then used as the payment rate for PSU’s operating profit. 
 
The target values and payment curve for operating profit in the current fiscal year are as shown in the section of “Short-
term incentive compensation, which is performance-linked compensation, etc. (FY2022-STI).” 
b. Relative TSR: 40% 
 
Twenty global medtech companies (companies with medical or life science related businesses) are set as a peer group, 
and 100% will be paid if the rank of our TSR is located at 50%. The evaluation table of 0 to 200% payment is calculated 
based on the logic reasonably set by relative comparison with the peer group. 
c. Strategic goals (ESG): 20% 
 
Indicators for ESG, which is announced to be reinforced in the management strategy, are used as strategic goals. 
 
The Dow Jones Sustainability Index (DJSI) is set as an evaluation index for the following reasons. 
 
It is a highly reliable external evaluation organization and ensures transparency and fairness. 
 
The breadth of coverage in the evaluation area contrasts with the expectations of a broad range of stakeholders. 
 
It provides comprehensive coverage of overall corporate activities. 
 
DJSI ratings are “World Index (W),” “Asia Pacific Index (AP),” and “Non-Index (N)” from the top ranks. Establish an 
assessment table that emphasizes Index to be acquired in the third year, considering the outcome in the first and second 
years, and decide payment rates of 200%, 150%, 100%, 50%, and 0%. 
 
 
(6) Transformational FY22-RSU 
The Compensation Committee believes that providing appropriate compensation to Executive Officers responsible for 
management to be highly motivated in their efforts to achieve the management strategies and for the results they produce will lead 
to the subsequent maximization of corporate value and enhancement of shareholder value. 
A new management strategy announced in November 2019 replaces the 2016 Corporate Strategic Plan (“16CSP”) and has 
progressed significantly in line with the long-term direction of the Company. Performance-linked stock compensation, for which 
the evaluation period was the three-year period from the fiscal year ended March 31, 2019, to the fiscal year ended March 31, 2021, 
was set based on the 2016 Corporate Strategic Plan (“16CSP”) and was not provided because the actual value in the performance 
evaluation index fell below the minimum value. 
Considering the various reform themes being promoted in the business transformation plan “Transform Olympus” based on the 
management strategy, the one-time costs due to the transfer of the Imaging Business implemented in the fiscal year ended 31, 2021, 
and the impact of the spread of COVID-19, etc. from the fiscal year ended March 31, 2020, and onward, although the actual value 
107

25 
of the performance evaluation index fell below the performance target minimum value linked to officers’ compensation, the 
Compensation Committee has determined that the management efforts of executive officers have produced results that will lead 
into the fiscal year ending March 31, 2022, and onward. 
In light of the above results and management efforts of the executive officers, and in the midst of an uncertain business environment, 
the Company considered it necessary to provide effective compensation to the executive officers to encourage them to continue to 
strive to maximize corporate value and increase shareholder value in the fiscal year ending March 31, 2022, and onward, as well 
as to encourage them to hold shares in order to further strengthen the sharing of interests with shareholders. Therefore, the 
Compensation Committee, after consulting with “Pay Governance,” an independent compensation consultant, decided at the 
discretion of the Compensation Committee to grant the following “Transformational FY22-RSU” as subsequent grant-type 
restricted stock compensation. 
(1) Grantees 
CEO and CTO 
(2) Form of payment 
The unit grant date for “Transformational FY22-RSU” is April 1, 2021, and the rights will be vested three years later or upon 
retirement at the Company’s request. In the event of retirement that is not due to the Company’s request, the Compensation 
Committee will decide how to respond. 
(3) Units granted 
The standard amount for “Transformational FY22-RSU” is set at 18% of the basic compensation for the fiscal year ending March 
31, 2022. The number of shares to be given will be calculated based on the share price on the business day prior to the grant date, 
and the number of shares will be given after vesting. 
 
[Support systems for outside directors] 
• The Company established the Board of Directors Office as a dedicated organization to support the execution of duties of outside 
directors as well as the effective and vigorous activities of the Board of Directors, Nominating Committee and Compensation 
Committee. 
• To support the effective execution of the roles and duties of outside directors, the Company works proactively to provide outside 
directors with information and distributes documents prior to Board of Directors meetings while setting an opportunity for the 
explanation of agendas in advance as necessary and working to stimulate discussions in the Board of Directors meetings. 
• Additionally, the Company provides training for newly inaugurated directors including outside officers, comprising visits to the 
Company’s major business bases such as business offices and factories, etc., and business study sessions such as briefing sessions, 
directors presentations, and technical result presentations based on a policy of promoting knowledge acquisition about the 
Company. Additionally, the Company arranges for, and covers the cost of, external training sessions for directors to acquire basic 
knowledge necessary for the performance of directors’ duties with a view to deepening directors’ understanding of their roles and 
responsibilities. 
 
2. Matters related to functions of business execution, audit and supervision, personnel nomination, 
determination of compensation, etc. (Outline of the current corporate governance structure) 
 
As its organizational design, the Company has adopted the form of a company with Nominating Committee, etc. By having the 
Board of Directors specialize in deciding important items related to the core of management and in management supervision, we 
are working to enhance our management speed and supervisory functions. For items related to the everyday execution of duties, 
authority has largely been delegated to executive officers as we work to increase the speed of management decision making and 
execution by management. Furthermore, related to points that should be discussed at the Board of Directors and matters to be 
reported, we are working to increase the effectiveness of the Board of Directors by promoting improvements based on the results 
of the effectiveness evaluation of the Board of Directors. 
 
[Supervisory functions of the Board of Directors] 
• The Board of Directors consists of 11 directors, including a majority of eight outside directors, thereof all independent outside 
directors. Tenures of directors continue for one year. The Board of Directors convenes once every three months and when needed. 
The Board of Directors determines matters related to basic policies of management and internal control systems and other important 
matters, and monitors the execution of the duties of directors and executive officers, etc. The Board of Directors is chaired by an 
independent outside director. In the exercise of supervisory functions at the Board of Directors, the eight outside directors are 
expected to bring their specialist knowledge to bear on management. The Company proactively provides directors with information 
to enable the effective execution of their roles and duties. Outside directors of the Company may at all times when needed or when 
considered appropriate require clarifications and reports or the submission of internal documents from internal directors, executive 
officers, and employees, so as to strengthen the functions of information transmission and supervision and to create systems to 
ensure the soundness of management. 
 
•So that the Company’s Board of Directors can contribute to enhancing Olympus’s corporate value by cooperating with executive 
officers, its duties to be fulfilled are (i) improving recognition and insight into the management environment and management 
issues through constructive discussion with executive officers, (ii) effectively supervising management decision making and 
execution from a strategic, broad perspective, and (iii) supporting the promotion of strategies so Olympus can develop itself as a 
truly global medtech company, and it will exercise effective monitoring capabilities. 
 
• Aiming for outside directors to mutually exchange information and share awareness, the Company is working to improve 
oversight functions with an “Opinion Exchange Meeting for Outside Directors,” which is held four times a year (once per quarter) 
Updated 
108

26 
as a regular meeting in which only outside directors can participate, and an “Executive Session,” which is held after the conclusion 
of every Board of Directors meeting. 
 
[The member structure of the Board of Directors] 
The member structure of the Board of Directors is shown below. The chairman of the Board of Directors is Sumitaka Fujita. 
 
Directors 
Yasuo Takeuchi, Stefan Kaufmann, Nobuyuki Koga 
 
Outside directors 
Sumitaka Fujita, Susumu Kaminaga, Tetsuo Iwamura, Yasumasa Masuda,  
Atsushi Iwasaki, David Robert Hale, Jimmy C. Beasley, Sachiko Ichikawa 
 
[Activities of the Board of Directors in FY2021] 
(1) Number of meetings held: 18 
(2) Attendance (average attendance rate): 100% 
Attendance for individual directors at meetings of the Board of Directors is described in the reference documentation to proposals 
for the election of directors, which is part of the convocation notice of the ordinary general meeting of shareholders. 
Notice Regarding the Convocation of the General Meeting of Shareholders For the Fiscal Year Ended March 31, 2021 (from April 
1, 2020 to March 31, 2021) 
https://www.olympus-global.com/ir/stock/pdf/meeting153p_02.pdf 
(3) Main matters to be discussed 
First quarter 
Report on cross-shareholdings, Report on results of internal audit 
Second quarter 
Evaluation of the Board of Directors’ effectiveness, Audit & Supervisory Board audit plan report 
Third quarter 
Status report on individual businesses and regions, Report on cross-shareholdings 
Fourth quarter  
Business plan, Internal audit plan, Executive Officer structure for the next fiscal year 
 
In addition to the above, the Chairman of the Board of Directors reports as necessary at the meeting of the Group Executive 
Committee on matters to be discussed and regularly receives status reports on the execution of duties from Executive Officers. 
Furthermore, separately from regular meetings of the Board of Directors, management strategy meetings were held on the state of 
progress and issues in the management strategy and on topics in the business plan, and active discussions took place. 
 
[Nominating-, Compensation-, and Audit Committees] 
• In addition, the three committees comprised of the Nominating-, Compensation-, and Audit Committees, each consisting in the 
majority of independent outside directors, determine director candidates (Nominating Committee) and the compensation of 
directors and executive officers (Compensation Committee), and audit the execution of the duties of directors and executive officers 
(Audit Committee). The members of each committee are as follows. 
 
Nominating Committee 
Chairman: 
Sumitaka Fujita (Independent outside director)  
 
Members: 
Tetsuo Iwamura, David Robert Hale (Independent outside directors) 
 
 
Yasuo Takeuchi (Director) 
 
 
 
Compensation Committee 
Chairman: 
Susumu Kaminaga (Independent outside director) 
 
Members: 
Tetsuo Iwamura, Jimmy C. Beasley  
(Independent outside directors) 
 
 
 
Audit Committee 
Chairman:  
Yasumasa Masuda (Independent outside director) 
 
Members:  
Atsushi Iwasaki, Sachiko Ichikawa (Independent outside directors) 
 
 
Nobuyuki Koga (Directors) 
 
[Activities of the committees in FY2021] 
(1) Nominating Committee (Number of meetings held: 12) 
• The Nominating Committee deliberated matters related to human resources at the director and executive officer level, and 
determined the content of proposals submitted to the general meeting of shareholders in relation to the appointment and dismissal 
of directors. 
• As a main item for consideration, in considering the plan for the composition of the Board of Directors, the Nominating 
Committee created a matrix of the experience and knowledge required from directors of the Company. 
• In selecting candidates for director, the Nominating Committee held discussions and interviews in accordance with the selection 
criteria and made decisions. 
• Regarding the selection plan for executive officers, the Nominating Committee discussed their suitability and made decisions 
after a year-long selection process. 
• Regarding the succession plan for executive officers, the Nominating Committee discussed whether they possessed the desired 
experience and knowledge in accordance with expected roles in the execution of duties at the Company. 
 
109

27 
(2) Compensation Committee (Number of meetings held: 11) 
• The Compensation Committee reviewed the determination policy for individual compensation for directors and executive officers 
and the contents of the compensation and made decisions. 
• The details are listed in the [Incentives] and [Compensations of directors and executive officers] sections above. 
 
(3) Audit Committee (Number of meetings held: 26) 
• In addition to maintaining an independent position and fair and unbiased attitude and auditing and overseeing the Accounting 
Auditor and internal audit department, the Audit Committee conducted effective, efficient audits by directly verifying the suitability 
and validity of the execution of duties by the directors and executive officers. 
• In addition to monitoring and evaluating whether the Accounting Auditor maintained an independent position and performed 
suitable audits, the Audit Committee received reports from the Accounting Auditor on the state of execution of its duties and 
requested explanations where necessary. 
• In addition to maintaining an independent position and fair and unbiased attitude and auditing and overseeing the Accounting 
Auditor and internal audit department, the Audit Committee conducts effective, efficient audits by directly verifying the suitability 
and validity of the execution of duties by the directors and executive officers. Additionally, due to COVID-19, from April 2020, 
the Audit Committee was forced to perform audits through remote online meetings. Nevertheless, it succeeded in conducting 
activities in line with the initial audit plan. 
 
[Contents of limitation of liabilities agreements and directors and officers insurance agreements] 
In order to enable directors to fully discharge their expected functions, the Company has entered with directors (excluding 
executive directors, etc.) into agreements based on the provisions of Article 427, paragraph (1) of the Companies Act which limit 
the indemnification liability pursuant to Article 423, paragraph (1) of the Companies Act, such that the indemnification liability 
under the said agreements corresponds to the statutory minimum indemnification liability amount. 
 
Furthermore, the Company has entered into directors and officers liability insurance agreements with an insurance company with 
directors and officers as the insured persons pursuant to Article 430-3, Paragraph 1 of the Companies Act. The insurance 
agreements cover damages that may arise when the insured person assumes liability for the execution of his or her duties or receives 
claims related to the pursuit of such liability. The Company will bear the full amount of the insurance premiums. 
 
[Resolution requirements for elections of directors] 
The Articles of Incorporation stipulate that directors of the Company are elected by majority vote of the general meeting of 
shareholders with at least one-third of shareholders eligible to exercise voting rights in attendance and that resolutions on elections 
are not adopted by cumulative voting. 
 
[Matters for resolution by the general meeting of shareholders which can be resolved on by the Board of Directors] 
In order to carry out capital policy in accordance with changes in the business environment and to carry out flexible return of 
profits to shareholders, the Company stipulates in its Articles of Incorporation that matters, including dividends from surplus, set 
forth in each item of Article 459, paragraph (1) of the Companies Act shall be decided by resolutions of the Board of Directors, 
not those of general meeting of shareholders, unless otherwise provided by laws and regulations. 
 
Furthermore, the Articles of Incorporation stipulate that in order to enable directors and executive officers to fully discharge their 
expected functions, the Company can, by a resolution of the Board of Directors, pursuant to the provisions of Article 426, paragraph 
(1) of the Companies Act, in cases where the statutory requirements are satisfied, exempt directors (including former directors) 
and executive officers (including former executive officers) from the indemnity liability pursuant to Article 423, paragraph (1) of 
the Companies Act, limited to the balance of the indemnity liability amount reduced by the statutory minimum liability amount. 
 
[Requirements for special resolutions of the general meeting of shareholders] 
The Articles of Incorporation stipulate that in order to facilitate the operations of the general meeting of shareholders by relaxing 
the quorum requirements for special resolutions of general meetings of shareholders pursuant to Article 309, paragraph (2) of the 
Companies Act, special resolutions of the general meetings of shareholders are adopted by a vote of two-thirds or higher of 
shareholders in attendance who hold one-third of voting rights. 
 
[Executive Officers] 
Executive officers are comprised of the following five persons: Chief Executive Officer, Chief Operating Officer, Chief Technology 
Officer, Chief Financial Officer, and Chief Administrative Officer, who accelerate and streamline the decision-making system in 
the Group and centrally manage risk management across the Group. 
 
3. Reasons for choosing the current corporate governance structure 
 
The Company aims to develop itself as a truly global medtech company, and as described below, to accelerate decision making in 
the execution of duties and to strengthen and further increase the transparency of governance, in June 2019, it transitioned to a 
company with Nominating Committee, etc. 
1. Acceleration of management decision making and business execution functions 
Functions are separated based on the basic principle of “separation of corporate oversight and business execution” in a “a company 
with nominating committee, etc.” The Board of Directors focuses on deciding important matters on core managerial elements and 
management supervision, and works to enhance management speed and supervisory functions. The Company will seek to 
Updated 
110

28 
accelerate management decision-making and execution by delegating more authority to executive officers concerning matters 
related to daily business execution. 
 
2. Reinforced supervisory function in management 
The Company will establish three committees; nominating committee, compensation committee and audit committee, which 
consist in the majority of independent outside directors, supervise management through the functions of each committee, and build 
more appropriate management supervisory system. 
 
3. Increased transparency in management 
The nominating committee, which consists in the majority of independent outside directors, will decide candidates for directors, 
while the compensation committee, which consists in the majority of independent outside directors, will decide compensation of 
directors and executive officers. These committees will improve the transparency of director and executive officer assignment and 
compensation decisions. The Company will seek to further increase its management transparency to domestic and foreign 
stakeholders. 
111

29 
III State of implementation of measures concerning shareholders and other stakeholders 
1. Status of efforts at activating general meetings of shareholders and facilitating voting rights exercise 
 
 
Supplementary explanation 
Advance dispatch of 
convocation notices of general 
meetings of shareholders 
In order to provide our shareholders with time to sufficiently review information on the 
convocation notice, the Company ships the convocation notice three weeks before the 
general meeting of shareholders. 
Additionally, a few days before shipment a PDF version of the convocation notice will be 
published electronically on the Company’s website, TDnet, and the electronic voting rights 
exercise platform for voting rights. 
Off-peak scheduling of general 
meetings of shareholders 
The policy is to appropriately set the date on which the general meeting of shareholders is to 
be held with the intention of shareholders attending after adequately considering proposals. 
Electronic voting rights 
exercise 
Voting rights can be exercised electronically by using the Company’s designated voting 
rights exercise website or the electronic voting rights exercise platform. 
Provision of English 
convocation (outline) notices  
The text English translation of the convocation notice is available on the Internet (on the 
electronic voting rights exercise platform and the Company’s website). 
Other matters 
The full text of the convocation notice and resolution notice is published on the Internet (on 
the electronic voting rights exercise platform and the Company’s website). 
In order to gain the understanding of shareholders, visuals are used to illustrate the matters 
reported in general meetings of shareholders. These materials are also published on the 
Internet (the Company’s website). 
Furthermore, by adopting an attendance-type virtual general meeting of shareholders in 
which questions can be asked and voting rights can be exercised through an online 
attendance method, the Company is working to secure the opportunity for all shareholders 
to exercise their voting rights. The video that is livestreamed on the day of the general 
meeting of shareholders is posted in the above materials on items to be reported and on the 
Company’s website after the meeting is held. 
 
2. IR related activities 
  
 
Supplementary explanations 
Availability of 
explanations from 
the representative 
Disclosure policy creation and 
publication 
The Company publishes its “Information Disclosure Policy” on the 
Company’s website. 
In addition, in accordance with its information disclosure policy, the 
Company has established information disclosure frameworks, 
disclosure standards, and pertinent information management 
regulations, as well as Information Disclosure Regulations for timely 
and appropriate information disclosure. 
 
Regular briefing sessions for 
individual investors 
The Company’s website provides an overview of the Company’s 
businesses, its strengths, and the steps that it has taken to develop 
cutting-edge 
optical 
equipment 
products. 
Furthermore, 
as 
opportunities for direct dialogue, the Company participates in 
individual investor briefings and online seminars held by securities 
companies and IR events. 
No 
Regular briefing sessions for 
analysts and institutional 
investors 
On the day that financial results are announced each quarter, the 
Company’s management holds results briefings for direct dialogue 
with analysts and institutional investors on the business environment, 
financial results, financial forecasts, and progress in the management 
strategy. 
Furthermore, in addition to holding events such as management 
strategy briefings, small meetings with the Company’s management, 
new product presentations, and factory tours as appropriate, the 
Company participates in conferences held by securities companies. 
Moreover, individual meetings are held by the Chief Executive 
Officer, Chief Financial Officer, and IR officers as needed, excluding 
the quiet period between the day quarterly results are calculated and 
the day financial results are announced. 
Yes 
Regular briefing sessions for 
international investors 
On the day that financial results are announced each quarter, the 
Company’s management holds the results briefing at the same time as 
Yes 
Updated 
Updated 
112

30 
the briefing for domestic analysts and institutional investors. 
Moreover, several times a year, the Chief Executive Officer, Chief 
Financial Officer, or an IR officer visits overseas institutional 
investors. Additionally, IR officers at U.S. locations hold individual 
meetings as needed, excluding the quiet period between the day 
quarterly results are calculated and the day financial results are 
announced. The IR officers also actively participate in conferences 
held by securities companies. 
In FY2021, we cancelled visits to overseas institutional investors due 
to the impact of COVID-19, but the Chief Executive Officer and Chief 
Financial Officer were proactively involved in teleconferences and 
online meetings, ensuring the same opportunities for dialogue with 
overseas investors as in the past. 
Publication of IR materials on 
the Company website 
The Company publishes financial results information (financial 
results, presentation materials, numerical reference materials) and 
other corporate disclosures, integrated reports, convocation notices to 
general meetings of shareholders, shareholder communications, 
securities reports and quarterly reports, medical fact books, and reports 
on CSR and environmental activities. The Company also publishes 
videos of various events including management strategy briefings and 
financial results briefings, new product presentations, general 
meetings of shareholders. 
IR Department (Officer) 
Officer in charge: 
Executive Officer, Chief Financial Officer Chikashi Takeda 
Department in charge: IR department. 
3.
Status of efforts at the integration of stakeholder viewpoints
Supplementary explanations 
Regulations on the integration 
of stakeholder viewpoints 
based on internal regulations, 
etc. 
The Group has established the “Olympus Global Code of Conduct,” which expressly 
prescribes behavior in accordance with laws and regulations and high ethical standards as 
well as fair and honest corporate conduct in relationships with customers, business partners, 
shareholders, employees, and local communities, etc. 
Updated 
113

31 
Implementation of 
environmental protection 
activities, CSR activities, etc. 
The Group, based on its Corporate Philosophy of “Making people’s lives healthier, safer, and 
more fulfilling,” strives to respond to all stakeholder expectations at a high level, acts as a 
good corporate citizen, and aims to achieve sustainable growth together with society. 
The Group has included ESG as an important element in its Corporate Strategy. In particular, 
the Group has included six important ESG fields: 1) corporate governance, 2) economic 
sustainability, 3) product sustainability, 4) the environment, 5) human resources, and 6) 
society. Additionally, the Group has established five important issues (materiality): 1) 
providing a wide range of healthcare opportunities and improving outcomes, 2) focusing on 
compliance and product quality and safety, 3) promoting a responsible supply chain, 4) 
promoting diversity and inclusion, 5) contributing to the realization of a carbon-neutral and 
circular society in harmony with society. While strengthening and promoting our initiatives 
in each materiality and fulfilling our responsibilities to society and our stakeholders, we will 
improve the Company’s economic value and realize sustainable growth. 
In May 2021, we newly added the materiality “contributing to the realization of a carbon-
neutral and circular society in harmony with society” to the materiality established in our 
Corporate Strategy announced in November 2019 and established environmental goals to 
realize carbon neutral by 2030. We also agreed with recommendations by the Task Force on 
Climate-related Financial Disclosures (TCFD) and decided to work on information 
disclosures based on the TCFD recommendations. 
We will continue to improve our manufacturing improvement activities and energy saving 
measures to achieve our target of carbon neutrality. At the same time, we will accelerate 
efforts to reduce CO2 by switching all power consumed at our business locations to 
renewable energy sources by 2030. We will also continue to concentrate on highly 
transparent information disclosure focused on analyses of the risks and opportunities posed 
by climate change. 
For specific CSR activities, the Company holds procurement policy briefings once a year for 
major domestic suppliers of the Company’s businesses in order to share the Group’s 
Corporate Strategy and procurement policy. In FY2021, to prevent the spread of COVID-19, 
we cancelled in-person briefings for suppliers but are considering holding online briefings 
going forward. Furthermore, in environmental activities, reducing the environmental burden 
throughout the entire product life cycle is regarded as an important issue by the “Olympus 
Group Environmental Policy.” Consequently, the Company engages in a range of activities 
to contribute to international society, civil society and local society by actively engaging in 
environmental improvement activities for production, business sites, and logistics. 
Furthermore, the Company recognizes climate change as a major environmental issue that 
affects our business activities. We see the risks as carbon tax, carbon emissions trading, 
stronger regulations for CO2 reduction by various countries, and supply chain disruptions 
caused by the growing scale of natural disasters such as typhoons, floods, etc. In response, 
we are implementing measures including activities aimed at improvements in energy 
efficiency, the expanded introduction of natural energy sources, and the diversification of 
suppliers. Based on the above initiatives, we have begun to evaluate the nature of the 
Company’s contributions to the “Sustainable Development Goals (SDGs)” of the United 
Nations. 
To facilitate understanding of the Group, the Company strives to actively disclose 
information and enhance communication. Detailed information is available in integrated 
report and published on the Company’s website. 
(https://www.olympus.co.jp/ir/data/integratedreport/) 
Formulation of policies 
concerning the provision of 
information to stakeholders 
In order to be correctly understood and trusted by all stakeholders, the Group has established 
the “Olympus Global Code of Conduct,” which prescribes the fair, timely, and appropriate 
disclosure of corporate information such as management policies, the status of business 
activities, and CSR activities. 
114

32 
Other matters 
[Initiatives for health and productivity management] 
The Company has prepared a health declaration in order to clarify that establishing a working 
environment where employees can work in an active and healthy manner is a major premise 
of the Company for proceeding with various activities, and that it is the management has 
resolved to properly support the maintenance and improvement of the health of employees 
and their families, in cooperation with the Health Insurance Association. The Company will 
promote health maintenance and enhancement among employees by further working to 
prevent second hand smoke, recommend lifestyle changes, encourage regular checkups and 
complete examinations for cancer screenings, and give advice when hospital visits are 
required. By actively developing health management initiatives, the Company was 
recognized as a “White 500” organization for five years in a row since 2017. 
[Promotion of Work-Life Integration] 
In order to prepare an environment where employees can demonstrate their abilities to the 
fullest and actively continue their career, even with different circumstances such as child-
rearing or nursing care, the Group is promoting initiatives for “Work-Life Integration” to 
support both employees’ work and lives to achieve synergy between them, and is working to 
introduce flexible systems related to working styles and expand users. 
As an enhancement of supporting measures for both work and childcare/nursing care, the 
Group has introduced the “work-from-home system,” “re-entry system,” “position flex 
system,” and “reduced working hours system.” The Group is aiming to realize a diverse 
workplace, increase productivity and increase employees’ motivation by supporting both 
work and family life. 
[Ensuring diversity in the Company including active roles for women] 
At the Company and its domestic Group companies, centered on the Human Resources 
Division, we establish and operate systems and policies to support active roles for diverse 
human resources. Through new workstyles centered on telework, by eliminating distance 
and time constraints, diverse personnel feel a sense of ease in their work and happiness in 
their growth as we work to create an environment in which they can flourish. In our hiring, 
promotions, and pay raises, we proactively use human resources that have both strong 
expertise and abilities and morals. 
Furthermore, in promoting “Work-Life Integration,” the Group has set the promotion of 
women’s participation and advancement as an important issue, and formulated a plan of 
action for general employers in accordance with the Act on the Promotion of Female 
Participation and Career Advancement in the Workplace in 2016. Major initiatives include 
expanding employees allowed to utilize the work-from-home system, implementing the 
provision of information for employees taking childcare leave, creating a system that can 
balance work and treatments for infertility or cancer, opening childcare facilities at certain 
workplaces, and establishing the “Diversity Promotion Group,” which is a dedicated 
organization to strengthen the diversity promotion system. The Group supports career 
advancement of female employees by assuming life events in advance and with the concept 
of feed forward, which quickly provides experience and opportunities. 
In 2020, we produced our first female corporate officer from within our company. As of the 
end of April 2020, 65 women were active in managerial positions (an increase of 122% from 
the previous year), and the number of female employee candidates for managerial positions 
rose to 247 (an increase of 116% from the previous year), as our ratio of female employees 
has increased each year. We also have an increasing number of foreign nationals in 
managerial positions. 
Aiming for LGBT persons to feel a sense of ease and happiness in their work, to create 
workplaces highly accepting of diversity, we offer education and events to promote 
understanding and are promoting the establishment of a dedicated helpdesk. 
In employing persons with disabilities, we approach disabilities as one element of 
individuality. We proactively hire persons with disabilities by focusing on what they can do, 
support them as they take their positions, and offer employee education. We see the hiring 
of disabled persons and their onboarding as an important issue, and in addition to engaging 
in regular hiring activities, we have established a specialized subsidiary and are improving 
our onboarding system. During the onboarding process, we provide training and education 
to promote understanding so that superiors and colleagues can understand the nature of their 
disabilities. As part of our onboarding, when disabled persons first joins the Company, they 
meet with the Human Resources Division, their superior, and an industrial physician. As of 
January 2021, we achieved a disabled person hiring ratio of 2.4%, higher than the statutory 
employment rate. 
The Company proactively hires older employees who are past retirement age and believes 
that it is important for personnel who have exercised strong expertise and produced results 
in the past to continue to have an active role in the Company. For employees who wish to 
continue working after the fixed retirement age of 60, we have created a system to allow 
115

33 
them to continue working until 65. After improving the treatment of employees in April 
2016, we began reforming our position-style human resources system, which deals with 
personnel based on job grade, from April 2020 for rehired personnel who have a high level 
of expertise in order to evaluate work after rehiring. Going forward, while considering the 
trends and tendencies in society, including laws and regulations, we will continue to build a 
vibrant working environment in which employees can exercise their expertise after 
mandatory retirement. 
[Reforming our human resources system to support the challenge of becoming a global 
medtech company] 
To win in future competition with competing global medtech companies, we cannot only 
engage in regional hiring. We must also create a comprehensive operating model for 
governance, operations, and human resources on an integrated, global level, and improve the 
management efficiency of the entire Group. To realize this goal, it is essential that we assign 
personnel with diverse abilities that support our global business to the appropriate positions 
irrespective of their home country or region. We are working to create a human resources 
system that encourages the desire for growth among the Group employees and to build a 
corporate culture that allows them to use their individual abilities to the maximum for the 
development of the Company. 
In April 2019, we changed our human resources evaluation system for managerial employees 
in Japan to a position-based wage system. The job description form clarifies the roles, 
responsibilities, and authorities of each employee. The treatment of employees is decided 
based on the scale of job responsibilities and results, and we promote a hiring system that 
does not consider age or nationality. Furthermore, in April 2020, we standardized goal setting 
and evaluation criteria for global senior management and clarified their responsibility for 
performance. Senior management has set forth strategic goals to achieve global shared KPI 
and is working toward organizational reform. As a result of promoting assignments based on 
capabilities and suitability rather than nationality, 40% personnel of our heads of business 
and capabilities are foreign nationals. 
In response to the spread of COVID-19, we established a global taskforce, enacted various 
policies that place the safety of all employees first, and are reviewing global workstyles to 
respond to the new normal. In Japan, we are moving forward with new workstyle reforms 
including eliminating limits on work-from-home days and building an environment for 
telework. 
[Hiring women, foreigners, and mid-career hires for managerial positions] 
At the Company, as our approach aimed at balancing work and personal life, we promote 
Work-Life Integration (WLI) and support diverse personnel exercising their capabilities. In 
promoting WLI, we position the promotion of active roles for women as one materiality and 
have formulated and disclosed an action plan. We also actively promote the hiring of mid-
career hires and foreigners to managerial positions. 
• Basic policy
(i) Strengthen the planned development of female candidates for managerial positions.
(ii) Strengthen an environment that realizes a balance between work and personal life.
(iii) Strengthen the hiring of women.
• Target
(i) By the start of FY2025, double the number of female managerial employees compared to
FY2020.
(ii) Strengthen an environment that realizes a balance between work and personal life.
(iii) Increase the percentage of female new graduate hires joining the Company in April
2024 by 25% or more.
• Previous conditions and future plans
(i) Policies to strengthen an environment that realizes a balance between work and personal
life
• Introducing flexible care and a balanced system, expanding the scope of work-from-
home system, introducing an hour-based annual leave system, and opening a childcare
facility at our Hachioji business office, etc.
(ii) Policies for personnel hiring irrespective of gender, age, or nationality
• Introducing a “position-style human resources system”
• Implementing talent reviews
[Risk management] 
Based on its “Internal Rules on Risk Management and Crisis Response” and related rules, 
the Olympus Group has built a global management system. The Group conducts risk 
management from the viewpoints of both “offense” that leads to the creation of sustainable 
growth and value for the company through proactive, sound risk-taking and “defense” to 
prevent fraud and accidents. We are also working to create a crisis management process to 
116

34 
minimize the effects of unpredicted incidents on corporate value. The status of our risk 
management initiatives is listed in our integrated report and posted on the Company’s 
website. 
 
[Compliance] 
The Olympus Group works to create an honest corporate culture that complies with laws and 
regulations. In September 2019, we established the “Olympus Group Code of Conduct,” 
which is published in 18 languages on the Company’s website. The status of our compliance 
initiatives is listed in our integrated report and posted on the Company’s website. 
 
[Information security] 
The Olympus Group recognizes the proper handling and protection of information as a social 
responsibility and formulated the “Information Security Policy,” working to ensure 
information security. The details of our information security are listed in our integrated report 
and posted on the Company’s website. 
 
117

35 
IV Matters concerning internal control systems, etc. 
1. Basic concepts and maintenance status on internal control systems 
 
All our activities are based on our Corporate Philosophy, “Making people’s lives healthier, safer and more fulfilling.” 
The Company, based on this basic concept, shall prepare and operate a framework which ensures the effectiveness and efficiency 
of operations and appropriateness and reliability of financial reporting of the Company and its subsidiaries (hereinafter, “the 
Olympus Group”), and make continuous improvements. 
 
1. 
Framework to ensure the compliance by Executive Officers and employees of the Company and Directors and employees of 
the its subsidiaries, in performance of duties, to applicable laws and regulations as well as the Articles of Incorporation 
 
(1) 
In order to ensure a system in which Executive Officers and employees of the Olympus Group perform their duties in 
compliance with applicable laws and regulations as well as the Articles of Incorporation, the Company shall establish 
“Management Basic Policy,” basic policy the Board of Directors relies on when the Board supervises the execution of duties of 
Directors and Executive Officers. Furthermore, it shall establish the Olympus Global Code of Conduct and internal corporate 
regulations, based on the Corporate Philosophy, and shall instill the policies and facilitate initiatives to raise awareness of 
compliance in the Olympus Group through continuing education and other measures. 
 
(2) 
The Company shall also establish a compliance promotion system by appointing an officer in charge of compliance (“Chief 
Compliance Officer”) and establishing a function in charge of group-wide compliance. The function in charge of group-wide 
compliance shall be responsible for activities toward the improvement of the group compliance system based on the Global 
Compliance Management System. Furthermore, it shall continuously conduct education of employees and measures relating to 
assessment. It shall establish a global contact desk which can be available 24 hours a day in multiple languages so that any employee 
and external stakeholders, when suspecting there is or may be a violation of laws and regulations, etc., may make a report in 
addition to a local hotline contact desk in each region. 
 
(3) 
The Chief Executive Officer shall be the person responsible for CSR at the Company, and shall determine the content, set 
objectives and conduct evaluations for CSR activities. Furthermore, beginning with instilling a strong sense of ethics, the Company 
shall drive initiatives to be in line with the Olympus Global Code of Conduct. 
 
(4) 
The Company shall set up an internal audit function reporting directly to the Chief Executive Officer. Based on the Internal 
Audit Charter, the internal audit function shall conduct audits to verify the effectiveness of the various processes for risk 
management, control and governance. The internal audit function shall report the results of internal audits to the Chief Executive 
Officer of the Company, and the Audit Committee. 
 
(5) 
In order to ensure the fairness of operations of subsidiaries, the Company shall dispatch Directors and Audit Committee to 
major subsidiaries and request them to obtain the Company’s approval for significant matters of subsidiaries based on the Job 
Authority Rules and any other related rules. 
 
(6) 
In order to ensure the appropriateness and reliability of financial reporting of the Olympus Group, the internal audit function 
shall continue to conduct improvement activities by regularly evaluating its efforts and operations to ensure that control activities 
relating to financial reporting function effectively under the internal control system. 
 
(7) 
The Company shall be responsible for working with lawyers, the police and other parties to systematically stand firm against 
anti-social forces and organizations which threaten societal order and safety. The Olympus Group continuously shall conduct 
measures for excluding anti-social forces and prepare relevant rules and regulations in order to maintain its social responsibility to 
exclude anti-social forces. 
 
2. 
Framework regarding the maintenance of records and management of information in relation to performance of duties by 
Executive Officers of the Company 
 
(1) 
Pursuant to laws and regulations and the internal rules on document management, the Company shall maintain and manage 
documents or electronic data. 
 
(2) 
Directors may access important documents such as the minutes of a meeting of the Board of Directors and documentary 
approvals at any time based on the internal rules on document management. 
 
3. 
Regulations and other framework relating to managing risks of loss of the Olympus Group 
 
(1) 
The Company shall manage its business risks of the Olympus Group based on due deliberations held at meetings of the 
Board of Directors and the Group Executive Committee, among other meetings, and appropriate operation of the internal approval 
procedure. 
The Board of Directors shall determine basic management policy, matters related to the internal control system, other important 
matters and important matters related to business execution, as well as deciding matters to delegate to Executive Officers. Also, 
for important matters not decided by the Board of Directors, Executive Officers shall make a decision, and make a report to the 
Board of Directors. 
 
Updated 
118

36 
(2)
The Company shall manage risks such as those relating to quality, product safety, export control, information security, health
and safety, the environment and disasters by designating functions in charge, establishing internal corporate regulations, working
for preventive risk management as the Olympus Group, and implementing education and training.
(3)
Based on the Internal Control Rules and other related rules, the Company shall prevent the emergence of serious risks
resulting from the business activities of the Olympus Group, and shall create, operate appropriately, and manage a risk management 
system to minimize damage in the event of such risks emerging.
Moreover, pursuant to the Risk Management Operation Rules, each function in charge in the Olympus Group shall be aware of
risks and take preventative measures, and the Company has a framework which enables prompt actions in the event of an emergency.
In the event of a violation of corporate ethics, or an earthquake, fire or accident, the function in charge shall make immediate
reports to the Executive Officers and relevant people. The final determination in such circumstance shall be made by the Chief
Executive Officer.
4.
Framework to ensure the effective performance of duties by Executive Officers of the Company and Directors of its
subsidiaries
(1)
The Board of Directors shall approve medium- and long-term Corporate Strategic Plans in which the business objectives of
the Olympus Group are set forth, and action plans for these, which are called annual business plans. The Board of Directors shall
decide on other important matters, and delegate except matters that should be resolved by the Board of Directors to Executive 
Officers in order to enhance efficient and agile decision-making on the execution of business. In addition, the Board of Directors
shall receive reports, at least once a quarter, on business performance in order to evaluate the status of the Company’s annual
business plan, and supervise Executive Officers’ performance of duties.
(2)
The Board of Directors shall determine the assignment of duties among the Executive Officers. In addition, the Board of
Directors shall receive, at least once a quarter, reports on their duties as performed.
(3)
Based on the Job Authority Rules, Organization Rules, and other related rules, the Board of Directors shall approve the
responsibilities and authorities of major job ranks. Based on internal corporate regulations including the internal rules on approval
procedures and organizational matters, the Board of Directors shall approve the management organization and the separation of
duties as well as the responsibility and authority of each of the Representative Director, other Operating Directors and Executive
Officers, and receive reports from major management organizations on their duties as performed.
(4)
With the establishment of Treasury Control Framework, which regulate financial policies as a base for financial operations
of the Olympus Group, the Company strengthens the governance of the Olympus Group from a financial aspect, and oversees and
manages funding, foreign exchange, and transactions with financial institutions for the Olympus Group including the subsidiaries.
5.
Framework for reporting to the Company on matters concerning execution of duties by the Directors and employees of the
subsidiaries
(1)
After the Company has clarified the management criteria of subsidiaries by means of the Affiliated Company Management
Rules and other related rules, the presidents of the regional headquarters shall conduct reviews of the situation faced by
management, and periodically report the results of the reviews to the President of the Company.
(2)
The Company shall ensure receiving reports as appropriate and in a timely manner from the subsidiaries in accordance with
the Global Consolidated Accounting Control Framework to ensure that the Company will remain accurately informed of financial
position and results of operation of the Olympus Group, and appropriately maintain and manage the consolidated accounting
policies.
6. Framework for matters related to employees whose assignment is to assist in the duties of Audit Committee of the Company,
and matters related to the independence of those employees from the Executive Officers of the Company, and matters related to
ensuring the effectiveness of instructions from Audit Committee of the Company to those employees
The Company shall allocate a dedicated employee who will assist with the Audit Committee’s duties. In addition, the Company
shall set forth internal corporate regulations to ensure independence from execution as stated below, and ensure effectiveness of
directions from the Audit Committee to such employees.
(1)
While employees who have been assigned to assist in the duties of the Audit Committee assist in those duties, Directors
(excluding Audit Committee members), Executive Officers and employees, etc. shall not give them commands or instructions.
(2)
The appointment, dismissal, transfer, wage or personnel evaluation of employees who are assisting the Audit Committee
with their duties shall be decided only after obtaining the approval of the Audit Committee.
7.
Framework regarding reports by Directors (except those who are members of the Audit Committee), Executive Officers and
employees of the Company to the Audit Committee of the Company, and reports by Directors and employees of the subsidiaries
of the Company or personnel who have received reports from them to the Audit Committee of the Company
(1)
Directors (except those who are members of the Audit Committee), Executive Officers and employees of the Company, as
well as Directors, Audit and Supervisory Board members and employees of subsidiaries shall promptly, and either directly or via
the relevant function, submit a report to the Audit Committee of the Company in cases where it becomes known that there has been 
119

37 
a significant violation of laws or regulations or of the Articles of Incorporation; or when it becomes known that there has been 
wrongdoing; or when it becomes known that there is risk of substantial harm to the Company. In other cases where the Audit 
Committee requests a report from an Executive Officer or employee, etc. of the Olympus Group, in accordance with laws and 
regulations, or Audit Committee Rules etc., the Executive Officer or employee in question shall promptly report to the Audit 
Committee. 
(2)
In case any material compliance issue arises in the Olympus Group, the Chief Compliance Officer shall make reports on
details and other matters to the Board of Directors in accordance with the Compliance Management System Rule. Reports on
details of issues reported and results of investigations shall also be made regularly to the Audit Committee.
(3)
The internal audit function of the Company shall regularly report the status of internal audit in the Olympus Group to the
Audit Committee of the Company. In addition, the Chief Compliance Officer shall report the status concerning compliance to the
Audit Committee regularly.
8.
Framework to ensure that any personnel who have made a report to the Audit Committee of the Company will not be
subjected to any unfair treatment due to the report made
The Company shall set forth internal corporate regulations and shall not impose any unfair treatment (including de-facto measures
such as restricting the personnel to engage in duties, or assigning the personnel solely to work on chores, in addition to measures
of personnel affairs such as dismissal, demotion, pay cut and other disciplinary actions and disadvantageous transfer) to any 
personnel who have made a report on the grounds of having made a report to the Audit Committee.
9.
Matters regarding procedures for advance payment of expenses incurred in connection with execution of duties by the Audit
Committee members of the Company and their reimbursement, and treatment of other expenses or liabilities incurred in connection
with execution of the duties
The Company shall set forth internal corporate regulations. When an advance payment or reimbursement of expenses is requested 
for execution of duties of Audit Committee members, the Company shall promptly process disbursement except for such case that
the expense is obviously deemed unnecessary for execution of duties by Audit Committee members.
10.
Other systems to ensure the effectiveness of audit by the Audit Committee of the Company
(1)
Directors, Executive Officers and employees of the Company and Directors and employees of the subsidiaries shall ensure
effectiveness of the audit by cooperating with the Audit Committee for investigations by interviews and on-site inspections.
(2)
The Company shall ensure that it provides the Audit Committee with opportunities to sufficiently exchange opinions with
Directors, Executive Officers, Accounting Auditors and any other personnel necessary.
(3)
The Company shall ensure that the Audit Committee is permitted to have its members attend important meetings, and that
they have an opportunity to state their opinion.
(4)
The Audit Committee and an internal audit function shall work closely, and the Audit Committee are allowed to exercise
authority to give instructions and make commands to the internal audit function as necessary.
(5)
The Company shall ensure that it provides the Audit Committee with, upon their request, opportunities of collaboration
between the Audit Committee and Audit Committee of the subsidiaries and collecting information from employees of the
subsidiaries.
2.
Elimination of organized crime - Basic concepts and their maintenance
The Company has in the basic policies of its internal control system defined policies against anti-social forces and has established
frameworks for systematic counteraction. Specifically, the Company has established an internal communication network,
cooperates with lawyers and the police force, and takes preventive measures by joining specialized organizations, along with
information gathering and training activities. Additionally, the Company works to constantly and completely shield itself by
stipulating in agreements with business partners the exclusion of anti-social forces.
120

38 
V Other matters 
1. Adoption of takeover defense measures
Adoption of takeover defense measure 
None 
Supplementary explanation of relevant items 
――― 
2. Other matters concerning the corporate governance structure, etc.
In disclosing information, Olympus shall comply with the laws and the Financial Instruments Exchange rules and shall disclose
information in compliance therewith. Olympus shall also proactively disclose the information which may have a material impact 
on its corporate value evaluation in accordance with the Article 27-36 of the Financial Instruments and Exchange Act (so-called 
“Fair Disclosure Rules”) and the Internal Information Disclosure Criteria regardless whether such disclosure is not required by the 
laws or the rules. To this end, we have established internal corporate regulations such as “Rules on Information Disclosure” and 
“Detailed Rules on Information Disclosure,” and set out specific duties and procedures for information disclosure. 
Based on the “Information Disclosure Flow,” information for disclosure is aggregated from the IR liaison (a person in each 
function/operating division who is in charge of the information disclosure as appointed by the IR Division) and the secretariats of 
the management meetings (the Board of Directors meeting and Group Executive Committee) and other committees, etc. and 
whether or not to disclose is determined by the head of Information Disclosure after deliberations with the head of the IR division 
and the head of the division disclosing the information. 
121

Corporate Governance Structure (June 2021)
Board of Directors
3 Directors, 8 Outside Directors   Chairman︓Independent Outside Director
Election / 
Dismissal
Accounting Auditor
Compensation Committee
Nominating Committee
Election / 
Dismissal
Compensation
Decision
Election / 
Dismissal
Supervision
Audit
Audit
Audit
Audit
General Meeting of shareholders
Election / Dismissal
Functional Divisions , Business units , Corporate Divisions , and Group Companies
Group Executive
Committee
Election / 
Dismissal
Decision on 
proposal of 
election/ 
dismissal of
directors
《Supervisory function》
《Execution function》
Compensation
Decision
Report
Cooper
-ation
Representative Executive Officer
Executive Officer
Cooper
-ation
Report
Order
Order
Report
Audit Committee
Internal Audit
Updated 
122

123

Management Meetings 
BoD (Secretary to the Board)
GEC (Corporate Strategy and Planning)
Olympus Groupʼs Policies, Rules and Detailed Rules on Information Disclosure (OGR)
Disclosure Route
Div. in Charge of Timely Disclosure
(IR Div.)
Head of the IR Div.
Head of Information Disclosure (CFO)
[Deliberation / Internal consensual decision-making] 1
[Disclosure] * Where to disclose will be decided based on what is to be disclosed.
Financial Instruments Exchange
Press Club
Website
[Decision]
Information Disclosure Flow
Deliberation / Decision
IR Liaison
[Collection of information]
Collection of Information
Source of Information
Collection Route
Nominating Committee 
(Secretary to the Board)
Compensation Committee 
(Secretary to the Board)
Audit Committee
(Office of Audit Committee)
[Confirmation of details]
Head of the division disclosing the information
1. When the case meets any of the Consensual Decision-Making Criteria in the Internal Information Disclosure Criteria, or when the case is not set forth in the Internal Information Disclosure Criteria and the head of the IR div. finds it necessary.
Directors
Executive Officers
Audit Committee
[Report]
124

Communication with Stakeholders
Basic Approach and Policy
The Olympus Group is committed to "making people's lives healthier, safer, and more fulfilling." This is our corporate philosophy and the fundamental
concept underlying our activities, enabling us to respond to the highest expectations of our stakeholders, conduct ourselves as a model corporate citizen,
and work towards sustainable growth together with society.
In acting as a global company to address the issues of international society, we are participating in the UN Global Compact, reporting our CSR activities to
them and conducting studies into what we can do to contribute to the Sustainable Development Goals (SDGs).
Initiatives
Customers
To implement a customer-centric approach and a constant quest for quality under the Olympus Group Quality Policy, the Olympus Group regularly monitors
customer satisfaction in each of our activities, from sales to after-sales service and repair, and provides feedback on our activities during and after sales to
improve the quality of our operations. Especially in the medical area, we are working to provide a safe and reliable healthcare environment for our
customers. Specifically, we are contributing to greater efficiency in medical care at medical institutions, including communicating important information to
customers, providing training on the appropriate use of our products, maintenance services and prompt recovery and repair services for our products.
Shareholders and Investors
We adhere closely to the Article 27-36 of the Financial Instruments and Exchange Act (so-called "Fair Disclosure Rules") and proactively disclose our
management policies, financial status, business activities, non-financial and corporate information in a fair, timely and appropriate manner according to the
Olympus Group's Disclosure Policy. We also invite investors to meetings in which our senior management, including the Representative Executive Officer,
relevant executive officers, and head of relevant business divisions, present our medium- to long-term corporate strategies and business plans.
Suppliers
Once a year, the Procurement Policy Meeting is held with key domestic suppliers for each business for the purpose of sharing with them the business
strategies and procurement policy of the Olympus Group.
In addition, Compliance Helpline, a service to receive inquiries on compliance, handles reports from the Olympus Group in Japan and from suppliers with
which Olympus has direct trade relations.
Employees
We conduct the Core Value Survey for all 35,000 Olympus Group employees to build a better corporate culture and working environment through listening to
our employees. The results of the survey are then shared by senior management in different regions and utilized to create various improvement measures.
We are particularly keen on disseminating open corporate culture and work style reform, as well as enhancing working efficiency. As a part of this movement,
Olympus launched the time-off scheme for voluntary activities and another system to allow side jobs. We also regularly publish the Global Newsletter. By
distributing news relevant to the entire Olympus Group, such as interviews with new senior managers, to all employees across the world, we encourage
borderless communications beyond the divisions and regions. In Olympus and its Japan subsidiaries, the Human Resources Division takes the initiative to
Investor Information
Investor Relations Activities (PDF: 35.2KB)
125

hold dialogs between senior management and employees or labor unions in order to establish and operate schemes and measures to help diverse human
resources exert their full capabilities. The senior management and labor union leaders discuss management-related issues including corporate culture,
bonuses, and future personnel system, and the results of such discussions are shared among union members and all managers through the intranet.
Communities
As a global med-tech company, Olympus actively participates in resolving local social issues based on our Corporate Citizenship Policy through working
together with a wide range of stakeholders, including local governments, schools, and corporations, in the communities across the world where our business
sites are located. We also take part in local community events, such as promoting cancer screenings through networks of healthcare administration and
NPOs, and providing classes jointly with NPOs for primary schools and junior high schools.
National and Local Governments
We are actively involved in a wide range of corporate citizenship programs in cooperation with national and local governments. In Japan, we maintain cancer
prevention agreements with several prefectural and city governments to encourage their citizens to take cancer screenings. As a part of these agreements,
Olympus provides leaflets to explain endoscopic examinations, which health administration then include in notice letters about strategic stomach cancer
screenings and colon cancer examinations. Also, Olympus and its Japan subsidiaries host classes in primary schools and junior high schools as a part of the
school curriculum for Period for Inquiry-Based Cross-Disciplinary Study and cancer education such as "Endoscope workshop for kids" to teach children
about endoscopes and cancer prevention, and "Microscope workshop for kids" to contribute to STEM education in schools.
We also donated funds and personal protective equipment to charity organizations across the world as a contribution to COVID-19 countermeasures.
Corporate Citizenship Activities
Olympus Increases Support for COVID-19 Measures to 100 Million Yen
126

Compliance
Basic Approach and Policy
Because What We Do Matters 
Olympus Global Code of Conduct
What we do at Olympus matters to the people we serve, and how we do our work matters to our stakeholders. To help our management team and
employees put Our Purpose and Our Core Values into practice, we developed a single, simplified resource, the Olympus Global Code of Conduct, which
replaces the Olympus Group Corporate Conduct Charter and Code of Ethics. The updated Global Code of Conduct went into effect on September 27, 2019,
and is available online in 18 languages.
Acting with Integrity Matters
The Olympus Global Code of Conduct builds on our 100-year tradition of innovation, positive contributions to society, and our unwavering commitment to
integrity. It explains the standards of conduct expected of our management team and employees, and guides them as they conduct business with integrity. 
The Olympus Global Code of Conduct reflects a comprehensive declaration of Olympus' stance on Environmental, Social, and Governance sustainability
matters (ESG), and we formulate specific ESG-related policies based on this Code. 
Our activities are based on Our Purpose of "making people's lives healthier, safer and more fulfilling." Following Our Purpose, we are committed to
conducting our affairs with integrity, and accordingly, will comply with applicable laws and regulations. The Olympus Global Code of Conduct is the
foundation for our policies and is required to be read, understood and followed by our management team and employees. We are committed to acting in
accordance with the Global Code of Conduct in our global corporate activities.
Promotion Structure
Compliance Management System
Our global Compliance function works to raise awareness of the Olympus Global Code of Conduct and related-compliance policies by providing the
management teams and employees with the resources and training they need to do business with integrity, treat customers, suppliers, third-party business
partners fairly, and report concerns when they arise.
Olympus has appointed a Global Chief Compliance Officer (CCO), who leads the global compliance function to collaborate across the Company to
continuously assess whether business activities are consistent with applicable legal requirements and Company policies and procedures. Our CCO reports
regularly to the Chief Executive Officer and the Audit Committee of our Board of Directors and more frequently as needed. We have also established a
Global Compliance Leadership Team (GCLT), which is composed of the CCO, Regional Compliance Officers (RCOs), and Global Operations and Planning
leaders, to implement compliance-related policies and measures globally, understand regional situations and challenges, and carry out necessary corrective
measures. The GCLT meets on a quarterly basis and more frequently as needed.
Policies and measures directed and confirmed by the GCLT are applied to each region by RCOs. In addition, compliance circumstances and issues
throughout the Olympus Group identified by the GCLT and RCOs are reported by the CCO on a regular basis to the Audit Committee and are discussed at
Board of Directors' meetings as needed.
Basic Approach and Policy
Promotion Structure
Initiatives
Systems and Mechanisms
Olympus Global Code of Conduct
Compliance Management System (As of April, 2021)
127

Initiatives
Compliance with Laws and Regulations
In FY2021, there were no violations that caused penalties or other punitive measures concerning these key laws/regulations (as stated below) and other
socially important legislation.
Jurisdiction
Name of Law/Regulation, etc.
Laws, regulations and guidelines
in Japan
Laws and regulations relating to anti-bribery such as Unfair Competition Prevention Act, etc. 
National Public Service Ethics Act/rules of ethics 
Agreements relating to fair competition 
Transparency guidelines for the medical device industry in relation to medical institutions, etc. (formulated by
the Japan Federation of Medical Devices Associations) 
Act on Prohibition of Private Monopolization and Maintenance of Fair Trade (Antimonopoly Act) 
Act against Delay in Payment of Subcontract Proceeds, etc. to Subcontractors (Subcontract Act) 
Laws and regulations relating to labor such as Labor Standards Act/Industrial Safety and Health Act, etc. 
Laws and regulations relating to insider trading 
Personal information protection laws/My Number ID Act 
Laws and guidelines relating to measures against antisocial forces
Laws, regulations and guidelines
in other countries
Foreign Corrupt Practices Act (FCPA, United States) 
U.K. Bribery Act 2010 (United Kingdom) 
Anti-Kickback Statute (United States) 
OECD agreements concerning the prevention of the bribery of foreign public officials in international
commercial transactions 
United Nations agreements concerning the prevention of corruption 
Other laws and regulations relating to the prevention of unfair competition 
Physician Payment Sunshine Provision (United States) 
Laws and regulations relating to anti-monopoly 
Laws and regulations relating to measures against antisocial forces
Systems and Mechanisms
Reporting System
The Olympus Group is committed to comply with the laws and industrial guidelines as well as acting based on high ethical standards.
As a system to support its practice, we implemented a reporting system that can be used by both our employees and suppliers.
In April 2019, we established the Integrity Line, for the Olympus organization worldwide.
Strengthening Compliance with Key Laws and Regulations
128

Integrity Line (Global Reporting System)
As stated in the Olympus Global Code of Conduct, all employees are responsible for immediately reporting any suspected violation of the Code or Company
policy.
Olympus is committed to our culture of integrity and provides a safe and open workplace for all employees to ask questions and raise concerns. We provide
a global reporting system, known as the Olympus Integrity Line, which is available to all Olympus employees, third parties, and the general public who may
wish to report a concern. The Olympus Integrity Line is operated by an independent third party and is available 24 hours a day, seven days a week, 365 days
a year, in multiple languages. The Global Compliance function expanded efforts to promote our Integrity Line and Disclosure Program. Olympus does not
tolerate retaliation against individuals who report concerns in good faith.
Th Global Compliance function manages and monitors the Integrity Line, and refers matters for review, as appropriate, to other functions, such as Human
Resources, depending on the nature of the concern. The Integrity Line system is continuously assessed and improved. In 2020, enhancements were
implemented to improve reporting and trending capabilities, which reporting is designed to support employee confidence that speaking-up and raising
concerns can make a difference in their organizations.
Facilitating an Environment That Encourages the Use of the Integrity Line
Additionally, the Global Compliance function, at the direction of the Global Chief Compliance Officer and the Regional Compliance Officers, raises awareness
of this system through consistent messaging in the Global Code of Conduct, and related e-learning programs and communications. During Fiscal Year 2021
Olympus received 250 reports, whether through the Integrity Line or other means. Olympus takes all reports of concern seriously. If a concern of misconduct
is substantiated following appropriate review, Olympus takes corrective action, including policy/process remediation, enhanced training and education for
individuals/groups, issuance of warning to individuals, and in serious cases, up to termination, in accordance with local regulations. In FY2021, 42.8% of
closed reports were substantiated following review.
Specifically, with the aim of enhancing the internal reporting system and increasing its trustworthiness, we conduct systematic training of internal reporting
system supervisors at Olympus and its subsidiaries.
Compliance Education
In order to raise compliance awareness and promote an understanding of important laws and internal rules, as well as to ensure consistent compliance with
them, the Global Compliance function strives continually to enhance compliance education programming. By example, in Japan, the Compliance Promotion
Department conducts education programs for various individuals using a variety of tools, course participants and training methods in accordance with the
characteristics of applicable laws. At the subsidiaries outside Japan, the Regional Compliance function undertakes compliance education in a systematic
manner at each regional headquarters according to its annual plan.
Category
Target
Method
Description
Results
General
All employees
E-learning and
group training
Education on compliance helpline
Frequency of program: 1 
Number of participants: 13,493
Selected
employees
Distribute Compliance Handbooks containing explanations of
the management philosophy and corporate code of ethics as
well as a Q&A summary
(The Compliance Handbook has been revised with an updated
Olympus Group Corporate Philosophy.)
Frequency of program: As
needed
Target: New employees,
midcareer employees, etc.
Whistleblowing System
Website for the Olympus Integrity Line 
Major Results in Compliance Education (Olympus and its Japan subsidiaries)
129

Category
Target
Method
Description
Results
Education in
Important Laws
and Regulations
Selected
employees
E-learning and
group training
Education on compliance helpline
Provide more comprehensive education
programs to departments and
supervisors that are deeply involved with
key laws and regulations related to
management
Frequency of program: 1 
Number of participants: 12,383
(employees in medical care-
related business)
Rank-Specific
Education
People at specific
ranks
Group training
Educational programs required for
management and executive personnel,
employees who have been promoted,
and new employees
Frequency of program: As
needed in accordance with the
plan
Messages from
Senior
Management
All employees
Intranet
Messages distributed from the President,
executives, and the CCO
CCO messages are sent out during
Compliance Month (October).
Message from the CCO
Frequency of program: 1
(October)
Management
Dialog
Opportunities
Managers and
employees
Town meetings
At town meetings, top management of
the Group explains the importance of
compliance.
Town meetings held on an ongoing basis
(include subsidiaries and local
corporations)
Small town hall meeting by the
RCO Frequency of program: 1
Number of participants: 71 (10
divisions)
130

Tax
Basic Approach and Policy
We established and adhere the Olympus Group Tax Policy based on our corporate philosophy and Olympus Global Code of Conduct, in order to undertake
and maintain appropriate tax procedures.
Olympus Group Tax Policy
Our Corporate Philosophy and Global Code of Conduct set out the legal and ethical principles that we apply to our business and defines our relationships
with all of our stakeholders, which includes tax authorities. Our Corporate Philosophy, "Our Core Values", includes Empathy and Integrity. We earn trust and
empathy with patients, customers, healthcare professionals, authorities and the communities with integrity in all aspects of our operations, and "Our Core
Values" governs the way we operate our business.
Group Tax Policy
This Group Tax Policy outlines the principles of how Olympus people are expected to operate with respect to tax matters. The Policy is set out in
detail below.
Olympus is committed to observing all applicable tax laws, rules, regulations, and reporting and disclosure requirements, wherever there is a
requirement to do so as a result of our business presence and transactions, in line with "Our Core Values", "Integrity", as described in the Corporate
Philosophy and Global Code of Conduct. 
A dedicated tax function (Group Tax) collaborates with the Group's businesses to provide advice and guidance necessary to ensure compliance,
obtaining external advice where necessary. There are clear management responsibilities, backed up by regular monitoring and review, carried out
by members of Group Tax with the necessary experience and skill set and where necessary support is provided by external professional advisors.
Tax decisions are made at all times in a manner which is consistent with and complements the Group's overall business strategy. Key business
decisions are made cognisant of the tax consequences. Group Tax partners with the businesses to ensure there is consistency.
Responsibility and accountability for the Group's tax affairs is clearly defined in accordance with a Tax Responsibility Matrix, and decisions are
taken at an appropriate level, determined by formal Group Delegation of Authority. 
Diligent professional care and judgement are employed to assess tax risks in order to arrive at well- reasoned conclusions on how the risks should
be managed. Olympus has a conservative approach to tax risks and seeks to mitigate tax risks as far as possible. Where there is uncertainty as to
the application or interpretation of tax law, appropriate written advice evidencing the facts, risks and conclusions may be taken from third party
advisers to support the decision-making process. 
In reviewing the risks of a tax action or decision, the following would be considered:
1. Compliance with laws, rules and regulations:
2. Consistency with Group strategy:
3. Governance, Assurance and Tax Risk Management:
The legal and fiduciary duties of directors,
The requirements of our Group compliance and ethics policies,
The maintenance of corporate reputation, having particular regard to the principles regarding the way we interact with the stakeholders around
us, embodied in the Group's approach to the stakeholders as described in the Corporate Philosophy of Olympus, "Empathy",
The tax benefits and impact on the Group's reported result comparative to the potential financial costs involved, including the risk of penalties
and interest,
131

Group Tax employs various risk management processes and systems to provide assurance that the requirements of the Group Tax Policy are being
met. This includes compliance and risk monitoring systems and internal audit reviews of tax compliance activity across the Group.
Olympus is committed to the principles of openness and transparency in its approach to dealing with tax authorities wherever we operate around
the world. Where there is uncertainty as to the application or interpretation of tax law, we secure certainty by consultation with advance information
disclosure. All dealings with the tax authorities and other relevant bodies are conducted in a collaborative, courteous and timely manner. The aim
would be to strive for early agreement on disputed matters, and to achieve certainty wherever possible.
Olympus pays its fair share of taxes in the countries where it operates, and considers this a part of its contribution to community. Olympus does not
undertake aggressive tax planning or artificial tax arrangements. Olympus maintains and follows a transfer pricing policy that is based on OECD
Transfer Pricing Guidelines and the Base Erosion and Profit Shifting ("BEPS") Action Plan which is the international framework to prevent cross-
border tax avoidance activities. In particular, Olympus adhere to the principle that profits should accrue where economic value is created and that
tax follows business reality and is underpinned by business substance.
Olympus believes that it should pay the amounts of tax legally due in any territory. There will, however, be circumstances where this amount may
not be clearly defined, or where alternative approaches may result in differing tax outcomes. The Group uses its best judgement in determining the
appropriate course of action, using available reliefs and incentives where possible for tax cost optimization.
The wider consequences, as a double taxation where a specific income is taxed by multiple countries, of potential disagreement with tax
authorities, and any possible impact on relationships with them.
4. Relationships with tax authorities:
5. Tax Planning:
6. Incentives and reliefs:
132

Anti-Corruption
Systems and Mechanisms
Prevention of Bribery
The Olympus Group will never engage in actions that could be deemed to be bribery in its dealings with any of its business partners, such as government
officials, and employees of government agencies (including international agencies), or any other parties. In addition to having established our own rules
based on key laws and regulations and thoroughly educating our employees on those rules, we are working on the prevention of actions that could be
interpreted as bribery by tightening the rules governing external business dealings and internal approval system as well as by implementing process controls.
With the Global Code of Conduct (PDF: 2.2MB)
, the Olympus Group has established a key guideline to preventing bribery, which has been disclosed on its
website.
The Olympus Group does business throughout the world and seeks to earn and maintain the respect and trust of all of our stakeholders - patients,
physicians, customers, governments and shareholders. Olympus expects that each and every one of our employees act in a manner that is consistent with
law, Olympus policies and our values. We also expect and require that third parties who act on Olympus' behalf operate in the same manner.
Olympus has developed policies, procedures and training on key issues, such as the prevention of bribery and the support of fair competition to help assure
that we provide our employees with the tools to meet these expectations. We encourage all our employees to speak up and share any concerns they might
have. We will continue to hold ourselves to high standards but are always working to improve, so that we can meet or exceed high expectations. The Global
Code of Conduct below summarizes our approach. We invite you to support these efforts and let us know if we have areas in which we can improve.
Thank you in advance for reading through the Global Code of Conduct and for your continued cooperation and support.
Exclusion of Antisocial Forces
The Olympus Group will have no involvement with organized crime syndicates, or any other antisocial forces that threaten the order of society and will never
engage in actions that could support their activities.
We will respond resolutely and in accordance with the law to any fraudulent demands from antisocial forces. In July 2012, "Regulations for the Elimination of
Antisocial Forces" covering the Olympus Group were formulated.
For Olympus and its Japan subsidiaries, in principle, we conclude contracts or memorandums of understanding incorporating provisions relating to the
exclusion of antisocial forces with all new business partners (including clients and suppliers as well as partners in joint research) of.
For subsidiaries outside Japan, we are confirming that our business suppliers and partners do not have any ties with antisocial forces in compliance with the
"Regulations for the Elimination of Antisocial Forces."
Prevention of Insider Trading
The Olympus Group is determined to ensure the fairness and soundness of security markets and earn the trust of shareholders and investors by working to
prevent insider trading. Formulated in June 2012, the Insider Trading Prohibition Regulations clearly forbid use of undisclosed information gained through
activities related to trading in stocks, and continuous education and training about these regulations is provided to all employees.
We have adopted rules, such as those concerning the buying and selling of our own shares by directors and employees, and we consistently comply with
those requirements, including the submission of notices concerning such transactions. In FY2021, an e-learning program to prevent insider trading was
implemented for all employees of Olympus Group in Japan. At the same time, lecturers were invited once a year from the Tokyo Stock Exchange to training
Requesting Your Support for the Olympus Global Code of Conduct and Your Cooperation in Fighting
Corruption
Olympus Global Code of Conduct (PDF: 2.2MB)
133

sessions for those employees from our corporate divisions who have ample opportunity to come into contact with insider information. There have not been
any insider trading matters in FY2021, same as past years.
Security Export Control and Appropriate Import Declaration
The Olympus Group works in compliance with security export control regulations around the world in order to contribute international peace and safety. In
Japan, we set up an export control system that conforms to the Compliance Programs designated by the Ministry of Economy, Trade and Industry. Since
2007, we have certified as an Authorized Economic Operator (AEO)* by Japan Customs and received preferential treatment as a company with superior
export controls. To maintain and improve this system, we renewed the internal training system in FY2021. While continuing the basic training programs to
cover nearly all executives and employees in Japan, we also provided specialized training programs covering import-export transaction based on employees'
degree of involvement in such work.
We are also establishing a global system in cooperation with the regional headquarters to respond to extraterritorially applied regulations and enhancements
in export regulations in countries concerned. Sharing with them regulatory information and classification data for products and technologies, we maintain and
improve the security export control with this global system. In FY2021, export control was strengthened by addressing issues specific to each region and in
compliance with the Corporate Strategic Plan. We also improved the operation level of the tools used to globally share classification data for each product
item under the laws of different countries.
On the other side, paying the appropriate tax for imported goods is also an important area of responsibility as a company. Therefore, as a general rule with
respect to products and parts procured from overseas, it is assumed that the import control department of Olympus and its Japan subsidiaries will have
assessed the import declaration price, which forms the basis of the tax payment, prior to the placement of the order from FY 2018. Such activities for
Olympus and its Japan subsidiaries continued in FY2021 to prevent import declarations with inappropriate prices and revisions to customs declarations.
* AEO (Authorized Economic Operator):
A program that offers relaxed or simplified custom processes to operators certified as having sufficient security and legal compliance systems in place for managing shipments, in
order to ensure both security and smooth operations in international distribution. In Japan, the program is certified by Japan Customs.
Target
Aim/Description of Training
Number of departments or
participants
Import-export control departments in Japan
subsidiaries
Legal knowledge required to "correctly perform import
control in general" for import control divisions that are
responsible for import assessment in each company.
4 departments
Departments responsible for import-export
transaction as a main task
Legal knowledge required to "declare an appropriate
price" for divisions that have discretion to determine the
import-export declaration price.
28 departments
Departments responsible for import-export
transaction as a supplementary task (import-
export system users)
Internal operation of import-export control transactions,
and contacts for inquiry (e-learning program).
Export: 1,729 participants
Import: 510 participants
Nearly all directors and employees working
in Japan (including subsidiaries)
Basic awareness of import-export controls (e-learning
program).
11,081 participants
Implementation Status of Training Designed to Maintain Security Export Control and Appropriate Import
Declaration (Olympus and its Japan subsidiaries/FY2021)
134

Disclosure of Medical Business Information
Ethics Committee
Developing and manufacturing medical equipment such as endoscopes, Olympus and its Japan subsidiaries held an Ethics Committee meeting and
assessed propriety from the points of view of ethics, science and reliability as well as conflicts of interest in its medical research to comply with the
"Declaration of Helsinki (Ethical Principles for Medical Research Involving Human Subjects)" and the "Ethical Guidelines for Medical and Health Research
Involving Human Subjects." We ensured the independence of the Committee by having it comprise internal and external experts not directly involved in the
research.
The scope of the assessment was all of the medical research conducted by Japan subsidiaries to which the Ethical Guidelines for Medical and Health
Research Involving Human Subjects applies. For greater transparency of the Ethics Committee, we disclose the Committee's rules, list of members and
summary of proceedings by registration on the Ethical Review Committee Reporting System of the Ministry of Health, Labour and Welfare.
We started the online Ethics Committee meetings in FY2021 to minimize the impact of COVID-19 on our new and ongoing research activities.
Transparency Guidelines
Olympus and its Japan subsidiaries have established Transparency Guidelines for Relations between Olympus and Medical Institutions and other
Organizations described below and are working to assure and increase transparency based on full disclosure of information on payments made to medical
institutions and personnel in accordance with the Guidelines. The approximate amount of the financial grants given by the Olympus Group in FY2021 is
US$5.3 million (equivalent to 586 million yen)
The Ethics Committee
Transparency Guidelines
Payments to Healthcare Professionals and Healthcare Organizations
135

Information Security
Basic Approach and Governance
Based on the recognition that the proper handling and protection of information is a social responsibility, the Olympus Group has established the Information
Security Policy and is working to ensure information security.
Information security is integrated into our business plan as a major risk, and the Board of Directors and Audit Committee oversee all critical corporate risks,
including information security. The Board of Directors and Executive Officers administer enterprise risk management for the entire Group, and information
security is one of the core areas. Risk management for each region and function is based on the instructions of the executive officers, and priority measures
for information security in business plan are implemented by the heads of each business and function based on risk assessment. Among the Executive
Officers, the CAO assumes executive responsibility in the area of information security, and the Chief Information Security Officer (CISO) strengthens the
governance of business execution under CAO's delegation. The CAO reports regularly on the status of information security to the Global Executive
Committee and the Board of Directors. The information security governance structure under the CISO, as shown in the diagram below, encompasses all of
the Olympus Group's businesses and functions worldwide.
We have a governance structure in place to ensure that our businesses and functions work together globally to implement measures and controls based on
initiatives in the four information security areas of information security governance and strategy, product security, enterprise information security, and data
protection.
In order to achieve effective information security governance, we are actively and continuously working to maintain and improve the comprehensive level of
information security, including monitoring the operational status through regular internal information security assessments and regular information security
education for all executives and employees.
Information security
governance and strategy
Manage information security risks and formulate strategies.
Product security
Ensure security of products across their life cycles, including the supply chain.
Enterprise information
security
Ensure enterprise information security, including cyber security, IT security, and physical security.
Data protection
Ensure management of property damage risks by incorporating risk control processes that are compliant with
legal obligations, and which include appropriate data classification and specification of privacy requirements,
within our business procedures.
Promotion Structure
To ensure the appropriate management and protection of information security concerning the Olympus Group's business, the information security
management structure is formed under the CISO with clear responsibility assignments. Under the direction of the CISO, and under a global governance
structure that incorporates four information security areas, the Olympus Group will work to manage and ensure information security and fulfill its
accountability to stakeholders.
In addition, the CAO, who is the executive officer in charge of the Olympus Group's information security function, reports to the Board of Directors, which
Basic Approach and Governance
Promotion Structure
Initiatives (Management)
Four Areas of Information Security
Olympus Group Information Security Policy
The Olympus Group Personal Information Protection Policy
136

supervises the execution of duties by executive officers.
The current CAO has a wide background that includes experience in information security and cyber
security involving project managing implementation of an IT system and IT security risk assessments.
Reports are made to the Group Executive Committee every month to ensure that management decisions are made promptly.
Initiatives (Management)
Information Security Risk Management
In order to carry out appropriate information security risk management, the Olympus Group implements the PDCA (Plan-Do-Check-Act) cycle, which
includes assessment, analysis, planning and implementation based on functional areas, and review of implementation results, according to the necessary
hierarchy. In the assessment process, we incorporate information from multiple third-party perspectives, including domestic and overseas regulatory
ministries and agencies, government agencies related to information security, independent agencies, industry organizations, and threat intelligence vendors,
as well as strive to gain a global understanding of our own situation.
In addition, in order to formulate effective countermeasures for the analyzed risks, we classify the risks appropriately and examine them from multiple
perspectives, including our own initiatives, collaboration with relevant organizations, and risk assurance.
Risk Management Processes
The Olympus Group conducts third-party assessments, including a penetration test to evaluate vulnerabilities, as well as global monitoring of information
security incidents, and takes measures to address risks according to any observed incidents.
The following table shows the global occurrence of information security incidents over the last three years.
Incidents
FY2019
FY2020
FY2021
Total number of information security breaches or other cybersecurity incidents
0
0
0
Report on Information Security to the Group Executive Committee
137

Incidents
FY2019
FY2020
FY2021
Total number of information security breaches involving customers' personally identifiable
information
0
0
0
Total number of customers affected by company's data breach
0
0
0
Total amount of fines/penalties paid in relation to information security breaches or other
cybersecurity incident
0
0
0
Risk Mitigation
To respond to IT security incidents, we have clarified the global rules for IT security incidents, and the Information Security Governance Committee shares
information on incidents as the situation demands. In order to maintain the effectiveness of our incident response system, we conduct training at least once a
year. In light of the recent frequency of cyber attacks targeting companies that are responsible for social infrastructure, the incident response plan is
constantly updated as necessary to ensure global information security.
Regarding product security, we have established a system to collect information on threats and vulnerabilities related to our products and analyze security
risks, and are working to implement security measures as soon as possible.
As for data protection, we are implementing appropriate protection by classifying the importance of data from the perspective of compliance and risk control,
as well as related laws and regulations, and introducing appropriate management methods.
In IT security, it is difficult to completely eliminate the occurrence of incidents. In addition to preparing measures to prevent incidents from occurring from
various angles, the Olympus Group has established a system for rapid detection, analysis, containment and recovery without delay. Based on recent events
such as cyber-attacks, the results of assessments of critical assets related to business continuity, and analysis of risk factors, we are working to formulate
more advanced information security measures. Although there have been no significant incidents at present, we are improving our plans to enable prompt
incident response based on the recognition of the increasing risk of cyber attacks targeting manufacturing and medical institutions.
In order to ensure that information security is thoroughly implemented in our business operations, it is important to cultivate each employee's security
awareness and the sense of ethics that is a prerequisite for such awareness. The Regional Information Security Manager appropriately monitors the
implementation of education for all employees and strives to improve information security literacy. Education through e-learning and other means, as well as
awareness of the information security policy and incident reporting process, is being implemented in all regions. For example, in Japan, we are providing e-
learning to all executives and employees based on the rule of IT Security Incident Handling established in 2020, which sets specific standards for handling
incidents.
Incident Response
Business Continuity Plans
Information Security Education
138

Risk Management System
Basic Approach and Policy
Based on the "Policy of Risk Management and Crisis Response" and related rules, the Olympus Group develops global risk management systems,
undertaking risk management from the perspective of both "offense" through active and sound risk taking leading to sustainable growth and value creation
for the Company and "defense" to prevent illegalities and accidents.
A crisis management process has also been established to minimize the impact of unforeseen incidents on corporate value.
Risk management in each region and organization within the Olympus Group is carried out by the manager of the respective businesses or functions under
the directions of executive officers. Priority measures in the business plan are planned and implemented based on the risk assessments. It contributes to
managing our businesses based on the business plan with risk transparency from the medium- to long-term perspective and in line with the changes in both
the internal and external environments.
Any major incident that is highly likely to affect business management in the Olympus Group is reported promptly to the president and other senior
management and handled appropriately by the managers in coordination with relevant divisions.
The Olympus Group strives for thorough infection prevention measures and has set measures such as maintaining physical distance and wearing masks in
the workplace, ventilation of facilities and self-restraint on business trips and events. In addition, a global task force will be established if necessary, to ensure
business continuity.
Amid the ongoing global spread of COVID-19, the Olympus Group has continued to implement training, demonstration and seminars online, and strives to
provide solutions responding to the new environment. In Japan, the Central Task Force led by the regional representative officer was established and
employees were advised to work from home from the end of March to the end of May 2020. In response to the termination of the state of emergency across
Japan, we relaxed the work-from-home restraints in June 2020 with limited attendance rates. To keep the working environment safe, we established
guidelines that take into account the "new lifestyle." 
Further, we revised our business continuity plans (BCPs), which conventionally focused on natural disasters, such as earthquakes and storms, to include
pandemics, as represented by COVID-19. We are also building viable BCPs with increased focus on the entire value chain. As a part of this effort, we are
constantly implementing our disaster prevention and reduction activities such as by formulating the "BCP/BCM Development Guideline". We provide training
and drills to employees to improve effectiveness of our BCPs.
We continuously implement every possible measure to keep our products and services available to our customers, giving the highest priority to the health
and safety of our employees, medical professionals, patients, and communities.
Promotion Structure
Risk Management
Crisis Management
Risk Management Structure
139

The Olympus Group's risk management systems clarify the Executive Officer in charge of risks that could affect the achievement of the Company's business
targets as well as the corporate strategy (establishing risk assurance) and each Executive Officer executes the necessary measures (organizational
structure, process preparation, focus measures, etc.) to keep within the acceptable level their designated area of risks.
In addition, the Olympus Group operates risk management processes with a PDCA cycle of risk assessment (identification, analysis and evaluation of risk
and setting countermeasures), implementation of risk countermeasures, monitoring and reporting, and improvement. Risk assessment is linked to the
process for formulating the fiscal year plan, with risk evaluated using common company-wide evaluation standards, and company-wide risks visualized and
uniformly managed. In addition, the status of response to the Group's key risks are periodically monitored and reported to the Group Executive Committee
and the Board of Directors.
We will achieve the "basis Management Policy" through these risk management.
140

Environmental Health and Safety Policy
All our activities are based on our corporate philosophy, "Making people's lives healthier, safer and more fulfilling." Following this philosophy, the Olympus
Group respects people’s security and health and the natural mechanisms that realize this. We will contribute to the realization of a sustainable society by
working to harmony with the environment and keep employees’ security and health.
1. Continual Improvement of Environmental Health and Safety Activities
We will maintain the environmental health and safety management system and mechanism on a global scale and monitor the progress of environmental
health and safety activities regularly so that we can continuously improve our environmental health and safety performance.
2. Compliance with Laws, Regulations, and Social Norms
We will fully comply with the laws and regulations, agreements with our stakeholders, and our voluntary standards in respect to the environment, health and
safety.
3. Reduction of Environmental Impact
Toward the solution of environmental issues, prevention of pollution, sustainable resource use, climate change mitigation and adaptation, and protection of
biodiversity, we will reduce environmental impact through all business activities from research, development, design, procurement, production, logistics,
sales and repair.
4. Keeping safety and health
We will keep a safe and hygienic work environment by taking measures to eliminate and reduce safety and health risk factors based on the risk
assessments.
5. Attributing Importance to Communication
We will ensure transparency and reliability in dispatch of information about environmental safety and health activities, deepen mutual understanding with our
stakeholders, and promote activities for solving environmental safety and health issues in cooperation with each other.
141

Control of Chemical Substances Used in Products
In recent years, governments worldwide have tightened regulations relating to the reduction or control of chemical substances.
Based on the Control Rules for Environment-Related Substances Used in Products, which was formulated in reference to the chemical substance-related
laws and regulations enforced in countries across the world, Olympus conducts surveys in the product design and development stages and also in its
procurement activities to ensure that its products do not contain environment-related substances.
Olympus Group Control Rules for Environment-related Substances Used in
Product
Control Rules for Environment-related Substances Used in Product Ver.15 ( July 2021 )
Japanese (PDF: 1.3MB)
English (PDF: 1.2MB)
Chinese (PDF: 1.4MB)
142

Published by Olympus Corporation Regulatory Affairs and Quality Audit, Global 
 
 
 
 
 
 
 
 
 
 
Control Rules for Environment-related 
Substances Used in Product 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ver. 15 
July 1, 2021 
 
 
 
 
 
 
 
143

Published by Olympus Corporation Regulatory Affairs and Quality Audit, Global 
Contents 
1. Purpose ..................................................................................................................... 1 
2. Scope ......................................................................................................................... 1 
2.1 Items ........................................................................................................................................ 1 
2.2 Laws and regulations .............................................................................................................. 1 
3. Terms and Definitions .............................................................................................. 2 
4. Rules ......................................................................................................................... 3 
4.1 The environment-related substances and control classification ............................................. 3 
4.2 Prohibited substances ............................................................................................................. 3 
4.3 Controlled substances ............................................................................................................. 4 
4.4 Control value ........................................................................................................................... 4 
Table 1 Environment-related Substances ..................................................................................... 5 
Table 2 Criteria for managing prohibited substances .................................................................. 7 
Table 3 Criteria for managing controlled substances ................................................................. 46 
5. Major Revisions ...................................................................................................... 47 
  
 
144

Ver. 15 
1/57 
[Control Rules for Environment-related Substances Used in Product] 
1. Purpose 
These rules pertain to environment-related substances used in the products of Olympus Group 
(this is hereinafter referred to as “Olympus”). They are to ensure that Olympus products 
comply with laws and regulations by defining criteria for prohibiting or controlling the 
substances, as well as to reduce environmental load. 
 
2. Scope 
2.1 Items 
(1) Products (shipped out by Olympus) 
- 
Products designed, manufactured and sold by Olympus 
- 
Products designed and manufactured by third parties, and sold by Olympus with 
its trademark attached 
- 
Products designed and manufactured by Olympus and supplied to a third party 
as OEM products. 
(Note1) In this case, third parties are responsible for requiring Olympus to comply 
with these regulations. 
(Note2) These rules do not apply to the components or materials specified by the 
third party. 
 (2) Parts and materials (delivered to Olympus, and used in “(1) Products” above) 
- 
Subassemblies (e.g., assembly parts such as function units, modules and board 
assemblies) 
- 
Components and materials (e.g., electrical components, components of machinery, 
components of electric machinery, semiconductors, printed wiring boards.) 
- 
Parts for repair and maintenance services 
- 
Accessories (e.g., accessories, such as AC adaptors, necessary for device operation) 
- 
Subsidiary materials (e.g., solder materials, adhesives, lubricants, reinforcing 
materials, tapes, paints, inks.) 
- 
Printed materials (e.g., instruction manuals, brochures.) 
- 
Materials for sales promotion (e.g., labels.) 
(3) Packaging materials 
- Packaging materials and components used to ship out products 
- Packaging subsidiary materials (e.g., adhesives, lubricants, reinforcing materials, 
tapes, paints, inks.) 
(Except for packaging materials disposed of during Olympus manufacturing 
processes.) 
 
(Note) Olympus may require our suppliers to comply with the rules herein in the following cases; 
- 
Products distributed by Olympus for sales promotion purposes 
 (e.g., novelty items bearing Olympus’s name) 
 
2.2 Laws and regulations  
These rules are established in accordance with major global treaties, laws, ordinances and 
industry standards (hereinafter called “regulations”). However, they may not cover all of these 
regulations. If there are additional requirements in regions where products are sold, Olympus 
global, regional, and local business centers and their suppliers shall obey those requirements. 
 
145

Ver. 15 
2/57 
[Control Rules for Environment-related Substances Used in Product] 
3. Terms and Definitions 
The following definitions are applied to the terms used in these rules. 
(1) Environment-related substances 
These substances have significant influence on human health and the environment. 
They are specified by Olympus as “prohibited” or “controlled” substances, in accordance 
with laws and regulations.  
 
(2) Joint Article Management Promotion-Consortium (JAMP) 
JAMP is a Japanese consortium that manages information on chemical substances 
contained in an article appropriately and operates a system to disclose and efficiently 
transmit this information through companies in the supply chain. 
 
(3) Substance group 
This is a collective term for a chemical substance and its chemical compounds, or a 
collective term for several substances that possess similar chemical structures, toxicities, 
and/or harmful effects on the environment. 
 
(4) Inclusion 
This is defined as the addition or adhesion of substances to, or mixture of substances 
with, raw materials, parts, or products, whether intentionally or otherwise. The 
addition, adhesion or mixture of impurities is also regarded as inclusion. 
 
(5) Intentional use 
This is the situation where a substance is contained in products because of deliberate 
addition, filling, blending, or adhesion, in order to provide a specific characteristic, 
appearance or quality. 
 
(6) Impurities 
Natural impurities contained in natural raw materials and technically impossible to be 
completely removed in the refining process for industrial materials, or substances that 
are created in the synthetic reaction process but technically impossible to be completely 
removed. 
(Note) Any substances added to materials to change their characteristics are deemed 
“intentional use”. (They are not impurities if they are called “impurities” in order 
to distinguish them from main raw materials.) 
 
(7) Article (REACH Article 3: Definitions) 
An object which during production is given a special shape, surface or design which 
determines its function to a greater degree than does its chemical composition. 
 
(8) Mixture (REACH Article 3: Definitions) 
A mixture or solution composed of two or more substances. 
 
(9) Homogeneous materials 
Homogeneous materials are materials that cannot be mechanically separated anymore 
and have a homogeneous composition. Examples are plastic, ceramics, glass, metals, 
alloys, paper, boards, resins and coatings. Mechanical separation means separation by 
146

Ver. 15 
3/57 
[Control Rules for Environment-related Substances Used in Product] 
mechanical processes, such as removing screws, cutting, crushing, grinding and 
polishing. 
 
(10) Metal conversion factor 
This is the factor used to calculate the weight of a metallic element in a metallic 
compound from the weight of the metallic compound. The weight of a metallic element 
in a metallic compound can be obtained by multiplying the weight of the metallic 
compound by the metal conversion factor. 
 
(11) CAS No. 
This is the registration number for chemical substances allocated by the Chemical 
Abstracts Service (CAS), which is a division of the American Chemical Society. CAS 
numbers are used globally to identify chemical substances since there are several 
different ways of writing the names of chemical substances. 
 
(12) JAMP Substance Numbers (JAMP-SN) 
The number introduced by JAMP for some substances and groups that do not have a 
CAS No. (SN stands for “Substance Number”). 
 
(13) Control value 
The concentrations defined by Olympus to ensure that the amounts of substances 
contained in items do not exceed the concentrations regulated. 
 
(14) Dates of ban on delivery 
Dates when Olympus imposes ban on delivery from their suppliers to Olympus. 
Olympus determines them to ensure observance of the effective dates of regulations. 
(They are six months before the effective dates.)  
In case that Olympus’s business centers set their own dates of ban on delivery, these 
dates set by business centers take precedence over the ones herein. 
 
4. Rules 
4.1 The environment-related substances and control classification 
The environment-related substances designated by Olympus are listed in Table 1. They are 
classified into two categories: “prohibited substances” and “controlled substances”. 
 
4.2 Prohibited substances 
Prohibited substances are classified into the two following levels based on their date of ban 
on delivery. 
 (1) Prohibited substances Level 1: 
These substances are immediately prohibited. Exceptions apply in the following cases: 
- 
They have ‘a control value’ and can be used below that value. 
- 
They have ‘an exemption’ and can be used for that application provided that their 
concentrations and their location of use shall be reported. 
 (2) Prohibited substances Level 2: 
147

Ver. 15 
4/57 
[Control Rules for Environment-related Substances Used in Product] 
These substances will be prohibited after their date of ban on delivery. 
- 
They are acceptable to use until their date of ban on delivery. 
- 
Date of ban on delivery will be revised if the regulation has been postponed in 
case an alternative substance cannot be found. 
 
Criteria for managing prohibited substances are shown in Table 2.  
- Prohibition level, date of ban on delivery, applications, control values, exemptions, notes 
- Examples of substances (They do not cover all the substances in this substance group.) 
or regulated substances 
- Principal uses for substances 
 
4.3 Controlled substances 
If the content of a controlled substance exceeds its control value, the substance, the 
concentrations, and the location of use shall all be reported. 
 Criteria for managing controlled substances are shown in Table 3. 
- Applications, control values and notes 
4.4 Control value 
Unless otherwise designated, the control values are the concentrations of substances in 
homogeneous materials. 
- In complex components (assemblies), it is the concentration in each article of that 
component (not what is in the whole component). 
- In surface treatment coatings, it is the concentration in the coating. 
- In metal compounds that have metal conversion factors, the control values are the 
respective concentrations of the metal elements included in those compounds. In metal 
compounds that have no metal conversion factors, the control values are the 
concentrations of the whole metal compound.  
148

Ver. 15 
5/57 
[Control Rules for Environment-related Substances Used in Product] 
Table 1 Environment-related Substances 
Class 
Major division 
No. 
Substance group 
Detail 
(I) 
Prohibited 
substances 
Metal and 
metal 
compounds 
(including 
their alloys) 
I-1 
Cadmium and its compounds 
Table 2-I-1 
I-2 
Hexavalent chromium compounds 
Table 2-I-2 
I-3 
Lead and its compounds 
Table 2-I-3 
I-4 
Mercury and its compounds 
Table 2-I-4 
I-5 
Trisubstituted organotin compounds (including 
tributyltin compounds (TBTs) and triphenyltin 
compounds (TPTs)) 
Table 2-I-5 
I-6 
Dibutyltin compounds (DBT) 
Table 2-I-6 
I-7 
Dioctyltin compounds (DOT) 
Table 2-I-7 
I-8 
Nickel and its compounds 
Table 2-I-8 
Halogenated 
organic 
compounds 
I-9 
Polybrominated biphenyl (PBBs) 
Table 2-I-9 
I-10 
Polybrominated diphenyl ether (PBDEs) 
Table 2-I-10 
I-11 
Polychlorinated biphenyl (PCBs) 
Table 2-I-11 
I-12 
Polychlorinated terphenyls (PCTs) 
Table 2-I-12 
I-13 
Polychlorinated naphthalene (with more than 3 
chlorine atoms) 
Table 2-I-13 
I-14 
Short-chained chlorinated paraffin (having the 
chain length of 10 - 13) 
Table 2-I-14 
I-15 
Polyvinyl chloride (PVC) 
Table 2-I-15 
I-16 
Hexabromocyclododecane (HBCDD) 
Table 2-I-16 
I-17 
Pentachlorothiophenol (PCTP) 
Table 2-I-17 
I-18 
Hexachlorobutadiene (HCBD) 
Table 2-I-18 
Others 
I-19 
Asbestos 
Table 2-I-19 
I-20 
Azo dyes and pigments (specific amines formed 
by degrading azo dies and pigments) 
Table 2-I-20 
I-21 
Ozone depleting substances (listed in Montreal 
Protocol) 
Table 2-I-21 
I-22 
Perfluorooctanesulfonic acid (PFOS) and PFOS 
analogs 
Table 2-I-22 
I-23 
Specific benzotriazole: 2-(2H-1,2,3-
Benzotriazol-2-yl)-4,6-di-tert-butylphenol 
Table 2-I-23 
I-24 
Formaldehyde 
Table 2-I-24 
I-25 
Dimethylfumarate (DMF) 
Table 2-I-25 
I-26 
Fluorinated Greenhouse Gases (PFC, SF6, 
HFC) 
Table 2-I-26 
I-27 
Phthalate esters (BBP, DBP, DEHP, DIDP, 
DINP, DNOP) 
Table 2-I-27 
I-28 
Perfluorooctanoic acid (PFOA) and its salts and 
esters and certain Long-Chain Perfluoroalkyl 
Carboxylates (LCPFAC) 
Table 2-I-28 
I-29 
Polycyclic aromatic hydrocarbon (PAH) 
Table 2-I-29 
I-30 
Pentachlorophenol and its salts and esters 
Table 2-I-30 
I-31 
Certain CMR substances 
Table 2-I-31 
I-32 
Phenol, isopropylated phosphate (3:1) 
Table 2-I-32 
I-33 
2,4,6-tris(tert-butyl)phenol (2,4,6-TTBP) 
Table 2-I-33 
(II) 
Controlled 
substances 
Others 
II-1 
Candidate List of Substances of Very High 
Concern in REACH(SVHC) 
Table 3-II-1 
II-2 
Substances subject to the European Union’s 
Medical Device Regulation (EU-MDR) or In 
Vitro Diagnostic Medical Device Regulation 
(EU-IVDR) 
Table 3-II-2 
149

Ver. 15 
6/57 
[Control Rules for Environment-related Substances Used in Product] 
(Note) 
- Applications of I-31 “Certain CMR substances” are limited to products that come into 
contact with human skin to an extent similar to clothing. Please see Table 2-I-31 for 
details. 
- I-17, I-18, I-32, I-33 are substances that are persistent, bio-accumulative, and toxic 
chemicals (PBTs) identified pursuant to section 6(h) of the Toxic Substances Control Act 
(TSCA). Please see Table 2-I-17, Table 2-I-18, Table 2-I-32, and Table 2-I-33 for details. 
- Applications of II-2 “Substances subject to the European Union’s Medical Device 
Regulation (EU-MDR) or In Vitro Diagnostic Medical Device Regulation (EU-IVDR)” are 
limited to components and subsidiary materials that are used in products subject to EU-
MDR or EU-IVDR, and that come into direct or indirect contact with the patient. Please 
see Table 3-II-2 for details. 
 
 
 
 
150

Ver. 15 
7/57 
[Control Rules for Environment-related Substances Used in Product] 
Table 2 Criteria for managing prohibited substances 
 
Table 2-I-1 Cadmium and its compounds 
(1) Details 
No. I-1 
Substance Group: Cadmium and its compounds 
Prohibition 
Level 
Date of ban 
on delivery 
*4 
Applications 
Control Value  
Note 
Level 1 
 
Immediate 
･Surface processing (e.g. plating) and 
coating (except for electrical contacts 
requiring a high level of safety and 
reliability, and for which no substitute 
exists) 
･Fluorescence lamps and photographic film 
･Stabilizer, pigment and dye used for 
plastics (including rubbers) 
･Paints and inks 
-Less than 75 ppm in 
homogeneous material 
*1 
･Packaging materials 
-Less than 100 ppm in 
homogeneous material 
*2 
Immediate 
 
Exclusions 
from RoHS 
Directive: 6 
months 
prior to 
expiration 
･Electric and electronic equipment subject 
to RoHS Directive (2011/65/EU) 
 
-100 ppm or less in 
homogeneous material 
*3 
 
Exemption 
Please refer to the EU RoHS ANNEX III and ANNEX IV. 
Note 
*1  Because the Danish cadmium control act has been amended to reflect RoHS Directive 
(2011/65/EU), the control value is set at 100 ppm for products subject to RoHS Directive 
(2011/65/EU) and 75 ppm for products not covered by RoHS Directive (2011/65/EU). 
Annex XVII to REACH (restriction), ChemVerbotsV (Germany) 
*2  The total concentration of four heavy metals (cadmium, hexavalent chromium, lead and 
mercury) in packaging materials must be considered. In the case of printing inks used 
on packaging, the total concentration of these four heavy metals included in the solid 
ingredients of the inks must be considered. EU Directive on packaging materials and 
Regulations on Heavy Metals in Packaging (U.S.A.). 
*3  RoHS Directive (2011/65/EU) 
*4  The date of ban on delivery is set as the date six months before the effective date of an 
applicable law or regulation. 
(2) Examples of substances (The table below does not cover all the substances in this substance group.) 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No. or 
JAMP-SN 
Metal 
conversion 
factor 
カドミウム 
Cadmium 
Cd 
7440-43-9 
1.000 
酸化カドミウム(II) 
Cadmium oxide 
CdO 
1306-19-0 
0.875 
硫化カドミウム 
Cadmium sulfide 
CdS 
1306-23-6 
0.778 
塩化カドミウム 
Cadmium chloride 
CdCl2 
10108-64-2 
0.613 
硫酸カドミウム(II) 
Cadmium sulfate 
CdSO4 
10124-36-4 
31119-53-6 
0.539 
 
CdH6O16S4 
119222-01-4 
0.224 
硝酸カドミウム 
Cadmium Nitrate 
Cd(NO3) 2 
10325-94-7 
0.475 
炭酸カドミウム 
Cadmium carbonate 
CdCO3 
513-78-0 
0.652 
硫セレン化カドミウム 
Cadmium selenide sulfide 
Cd2SSe 
12214-12-9 
0.669 
151

Ver. 15 
8/57 
[Control Rules for Environment-related Substances Used in Product] 
セレン化カドミウム 
Cadmium Selenide 
CdSe 
1306-24-7 
0.587 
テルル化カドミウム 
Cadmium Telluride 
CdTe 
1306-25-8 
0.468 
水酸化カドミウム 
Cadmium Hydroxide 
Cd(OH) 2 
21041-95-2 
0.768 
ステアリン酸カドミウム 
Cadmium Stearate 
Cd(C17H35COO
)2 
2223-93-0 
0.166 
フッ化カドミウム 
Cadmium fluoride 
CdF2 
7790-79-6 
0.747 
シロキサンおよびシリコーン, 3-
[(2-アミノエチル)アミノ]プロピ
ルメチル, ジメチル, セレン化
硫化亜鉛カドミウム, ラウリン
酸, オレイルアミンとの反応生
成物 
Siloxanes and Silicones, 3-[(2-
aminoethyl)amino]propyl Me, 
di-Me, reaction products with 
cadmium zinc selenide sulfide, 
lauric acid and oleylamine 
- 
1623456-05-2 - 
その他のカドミウム化合物 
Other cadmium compounds 
- 
JAMP-SN0016 - 
(3)Principal uses for substances 
Part 
Purpose 
Corrosion-resistant plating, decorative coatings, 
printing inks, NiCd batteries, vinyl chloride sheaths 
for wires and cords, fuses, fluorescent materials, 
optical glasses (filters) 
Anticorrosion surface treatment, pigments, 
battery and electrical materials, plastic 
stabilizers, optical materials 
 
Table 2-I-2 Hexavalent chromium compounds 
(1) Details 
No. I-2 
Substance Group: Hexavalent chromium compounds 
Prohibition 
Level 
Date of ban 
on delivery 
*5 
Applications 
Control Value  
Note 
Level 1 
Immediate 
･Packaging materials 
-Less than 100 ppm 
in homogeneous 
material 
*1 
･Leather articles and articles containing 
leather parts, which come into contact with the 
skin 
-Less than 3 mg/kg 
(0.0003%) of the 
total dry weight of 
the leather 
*2 
･Substances and mixtures that contain 
chemicals with the following CAS numbers: 
Lead (II) chromate: 7758-97-6 
Lead chromate molybdate sulphate red: 
12656-85-8 
 Chromium (VI) trioxide: 1333-82-0 
Oligomers of chromic acid and dichromic acid: 
13530-68-2 
Chromic acid: 7738-94-5 
Sodium dichromate: 10588-01-9 
Sodium dichromate dihydrate: 7789-12-0 
Potassium dichromate: 7778-50-9 
Ammonium dichromate: 7789-09-5 
Potassium chromate: 7789-00-6 
Sodium chromate: 7775-11-3 
Pentazinc chromate octahydroxide: 49663-84-5 
Strontium chromate: 7789-06-2 
Dichromium tris(chromate): 24613-89-6 
Potassium 
hydroxyoctaoxodizincatedichromate: 11103-86-
9 
Intentional inclusion 
prohibited 
*3 
152

Ver. 15 
9/57 
[Control Rules for Environment-related Substances Used in Product] 
Immediate 
 
Exclusions 
from RoHS 
Directive: 6 
months 
prior to 
expiration 
･Electric and electronic equipment subject to 
RoHS Directive (2011/65/EU) 
 
-1000 ppm or less in 
homogeneous 
material 
 
*4 
 
Exemption 
Please refer to the EU RoHS ANNEX III and ANNEX IV. 
Note 
*1  The total concentration of four heavy metals (cadmium, hexavalent chromium, lead and 
mercury) in packaging materials must be considered. In the case of printing inks used 
on packaging, the total concentration of these four heavy metals included in the solid 
ingredients of the inks must be considered. EU Directive on packaging materials and 
Regulations on Heavy Metals in Packaging (U.S.A.). 
*2  Annex XVII to REACH (restriction) 
*3  Annex XIV to REACH (authorizations) 
*4  RoHS Directive (2011/65/EU) 
*5  The date of ban on delivery is set as the date six months before the effective date of an 
applicable law or regulation. 
(2) Examples of substances (The table below does not cover all the substances in this substance group.) 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No. or 
JAMP-SN 
Metal 
conversion 
factor 
重クロム酸ナトリウム 
Sodium dichromate 
Na2Cr2O7 
10588-01-9 
0.349 
重クロム酸ナトリウム・２水和
物 
Sodium dichromate, dihydrate 
Na2Cr2O7
、
2H2O 
7789-12-0 
0.349 
酸化クロム(VI) 
Chromium (VI) trioxide 
CrO3 
1333-82-0 
0.520 
クロム酸カルシウム 
Calcium chromate 
CaCrO4 
13765-19-0 
0.333 
クロム酸鉛(II) 
Lead (II) chromate 
PbCrO4 
7758-97-6 
0.161 
重クロム酸カリウム 
Potassium dichromate 
K2Cr2O7 
7778-50-9 
0.354 
クロム酸カリウム 
Potassium chromate 
K2CrO4 
7789-00-6 
0.268 
クロム酸バリウム 
Barium chromate 
BaCrO4 
10294-40-3 
0.205 
クロム酸ナトリウム 
Sodium chromate 
Na2CrO4 
7775-11-3 
0.321 
クロム酸ストロンチウム(II) 
Strontium chromate 
SrCrO4 
7789-06-2 
0.255 
クロム酸亜鉛(II) 
Zink chromate 
ZnCrO4 
13530-65-9 
0.287 
クロム酸鉛(C.Iピグメントイエ
ロー34) 
Lead sulfochromate yellow 
(C.I.Pigment Yellow 34) 
Unspecified 
1344-37-2 
- 
塩基性クロム酸鉛 
C.I. Pigment Orange 21 
Unspecified 
1344-38-3 
- 
クロム酸 
Chromic acid 
CrH2O4 
7738-94-5 
0.441 
クロム酸及び重クロム酸オリゴ
マー 
Oligomers of chromic acid and 
dichromic acid 
- 
JAMP-SN0071  
重クロム酸、二クロム酸 
Dichromic acid; Chromic acid 
H2Cr2O7 
13530-68-2 
0.477 
二クロム酸アンモニウム 
Ammonium dichromate 
(NH4)2Cr2O7 
7789-09-5 
0.413 
硫酸モリブデン酸クロム酸鉛
(C.Iピグメントレッド104) 
Lead chromate molybdate 
sulphate red (C.I. Pigment Red 
104) 
Unspecified 
12656-85-8 
- 
トリス(クロム酸)二クロム(III) 
Dichromium tris(chromate) 
Cr5O12 
24613-89-6 
0.575 
クロム酸八水酸化五亜鉛 
Pentazinc chromate 
octahydroxide 
CrH8O12Zn5 
49663-84-5 
0.090 
ヒドロキシオクタオキソ二亜鉛
酸二クロム酸カリウム 
Potassium 
hydroxyoctaoxodizincatedichro
mate 
Cr2K2O8Zn 
11103-86-9 
0.277 
153

Ver. 15 
10/57 
[Control Rules for Environment-related Substances Used in Product] 
その他の六価クロム化合物 
Other hexavalent chromium 
compounds 
- 
JAMP-SN0019 - 
(3) Principal uses for substances 
Part 
Purpose 
Metal corrosion-proof chromate treatment 
(galvanizing, electrode plating, alloys, die-casting), 
alumite dyes, anticorrosion paints, black chrome 
plating 
Anticorrosion surface treatment, pigments, 
anticorrosion pigments, paint desiccants 
 
Table 2-I-3 Lead and its compounds 
(1) Details 
No. I-3 
Substance Group: Lead and its compounds 
Prohibition 
Level 
Date of ban 
on delivery 
*5 
Applications 
Control Value 
Note 
Level 1 
 
Immediate 
･Packaging materials 
-Less than 100 ppm in 
homogeneous material 
*1 
･Cable stabilizer used for insulating 
sheaths whose main ingredient is PVC 
(especially used in the parts of the sheaths 
touched routinely with hands) 
-Less than 300 ppm in 
PVC cable insulating 
sheath 
*2 
･Substances and mixtures that contain 
chemicals with the following CAS 
numbers: 
Lead (II) chromate: 7758-97-6 
Lead sulfochromate yellow (C.I. Pigment 
Yellow 34): 1344-37-2 
Lead chromate molybdate sulphate red 
(C.I. Pigment Red 104): 12656-85-8 
-Intentional inclusion 
prohibited  
 
*3 
Immediate 
 
Exclusions 
from RoHS 
Directive: 6 
months 
prior to 
expiration 
･Electric and electronic equipment subject 
to RoHS Directive (2011/65/EU) 
 
-1000 ppm or less in 
homogeneous material 
*4 
 
Exemption 
Please refer to the EU RoHS ANNEX III and ANNEX IV. 
Note 
*1  The total concentration of four heavy metals (cadmium, hexavalent chromium, lead and 
mercury) in packaging materials must be considered. In the case of printing inks used 
on packaging, the total concentration of these four heavy metals included in the solid 
ingredients of the inks must be considered. EU Directive on packaging materials and 
Regulations on Heavy Metals in Packaging (U.S.A.). 
*2  Labeling is required if the inclusion level exceeds the 300 ppm level stipulated in the 
out-of-court settlement of a lawsuit alleging non-compliance with the warning labeling 
requirements provided by Proposition 65 in the State of California. The control value, 
therefore, is set at less than 300 ppm.  
*3  Annex XIV to REACH (authorizations) 
*4  RoHS Directive (2011/65/EU), Annex XVII to REACH (restriction), ChemVerbotsV 
(Germany) 
*5  The date of ban on delivery is set as the date six months before the effective date of an 
applicable law or regulation. 
(2) Examples of substances (The table below does not cover all the substances in this substance group.) 
154

Ver. 15 
11/57 
[Control Rules for Environment-related Substances Used in Product] 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No. or 
JAMP-SN 
Metal 
conversion 
factor 
鉛 
Lead 
Pb 
7439-92-1 
1.000 
炭酸鉛 
Lead carbonate  
PbCO3 
598-63-0 
0.775 
二酸化鉛 
Lead (IV) oxide 
PbO2 
1309-60-0 
0.866 
四三酸化鉛 
Orange lead (Lead tetroxide) 
Pb3O4 
1314-41-6 
0.907 
硫化鉛 
Lead (II) sulfide 
PbS 
1314-87-0 
0.866 
一酸化鉛 
Lead monoxide (Lead oxide)；
Lead (II) oxide 
PbO 
1317-36-8 
0.928 
水酸化炭酸鉛(II) 
Trilead 
bis(carbonate)dihydroxide 
C2H2O8Pb3  
1319-46-6 
0.801 
水酸化炭酸鉛(2) 
Lead (II) hydroxidcarbonate 
C2H2O6Pb  
1344-36-1 
0.629 
硫酸鉛 
Lead sulfate 
PbSO4 
7446-14-2 
0.683 
燐酸鉛 
Trilead bis(orthophosphate) 
Pb3(PO4)2 
7446-27-7 
0.766 
クロム酸鉛(II) 
Lead chromate 
PbCrO4 
7758-97-6 
0.641 
チタン酸鉛 
Lead titanate   
PbTiO3 
12060-00-3 
0.684 
硫酸鉛 
Lead sulfate 
PbXSO4 
15739-80-7 
- 
三塩基性硫酸鉛 
Tetralead trioxide sulphate 
Pb4O3(SO4) 
12202-17-4 
0.852 
ステアリン酸鉛 
Lead stearate 
Pb(C17H35CO
O)2 
1072-35-1 
0.268 
ステアリン酸二鉛 
Dibasic lead stearate 
2PbO・
Pb(C17H35CO
O)2 
56189-09-4 
0.409 
酢酸鉛(II) 
Lead di(acetate) 
Pb(CH3COO) 2 301-04-2 
0.637 
酢酸鉛(II)・三水和物 
Lead (II) acetate trihydrate 
Pb(CH3COO) 2 
 ･3H2O 
6080-56-4 
0.546 
セレン化鉛 
Lead selenide 
PbSe 
12069-00-0 
0.724 
ジルコン酸鉛 
Lead zirconate 
PbZrO3 
12060-01-4 
0.598 
水酸化鉛 
Hydroxylead 
Pb(OH)2 
1311-11-1 
0.859 
硝酸鉛 
Lead dinitrate 
Pb(NO3)2 
10099-74-8 
0.626 
ヒ酸鉛(II) 
Trilead diarsenate 
Pb3(AsO4)2 
3687-31-8 
0.691 
酸性ヒ酸鉛 
Lead hydrogen arsenate 
AsH3O4.Pb 
7784-40-9 
0.593 
トリニトロレゾルシン鉛 
Lead styphnate 
C6HN3O8Pb 
15245-44-0 
0.460 
アジ化鉛 
Lead diazide 
N6Pb 
13424-46-9 
0.711 
ピクリン酸鉛(II) 
Lead dipicrate 
C12H4N6O14Pb 6477-64-1 
0.312 
メタンスルホン酸鉛(II) 
Lead (II) bis(methanesulfonate) C2H6O6PbS2 
17570-76-2 
0.521 
硫酸モリブデン酸クロム酸鉛
(C.Iピグメントレッド104) 
Lead chromate molybdate 
sulphate red (C.I. Pigment Red 
104) 
Unspecified 
12656-85-8 
- 
クロム酸鉛(C.Iピグメントイエ
ロー34) 
Lead sulfochromate yellow 
(C.I.Pigment Yellow 34) 
Unspecified 
1344-37-2 
- 
ジオキソ（フタラト）三鉛 
[Phthalato(2-)]dioxotrilead 
C8H4O6Pb3 
69011-06-9 
0.760 
ケイ酸とバリウムの塩(1：1)(鉛
ドープ) 
Silicic acid (H2Si2O5), barium 
salt (1:1), lead-doped   
Unspecified 
68784-75-8 
 
ケイ酸と鉛の塩 
Silicic acid, lead salt 
Unspecified 
11120-22-2 
 
シアナミド鉛 
Lead cyanamidate 
CH2N2Pb 
20837-86-9 
0.831 
ジオキソビス(ステアリン酸)三
鉛 
Dioxobis(stearato)trilead 
C36H70O6Pb3 
12578-12-0 
0.509 
ジルコン酸チタン酸鉛 
Lead titanium zirconium oxide Unspecified 
12626-81-2 
 
四エチル鉛 
Tetraethyllead 
C8H20Pb 
78-00-2 
0.641 
155

Ver. 15 
12/57 
[Control Rules for Environment-related Substances Used in Product] 
ピグメントエロー41 
Pyrochlore, antimony lead 
yellow 
Unspecified 
8012-00-8 
 
四フッ化ホウ酸鉛(II) 
Lead bis(tetrafluoroborate) 
B2F8Pb 
13814-96-5 
0.544 
塩基性クロム酸鉛 
C.I. Pigment Orange 21 
Unspecified 
1344-38-3 
 
塩基性亜硫酸鉛 
Sulfurous acid, lead salt, 
dibasic 
Unspecified 
62229-08-7 
 
塩基性酢酸鉛 
Acetic acid, lead salt, basic 
Unspecified 
51404-69-4 
 
塩基性硫酸鉛 
Lead oxide sulfate (Pb2O(SO4)) Pb2O(SO4) 
12036-76-9 
0.787 
塩基性硫酸鉛 
Pentalead tetraoxide sulphate; 
Lead oxide sulfate 
(Pb5O4(SO4)) 
Pb5O4(SO4) 
12065-90-6 
0.866 
 
脂肪酸鉛塩(炭素数16～18) 
Fatty acids, C16-18, lead salts 
- 
91031-62-8 
 
二塩基性リン酸鉛 
Trilead dioxide phosphonate; ; 
Lead 
oxide 
phosphonate 
(Pb3O2(HPO3)) 
Pb3O2(HPO3) 12141-20-7 
0.847 
銅、鉄、鉛マット（かわ）の残
渣の非水溶性亜硫酸化合物 
Residues, copper-iron-lead-
nickel matte, sulfuric acid-
insol. 
- 
102110-49-6 
- 
その他の鉛化合物 
Other lead compounds 
- 
JAMP-SN0023 - 
(3) Principal uses for substances 
Part 
Purpose 
Electrodes for lead accumulators, optical glasses 
(lens, filters), structural parts (steel, aluminum, 
copper), vinyl chloride sheaths for wires and cords, 
paints, inks, X-ray shield plastic plates, CRTs for 
monitors, electro soldering, die bonding, mechanical 
soldering, vulcanized rubber molded items, 
manganese cells, alkaline button cells 
Battery materials, free-machining alloy materials, 
optical materials, plastic stabilizers, pigments, 
radiation shielding materials, electric solder 
materials, mechanical solder materials, rubber 
vulcanizing agents 
 
Table 2-I-4 Mercury and its compounds 
(1) Details 
No. I-4 
Substance Group: Mercury and its compounds 
Prohibition 
Level 
Date of ban 
on delivery 
*4 
Applications 
Control Value  
Note 
Level 1 
 
Immediate 
･Packaging materials 
-Less than 100 ppm in 
homogeneous material 
*1 
･Use in appliances used fully or partially in 
water 
-Intentional inclusion 
prohibited  
-Not detected 
*2 
Immediate 
 
Exclusions 
from RoHS 
Directive: 6 
months 
prior to 
expiration 
･Electric and electronic equipment subject 
to RoHS Directive (2011/65/EU) 
-1000 ppm or less in 
homogeneous material 
*3 
 
Exemption 
Please refer to the EU RoHS ANNEX III and ANNEX IV. 
Note 
*1  The total concentration of four heavy metals (cadmium, hexavalent chromium, lead and 
mercury) in packaging materials must be considered. In the case of printing inks used 
on packaging, the total concentration of these four heavy metals included in the solid 
ingredients of the inks must be considered. EU Directive on packaging materials and 
Regulations on Heavy Metals in Packaging (U.S.A.). 
156

Ver. 15 
13/57 
[Control Rules for Environment-related Substances Used in Product] 
*2  Annex XVII to REACH (restriction), ChemVerbotsV (Germany) 
*3  RoHS Directive (2011/65/EU) 
*4  The date of ban on delivery is set as the date six months before the effective date of an 
applicable law or regulation. 
(2) Examples of substances (The table below does not cover all the substances in this substance group.) 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No. or 
JAMP-SN 
Metal 
conversion 
factor 
水銀 
Mercury 
Hg 
7439-97-6 
1.000 
塩化第二水銀 
Mercury dichloride 
HgCl2 
7487-94-7 
0.739 
酸化水銀(II) 
Mercury (II) oxide 
HgO 
21908-53-2 
0.926 
硫酸第二水銀 
Mercury sulphate  
HgSO4 
7783-35-9 
0.676 
硝酸水銀(II) 
Mercury (II) nitrate  
Hg(NO3) 2 
10045-94-0 
0.618 
硫化第二水銀 
Mercury (II) sulfide 
HgS 
1344-48-5 
0.862 
酸化水銀(I)(黒色) 
Mercury(I) oxide (black)  
Hg 2O 
15829-53-5 
0.962 
ジメチル水銀 
Dimethyl mercury 
(CH3) 2Hg 
593-74-8 
0.870 
塩化第一水銀 
Mercury chloride 
Hg2Cl2 
10112-91-1 
0.850 
その他の水銀化合物 
Other mercury compounds 
- 
JAMP-SN0024 - 
(3) Principal uses for substances 
Part 
Purpose 
Lamps (mercury lamps, fluorescent tubes, back 
lights for liquid crystal displays), electrodes, 
batteries, electric contacts, plastics, paints, printing 
inks 
Fluorescent materials, electrical contact materials, 
mercury batteries, color pigments 
 
Table 2-I-5 Trisubstituted organotin compounds (including bis (tributyltin) oxide (TBTO), tributyltin 
compounds (TBTs, excluding TBTO) and triphenyltin compounds (TPTs)) 
(1) Details 
No. I-5 
Substance Group: Trisubstituted organotin compounds (including bis (tributyltin) oxide 
(TBTO), tributyltin compounds (TBTs, excluding TBTO) and triphenyltin compounds (TPTs)) 
Prohibition 
Level 
Date of ban 
on delivery 
Applications 
Control Value  
Note 
Level 1 
Immediate 
[TBTO (CAS No.: 56-35-9) only] 
･All applications 
-Intentional inclusion 
prohibited  
*1 
[Trisubstituted organotin compounds 
except TBTO (CAS No.: 56-35-9)] 
･All applications 
- Less than 1000 ppm 
(tin conversion) in 
article or part thereof 
*2 
Note 
*1  Class I Specified Chemical Substances (TBTO: Cas No.56-35-9) designated by Japanese 
Chemical Substances Control Act. 
*2  Annex XVII to REACH (restriction), ChemVerbotsV (Germany) 
(2) Examples of substances (The table below does not cover all the substances in this substance group.) 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No. or 
JAMP-SN 
Metal 
conversion 
factor 
ビス(トリブチルスズ)=オキシド
(TBTO) 
Bis(tri-n-butyltin) oxide  
O(Sn(C4H9)3)2 56-35-9 
0.398 
トリフェニルスズ=N,N-ジメチ
ルジチオカルバマート 
Triphenyltin 
dimethyldithiocarbamate 
(C6H5)3Sn(CH
3)2NCS2 
1803-12-9 
0.252 
トリフェニルスズ=フルオリド 
Triphenyltin fluoride 
(C6H5)3SnF 
379-52-2 
0.322 
酢酸トリフェニルスズ 
Triphenyltin acetate 
(C6H5)3SnOC
OCH3 
900-95-8 
0.290 
トリフェニルスズ=クロリド 
Triphenyltin chloride 
(C6H5)3SnCl 
639-58-7 
0.308 
157

Ver. 15 
14/57 
[Control Rules for Environment-related Substances Used in Product] 
トリフェニルスズ=ヒドロキシ
ド 
Triphenyltin hydroxide 
(C6H5)3SnOH 76-87-9 
0.323 
トリフェニル［（２，２，４，
４－テトラメチル－１－オキソ
ペンチル）オキシ］スタンナン 
Stannane, triphenyl[(2,2,4,4-
tetramethyl-oxopentyl)oxy]- 
 
C27H32O2Sn  18380-71-7 
 
0.234 
 
［［２，３－ジメチル－２－
（１－メチルエチル）－１－オ
キソブチル］トリフェニルスタ
ンナン 
Stannane, [[2,3-dimethyl-2-(1-
methylethyl)-
oxobutyl]oxy]triphenyl- 
C27H32O2Sn 
18380-72-8 
0.234 
［（１－オキソデシル）オキ
シ］トリフェニルスタンナン 
Stannane, [(1-
oxodecyl)oxy]triphenyl- 
C28H34O2Sn 
47672-31-1 
0.228 
［（１－オキソウンデシル）オ
キシ］トリフェニルスタンナン 
Stannane, [(1-
oxoundecyl)oxy]triphenyl- 
C29H36O2Sn 
94850-90-5 
0.222 
トリフェ ニルスズ=クロロアセ
タート 
Triphenyltin chloroacetate 
(C6H5)3SnOC
OCH2Cl 
7094-94-2 
0.268 
トリブチルスズ=メタクリラー
ト 
Tributyltin methacrylate 
(C4H9)3SnC4H
5O2 
2155-70-6 
0.317 
ビス(トリブチルスズ)=フマラー
ト 
Bis(tributyltin) fumarate 
C2H2(COO)2((
C4H9)3Sn)2 
6454-35-9 
0.342 
トリブチルスズ=フルオリド 
Tributyltin fluoride 
(C4H9)3SnF 
1983-10-4 
0.384 
トリブチルスズ=2,3-ジブロモス
クシナート 
Bis(tributyltin) meso-2,3-
dibromosuccinate  
((C4H9)3Sn)2C
2H2(Br)2(COO
)2 
31732-71-5 
0.278 
 
トリブチルスズ=アセタート 
Tributyltin acetate 
(C4H9)3SnOC
OCH3 
56-36-0 
0.340 
トリブチルスズ=ラウラート 
Tributyltin laurate 
(C4H9)3SnC12
H23O2 
3090-36-6 
0.243 
ビス(トリブチルスズ)=フタラー
ト 
Bis(tributyltin) phthalate 
(C6H4)(COO)2((
C4H9)3Sn)2 
4782-29-0 
0.319 
アルキル=アクリラート・メチ
ル=メタクリラート・トリブチ
ルスズ=メタクリラート、共重
合物(アルキル=アクリラートの
アルキル基の炭素数が8のもの
に限る) 
Copolymer of alkyl acrylate, 
methyl-methacrylate and 
tributyltin-methacrylate(alkyl; 
C=8) 
- 
67772-01-4 
 
トリブチルスズ=スルファマー
ト 
Tributyltin sulfamate 
(C4H9)3SnSO3
NH2 
6517-25-5 
0.307 
ビス(トリブチルスズ)=マレアー
ト 
Bis(tributyltin) maleate 
C2H2(COO)2((
C4H9)3Sn)2 
14275-57-1 
0.342 
トリブチルスズ=クロリド 
 
Tributyltin chloride 
(C4H9)3SnCl 
1461-22-9 
7342-38-3 
0.365 
トリブチルスズ=シクロペンタ
ンカルボキシラート及びこの類
縁化合物の混合物 
Mixture of tributyltin 
 -cyclopentanecarboxylate and 
its –analogs 
 (Tributyltin naphthenate) 
(C4H9)3SnCO3
C5H9 
85409-17-2 
- 
トFリブタン-1-イルスタンニル
=(1R,4aR,4bR,10aR)-7-イソプ
ロピル-1,4a-ジメチル-
1,2,3,4,4a,4b,5,6,10,10a-デカヒ
ドロフェナントレン-1-カルボキ
シラート 
Tributan-1-ylstannyl 
(1R,4aR,4bR,10aR)-7-isopropyl-
1,4a-dimethyl-
1,2,3,4,4a,4b,5,6,10,10a-
decahydrophenanthrene-1-
carboxylate 
C32H56O2Sn 
26239-64-5 
0.201 
その他の三置換有機スズ化合物 Other Trisubstituted organotin 
compounds 
- 
JAMP-
SN0068 
- 
158

Ver. 15 
15/57 
[Control Rules for Environment-related Substances Used in Product] 
(3) Principal uses for substances 
Part 
Purpose 
Paints, printing inks 
Paints, antifouling (sterilization) pigments, 
preservatives, stabilizers, antioxidants 
 
Table 2-I-6 Dibutyltin compounds 
(1) Details 
No. I-6 
Substance Group: Dibutyltin compounds 
Prohibition 
Level 
Date of ban 
on delivery 
Applications 
Control Value  
Note 
Level 1 
 
 
Immediate 
 
 
・All applications  
- Less than 1000 ppm 
(tin conversion) in 
mixture, article or 
part thereof 
*1 
Note 
*1 Annex XVII to REACH (restriction) 
(2) Examples of substances (The table below does not cover all the substances in this substance group.) 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No. or 
JAMP-SN 
Metal 
conversion 
factor 
ジブチルスズオキシド  
Dibutyltin oxide  
C8H18OSn 
818-08-6 
0.477 
ジブチルスズ二酢酸 
Dibutyltin diacetate  
C12H24O4Sn 
1067-33-0 
0.338 
ジブチル［(1-オキソドデシル)オ
キシ］スズ；ジブチルスズジラウ
レート 
Dibutyltin dilaurate  
C32H64O4Sn 
77-58-7 
0.188 
マレイン酸ジ-n-ブチルスズ  
Dibutyltin maleate  
C12H20O4Sn 
78-04-6 
0.342 
ジブチルスズジクロライド
（DBTC） 
Dibutyltin dichloride (DBTC) 
C8H18Cl2Sn 
683-18-1 
0.391 
その他のジブチルスズ化合物  
Other dibutyltin compounds  
- 
JAMP-
SN0072 
- 
(3) Principal uses for substances 
Part 
Purpose 
Stabilizer for PVC, curing catalyst for silicone resin 
and urethane resin 
Stabilizer for PVC, curing catalyst for silicone resin 
and urethane resin 
 
Table 2-I-7 Dioctyltin compounds (DOT) 
(1) Details 
No. I-7 
Substance Group: Dioctyltin compounds (DOT) 
Prohibition 
Level 
Date of ban 
on delivery 
Applications 
Control Value  
Note 
Level 1 
Immediate 
･Textile and leather articles intended to 
come into contact with the skin 
･Childcare articles 
･Two-component room temperature 
vulcanization molding kits 
 (RTV-2 sealant molding kits) 
- Less than 1000 ppm 
(tin conversion) in 
article or part thereof 
*1 
Note 
*1  Annex XVII to REACH (restriction) 
(2) Examples of substances (The table below does not cover all the substances in this substance group.) 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No. or 
JAMP-SN 
Metal 
conversion 
factor 
ジオクチルスズオキシド  
Dioctyltin oxide 
C16H34OSn 
870-08-6 
0.326 
159

Ver. 15 
16/57 
[Control Rules for Environment-related Substances Used in Product] 
ジオクチルビス［(1-オキソドデ
シル)オキシ］スズ 
Dioctyltin dilaurate 
C40H80O4Sn 
3648-18-8 
0.160 
ジオクチルスズビス(2－エチル
ヘキシルチオグリコラート) 
'Dioctyltin bis(2-ethylhexyl 
thioglycolate) 
C36H72O4S2Sn 15571-58-1 
0.158 
その他のジオクチルスズ化合物  Other Dioctyltin compounds 
- 
- 
- 
(3) Principal uses for substances 
Part 
Purpose 
Stabilizer for PVC, curing catalyst for silicone resin 
and urethane resin 
Stabilizer for PVC, curing catalyst for silicone resin 
and urethane resin 
 
Table 2-I-8 Nickel and its compounds 
(1) Details 
No. I-8 
Substance Group: Nickel and its compounds 
Prohibition 
Level 
Date of ban 
on delivery 
Applications 
Control Value  
Note  
Level 1 
Immediate 
The following types of articles that 
maintain direct, sustained contact with the 
skin: 
･ Earrings, necklaces, bracelets, chains, 
anklets, rings 
･ Wristwatch cases, wristwatch bands, rivet 
buttons used in clothing, belts, rivets, 
zippers, and metal marks. 
 
-The rate of nickel 
release from the 
article is less than 0.5 
μg/cm2 per week. 
*1 
Note 
*1  Annex XVII to REACH (restriction) 
The use of articles is prohibited if the rate of nickel released from those articles equals or 
exceeds 0.5 μg/cm2 per week. (In cases where the above-mentioned articles have non-nickel 
coatings on them, the use of the articles will still be prohibited if the rate of nickel released 
from them under normal usage conditions for at least two years exceeds 0.5 μg/cm2per week.) 
(2) Examples of substances (The table below does not cover all the substances in this substance group.) 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No. or 
JAMP-SN 
Metal 
conversion 
factor 
一酸化ニッケル 
Nickel oxide 
NiO 
1313-99-1 
0.786 
炭酸ニッケル 
Nickel carbonate 
NiCO3 
3333-67-3 
0.494 
硫酸ニッケル 
Nickel Sulphate 
NiSO4 
7786-81-4 
0.379 
ニッケル 
Nickel 
Ni 
7440-02-0 
1.000 
塩化第一ニッケル 
Nickel (II) chloride 
NiCl2 
7718-54-9 
0.453 
その他のニッケル化合物 
Other nickel compounds 
- 
JAMP-SN0027 - 
(3) Principal uses for substances 
Part 
Purpose 
Headphones, accessories 
Stainless steel, plating 
 
Table 2-I-9 Polybrominated biphenyl (PBBs) 
(1) Details 
No. I-9 
Substance Group: Polybrominated biphenyl (PBBs) 
Prohibition 
Level 
Date of ban 
on delivery 
*3 
Applications 
Control Value  
Note 
Level 1 
Immediate 
･Electric and electronic equipment subject 
to RoHS Directive (2011/65/EU) 
-1000 ppm or less in 
homogeneous material 
*1 
160

Ver. 15 
17/57 
[Control Rules for Environment-related Substances Used in Product] 
･The following types of articles that 
maintain direct, sustained contact with 
the skin: 
・Fiber products such as clothes, 
underwear, and linens 
-Intentional 
inclusion 
prohibited 
 
*2 
Note 
*1  RoHS Directive (2011/65/EU); monitoring chemical substances by Japanese Chemical 
Substances Control Act. 
*2  Annex XVII to REACH (restriction) 
*3  The date of ban on delivery is set as the date six months before the effective date of an 
applicable law or regulation. 
(2) Examples of substances (The table below does not cover all the substances in this substance group.) 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No. or 
JAMP-SN 
Metal 
conversion 
factor 
ポリ臭化ビフェニル類 
Polybrominated Biphenyls 
 
59536-65-1 
JAMP-SN0065 
- 
4,4’-ジブロモビフェニル 
4,4'-Dibromobiphenyl 
C6H4BrC6H4Br 92-86-4 
- 
2-ブロモビフェニル 
2-Bromobiphenyl 
C6H5C6H4Br  
2052-07-5 
- 
3-ブロモビフェニル 
3-Bromobiphenyl 
C6H5C6H4Br 
2113-57-7 
- 
4-ブロモビフェニル 
4-Bromobiphenyl 
C6H5C6H4Br 
92-66-0 
- 
トリブロモビフェニル 
1,1'-Biphenyl, 2,2',5-tribromo- C12H7Br3 
59080-34-1 
- 
テトラブロモビフェニル 
Tetrabromobiphenyl 
C12H6Br4 
40088-45-7 
- 
ペンタブロモビフェニル 
Pentabromobiphenyl 
C12H5Br5 
56307-79-0 
 
2,2',4,4',5,5'-ヘキサブロモビフ
ェニル 
2,2',4,4',5,5'-
Hexabromobiphenyl 
Hexabromobiphenyl 
C6H2Br3C6H2B
r3 
59080-40-9 
- 
ヘキサブロモ-1,1-ビフェニル 
Hexabromo-1,1-biphenyl 
C6H2Br3C6H2B
r3 
36355-01-8 
- 
ファイアーマスターFF-1 
Firemaster FF-1 
C12H4Br6 
67774-32-7 
- 
ヘプタブロモビフェニル 
Heptabromobiphenyl 
C6Br5C6H3Br2 35194-78-6 
- 
オクタブロモビフェニル 
Octabromobiphenyl 
C6HBr4C6HBr4 
61288-13-9 
- 
ノナブロモ-1,1-ビフェニル 
Nonabiphenyl 
C12HBr9 
27753-52-2 
- 
デカブロモビフェニル 
Decabromobiphenyl 
C6BrC6Br5 
13654-09-6 
- 
[1,1'-ビフェニル]-ar,ar'-ジオー
ル, テトラブロモ-, (クロロメチ
ル)オキシラン及び4,4'-(1-メチ
ルエチリデン)ビス[フェノール]
とのポリマー 
[1,1'-Biphenyl]-ar,ar'-diol, 
tetrabromo-, 
polymer 
with 
(chloromethyl)oxirane and 4,4'-
(1-
methylethylidene)bis[phenol] 
(C15H16O2.C1
2H6Br4O2.C3
H5ClO)x 
68758-75-8 
- 
(3) Principal uses for substances 
Part 
Purpose 
Flame-retardant plastic enclosure molded items 
Plastic flame retardants 
 
Table 2-I-10 Polybrominated diphenyl ethers (PBDEs) 
(1) Details 
No. I-10 
Substance Group: Polybrominated diphenyl ethers (PBDEs) 
Prohibition 
Level 
Date of ban 
on delivery 
Applications 
Control Value  
Note 
Level 1 
Immediate 
･Electric and electronic equipment subject 
to RoHS Directive (2011/65/EU) 
-1000 ppm or less in 
homogeneous material 
*1 
*3 
[PBDEs excluding DecaBDE (CAS No.: 
1163-19-5)] 
・All applications other than the items 
subject to RoHS Directive (2011/65/EU) 
･Less than 500 ppm as 
a total amount in 
article 
*2 
161

Ver. 15 
18/57 
[Control Rules for Environment-related Substances Used in Product] 
[DecaBDE (CAS No.: 1163-19-5) only] 
・All applications 
-Intentional inclusion 
prohibited 
 
*3 
*4 
*4 
Exemption 
«FDA-registered medical devices» 
The following Official Journal is applicable. 
TSCA: CHAPTER 53—TOXIC SUBSTANCES CONTROL SUBCHAPTER I—CONTROL OF 
TOXIC SUBSTANCES Sec. 2602. Definitions. (2)(vi) 
(https://www.govinfo.gov/content/pkg/USCODE-2018-title15/pdf/USCODE-2018-title15-chap53.pdf) 
(Note) FDA-registered medical devices are not subject to TSCA but Olympus may require suppliers to 
report the contents of these substances so that Olympus can confirm the exemptions are applied. 
«Exceptions to US TSCA PBT Rules » 
・ Regulated substances, products or articles containing regulated substances, which have already 
been sold to end-consumers (such as secondhand articles and donations to charity) 
・ Disposal of regulated substances, products or articles containing regulated substances 
・ Production, treatment, distribution in commerce and use of regulated substances, products or 
articles containing regulated substances for research and development purposes 
・ Processing and distribution in commerce for recycling of plastic containing DecaBDE from 
products or articles 
(Note) Items other than the “FDA-registered medical devices” described above 
Note 
 
*1 RoHS Directive (2011/65/EU) 
*2 EU POPs regulation 
*3 Class I Specified Chemical Substances (CAS No.：1163-19-5) designated by Japanese 
Chemical Substances Control Act., US TSCA PBT Rules 
(2) Examples of substances (The table below does not cover all the substances in this substance group.) 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No. or 
JAMP-SN 
Metal 
conversion 
factor 
ポリ臭化ジフェニルエーテル類 Polybrominated diphenyl 
ethers  
C12HXBr(10-X)O 
JAMP-SN0066 - 
ブロモジフェニルエーテル 
Bromodiphenyl ether 
Br(C6H4)O(C6H5) 101-55-3 
- 
ジブロモジフェニルエーテル 
Dibromodiphenyl ethers 
C6H4BrOC6H4Br 2050-47-7 
- 
トリブロモジフェニルエーテル Tribromodiphenyl ether 
C12H7Br3O 
49690-94-0 
- 
テトラブロモジフェニルエーテ
ル 
Tetrabromobiphenyl ethers 
C12H6Br4O 
40088-47-9 
- 
ペンタブロモジフェニルエーテ
ル (注:市販のPeBDPDは、種々
の臭素化ジフェニルオキシドを
含む複雑な反応混合物である) 
Pentabromodiphenyl ether 
(note:Commercially available 
PeBDPD is a complex 
reaction mixture containing a 
variety of brominated 
diphenyloxides) 
- 
32534-81-9 
(CAS No. 
used for 
commercial 
grades of  
PeBDPD) 
- 
ヘキサブロモジフェニルエーテ
ル 
Hexabromodiphenyl ether 
C12H4Br6O 
36483-60-0 
- 
ヘプタブロモジフェニルエーテ
ル 
Heptabromodiphenyl ether 
C12H3Br7O 
68928-80-3 
- 
オクタブロモジフェニルエーテ
ル 
Octabromobiphenyl ether 
C12H2Br8O 
32536-52-0 
- 
ノナブロモジフェニルエーテル Nonabromodiphenyl ether 
C12HBr9O 
63936-56-1 
- 
162

Ver. 15 
19/57 
[Control Rules for Environment-related Substances Used in Product] 
デカブロモジフェニルエーテル 
(DecaBDE) 
Bis(pentabromophenyl) ether 
(decabromodiphenyl ether; 
DecaBDE) 
Br5C6OC6Br5 
1163-19-5 
- 
(3) Principal uses for substances 
Part 
Purpose 
Flame-retardant plastic enclosure molded items 
Plastic flame retardants 
 
Table 2-I-11 Polychlorinated biphenyl (PCBs) 
(1) Details 
No. I-11 
Substance Group: Polychlorinated biphenyl (PCBs) 
Prohibition 
Level 
Date of ban 
on delivery 
Applications 
Control Value  
Note 
Level 1 
Immediate 
･All applications 
-Intentional inclusion 
prohibited  
*1 
Note 
*1  Class I Specified Chemical Substances designated by Japanese Chemical Substances 
Control Act., TSCA(USA) 
(2) Examples of substances (The table below does not cover all the substances in this substance group.) 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No. or 
JAMP-SN 
Metal 
conversion 
factor 
ポリクロロビフェニル 
Polychlorobiphenyl 
Unspecified 
1336-36-3 
- 
アロクロール(Aroclor) 
Aroclor 
(C6-C6)HxCly 12767-79-2 
- 
クロロジフェニル(アロクロール
1260) 
Aroclor 1260 
- 
11096-82-5 
- 
クロロビフェニル 
Chlorobiphenyl 
C12H9Cl 
27323-18-8 
- 
アロクロール1254 
Aroclor 1254 
Unspecified 
11097-69-1 
- 
モノメチル -テトラクロロ-ジフ
ェニルメタン(Ugilec 141) 
Monomethyl-tetrachloro-
diphenyl methane (Ugilec 141) 
C14H10Cl4 
76253-60-6 
- 
モノメチル -ジクロロ -ジフェ
ニルメタン (Ugilec121, 
Ugilec21) 
Monomethyl-dichloro-diphenyl 
methane (Ugilec 121, Ugilec 21) 
‐ 
81161-70-8 
- 
モノメチル -ジブロモ -ジフェ
ニルメタン (DBBT) 
Monomethyl-dibromo-diphenyl 
methane (DBBT) 
‐ 
99688-47-8 
- 
(3) Principal uses for substances 
Part 
Purpose 
Insulating oil for transformers and capacitors 
Electrical insulation medium, solvents 
 
Table 2-I-12 Substance Group: Polychlorinated Terphenyls (PCTs) 
(1) Details 
No.I-12 
Substance Group: Polychlorinated Terphenyls (PCTs) 
Prohibition 
Level 
Date of ban 
on delivery 
Applications 
Control Value  
Note 
Level 1 
Immediate 
･All applications 
-Less than 50 ppm in 
mixture or article 
*1 
Note 
*1  Annex XVII to REACH (restriction) 
(2) Examples of substances (The table below does not cover all the substances in this substance group.) 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No. or 
JAMP-SN 
Metal 
conversion 
factor 
ポリ塩化ターフェニル;PCTs 
(全ての異性体および同族体) 
Polychlorinated terphenyls 
(PCTs; all isomers and 
congeners) 
Unspecified 
61788-33-8 
- 
163

Ver. 15 
20/57 
[Control Rules for Environment-related Substances Used in Product] 
テルフェニル類 
Terphenyls 
C6H4(C6H5)2 
26140-60-3 
- 
(3) Principal uses for substances 
Part 
Purpose 
Insulating oil for transformers and capacitors 
Electrical insulation medium, solvents 
 
Table 2-I-13 Polychlorinated naphthalene (number of chlorine: 2 or more) 
(1) Details 
No. I-13 
Substance Group: Polychlorinated naphthalene (number of chlorine: 2 or more) 
Prohibition 
Level 
Date of ban 
on delivery 
Applications 
Control Value  
Note 
Level 1 
Immediate 
・All applications 
-Intentional inclusion 
prohibited  
*1 
Note 
*1 Class I Specified Chemical Substances designated by Japanese Chemical Substances 
Control Act. 
(2) Examples of substances (The table below does not cover all the substances in this substance group.) 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No. or 
JAMP-SN 
Metal 
conversion 
factor 
ポリ塩化ナフタレン(塩素数が2
以上)  
Polychlorinated 
Naphthalenes(Cl≥2) 
Unspecified 
70776-03-3 
- 
2塩化ナフタレン 
Dichloronaphtalene 
C10H6Cl2 
28699-88-9 
- 
3塩化ナフタレン 
Trichloronaphtalene 
C10H5Cl3 
1321-65-9 
- 
4塩化ナフタレン 
Tetrachloronaphtalene 
C10H4Cl4 
1335-88-2 
- 
5塩化ナフタレン 
Pentachloronaphtalene 
C10H3Cl5 
1321-64-8 
- 
その他のポリ塩化ナフタレン(塩
素数が2以上) 
Other polychlorinated 
Naphthalenes (Cl≥2) 
- 
- 
- 
(3) Principal uses for substances 
Part 
Purpose 
Flexible rubber, elastomer belts, rolls, packing, 
sealing materials, insulating oil for capacitors 
Plastic stabilizers (electrical characteristics, flame-
proofing, water-proofing, biocidal characteristics), 
electrical insulation medium 
 
Table 2-I-14 Short-chained chlorinated paraffin (having the chain length of 10 - 13) 
(1) Details 
No. I-14 
Substance Group: Short-chained chlorinated paraffin (having the chain length of 10 - 13) 
Prohibition 
Level 
Date of ban 
on delivery 
Applications 
Control Value  
Note 
Level 1 
Immediate 
・All applications 
-Intentional inclusion 
prohibited  
*1 
Note 
*1 Class I Specified Chemical Substances designated by Japanese Chemical Substances 
Control Act., EU POPs regulation  
(2) Examples of substances (The table below does not cover all the substances in this substance group.) 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No. or 
JAMP-SN 
Metal 
conversi
on 
factor 
塩素化パラフィン(短鎖) 
(C10-13) 
Alkanes,C10-13,chloro(Short 
Chain Chlorinated Paraffins) 
Unspecified 
85535-84-8 
- 
クロロアルカンC10-12 
Alkanes, C10-12, chloro 
Unspecified 
104948-36-9 
- 
1,1,1,3,5,7,9,11,11-ノナクロ
Undecane, 1,1,1,3,5,7,9,11,11- 
C11H15Cl9 
18993-26-5 
- 
164

Ver. 15 
21/57 
[Control Rules for Environment-related Substances Used in Product] 
ロウンデカン 
nonachloro- 
ヘプタクロロウンデカン 
Undecane, heptachloro- 
- 
219697-10-6 
- 
ノナクロロウンデカン 
Undecane, nonachloro- 
- 
219697-11-7 
- 
1,2,10,11,? ,? ,? ,?-オクタク
ロロウンデカン 塩素化パラ
フィン（C11、Cl7-12） 
Undecane, 1,2,10,11,?,?,?,?- 
octachloro- 
- 
221174-07-8 
- 
デカクロロウンデカン 
Undecane, decachloro- 
- 
276673-33-7 
- 
オクタクロロウンデカン 
Undecane, octachloro- 
C11H16Cl8 
36312-81-9 
- 
クロロワックス 
Chlorowax 
- 
51990-12-6 
- 
1,1,1,3,6,7,10,11-オクタクロ
ロウンデカン 
Undecane, 1,1,1,3,6,7,10,11- 
octachloro- 
- 
601523-20-0 
- 
1,1,1,3,9,11,11,11-オクタク
ロロウンデカン 
Undecane, 1,1,1,3,9,11,11,11- 
octachloro- 
- 
601523-25-5 
- 
クロロアルカン 
Alkanes, chloro;  
chloroparaffins 
Unspecified 
61788-76-9 
- 
1,1,1,2-テトラクロロ-ウンデ
カン 
Undecane, 1,1,1,2-tetrachloro- 
C11H20Cl4 
63981-28-2 
- 
クロロアルカン C12-24 
Alkene, C12-24-, Chloro- 
Unspecified 
68527-02-6 
- 
クロロパラフィン（C6-18）
（組成不定） 
Chlorinated n-paraffins  
(C6-18) 
Unspecified 
68920-70-7 
- 
塩素化マイクロクリスタリ
ン炭化水素ワックス(石油系) 
Hydrocarbon waxes  
(petroleum), microcryst.,  
chlorinated 
Unspecified 
68938-43-2 
- 
クロロアルカン（炭化水素化
合物）（C12-13） 
Alkanes, C12-13, chloro 
Unspecified 
71011-12-6 
- 
クロロアルカン（塩化炭化水
素）（C10-21） 
Alkanes, C10-21, chloro 
Unspecified 
84082-38-2 
- 
クロロアルカン類, C10-32 
Alkanes, C10-32, chloro 
Unspecified 
84776-06-7 
- 
クロロパラフィン油 
Paraffin oils, chloro- 
Unspecified 
85422-92-0 
- 
クロロパラフィン（C12-14） 
Alkane, C12-14-, Chloro- 
Unspecified 
85536-22-7 
- 
クロロパラフィン（C10-14） 
Alkane, C10-14-, Chloro- 
Unspecified 
85681-73-8 
- 
クロロアルカン(C12-16) 
Alkanes, C12-16, chloro 
Unspecified 
866758-65-8 
- 
塩素化パラフィン（石油）、
標準C>10 
Paraffins (petroleum), normal 
C>10, chloro 
Unspecified 
97553-43-0 
- 
クロロアルカン類, C10-26 
Alkanes, C10-26, chloro 
Unspecified 
97659-46-6 
- 
塩素化パラフィン 
（SCCP( 短鎖) または
MCCP(中鎖)か分からないも
の） 
Chlorinated Paraffins may or 
may not be SCCP or MCCP 
- 
JAMP- 
SN1020 
- 
(3) Principal uses for substances 
Part 
Purpose 
Flexible polyvinyl chloride molded items 
Polyvinyl chloride plasticizers 
 
Table 2-I-15 Polyvinyl chloride (PVC) 
(1) Details 
No. I-15 
Substance Group: Polyvinyl chloride (PVC) 
Prohibition 
Date of ban 
Applications 
Control Value  
Note 
165

Ver. 15 
22/57 
[Control Rules for Environment-related Substances Used in Product] 
Level 
on delivery 
Level 1 
Immediate 
･Packaging materials 
-Intentional inclusion 
prohibited 
－ 
Exemption 
Other applications are permitted. 
(2) Examples of substances (The table below does not cover all the substances in this substance group.) 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No. or 
JAMP-SN 
Metal 
conversio
n factor 
塩化ビニル、クロロエチレン 
Chloroethene 
- 
75-01-4 
- 
ポリ塩化ビニル(PVC)およびそ
の混合物 
Polyvinyl chloride (PVC) and its 
mixture 
(CH2CHCl)n 
9002-86-2 
- 
ポリ塩化ビニル酢酸ビニル共重
合体 
Vinyl chloride/vinyl acetate 
copolymer 
- 
9003-22-9 
- 
(3) Principal uses for substances 
Part 
Purpose 
Coated wiring cords, electric insulation molded 
items, chemical-resistant molded parts, plumbing 
components, transparent covers 
Electrical insulation medium, chemical-resistance, 
transparency 
 
Table 2-I-16 Hexabromocyclododecane (HBCDD) 
(1) Details 
No. I-16 
Substance Group: Hexabromocyclododecane (HBCDD) 
Prohibition 
Level 
Date of ban 
on delivery  
Applications 
Control Value  
Note 
Level 1 
Immediate 
･All applications 
-Intentional inclusion 
prohibited 
*1 
･Substances 
･Mixtures 
-Intentional inclusion 
prohibited  
*2 
 
Exemption 
*2 Applications that are submitted to, and approved by, the European Chemicals Agency 
will be permitted. 
Note 
*1  Class I Specified Chemical Substances designated by Japanese Chemical Substances 
Control Act., EU POPs regulation  
*2  Annex XIV to REACH (authorizations) 
(2) Regulated substances (Japanese Chemical Substances Control Act.) 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No or 
JAMP-SN 
1,2,5,6,9,10-ヘキサブロモシクロドデ
カン 
1,2,5,6,9,10-hexabromocyclododecane 
C12H18Br6 
3194-55-6 
ヘキサブロモシクロドデカン 
(HBCDD)  
Hexabromocyclododecane (HBCDD)  
C12H18Br6 
25637-99-4 
rel-(1R,2R,5S,6R,9R,10S)-
1,2,5,6,9,10-ヘキサブロモシクロドデ
カン; 
アルファ-ヘキサブロモシクロドデカン 
rel-(1R,2R,5S,6R,9R,10S)-1,2,5,6,9,10-
Hexabromocyclododecane; 
Alpha-hexabromocyclododecane 
C12H18Br6 
134237-50-6 
rel-(1R,2S,5R,6R,9R,10S)-
1,2,5,6,9,10-ヘキサブロモシクロドデ
カン; 
ベータ-ヘキサブロモシクロドデカン 
rel-(1R,2S,5R,6R,9R,10S)-1,2,5,6,9,10-
hexabromocyclododecane 
Beta-hexabromocyclododecane 
C12H18Br6 
134237-51-7 
rel-(1R,2R,5R,6S,9S,10R) -
1,2,5,6,9,10-ヘキサブロモシクロドデ
カン; 
ガンマ-ヘキサブロモシクロドデカン 
rel-(1R,2R,5R,6S,9S,10R)-1,2,5,6,9,10-
hexabromocyclododecane 
Gamma-hexabromocyclododecane 
C12H18Br6 
134237-52-8 
166

Ver. 15 
23/57 
[Control Rules for Environment-related Substances Used in Product] 
rel-(1R,2S,5R,6S,9R,10S)-
1,2,5,6,9,10-ヘキサブロモシクロドデ
カン 
rel-(1R,2S,5R,6S,9R,10S)-1,2,5,6,9,10-
Hexabromocyclododecane 
C12H18Br6 
4736-49-6 
 
rel-(1R,2S,5R,6S,9S,10R)-
1,2,5,6,9,10-ヘキサブロモシクロドデ
カン 
rel-(1R,2S,5R,6S,9S,10R)-1,2,5,6,9,10-
Hexabromocyclododecane 
C12H18Br6 
65701-47-5 
(1R,2R,5R,6S,9S,10S)-1,2,5,6,9,10-ヘ
キサブロモシクロドデカン 
(1R,2R,5R,6S,9S,10S)-1,2,5,6,9,10-
Hexabromocyclododecane 
C12H18Br6 
138257-17-7 
(1R,2R,5R,6S,9R,10S)-1,2,5,6,9,10-ヘ
キサブロモシクロドデカン 
(1R,2R,5R,6S,9R,10S)-1,2,5,6,9,10-
Hexabromocyclododecane 
C12H18Br6 
138257-18-8 
(1R,2S,5S,6R,9S,10S)-1,2,5,6,9,10-ヘ
キサブロモシクロドデカン 
(1R,2S,5S,6R,9S,10S)-1,2,5,6,9,10-
Hexabromocyclododecane 
C12H18Br6 
138257-19-9 
(1R,2S,5S,6S,9S,10R)-1,2,5,6,9,10-ヘ
キサブロモシクロドデカン 
(1R,2S,5S,6S,9S,10R)-1,2,5,6,9,10-
Hexabromocyclododecane 
C12H18Br6 
169102-57-2 
(1R,2R,5S,6R,9R,10S)-1,2,5,6,9,10-ヘ
キサブロモシクロドデカン 
(1R,2R,5S,6R,9R,10S)-1,2,5,6,9,10-
Hexabromocyclododecane 
C12H18Br6 
678970-15-5 
(1R,2S,5R,6S,9S,10S)-1,2,5,6,9,10-ヘ
キサブロモシクロドデカン 
(1R,2S,5R,6S,9S,10S)-1,2,5,6,9,10-
Hexabromocyclododecane 
C12H18Br6 
678970-16-6 
(1R,2R,5R,6S,9S,10R)-1,2,5,6,9,10-ヘ
キサブロモシクロドデカン 
(1R,2R,5R,6S,9S,10R)-1,2,5,6,9,10-
Hexabromocyclododecane 
C12H18Br6 
678970-17-7 
Regulated substances (REACH) 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No or 
JAMP-SN 
1,2,5,6,9,10-ヘキサブロモシクロドデ
カン  
1,2,5,6,9,10-hexabromocyclododecane 
C12H18Br6  
3194-55-6 
ヘキサブロモシクロドデカン 
(HBCDD)  
アルファ-ヘキサブロモシクロドデカン 
 
ベータ-ヘキサブロモシクロドデカン 
 
ガンマ-ヘキサブロモシクロドデカン 
Hexabromocyclododecane (HBCDD) and 
all major diastereoisomers identified:  
Alpha-hexabromocyclododecane  
 
Beta-hexabromocyclododecane  
 
Gamma-hexabromocyclododecane 
C12H18Br6 
25637-99-4 
 
134237-50-6, 
 
134237-51-7, 
 
134237-52-8 
(3) Principal uses for substances 
Part 
Purpose 
Expanded polystyrene molded parts, adhesive agents, 
fiber coating 
Fire-retardant for resins and fibers 
 
Table 2-I-17 Pentachlorothiophenol (PCTP)  
(1) Details 
No. I-17 
Substance Group: Pentachlorothiophenol (PCTP) 
Prohibition 
Level 
Date of ban 
on delivery 
Applications 
Control Value  
Note 
Level 1 
Immediate 
･All applications 
-1% (10, 000 ppm) by 
weight or less of the 
weight of an article 
*1 
Exemption 
«FDA-registered medical devices» 
The following Official Journal is applicable. 
TSCA: CHAPTER 53—TOXIC SUBSTANCES CONTROL SUBCHAPTER I—CONTROL OF TOXIC 
SUBSTANCES Sec. 2602. Definitions. (2)(vi) 
(https://www.govinfo.gov/content/pkg/USCODE-2018-title15/pdf/USCODE-2018-title15-chap53.pdf) 
(Note) FDA-registered medical devices are not subject to TSCA but Olympus may require suppliers to 
report the contents of these substances so that Olympus can confirm the exemptions are applied. 
167

Ver. 15 
24/57 
[Control Rules for Environment-related Substances Used in Product] 
«Exceptions to US TSCA PBT Rules » 
・ Regulated substances, products or articles containing regulated substances, which have been 
already sold to end-consumers (such as secondhand articles and donations to charity) 
・ Disposal of regulated substances, products or articles containing regulated substances 
・ Production, treatment, distribution in commerce and use of regulated substances, products or 
articles containing regulated substances for research and development purposes 
(Note) Items other than the “FDA-registered medical devices” described above 
Note 
*1 US TSCA PBT Rules 
(2) Regulated substances 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No or 
JAMP-SN 
ペンタクロロチオフェノール 
(PCTP) 
Pentachlorothiophenol (PCTP) 
C6HCl5S 
133-49-3 
(3) Principal uses for substances 
Part 
Purpose 
Rubber 
Additive to improve stiffness modulus 
 
Table 2-I-18 Hexachlorobutadiene (HCBD) 
 (1) Details 
No. I-18 
Substance Group: Hexachlorobutadiene (HCBD) 
Prohibition 
Level 
Date of ban 
on delivery 
Applications 
Control Value  
Note 
Level 1 
Immediate 
･All applications 
-Intentional inclusion 
prohibited 
*1 
Exemption 
«FDA-registered medical devices» 
The following Official Journal is applicable. 
TSCA: CHAPTER 53—TOXIC SUBSTANCES CONTROL SUBCHAPTER I—CONTROL OF 
TOXIC SUBSTANCES Sec. 2602. Definitions. (2)(vi) 
(https://www.govinfo.gov/content/pkg/USCODE-2018-title15/pdf/USCODE-2018-title15-chap53.pdf) 
(Note) FDA-registered medical devices are not subject to TSCA but Olympus may require suppliers to 
report the contents of these substances so that Olympus can confirm the exemptions are applied. 
«Exceptions to US TSCA PBT Rules » 
・ Regulated substances, products or articles containing regulated substances, which have been 
already sold to end-consumers (such as secondhand articles and donations to charity) 
・ Disposal of regulated substances, products or articles containing regulated substances 
・ Production, treatment, distribution in commerce and use of regulated substances, products or 
articles containing regulated substances for research and development purposes 
(Note) Only the exceptions related to Olympus Group products are listed above. 
(Note) Items other than the “FDA-registered medical devices” described above 
Note 
*1 Class I Specified Chemical Substances designated by Japanese Chemical Substances 
Control Act., US TSCA PBT Rules 
(2) Regulated substances 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No or 
JAMP-SN 
ヘキサクロロブタジエン 
(HCBD) 
Hexachlorobutadiene (HCBD) 
C4Cl6 
87-68-3 
(3) Principal uses for substances 
Part 
Purpose 
Rubber compounds 
Chemical intermediates 
 
Table 2-I-19 Asbestos 
(1) Details 
168

Ver. 15 
25/57 
[Control Rules for Environment-related Substances Used in Product] 
No. I-17 
Substance Group: Asbestos 
Prohibition 
Level 
Date of 
ban on 
delivery 
Applications 
Control Value  
Note 
Level 1 
Immediate 
･All applications 
-Intentional inclusion 
prohibited  
*1 
Note 
*1  Annex XVII to REACH (restriction), Industrial Safety and Health Law (Japan) 
(Specified Chemical Substances Class II: Applicable only to Amosite, Chrysotile and 
Crocidolite) 
(2) Examples of substances (The table below does not cover all the substances in this substance group.) 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No. or 
JAMP-SN 
Metal 
conversion 
factor 
アクチノライト 
Actinolite 
Unspecified 
77536-66-4 
- 
アモサイト 
Amosite 
Unspecified 
12172-73-5 
- 
アンソフィライト 
Anthophyllite 
Unspecified 
77536-67-5 
- 
クリソタイル 
Chrysotile 
Unspecified 
12001-29-5 
132207-32-0 
- 
クロシドライト 
Crocidolite 
Unspecified 
12001-28-4 
- 
トレモライト 
Tremolite 
Unspecified 
77536-68-6 
- 
アスベスト繊維 
Asbestos fibres 
- 
1332-21-4 
JAMP-
SN0056 
- 
(3) Principal uses for substances 
Part 
Purpose 
Brake lining pads, electrical insulation parts, seals for 
chemical installations 
Friction material, insulation materials, fillers 
 
Table 2-I-20 Azo dyes and pigments (specific amines formed by degrading azo dyes and pigments) 
(1) Details 
No. I-18 
Substance Group: Azo dyes and pigments (specific amines formed by degrading azo dyes and 
pigments) 
Prohibition 
Level 
Date of ban 
on delivery 
*3 
Applications 
Control Value  
Note 
Level 1 
Immediate 
･Use of Azo dyes and pigments forming 
specific amines by degradation of the 
parts of articles being routinely touched 
by skin for a long time (such as 
earphones, headphones and straps) 
-Less than 30 ppm in 
article 
*1 
･Substances and mixtures that contain the 
following substances:  
CAS No.101-77-9: 
4,4'-Diaminodiphenylmethane 
CAS No. 101-14-4: 2,2'-dichloro-4,4'-
methylenedianiline  
-Intentional inclusion 
prohibited 
*2 
Exemption 
*2 Applications that are submitted to, and approved by, the European Chemicals Agency will 
be permitted. 
Note 
*1 Annex XVII to REACH (restriction), Consumer Goods Ordinance (BedGgstV) (Germany) 
*2 Annex XIV to REACH (authorizations) 
(2) Regulated substances 
Substance 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No. or 
JAMP-SN 
169

Ver. 15 
26/57 
[Control Rules for Environment-related Substances Used in Product] 
4-アミノアゾベンゼン 
4-aminoazobenzene 
C12H11N3  
60-09-3 
2-メトキシアニリン; 
o-アニシジン 
2-Methoxyaniline; 
o-Anisidine 
C7H9NO 
90-04-0 
2-ナフチルアミン 
2-naphthylamine 
C10H9N 
91-59-8 
3,3’-ジクロロベンジジン 
3,3'-dichlorobenzidine 
C12H10Cl2N2 
91-94-1 
ビフェニル-4-イルアミン; 
4-アミノビフェニル 
Biphenyl-4-ylamine; 
4-aminobiphenyl 
C12H11N 
92-67-1 
ベンジジン 
Benzidine 
C12H12N2 
92-87-5 
o-トルイジン 
o-toluidine 
C7H9N 
95-53-4 
o-塩化トルイジン 
4-chloro-o-toluidine 
C7H8ClN 
95-69-2 
2,4-ジアミノトルエン 
4-methyl-m-phenylenediamine(toluene-2,4-
diamine) 
C7H10N2 
95-80-7 
o-アミノアゾトルエン 
o-aminoazotoluene 
C14H15N3 
97-56-3 
5-ニトロ-o-トルイジン 
5-nitro-o-toluidine 
C7H8N2O2 
99-55-8 
2,2’-ジクロロ-4,4’-メチレンジアニリン 2,2'-dichloro-4,4'-methylenedianiline 
C13H12Cl2N2 
101-14-4 
4,4’-ジアミノジフェニルメタン 
4,4'-diaminodiphenylmethane(MDA); 
C13H14N2 
101-77-9 
4,4’-オキシジアニリン及びその塩 
4,4'-oxydianiline and its salts 
C12H12N2O 
101-80-4 
ｐ-クロロアニリン 
p-chloroaniline 
C6H6ClN 
106-47-8 
3,3’-ジメトキシベンジジン 
3,3'-dimethoxybenzidine 
C14H16N2O2 
119-90-4 
3,3’-ジメチルベンジジン 
3,3'-dimethylbenzidine 
C14H16N2 
119-93-7 
6-メトキシ-ｍ-トルイジン 
6-methoxy-m-toluidine 
C8H11NO 
120-71-8 
2,4,5-トリメチルアニリン 
2,4,5-trimethylaniline 
C9H13N 
137-17-7 
4,4’-ジアミノジフェニルスルフィド 4,4'-thiodianiline 
C12H12N2S 
139-65-1 
2,4-ジアミノアニソール 
2,4-diaminoanisole 
C7H10N2O 
615-05-4 
4,4’-メチレンビス(ｏ-トルイジン) 
4,4'-methylenedi-o-toluidine 
C15H18N2 
838-88-0 
(3) Principal uses for substances 
Part 
Purpose 
Fiber products, printing inks 
Dyes and pigments 
 
Table 2-I-21 Ozone depleting substances 
(1) Details 
No. I-19 
Substance Group: Ozone depleting substances 
Prohibition 
Level 
Date of ban 
on delivery 
Applications 
Control Value  
Note 
Level 1 
Immediate 
･All applications 
-Intentional inclusion 
prohibited  
*1 
Note 
*1  Montreal Protocol, Section 611 on the Clean Air Act Amendments of 1990 (U.S.A.), 
(EC)No 2037/2000, (EC)No 1005/2009, Law Concerning the Protection of the Ozone 
Layer (Japan). 
(2) Examples of substances (The table below does not cover all the substances in this substance group.) 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No. or 
JAMP-SN 
・Annex A  Group I : CFC 
トリクロロフルオロメタン；CFC-11 Trichlorofluoromethane；CFC-11 
CFCl3 
75-69-4 
ジクロロジフルオロメタン；CFC-12 Dichlorodifluoromethane；CFC-12 
CF2Cl2 
75-71-8 
トリクロロトリフルオロエタン； 
1,1,2トリクロロ-1,2,2トリフルオロエ
タン；CFC-113 
Trichlorofluoroethane； 
1,1,2 Trichloro-1,2,2 trifluoroethane； 
CFC-113 
C2F3Cl3 
354-58-5 
76-13-1 
ジクロロテトラフルオロエタン；
CFC-114 
Dichlorotetrafluoroethane；CFC-114 
C2F4Cl2 
1320-37-2 
76-14-2 
モノクロロペンタフルオロエタン；
Monochloropentafluoroethane；CFC-115 
C2F5Cl 
76-15-3 
170

Ver. 15 
27/57 
[Control Rules for Environment-related Substances Used in Product] 
CFC-115 
・Annex A  Group II : Halons 
ブロモクロロジフルオロメタン；ハロ
ン-1211 
Bromochlorodifluoromethane；Halon 1211 
CF2BrCl 
353-59-3 
ブロモトリフルオロメタン；ハロン-
1301 
Bromotrifluoromethane；Halon 1301 
CF3Br 
75-63-8 
ジブロモテトラフルオロエタン；ハロ
ン-2402 
Dibromotetrafluoroethane ；Halon 2402 
C2F4Br2 
124-73-2 
・Annex B  Group I:Other CFCs 
塩化フッ化メタン；CFC-13 
Chlorotrifluoromethane；CFC-13 
CF3Cl 
75-72-9 
ペンタクロロフルオロエタン；CFC-
111 
Pentachlorofluoroethane；CFC-111 
C2FCl5 
354-56-3 
テトラクロロジフルオロエタン；
CFC-112 
Tetrachlorodifluoroethane；CFC-112 
C2F2Cl4 
28605-74-5 
76-12-0 
1.1.1.2-テトラクロロ-2.2-ジフオロエ
タン；CFC-112a 
1,1,1,2-Tetrachloro-2,2- difluoroethane ；
CFC-112a 
C2F2Cl4 
76-11-9 
ヘプタクロロフルオロプロパン；
CFC-211 
Heptachlorofluoropropane；CFC-211 
C3FCl7 
 
135401-87-5 
422-78-6 
1.1.1.2.3.3.3-ヘプタクロロ-2-フルオ
ロプロパン；CFC-211ba 
1,1,1,2,3,3,3-Heptachloro-2-fluoropropane；
CFC-211ba 
C3Cl7F  
422-81-1 
ヘキサクロロジフルオロプロパン；
CFC-212 
Hexachlorodifluoropropane； 
1,1,1,3,3,3-Hexachlor-2,2-difluoropropane；
CFC-212 
C3F2Cl6 
3182-26-1 
ペンタクロロトリフルオロプロパン；
CFC-213 
Pentachlorotrifluoropropane；CFC-213 
C3F3Cl5 
- 
134237-31-3 
2354-06-5 
テトラクロロテトラフルオロプロパ
ン；CFC-214 
Tetrachlorotetrafluoropropane；CFC-214 
C3F4Cl4 
29255-31-0 
1,1,1,3-テトラクロロテトラフルオロ
プロパン 
1,1,1,3-Tetrachlorotetrafluoropropane 
C3Cl4F4 
2268-46-4 
トリクロロペンタフルオロプロパン；
CFC-215 
Trichloropentafluoropropane； 
1,2,2-trichloropentafluoropropane; 
CFC-215 
C3F5Cl3 
1599-41-3 
 
1,2,3-トリクロロペンタフルオロプロ
パン；CFC-215ba 
1,2,3-trichloropentafluoropropane；CFC-
215ba 
C3Cl3F5 
76-17-5 
1,1,2-トリクロロペンタフルオロプロ
パン；CFC-215bb 
1,1,2-trichloropentafluoropropane；CFC-
215bb 
C3HCl3F4 812-30-6 
1,1,3-トリクロロペンタフルオロプロ
パン；CFC-215ca 
 
1,1,3-trichloropentafluoropropane；CFC-
215ca 
C3Cl3F5 
1652-81-9 
 
1,1,1-トリクロロペンタフルオロプロ
パン；CFC-215cb 
1,1,1-trichloropentafluoropropane；CFC-
215cb 
C3Cl3F5 
4259-43-2 
ジクロロヘキサフルオロプロパン；
CFC-216 
Dichlorohexafluoropropane； 
1,2-Dichloro-1,1,2,3,3,3-hexafluoropropane；
CFC-216 
C3F6Cl2 
661-97-2 
モノクロロヘプタフルオロプロパン；
CFC-217 
Monochloroheptafluoropropane；CFC-217 
C3F7Cl 
422-86-6 
・Annex B  Group II :tetrachloride 
四塩化炭素（テトラクロロメタン） 
Carbon tetrachloride 
CCl4 
56-23-5 
・Annex B  Group III :1,1,1-Trichloroethane 
1,1,1-トリクロロエタン 
1,1,1-trichloroethane 
C2H3Cl3 
71-55-6 
・Annex C  Group II :HBFC 
ジブロモフルオロメタン 
Dibromofluoromethane 
CHFBr2 
1868-53-7 
171

Ver. 15 
28/57 
[Control Rules for Environment-related Substances Used in Product] 
ブロモジフルオロメタンおよび異性体
(HBFC類) 
Bromodifluoromethane and Isomers 
(HBFCs) 
CHF2Br 
1511-62-2 
ブロモフルオロメタン 
Bromofluoromethane 
CH2FBr 
373-52-4 
テトラブロモフルオロエタン 
Tetrabromofluoroethane 
C2HFBr4 
306-80-9 
トリブロモジフルオロエタン 
Tribromodifluoroethane 
C2HF2Br3 - 
ジブロモトリフルオロエタン 
Dibromotrifluoroethane; 
1,2-Dibromo-1,1,2-trifluoroethane 
C2HF3Br2 354-04-1 
ブロモテトラフルオロエタン 
Bromotetrafluoroethane 
C2HF4Br 
124-72-1 
トリブロモフルオロエタン 
Tribromofluoroethane 
C2H2FBr3 - 
ジブロモジフルオロエタン 
Dibromodifluoroethane 
C2H2F2Br2 75-82-1 
ブロモトリフルオロエタン 
Bromotrifluoroethane 
C2H2F3Br 421-06-7 
ジブロモフルオロエタン 
Dibromofluoroethane 
C2H3FBr2 358-97-4 
ブロモジフルオロエタン 
Bromodifluoroethane 
C2H3F2Br 420-47-3 
2-ブロモ-1,1-ジフルオロエタン 
2-Bromo-1,1-difluoroethane 
C2H3F2Br 359-07-9 
ブロモフルオロエタン 
Bromofluoroethane 
C2H4FBr 
762-49-2 
ヘキサブロモフルオロプロパン 
Hexabromofluoropropane 
C3HFBr6 
- 
ペンタブロモジフルオロプロパン 
Pentabromodifluoropropane 
C3HF2Br5 - 
テトラブロモトリフルオロプロパン 
Tetrabromotrifluoropropane 
C3HF3Br4 - 
トリブロモテトラフルオロプロパン 
Tribromotetrafluoropropane 
C3HF4Br3 666-48-8 
ジブロモペンタフルオロプロパン 
Dibromopentafluoropropane 
C3HF5Br2 431-78-7 
ブロモヘキサフルオロプロパン 
Bromohexafluoropropane 
C3HF6Br 
2252-79-1 
2252-78-0 
ペンタブロモフルオロプロパン 
Pentabromofluoropropane 
C3H2FBr5 - 
テトラブロモジフルオロプロパン 
Tetrabromodifluoropropane 
C3H2F2Br4 148875-98-3 
トリブロモトリフルオロプロパン 
Tribromotrifluoropropane 
C3H2F3Br3 - 
ジブロモテトラフルオロプロパン 
Dibromotetrafluoropropane 
C3H2F4Br2 - 
ブロモペンタフルオロプロパン 
Bromopentafluoropropane 
C3H2F5Br 460-88-8 
テトラブロモフルオロプロパン 
Tetrabromofluoropropane 
C3H3FBr4 148875-95-0 
トリブロモジフルオロプロパン 
Tribromodifluoropropane 
C3H3F2Br3 70192-80-2 
ジブロモトリフルオロプロパン 
Dibromotrifluoropropane 
C3H3F3Br2 70192-83-5 
431-21-0 
ブロモテトラフルオロプロパン 
Bromotetrafluoropropane 
C3H3F4Br 679-84-5 
トリブロモフルオロプロパン 
Tribromofluoropropane 
C3H4FBr3 75372-14-4 
ジブロモジフルオロプロパン 
Dibromodifluoropropane 
C3H4F2Br2 460-25-3 
ブロモトリフルオロプロパン 
Bromotrifluoropropane 
C3H4F3Br 421-46-5 
ジブロモフルオロプロパン 
Dibromofluoropropane 
C3H5FBr2 51584-26-0 
ブロモジフルオロプロパン 
Bromodifluoropropane 
C3H5F2Br - 
ブロモフルオロプロパン 
Bromofluoropropane 
C3H6FBr 
1871-72-3 
1-ブロモ-3-フルオロプロパン 
1-Bromo-3-fluoropropane 
C3H6FBr 
352-91-0 
・Annex C  Group III :Bromochloromethane 
ブロモクロロメタン 
Bromochloromethane 
CH2BrCl 
74-97-5 
・Annex E  Group I :Bromomethane 
ブロモメタン(臭化メチル) 
Bromomethane (Methyl Bromide)  
CH3Br 
74-83-9 
・Annex C  Group I :HCFCs 
ジクロロフルオロメタン；HCFC-21 Dichlorofluoromethane；HCFC-21 
CHFCl2 
75-43-4 
クロロジフルオロメタン；HCFC-22 Chlorodifluoromethane；HCFC-22 
CHF2Cl 
75-45-6 
クロロフルオロメタン；HCFC-31 
Chlorofluoromethane；HCFC-31 
CH2FCl 
593-70-4 
テトラクロロフルオロエタン；
HCFC-121 
Tetrachlorofluoroethane ；HCFC-121 
C2HFCl4 
134237-32-4 
1,1,1,2-テトラクロロ-2-フルオロエタ1,1,1,2-tetrachloro-2-fluoroethane；HCFC 
C2HCl4F  
354-11-0 
172

Ver. 15 
29/57 
[Control Rules for Environment-related Substances Used in Product] 
ン；HCFC-121a 
121a 
1,1,2,2-テトラクロロ-1-フルオロエタ
ン 
1,1,2,2-tetracloro-1-fluoroethane 
C2HCl4F  
354-14-3 
トリクロロジフルオロエタン；
HCFC-122 
Trichlorodifluoroethane；HCFC-122 
C2HF2Cl3 
41834-16-6 
1,2,2-トリクロロ-1,1-ジフルオロエタ
ン；HCFC-122 
1,2,2-trichloro-1,1-difluoroethane；HCFC-
122 
C2HCl3F2 
354-21-2 
1,1,2-トリクロロ-1,2-ジフルオロエタ
ン；HCFC-122a 
Ethane, 1,2-difluoro-1,1,2-trichloro-；
HCFC-122a 
C2HF2Cl3 
354-15-4 
1,1,1-トリクロロ-2,2-ジフルオロエタ
ン；HCFC-122b 
1,1,1-trichloro-2,2-difluoroethane；HCFC-
122b 
C2HF2Cl3 
354-12-1 
ジクロロトリフルオロエタン；
HCFC-123 
Dichlorotrifluoroethane；HCFC-123 
C2HF3Cl2 
34077-87-7 
2,2-ジクロロ-1,1,1-トリフルオロエタ
ン；HCFC-123 
2.2-dichloro1,1,1-fluoroethane；HCFC-123 C2HCl2F3 
306-83-2 
ジクロロ-1,1,2-トリフルオロエタン 
Dichloro-1,1,2-trifluoroethane 
C2HCl2F3 
90454-18-5 
1,2-ジクロロ-1,1,2-トリフルオロエタ
ン；HCFC-123a 
1,2-dichloro-1,1,2-trifluroethane；HCFC-
123a 
C2HCl2F3 
354-23-4 
1,1-ジクロロ-1,2,2-トリフルオロエタ
ン；HCFC-123b 
1,1-dichloro-1,2,2-trifluroethane；HCFC-
123b 
C2HCl2F3 
812-04-4 
その他のジクロロトリフルオロエタン Other dichlorotrifluoroethane 
- 
- 
2-クロロ-1,1,1,2-テトラフルオロエタ
ン；HCFC-124 
2-chloro-1,1,1,2-tetrafluoroethane；HCFC-
124 
C2HF4Cl 
2837-89-0 
クロロテトラフルオロエタン；
HCFC-124 
Chlorotetrafluoroethane；HCFC-124 
CHFClCF3 
63938-10-3 
1-クロロ-1,1,2,2-テトラフルオロエタ
ン；HCFC-124a 
1-chloro-1,1,2,2-tetrafluoroethane；HCFC 
124a 
C2HClF4 
354-25-6 
その他のクロロテトラフルオロエタン Other chlorotetrafluoroethane 
- 
- 
トリクロロフルオロエタン；HCFC-
131 
Trichlorofluoroethane；HCFC-131 
C2H2FCl3 
134237-34-6 
27154-33-2 
1-フルオロ-1,2,2-トリクロロエタン；
HCFC-131 
1-Fluoro-1,2,2-trichloroethane ；HCFC131 C2H2Cl3F  359-28-4 
1,1,2-トリクロロ-1-フルオロエタン；
HCFC-131a 
1,1,2-trichloro-1-fluoroethane；HCFC131a C2H2Cl3F  811-95-0 
1,1,1-トリクロロ-2-フルオロエタン；
HCFC-131b 
Ethane, 1,1,1-trichloro-2-fluoro-；
HCFC131b 
C2H2Cl3F 
2366-36-1 
ジクロロジフルオロエタン；HCFC-
132 
Dichlorodifluoroethane；HCFC-132 
C2H2F2Cl2 
25915-78-0 
1,2-ジクロロ-1,1-ジフルオロエタン；
HCFC-132b 
1,2-dichloro-1,1-difluoroethane；HCFC 
132b 
C2H2Cl2F2 1649-08-7 
1,1-ジクロロ-1,2-ジフルオロエタン；
HCFC-132c 
1,1-dichloro-1,2-difluoroethane；HFCF 
132c 
C2H2Cl2F2 1842-05-3 
1,1-ジクロロ-2,2-ジフルオロエタン 
1,1-dichloro-2,2-difluoroethane 
C2H2Cl2F2 471-43-2 
1,2-ジクロロ-1,2-ジフルオロエタン 
1,2-dichloro-1,2-difluoroethane 
C2H2Cl2F2 431-06-1 
クロロトリフルオロエタン；1-クロロ
-1,2,2-トリフルオロエタン; 
HCFC-133 
Chlorotrifluoroethane； 
1-chloro-1,2,2-trifluoroethane; 
HCFC 133 
C2H2F3Cl  1330-45-6 
431-07-2 
2-クロロ-1,1,1-トリフルオロエタン；
HCFC-133a 
2-chloro-1,1,1-trifluoroethane ；HCFC-
133a 
C2H2F3Cl 
75-88-7 
1-クロロ-1,1,2-トリフルオロエタン；
HCFC-133b 
1-chloro-1,1,2-trifluoroethane；HCFC-133b C2H2F3Cl 
421-04-05 
ジクロロフルオロエタン；HCFC-141 Dichlorofluoroethane；HCFC-141 
C2H3FCl2 
25167-88-8 
173

Ver. 15 
30/57 
[Control Rules for Environment-related Substances Used in Product] 
1,2-ジクロロ-1-フルオロエタン；
HCFC-141 
1,2-dichloro-1-fluoroethane；HCFC-141 
C2H3FCl2 
430-57-9 
1,1-ジクロロ-2-フルオロエタン；
HCFC-141a 
1,1-dichloro-2-fluoroethane；HCFC-141a 
C2H3FCl2 
430-53-5 
1,1-ジクロロ-1-フルオロエタン；
HCFC-141b 
1,1-dichloro-1-fluoroethane；HCFC-141b 
CH3CFCl2 
1717-00-6 
その他のジクロロフルオロエタン 
Other dichlorofluoroethane 
- 
- 
クロロジフルオロエタン；HCFC-142 ChlorodiFluoroethane；HCFC-142 
C2H3F2Cl 
25497-29-4 
2-クロロ-1,1-ジフルオロエタン；
HCFC-142 
2-Chloro-1,1-difluoroethane；HCFC-142 
CH3CF2Cl 
338-65-8 
1-クロロ-1,1-ジフルオロエタン；
HCFC-142b 
1-chloro-1,1-difluoroethane；HCFC-142b 
CH3CF2Cl 
75-68-3 
1-クロロ-1,2-ジフルオロエタン；
HCFC-142a 
1-Chloro-1,2-difluoroethane；HCFC-142a 
CH3CF2Cl 
338-64-7 
その他のクロロジフルオロエタン 
Other chlorodifluoroethane 
- 
- 
クロロフルオロエタン；HCFC-151 
chlorofluoroethane；HCFC-151 
C2H4FCl 
110587-14-9 
1-クロロ-2-フルオロエタン；HCFC-
151 
1-chloro-2-fluoroethane；HCFC-151 
C2H4FCl 
762-50-5 
1-クロロ-1-フルオロエタン；HCFC-
151 
1-chloro-1-fluoroethane；HCFC-151 
C2H4FCl 
1615-75-4 
ヘキサクロロフルオロプロパン；
HCFC-221 
Hexachlorofluoropropane；HCFC-221 
C3HFCl6 
134237-35-7 
29470-94-8 
1,1,1,2,2,3-ヘキサクロロ-1-フルオロ
プロパン；HCFC-221ab 
1,1,1,2,2,3-Hexachloro-1-fluoropropane；
HCFC-221ab 
C3HFCl6 
422-26-4 
ペンタクロロジフルオロプロパン；
HCFC-222 
Pentachlorodifluoropropane；HCFC-222 
C3HF2Cl5 
134237-36-8 
1,1,1,3,3,-ペンタクロロ-2,2-ジフルオ
ロプロパン；HCFC-222ca 
1,1,1,3,3-Pentachloro-2,2-difluoropropane；
HCFC-222ca 
C3HF2Cl5 
422-49-1 
1,2,2,3,3-ペンタクロロ-1,1-ジフルオ
ロプロパン；HCFC-222aa 
1,2,2,3,3-Pentachloro-1,1-difluoropropane；
HCFC-222aa 
C3HF2Cl5 
422-30-0 
テトラクロロトリフルオロプロパン；
HCFC-223 
Tetrachlorotrifluoropropane；HCFC-223 
C3HF3Cl4 
134237-37-9 
1,1,3,3-テトラクロロ-1,2,2-トリフル
オロプロパン 
1,1,3,3-Tetrachloro-1,2,2-trifluoropropane 
C3HF3Cl4 
422-52-6 
1,1,1,3-テトラクロロ-2,2,3-トリフル
オロプロパン 
1,1,1,3-Tetrachloro-2,2,3-trifluoropropane 
C3HF3Cl4 
422-50-4 
トリクロロテトラフルオロプロパン 
；HCFC-224 
Trichlorotetrafluoropropane；HCFC-224 
C2HF4Cl3 
134237-38-0 
1,3,3-トリクロロ-1,1,2,2,-テトラフル
オロプロパン；HCFC-224 
1,3,3-Trichloro-1,1,2,2-tetrafluoropropane；
HCFC-224 
C2HF4Cl3 
422-54-8 
1,1,3-トリクロロ-1,2,2,3-テトラフル
オロプロパン 
1,1,3-Trichloro-1,2,2,3-tetrafluoropropane 
C2HF4Cl3 
422-53-7 
1,1,1-トリクロロ-2,2,3,3-テトラフル
オロプロパン 
1,1,1-Trichloro-2,2,3,3-tetrafluoropropane 
C3HF4Cl3 
422-51-5 
ジクロロペンタフルオロプロパン；
HCFC-225 
Dichloropentafluoropropane；HCFC-225 
C3HF5Cl2 
- 
127564-92-5 
 
2,2-ジクロロ-1,1,1,3,3,-ペンタフルオ
ロプロパン；HCFC-225aa 
2,2-Dichloro-1,1,1,3,3-pentafluoropropane 
；HCFC-225aa 
C3HF5Cl2 
128903-21-9 
2,3-ジクロロ-1,1,1,2,3-ペンタフルオ
ロプロパン；HCFC-225ba 
2,3-dichloro-1,1,1,2,3-pentafluoropropane；
HCFC-225ba 
C3HF5Cl2 
422-48-0 
1,2-ジクロロ-1,1,2,3,3-ペンタフルオ
ロプロパン；HCFC-225bb 
1,2-dichloro-1,1,2,3,3-pentafluoropropane；
HCFC-225bb 
C3HF5Cl2 
422-44-6 
174

Ver. 15 
31/57 
[Control Rules for Environment-related Substances Used in Product] 
3,3-ジクロロ-1,1,1,2,2-ペンタフルオ
ロプロパン；HCFC-225ca 
3.3-dichloro-1,1,1,2,2-pentafluoropropane；
HCFC-225ca 
C3HCl2F5 
422-56-0 
1,3-ジクロロ-1,2,2,3,3,-ペンタフルオ
ロプロパン；HCFC-225cb 
1,3-dichloro-1,1,2,2,3-pentafluoropropane；
HCFC-225cb 
C3HCl2F5 
507-55-1 
1,1-ジクロロ-1,2,2,3,3-ペンタフルオ
ロプロパン；HCFC-225cc 
1,1-dichloro-1,2,2,3,3-pentafluoropropane；
HCFC-225cc 
C3HCl2F5 
13474-88-9 
1,2-ジクロロ-1,1,3,3,3-ペンタフルオ
ロプロパン；HCFC-225da 
1,2-dichloro-1,1,3,3,3-pentafluoropropane；
HCFC-225da 
C3HCl2F5 
431-86-7 
1,3-ジクロロ-1,1,2,3,3-ペンタフルオ
ロプロパン；HCFC-225ea 
1,3-dichloro-1,1,2,3,3-pentafluoropropane；
HCFC-225ea 
C3HCl2F5 
136013-79-1 
1,1-ジクロロ-1,2,3,3,3-ペンタフルオ
ロプロパン；HCFC-225eb 
1,1-dichloro-1,2,3,3,3-pentafluoropropane；
HCFC-225eb 
C3HCl2F5 
111512-56-2 
その他のジクロロペンタフルオロプロ
パン 
Other dichloropentafluoropropane 
- 
- 
クロロヘキサフルオロプロパン；
HCFC-226 
Chlorohexafluoropropane；HCFC-226 
C3HF6Cl 
134308-72-8 
2-クロロ-1,1,1,3,3,3-ヘキサフルオロ
プロパン；HCFC-226da 
2-Chloro-1,1,1,3,3,3-hexafluoropropane；
HCFC-226da 
C3HF6Cl 
431-87-8 
ペンタクロロフルオロプロパン；
HCFC-231 
Pentachlorofluoropropane；HCFC-231 
C3H2FCl5 
134190-48-0 
1,1,1,2,3-ペンタクロロ-2-フルオロプ
ロパン 
1,1,1,2,3-Pentachloro-2-fluoropropane 
C3H2FCl5 
421-94-3 
テトラクロロジフルオロプロパン；
HCFC-232 
Tetrachlorodifluoropropane；HCFC-232 
C3H2F2Cl4 
134237-39-1 
1,1,1,3-テトラクロロ-3,3-ジフルオロ
プロパン 
1,1,1,3-Tetrachloro-3,3-difluoropropane 
C3H2F2Cl4 
460-89-9 
トリクロロトリフルオロプロパン；
HCFC-233 
Trichlorotrifluoropropane；HCFC-233 
C3H2F3Cl3 
134237-40-4 
1,1,1-トリクロロ-3,3,3-トリフルオロ
プロパン 
1,1,1-trichloro-3,3,3-trifluoropropane 
C3H2F3Cl3 
7125-83-9 
ジクロロテトラフルオロプロパン；
HCFC-234 
Dichlorotetrafluoropropane；HCFC-234 
C3H2F4Cl2 
127564-83-4 
1,2-ジクロロ-1,2,3,3-テトラフルオロ
プロパン 
1,2-Dichloro-1,2,3,3-tetrafluoropropane 
C3H2F4Cl2 
425-94-5 
クロロペンタフルオロプロパン；
HCFC-235 
Chloropentafluoropropane；HCFC-235 
C3H2F5Cl 
134237-41-5 
1-クロロ-1,1,3,3,3-ペンタフルオロプ
ロパン 
1-chloro-1,1,3,3,3-pentafluoropropane 
C3H2F5Cl  460-92-4 
テトラクロロフルオロプロパン；
HCFC-241 
Tetrachlorofluoropropane；HCFC-241 
C3H3FCl4 
134190-49-1 
1,1,2,3-テトラクロロ-1-フルオロプロ
パン 
1,1,2,3-Tetrachloro-1-fluoropropane 
C3H3FCl4 
666-27-3 
トリクロロジフルオロプロパン；
HCFC-242 
Trichlorodifluoropropane；HCFC-242 
C3H3F2Cl3 
134237-42-6 
1,3,3-トリクロロ-1,1-ジフルオロプロ
パン 
1,3,3-Trichloro-1,1-difluoropropane 
C3H3F2Cl3 
460-63-9 
ジクロロトリフルオロプロパン；
HCFC-243 
Dichlorotrifluoropropane；HCFC-243 
C3H3F3Cl2 
134237-43-7 
1,1-ジクロロ-1,2,2-トリフルオロプロ
パン 
1,1-dichloro-1,2,2-trifluoropropane 
C3H3F3Cl2 
7125-99-7 
2,3-ジクロロ-1,1,1-トリフルオロプロ
パン 
2,3-dichloro-1,1,1-trifluoropropane 
C3H3F3Cl2 
338-75-0 
175

Ver. 15 
32/57 
[Control Rules for Environment-related Substances Used in Product] 
3,3-ジクロロ-1,1,1-トリフルオロプロ
パン 
3,3-Dichloro-1,1,1-trifluoropropane 
C3H3F3Cl2 
460-69-5 
クロロテトラフルオロプロパン；
HCFC-244 
Chlorotetrafluoropropane；HCFC-244 
C3H3F4Cl 
134190-50-4 
3-クロロ-1,1,2,2-テトラフルオロプロ
パン 
3-chloro-1,1,2,2-tetrafluoropropane 
C3H3F4Cl  679-85-6 
1-クロロ-1,1,2,2-テトラフルオロプロ
パン 
1-chloro-1,1,2,2-tetrafluoropropane 
C3H3F4Cl  421-75-0 
トリクロロフルオロプロパン；
HCFC-251 
Trichlorofluoropropane；HCFC-251 
C3H4FCl3 
134190-51-5 
1,1,3-トリクロロ-1-フルオロプロパン 1,1,3-trichloro-1-fluoropropane 
C3H4FCl3 
818-99-5 
1,1,2-トリクロロ-1-フルオロプロパ
ン；HCFC-251dc 
1,1,2-trichloro-1-fluoropropane；HCFC-
251dc 
C3H4FCl3 
421-41-0 
ジクロロジフルオロプロパン；
HCFC-252 
Dichlorodifluoropropane；HCFC-252 
C3H4F2Cl2 
134190-52-6 
1,3-ジクロロ-1,1-ジフルオロプロパ
ン；HCFC-252fb 
1,3-Dichloro-1,1-difluoropropane；HCFC-
252fb 
C3H4F2Cl2 
819-00-1 
 
クロロトリフルオロプロパン；
HCFC-253 
Chlorotrifluoropropane；HCFC-253 
C3H4F3Cl 
134237-44-8 
3-クロロ-1,1,1-トリフルオロプロパ
ン;HCFC253fb 
3-chloro-1,1,1-trifluoropropane；HCFC 
253fb 
C3H4F3Cl  460-35-5 
ジクロロフルオロプロパン；HCFC-
261 
Dichlorofluoropropane；HCFC-261 
C3H5FCl2 
134237-45-9 
1,1-ジクロロ-1-フルオロプロパン 
1,1-dichloro-1-fluoropropane 
C3H5FCl2 
7799-56-6 
1,2-ジクロロ-2-フルオロプロパン 
；HCFC-261b 
1,2-dichloro-2-fluoropropane；HCFC-261b C3H5FCl2 
420-97-3 
クロロジフルオロプロパン；HCFC-
262 
Chlorodifluoropropane；HCFC-262 
C3H5F2Cl 
134190-53-7 
1-クロロ-2,2-ジフルオロプロパン 
1-chloro-2,2-difluoropropane 
C3H5F2Cl  420-99-5 
2-クロロ-1,3-ジフルオロプロパン 
2-chloro-1,3-difluoropropane 
C3H5F2Cl  102738-79-4 
1-クロロ-1,1-ジフルオロプロパン；
HCFC-262fc 
1-chloro-1,1-difluoropropane；HCFC-262fc C3H5F2Cl  421-02-3 
クロロフルオロプロパン；HCFC-271 Chlorofluoropropane；HCFC-271 
C3H6FCl 
134190-54-8 
2-クロロ-2-フルオロプロパン 
2-chloro-2-fluoropropane 
C3H6FCl  
420-44-0 
1-クロロ-1-フルオロプロパン 
1-chloro-1-fluoropropane 
- 
430-55-7 
・Others 
ジフルオロジブロモメタン 
Difluorodibromomethane  
CBr2 F2 
75-61-6 
1-ブロモプロパン(臭化n-プロピル) 
1-Bromopropane (n-propyl bromide) 
C3H7Br 
106-94-5 
ブロモエタン(臭化エチル) 
Bromoethane (ethyl bromide) 
C2H5Br 
74-96-4 
トリフルオロイオドメタン(ヨウ化ト
リフルオロメチル) 
Trifluoroiodomethane (trifluoromethyl 
iodide) 
CF3I 
2314-97-8 
クロロメタン(塩化メチル) 
Chloromethane (methyl chloride) 
CH3Cl 
74-87-3 
(3) Principal uses for substances 
Part 
Purpose 
Compressors, foamed plastics, fire extinguishers 
Refrigerants, foaming agents, extinguishants 
(Labeling requirements apply not only to products, 
but also to cleaning agents and other items used in 
production processes.) 
 
Table 2-I-22 Perfluorooctanesulfonic acid (PFOS) and PFOS analogs 
(1) Details 
No. I-20 
Substance Group: Perfluorooctanesulfonic acid (PFOS) and PFOS analogs 
176

Ver. 15 
33/57 
[Control Rules for Environment-related Substances Used in Product] 
Prohibition 
Level 
Date of ban 
on delivery 
Applications 
Control Value  
Note 
Level 1 
Immediate 
･All applications 
-Intentional inclusion 
prohibited  
*1 
Note 
*1  Class I Specified Chemical Substances designated by Japanese Chemical Substances 
Control Act., EU POPs Regulation, Canadian Environmental Protection Act (CEPA 
1999 SOR) 
(2) Examples of substances (The table below does not cover all the substances in this substance group.) 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No. or 
JAMP-SN 
Metal 
conversion 
factor 
ペルフルオロ-1-オクタンスルホ
ン酸カリウム(PFOS) 
Perfluorooctane sulfonate 
potassium salt  
C8F17SO2X 
(X = Other 
derivatives 
including 
hydroxyls, 
metal salts, 
halogenated 
compounds, 
amides and 
polymers) 
2795-39-3 
JAMP-SN0035 
- 
(3) Principal uses for substances 
Part 
Purpose 
Paints, coating materials, industrial cleaning agents, 
semiconductor manufacturing processes, 
electroplating processes 
Smoothing agents, surfactants, anti-foaming agents 
 
Table 2-I-23 Specific benzotriazole: 2-(2H-1,2,3-Benzotriazol-2-yl)-4,6-di-tert-butylphenol 
(1) Details 
No. I-23 
Substance Group: Specific benzotriazole: 2-(2H-1,2,3-Benzotriazol-2-yl)-4,6-di-tert-
butylphenol 
Prohibition 
Level 
Date of ban 
on delivery 
Applications 
Control Value  
Note 
Level 1 
Immediate 
Anti-UV materials and UV absorbers used 
in the following applications 
･Molded plastic parts 
･Decorative laminates 
･Photographic paper 
･Adhesives (excluding animal and plant-
based adhesives), putties, stopping and 
sealing fillers 
･Paints and printing inks 
-Intentional inclusion 
prohibited  
*1 
Note 
*1  Class I Specified Chemical Substances designated by Japanese Chemical Substances 
Control Act. 
(2) Regulated substances 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No or 
JAMP-SN 
特定ベンゾトリアゾール：2-(2H-
1,2,3-ベンゾトリアゾール-2-イル)-
4,6-ジ-tert-ブチルフェノール 
Specific benzotriazole:2-(2H-1,2,3-
Benzotriazol-2-yl)-4,6-di-tert-butylphenol 
C20H25N3O 3846-71-7 
(3) Principal uses for substances 
Part 
Purpose 
177

Ver. 15 
34/57 
[Control Rules for Environment-related Substances Used in Product] 
Molded plastic parts, decorative laminates, 
photographic paper, adhesives (excluding animal and 
plant-based adhesives), putties, stopping and sealing 
fillers, paints and printing inks 
Anti-UV materials and UV absorbers 
 
Table 2-I-24 Formaldehyde 
(1) Details 
No. I-24 
Substance Group: Formaldehyde   CAS No: 50-00-0 
Prohibition 
Level 
Date of ban 
on delivery 
Applications 
Control Value  
Note 
Level 1 
Immediate 
･Wood products and parts (excluding 
packaging materials) using materials such 
as particle boards and MDF (medium 
density fiberboard) 
-Less than 0.05ppm as 
gas discharge from 
product 
*1 
･Fabrics 
-Less than 75 ppm in 
product 
*2 
Note 
*1  ChemVerbotsV (Germany), Formaldehyde Regulations (Denmark), California USA CARB 
Regulations, U.S. federal law 111-199/TSCA Article 601 
*2  Austria BGB I 1990/194, Formaldehyde Regulation §2, 12/2/1990 
    Lithuanian Health Standard NH 96:2000 (health standards and regulations) 
(2) Regulated substances 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No or 
JAMP-SN 
ホルムアルデヒド 
Formaldehyde 
CH2O 
50-00-0 
(3) Principal uses for substances 
Part 
Purpose 
Wood products using materials such as particle boards 
and MDF (medium density fiberboard) 
Adhesives and preservatives for wood 
 
Table 2-I-25 Dimethylfumarate (DMF) 
(1) Details 
No. I-25 
Substance Group: Dimethylfumarate (DMF)   CAS No: 624-49-7 
Prohibition 
Level 
Date of ban 
on delivery 
Applications 
Control Value  
Note 
Level 1 
Immediate 
･All applications 
-Less than 0.1ppm in 
article or part thereof 
*1 
Note 
*1  Annex XVII to REACH (restriction) 
(2) Regulated substances 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No or 
JAMP-SN 
ジメチルフマレート(DMF) 
Dimethyl fumarate 
C6H8O4 
624-49-7 
(3) Principal uses for substances 
Part 
Purpose 
Biocide, electronic leather seats including recliners 
and massage chairs 
Biocide, mold treatment 
 
 
Table 2-I-26 Fluorinated Greenhouse Gases (PFC, SF6, HFC) 
(1) Details 
No. I-26 
Substance Group: Fluorinated Greenhouse Gases (PFC, SF6, HFC) 
Prohibition 
Level 
Date of ban 
on delivery 
Applications 
Control Value  
Note 
178

Ver. 15 
35/57 
[Control Rules for Environment-related Substances Used in Product] 
Level 1 
Immediate 
1) SF6, HFC 
･All applications 
-Intentional inclusion 
prohibited  
*1 
2) PFC 
･All applications listed below 
Disposable containers, can-cooling systems 
containing refrigerants, fire prevention 
systems and fire extinguishers, household 
windows, other windows, shoes, tires, one-
component foaming agents 
Note 
*1  (EC)No 517/2014 The Regulation on certain fluorinated greenhouse gases 
(2) Regulated substances 
Substance (Japanese) 
Substance (English) 
CAS No. or 
JAMP No. 
テトラフルオロメタン  
(4 フッ化炭素、PFC-14)  
Tetrafluoromethane 
(Carbon tetrafluoride, PFC-14)  
75-73-0 
ヘキサフルオロエタン(PF C-116)  
Hexafluoroethane (PFC-116)  
76-16-4 
オクタフルオロプロパン(PFC-218)  
Octafluoropropane (PFC-218)  
76-19-7 
デカフルオロブタン(PFC-31-10)  
Decafluorobutane (PFC-31-10)  
355-25-9 
ドデカフルオロペンタン(PFC-41-12)  
Dodecafluoropentane (PFC-41-12)  
678-26-2 
テトラデカフルオロヘキサン(PFC-51-14)  
Tetradecafluorohexane (PFC-51-14)  
355-42-0 
オクタフルオロシクロブタン(PFC-c318)  
Octafluorocyclobutane (PFC-c318)  
115-25-3 
6 フッ化硫黄(SF6)  
Sulfur Hexafluoride (SF6)  
2551-62-4 
トリフルオロメタン 
Trifluoromethane 
75-46-7 
ジフルオロメタン 
Difluoromethane 
75-10-5 
フルオロメタン 
Methyl fluoride 
593-53-3 
1,1,1,2,2,3,4,5,5,5-デカフルオロペンタン 
(HFC-43-10mee)  
Pentane, 1,1,1,2,2,3,4,5,5,5-decafluoro- (HFC-43-
10mee)  
138495-42-8 
ペンタフルオロエタン 
Ethane, pentafluoro- 
354-33-6 
1,1,2,2-テトラフルオロエタン  (HFC-134)  1,1,2,2-Tetrafluoroethane (HFC-134)  
359-35-3 
1,1,1,2-テトラフルオロエタン (HFC-134a)  1,1,1,2-Tetrafluoroethane  (HFC-134a)  
811-97-2 
1,1-ジフルオロエタン  (HFC-152a)  
1,1-Difluoroethane  (HFC-152a)  
75-37-6 
1,1,2-トリフルオロエタン(H FC-143 )  
1,1,2-Trifluoroethane.(HFC-143 )  
430-66-0 
1,1,1-トリフルオロエタン 
Ethane, 1,1,1-trifluoro- 
420-46-2 
1,1,1,2,3,3,3-ヘプタフルオロプロパン 
Propane, 1,1,1,2,3,3,3-heptafluoro- 
431-89-0 
1,1,1,2,2,3-ヘキサフルオロプロパン ( HFC-
236cb)  
1,1,1,2,2,3-hexafluoro-propane ( HFC-236cb)  
677-56-5 
1,1,1,2,3,3-ヘキサフルオロプロパン(HFC-
236ea)  
1,1,1,2,3,3-Hexafluoropropane (HFC-236ea)  
431-63-0 
1,1,1,3,3,3-ヘキサフルオロプロパン(HFC-
236fa)  
1,1,1,3,3,3-Hexafluoropropane (HFC-236fa)  
690-39-1 
1,1,2,2,3-ペンタフルオロプロパン(HFC-
245ca)  
1,1,2,2,3-Pentafluoropropane (HFC-245ca)  
679-86-7 
1,1,1,3,3-ペンタフルオロプロパン 
1,1,1,3,3-Pentafluoropropane 
460-73-1 
1,1,1,3,3-ペンタフルオロブタン 
1,1,1,3,3-Pentafluorobutane 
406-58-6 
1,1,1,2,2-ペンタフルオロプロパン 
1,1,1,2,2-Pentafluoropropane 
1814-88-6 
1,1,1,2,2,3,3-ヘプタフルオロプロパン 
1,1,1,2,2,3,3-Heptafluoropropane 
2252-84-8 
ジフルオロエタン 
Difluoroethane 
25497-28-3 
ヘキサフルオロプロパン 
Propane, hexafluoro- 
27070-61-7 
トリフルオロエタン 
Trifluoroethane 
27987-06-0 
フルオロエタン 
Ethyl fluoride 
353-36-6 
1,2-ジフルオロエタン 
1,2-Difluoroethane 
624-72-6 
1,1-ジフルオロエチレン 
Vinylidene fluoride 
75-38-7 
179

Ver. 15 
36/57 
[Control Rules for Environment-related Substances Used in Product] 
ハイドロフルオロカーボン(HFC)類 
Hydrofluorocarbons (HFC's) 
SN0062 
(3) Principal uses for substances 
Part 
Purpose 
Tires, windows, fire extinguishers, shoes, disposable 
containers, aerosols 
Refrigerants, blowing agents, extinguishants, 
cleaning agents, insulating media, caustic gas 
 
Table 2-I-27 Phthalate esters (BBP, DBP, DEHP, DIDP, DINP, DNOP, DIBP) 
(1) Details 
No. I-27 
Substance Group: Phthalate esters (BBP, DBP, DEHP, DIDP, DINP, DNOP, DIBP) 
Prohibition 
Level 
Date of ban 
on delivery 
*4 
Applications 
Control Value 
Note 
Level 1 
Immediate 
･BBP, DBP, DEHP: 
Prohibited in children's toys and child care 
articles 
･DIDP, DINP, DNOP: 
Prohibited in children's toys and child care 
articles that can be placed in a child's 
mouth 
-Less than 1000 ppm in 
plasticized material 
*1 
･Substances and mixtures that contain 
DEHP, BBP, DBP and/or DIBP 
-Intentional inclusion 
prohibited  
*2 
-DEHP, BBP, DBP, DIBP: Articles 
specified in Categories 1 through 11 of 
Annex I to RoHS Directive (2011/65/EU) 
-1000 ppm or less in 
homogeneous 
material 
*3 
-Articles containing plasticized material 
that includes DEHP, BBP, DBP and/or 
DIBP 
"Plasticized material" means any of the 
following homogeneous materials: 
- Polyvinyl chloride (PVC), polyvinylidene 
chloride (PVDC), any other polymer similar 
to polyvinyl acetate (PVA), and any other 
plastics, excluding polyolefin 
- Polyurethane and any other foamed 
rubber and plastics, excluding rubber, 
silicone rubber and natural latex coatings 
- Surface coatings, non-slip coatings, 
finishes, decals, printed designs, 
- Adhesives, sealants, paints and inks 
-Less than 1000 ppm in 
total of these four 
substances in 
homogeneous 
material 
*5 
Exemption 
*2  Applications that are submitted to, and approved by, the European Chemicals Agency 
will be permitted. 
*5 Exempted applications are as follows: 
・ Electrical and electronic equipment subject to RoHS Directive (2011/65/EU) 
・ Medical devices, or parts thereof, subject to Medical Device Directive (93/42/EEC), 
In-Vitro Diagnostic Devices Directive (98/79/EC) and Active Implantable Medical 
Devices Directive (90/385/EEC) 
・ Articles exclusively for industrial or agricultural use, or for use exclusively in the open air, 
provided that no plasticized material comes into contact with human mucous membranes 
or prolonged contact with human skin 
・ Measuring devices for laboratory use, or parts thereof 
Note 
*1  Annex XVII to REACH (restriction), U.S. Consumer Product Safety Improvement Act 
*2  Annex XIV to REACH (authorizations) 
*3  Annex II to RoHS Directive (2011/65/EU), addition of prohibited substances, (EU) 
2015/863 
*4  The date of ban on delivery is set as the date six months before the effective date of an 
180

Ver. 15 
37/57 
[Control Rules for Environment-related Substances Used in Product] 
applicable law or regulation. 
*5  Annex XVII to REACH (restriction) 
(2) Regulated substances 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No. or 
JAMP-SN 
Metal 
conversion 
factor 
フタル酸n- ブチル= ベンジル 
(BBP) 
Benzyl butyl phthalate (BBP) 
C19H20O4 
85-68-7 
- 
フタル酸ジ-n-ブチル(DBP) 
Dibutyl phthalate (DBP) 
C16H22O4  
84-74-2 
- 
フタル酸ビス(2-エチルヘキシ
ル)(DEHP) 
Bis (2-ethylhexyl)phthalate 
(DEHP) 
C24H38O4 
117-81-7 
- 
フタル酸ジイソデシル(DIDP) 
Di-''isodecyl'' phthalate 
C28H46O4 
26761-40-0 
- 
1,2-Benzenedicarboxylic acid, 
di-C9-11-branched alkyl esters, 
C10-rich 
68515-49-1 
- 
フタル酸ジイソノニル(DINP) 
Diisononyl phthalate 
C24H38O4 
28553-12-0 
- 
68515-48-0 
 
フタル酸ジ-n-オクチル(DNOP) Bis(n-octyl)Phthalate 
C6H4(COOC8H
17)2 
117-84-0 
- 
フタル酸ジイソブチル(DIBP) 
Diisobutyl phthalate 
C16H22O4 
84-69-5 
- 
(3) Principal uses for substances 
Part 
Purpose 
Flexible polyvinyl chloride molded items, rubber, 
elastomer 
Plastic plasticizers, dye, pigment, paint, ink, 
adhesive, lubricant 
 
Table 2-I-28 Perfluorooctanoic acid (PFOA) and its salts and esters and certain Long-Chain 
Perfluoroalkyl Carboxylates (LCPFAC） 
(1) Details 
No. I-28 
Substance Group: Perfluorooctanoic acid (PFOA) and its salts and esters and certain Long-
Chain Perfluoroalkyl Carboxylates (LCPFAC） 
Prohibition 
Level 
Date of ban 
on delivery*4 
Applications 
Control Value 
Note 
Level 1 
 
Immediate 
 
・Substances or mixtures 
・Articles other than invasive and 
implantable medical devices*2 
・Intentional inclusion 
prohibited 
・Less than 25ppb as 
PFOA including salts, 
or less than 1ppm as a 
total of all PFOA-
related substances, in 
mixture or article 
*1 
*2 
*3 
Level 2 
January 4, 
2025*1, *4 
・Invasive and implantable medical 
devices*1, *2, *5 
Level 1 
 
Immediate 
 
・Surface coating on article 
-Intentional inclusion 
prohibited  
*6 
Exemption 
*6 
- Medical devices under FDA 
- All applications that they have already used for before 2015. 
- Impurities 
- 13 specific usages defined by US TSCA. 
E.g., for use in an antireflective coating, photoresists, or surfactant for use in photo 
microlithography or other process to produce semiconductors or similar components 
for electronics or other miniaturized devices 
(https://www.govinfo.gov/content/pkg/FR-2020-07-27/pdf/2020-13738.pdf) 
*7 
Medical devices other than invasive and implantable medical devices: The control value 
181

Ver. 15 
38/57 
[Control Rules for Environment-related Substances Used in Product] 
should be under 2 mg/kg (0.0002wt%). 
Note 
*1: Class I Specified Chemical Substances designated by Japanese Chemical Substances 
Control Act., Enforcement of the revised EU POPs regulation (EU 2021/115) 
*2: The definitions of medical devices and implantable medical devices are as provided 
by the Medical Device Directive 93/42/EEC. 
*3: PFOA-related substances are any related substances (including salts and polymers) having 
a linear or branched perfluoroheptyl group with the formula C7F15- directly attached to 
another carbon atom, as one of the structural elements, or any related substance (including 
its salts and polymers) having a linear or branched perfluorooctyl group with the formula 
C8F17-, as one of the structural elements. The following substances are excluded from this 
designation: 
・C8F17-X, where X = F, Cl, Br. 
・C8F17-C(=O)OH, C8F17-C(=O)O-X or C8F17-CF2-X 
(X = any group, including salts). 
*4: The date of ban on delivery is set as the date six months before the effective date of an 
applicable law or regulation. 
*5: Only applies to the invasive and implantable medical devices that are submitted and 
approved. 
*6: Significant New Use Rules (SNURs) under US TSCA,§721.9582 and §721.10536. The 
substances are Perfluorooctanoic acid (PFOA) and its salts and esters and the above 
Long-Chain Perfluoroalkyl Carboxylates (LCPFAC). 
(2) Examples of substances (The table below does not cover all the substances in this substance group.) 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No. or 
JAMP-SN 
Metal 
conversion 
factor 
ペルフルオロオクタン酸 
Pentadecafluorooctanoic acid; 
PFOA - perfluorooctanoic acid 
C8HF15O2 
335-67-1 
 
ペンタデカフルオロオクタン酸
フルオリド 
Pentadecafluorooctyl fluoride 
C8F16O 
335-66-0 
- 
ペンタデカフルオロオクタン酸
銀(I) 
Pentadecafluorooctanoic acid  
silver(I) salt 
C8AgF15O2 
335-93-3 
- 
ペンタデカフルオロオクタン酸
ナトリウム 
Perfluorooctanoic acid sodium 
salt;  Sodium salt of PFOA 
C8F15NaO2 
335-95-5 
 
ペンタデカフルオロオクタン酸
メチル 
Methyl perfluorooctanoate 
C9H3F15O2 
376-27-2 
- 
ペルフルオロオクタン酸カリウ
ム 
Potassium salt of PFOA 
C8F15KO2 
2395-00-8 
- 
ペンタデカフルオロオクタン酸
エチル 
Ethyl perfluorooctanoate 
C10H5F15O2 3108-24-5 
- 
ペンタデカフルオロオクタン酸
アンモニウム 
Ammonium 
pentadecafluorooctanoate 
(APFO); 
Ammonium salt of PFOA 
C8H4F15NO2 3825-26-1 
- 
PFOA とその塩 
PFOA and its salts 
- 
JAMP-
SN0036 
- 
ペルフルオロオクタン酸 
（PFOA）の塩 
PFOA salts 
- 
JAMP-
SN0102 
- 
PFOA 関連のポリマー 
PFOA-related polymer 
- 
JAMP-
SN0103 
- 
(3) Principal uses for substances 
Part 
Purpose 
Surface coating agents, extinguishants 
Additives, leveling agents for paints, aqueous film-
forming foam extinguishants, surfactants 
(2) Regulated substances 
182

Ver. 15 
39/57 
[Control Rules for Environment-related Substances Used in Product] 
Substance (Japanese) 
Substance (English) 
CAS No. or 
JAMP-SN 
1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8- ヘ
プタデカフルオロ-8-ヨードオクタ
ン 
Perfluorooctyl iodide 
507-63-1 
2-(ペルフルオロオクチル)エタノー
ル 
Tetrahydroperfluoro-1-decanol 
678-39-7 
3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,
11,12,12,12-ヘンエイコサフルオロ
ドデカン-1-オール 
Perfluoro-1-dodecanol 
865-86-1 
1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8- ヘ
プタデカフルオロ-10-ヨードデカン Perfluorodecyl iodide 
2043-53-0 
1-ヨード- 
3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,
11,12,12,12-ヘニコサフルオロドデ
カン 
1,1,2,2-Tetrahydroperfluorododecyl iodide 
2043-54-1 
α-[2-(アクリロイルオキシ)エチル]-
ω - フルオロペルフルオロ(ポリ
(2~7)エチレン) 
Perfluorodecylethyl acrylate 
17741-60-5 
3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10
-ヘプタデカフルオロデシル=アク
リラｰト 
1,1,2,2-Tetrahydroperfluorodecyl acrylate 
27905-45-9 
1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,
10,10,11,11,12,12-ペンタコサフル
オロ-14-ヨードテトラデカン 
1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12
-Pentacosafluoro-14-iodotetradecane 
30046-31-2 
3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,
11,12,12,13,13,14,14,14- ペンタコ
サフルオロテトラデカン-1-オｰル 
3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14
,14,14-Pentacosafluorotetradecan-1-ol 
39239-77-5 
3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,
11,12,12,13,13,14,14,15,15,16,16,1
6-ノナコサフルオロヘキサデカン-
1-オｰル 
3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14
,14,15,15,16,16,16-Nonacosafluorohexadecan-1-ol 
60699-51-6 
1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,
10,10,11,11,12,12,13,13,14,14-
ノ
ナコサフルオロ-16-ヨードヘキサデ
カン 
1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12
,13,13,14,14-Nonacosafluoro-16-iodohexadecane 
65510-55-6 
ナトリウム=2- メチル-2-{3-
[(1,1,2,2-テトラヒドロペルフルオ
ロアルキル(C4-C16)スルファニル)
プロパナミド]プロパン-1-スルホナ
ート 
Sodium;2-methylpropane-1-sulfonate 
68187-47-3 
γ-ω-ペルフルオロアルコール(C8-
C14) 
1,1,2,2-Tetrahydroperfluoroalkyl (C8-C14) alcohol 
68391-08-2 
チオール、C8-20、ガンマ-オメガ-パ
ーフルオロ、アクリルアミドを含む
テロマー 
Thiols, 
C8-20, 
gamma-omegaperfluoro,telomers 
with acrylamide 
70969-47-0 
183

Ver. 15 
40/57 
[Control Rules for Environment-related Substances Used in Product] 
ケイ酸 (H4SiO4), 二ナトリウム塩, 
クロロトリメチルシランと
3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10
-ヘプタデカフルオロ-1-デカノール
との反応生成物 
Silicic acid (H4SiO4), sodium salt (1:2), reaction 
products 
with 
chlorotrimethylsilane 
and 
3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluoro-
1-decanol 
125476-71-3 
チオール、C4-20、γ-オメガ-パーフ
ルオロ、アクリルアミドとアクリル
酸のテロマー、ナトリウム塩 
Thiols, C4-20, gamma-omegaperfluoro, telomers 
with acrylamide and acrylic acid, sodium salts) 
1078712-88-
5 
1-プロパナミニウム、3-アミノ-N-
（カルボキシメチル）-N、N-ジメチ
ル-、N-（2-（（ガンマ-オメガ-ペル
フルオロ-C4-20-アルキル）チオ）ア
セチル）誘導体、内部塩 
1-Propanaminium, 
3-amino-N-(carboxymethyl)-
N,N-dimethyl-, N-(2-((gamma-omega-perfluoro-C4– 
20-alkyl)thio)acetyl) derivs., inner salts 
1078715-61-
3 
ポリフルオロアルキルベタイン（一
般名） 
Polyfluoroalkyl betaine (generic) 
-(CBI) 
変性フルオロアルキルウレタン（一
般名） 
Modified fluoroalkyl urethane (generic) 
-(CBI) 
過フッ素化ポリアミン（一般名） 
Perfluorinated polyamine (generic) 
-(CBI) 
 
Table 2-I-29 Polycyclic-aromatic hydrocarbons (PAH) 
(1) Details 
No. I-29 
Substance Group: Polycyclic-aromatic hydrocarbons (PAH) 
Prohibition 
Level 
Date of ban 
on delivery 
Applications 
Control Value 
Note 
Level 1 
Immediate 
・Rubber or plastic components that come 
into direct as well as prolonged or short-
term repetitive contact with human skin 
or the oral cavity under normal or 
reasonably foreseeable conditions of use 
-Less than 1mg/kg of 
any of the listed PAHs 
in components of 
articles for the 
general public (less 
than 0.0001% [1ppm] 
of the weight of such 
components) 
*1 
Note 
*1  Annex XVII to REACH (restriction) 
(2) Regulated substances 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No.or 
JAMP-SN 
ベンゾ(a)ピレン 
Benzo[a]pyrene (BaP) 
C20H12 
50-32-8 
ベンゾ(e)ピレン 
Benzo[e]pyrene (BeP) 
C20H12 
192-97-2 
ベンゾ(a)アントラセン 
Benzo[a]anthracene (BaA) 
C20H12 
56-55-3 
クリセン 
Chrysene (CHR) 
C20H12 
218-01-9 
ベンゾ(b)フルオランテン 
Benzo[b]fluoranthene (BbFA) 
C20H12 
205-99-2 
ベンゾ(j)フルオランテン 
Benzo[j]fluoranthene (BjFA) 
C20H12 
205-82-3 
ベンゾ(k)フルオランテン 
Benzo[k]fluoranthene (BkFA) 
C20H12 
207-08-9 
ジベンズ(a,h)アントラセン 
Dibenzo[a,h]anthracene (DBAhA) 
C22H14 
53-70-3 
(3) Principal uses for substances 
Part 
Purpose 
Byproducts generated by combustion of petroleum 
products 
Volatile PAHs are contained in some industrial articles 
(essential oils, lubricants, biocides, adhesives, and 
paints) 
- 
 
184

Ver. 15 
41/57 
[Control Rules for Environment-related Substances Used in Product] 
Table 2-I-30 Pentachlorophenol and its salts and esters 
(1) Details 
No. I-30 
Subject Group: Pentachlorophenol and its salts and esters 
Prohibition 
Level 
Date of ban on 
delivery 
Applications 
Control Value 
Note 
Level 1 
Immediate 
-All applications 
Intentional inclusion prohibited 
*1 
Note 
*1 Class I Specified Chemical Substances designated by Japanese Chemical Substances Control 
Act., the EU POPs regulation 
(2) Examples of substances (The table below does not cover all the substances in this substance group.) 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No. or 
JAMP-SN 
Metal 
conversion 
factor 
ペンタクロロフェノール 
Pentachlorophenol 
C6Cl5OH 
87-86-5 
- 
ペンタクロロフェノールナトリ
ウム 
Sodium pentachlorophenol 
C6Cl5NaO 
131-52-2 
- 
ペンタクロロフェノールナトリ
ウム一水和物 
Sodium pentachlorophenol 
monohydrate 
C6Cl5NaO
・
H2O 
27735-64-4 
- 
ペンタクロロフェニルラウレー
ト 
Pentachlorophenyl laurate 
C18H23Cl5O2 
3772-94-9 
- 
ペンタクロロアニソール 
Pentachloreanisole 
C7H3Cl5O 
1825-21-4 
- 
メチル水銀ペンタクロロフェノ
キシド 
Methyl(pentachlorophenolato)m
ercury 
C7H4Cl5HgO 5902-76-1 
- 
ペンタクロロフェノール＝ナト
リウム塩 
Phenol, pentachloro-, sodium 
salt, decahydrate 
C6Cl5NaO・ 
(H2O)10 
27735-63-3 
- 
カルシウム＝ビス（ペンタクロ
ロフェノラート） 
Calcium 
bis(pentachlorophenolate) 
C12CaCl10O
2 
55868-72-9 
- 
ペンタクロルフェノール塩類及
びこれを含有する製剤 
PCP-Na hydrate 
C6H2Cl5NaO
2 
123333-54-0 
- 
(3) Principal uses for substances 
Part 
Purpose 
Wood products, leather products 
Preservative 
 
Table 2-I-31  Certain CMR substances 
(1) Details  
No. I-31 
Subject Group: Certain CMR substances 
Prohibition 
Level 
Date of ban on delivery 
Applications 
Control Value 
Note 
Level 1 
Immediate 
・Clothing or related 
accessories such as bags 
(shoulder bags), neck straps 
and hand straps 
・Textiles other than clothing 
which, under normal or 
reasonably foreseeable 
conditions of use, come into 
contact with human skin to 
an extent similar to clothing 
・Footwear 
・Control values vary 
among controlled 
substances. For details, 
please refer to the control 
value of each substance. 
*1 
Exemption 
・Medical devices subject to Medical Devices Regulation((EU) 2017/745) 
・Personal protective equipment subject to Personal Protective Equipment Regulation ((EU) 
2016/425) 
185

Ver. 15 
42/57 
[Control Rules for Environment-related Substances Used in Product] 
・Clothing, related accessories or footwear, or parts of clothing, related accessories or footwear, 
made exclusively of natural leather, fur or hide 
・Non-textile fasteners and non-textile decorative attachments 
・Second-hand clothing, related accessories, textiles other than clothing, or footwear 
・Wall-to-wall carpets and textile floor coverings for indoor use, rugs and runners 
Note 
*1: Annex XVII to REACH (restriction), Entry 72, Appendix 12 
(2) Regulated substances 
Substance (Japanese) 
Substance (English) 
Control value 
CAS No. or 
JAMP-SN 
カドミウム及びその化合物 
Cadmium and its compounds 
･1 mg/kg after 
extraction 
(expressed as Cd 
metal that can be 
extracted from the 
material) 
Please see 
Table 2-I-1 
(2). 
六価クロム化合物 
Chromium VI compounds 
･1 mg/kg after 
extraction 
(expressed as Cr 
VI that can be 
extracted from the 
material) 
Please see 
Table 2-I-2 
(2). 
ヒ素化合物 
Arsenic compounds 
･1 mg/kg after 
extraction 
(expressed as As 
metal that can be 
extracted from the 
material) 
Please see 
examples 
table (2) of 
this chapter 
below. 
鉛及びその化合物 
Lead and its compounds 
･1 mg/kg after 
extraction 
(expressed as Pb 
metal that can be 
extracted from the 
material) 
Please see 
Table 2-I-3 
(2). 
ベンゼン 
Benzene 
･Less than 5ppm 
71-43-2 
ベンゾ[a]アントラセン 
Benz[a]anthracene 
･Less than 1ppm 
56-55-3 
ベンゾ[b]フルオランテン 
Benz[e]acephenanthrylene 
･Less than 1ppm 
205-99-2 
ベンゾ[a]ピレン 
ベンゾ[def]クリセン 
benzo[a]pyrene; 
benzo[def]chrysene 
･Less than 1ppm 
50-32-8 
ベンゾ[e]ピレン 
Benzo[e]pyrene 
･Less than 1ppm 
192-97-2 
ベンゾ[j]フルオランテン 
Benzo[j]fluoranthene 
･Less than 1ppm 
205-82-3 
ベンゾ[k]フルオランテン 
Benzo[k]fluoranthene 
･Less than 1ppm 
207-08-9 
クリセン 
Chrysene 
･Less than 1ppm 
218-01-9 
ジベンゾ[a,h]アントラセン 
Dibenz[a,h]anthracene 
･Less than 1ppm 
53-70-3 
p-(トリクロロメチル)クロロベン
ゼン 
α, α,α,4-tetrachlorotoluene; 
p-chlorobenzotrichloride 
･Less than 1ppm 
5216-25-1 
トリクロロメチルベンゼン 
α, α,α-trichlorotoluene; 
benzotrichloride 
･Less than 1ppm 
98-07-7 
クロロメチルベンゼン 
α-chlorotoluene; 
benzyl chloride 
･Less than 1ppm 
100-44-7 
ホルムアルデヒド 
Formaldehyde 
･Less than 75ppm 
50-00-0 
ジアルキル(c=6,7(主成分),8,分岐
型)=フタラート 
1,2-benzenedicarboxylic acid; 
di-C 6-8-branched alkylesters, C 
7-rich 
･Less than 
1000ppm 
71888-89-6 
186

Ver. 15 
43/57 
[Control Rules for Environment-related Substances Used in Product] 
ビス(2-メトキシエチル)=フタラ
ート 
Bis(2-methoxyethyl) phthalate 
･Less than 
1000ppm 
117-82-8 
ジイソペンチル=フタラート 
Diisopentylphthalate 
･Less than 
1000ppm 
605-50-5 
ジペンタル-1-イル=フタラート
(DPP) 
Di-n-pentyl phthalate (DPP) 
･Less than 
1000ppm 
131-18-0 
ジヘキサン-1-イル=フタラート
(DnHP) 
Di-n-hexyl phthalate (DnHP) 
･Less than 
1000ppm 
84-75-3 
1-メチル-2-ピロリドン(NMP) 
N-methyl-2-pyrrolidone;  
1-methyl-2-pyrrolidone (NMP) 
･Less than 
3000ppm 
872-50-4 
N,N-ジメチルアセトアミド
(DMAC) 
N,N-dimethylacetamide (DMAC) 
･Less than 
3000ppm 
127-19-5 
N,N-ジメチルホルムアミド 
N,N-dimethylformamide; 
dimethyl formamide (DMF) 
･Less than 
3000ppm 
68-12-2 
1,4,7,8-テトラアミノアントラキ
ノン; C.I.ディスパーブルー1 
1,4,5,8-
tetraaminoanthraquinone; C.I. 
Disperse Blue 1 
･Less than 50ppm 
2475-45-8 
4,4-(4-イミノシクロヘキサ-2,5-
ジエニデンメチレン)ジアニリン
塩酸塩 
Benzenamine, 4,4′-(4-
iminocyclohexa-2,5- 
dienylidenemethylene)dianiline 
hydrochloride; C.I. Basic Red 9 
･Less than 50ppm 
569-61-9 
C.I.ベーシックバイオレット3 
[4-[4,4′-
bis(dimethylamino)benzhydrylid
ene]cyclohexa-2,5-dien-1-
ylidene]dimethylammonium 
chloride; C.I. Basic 
Violet 3 with ≥ 0,1 % of 
Michler's ketone (EC no. 202-
027-5) 
･Less than 50ppm 
548-62-9 
4-クロロ-2-メチルアニリウム=ク
ロリド 
4-chloro-o-toluidinium chloride 
･Less than 30ppm 
3165-93-3 
2-ナフタレンアミン・酢酸 
2-Naphthylammoniumacetate 
･Less than 30ppm 
553-00-4 
硫酸2,4-ジアミノエーテル 
4-methoxy-m-phenylene 
diammonium sulphate;  
2,4-diaminoanisole sulphate 
･Less than 30ppm 
39156-41-7 
2,4,5-トリミチルアニリン・塩酸
塩 
2,4,5-trimethylaniline 
hydrochloride 
･Less than 30ppm 
21436-97-5 
キノリン 
Quinoline 
･Less than 50ppm 
91-22-5 
(2) Examples of arsenic compounds among certain CMR substances (The table below does not cover all the 
substances in this substance group.) 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No. or 
JAMP-SN 
Metal 
conversion 
factor 
ヒ素 
Arsenic 
As 
7440-38-2 
1.000 
ヒ酸 
Arcenic acid 
AsH3O4 
7778-39-4 
0.528 
亜ヒ酸銀 
Trisilverarsenite 
Ag.1/3AsH3O3 
7784-08-9 
0.167 
亜ヒ酸鉛 
Lead arsenite 
As2O4Pb 
10031-13-7 
0.356 
ヒ酸鉛 
Lead arsenate 
Pb3(AsO4)2 
10102-48-4 
0.267 
ヒ酸鉄(III) 
Ferric arsenate 
AsFeO4 
10102-49-5 
0.384 
亜ヒ酸鉛(II) 
Zinc arsenite 
As2O4Zn 
10326-24-6 
0.537 
ヒ化マンガン 
Manganese arsenide 
MnAs 
12005-95-7 
0.577 
ヒ化亜鉛 
Zinc arsenide  
Zn3As3 
12006-40-5 
0.433 
187

Ver. 15 
44/57 
[Control Rules for Environment-related Substances Used in Product] 
ヒ化スズ 
Tin arsenide 
SnAs 
12044-32-5 
0.386 
ヒ化ガリウム 
Gallium arsenide 
AsGa 
1303-00-0 
0.518 
五酸化二ヒ素 
Arsenic pentoxide 
As2O5 
1303-28-2 
0.652 
三酸化二ヒ素 
Diarsenic trioxide 
 As2O3 
1327-53-3 
0.757 
ヒ酸トリエチル 
Triethyl arsenate 
C6H15AsO4 
15606-95-8 
0.331 
亜ヒ酸カルシウム 
Calcium arsenite 
As2Ca3O6 
27152-57-4 
0.409 
ビス(ヒ酸)三鉛(II) 
Trilead diarsenate 
As2O8Pb3 
3687-31-8 
0.167 
ビス(ヒ酸)三カルシウム 
Calcium arsenate 
As2Ca3O8 
7778-44-1 
0.376 
ヒ酸水素鉛(II) 
Lead hydrogen arsenate 
AsH3O4.Pb 
7784-40-9 
0.215 
ヒ酸二水素カリウム 
Potassium arsenate 
AsH2KO4 
7784-41-0 
0.416 
ヒ酸及びその塩 
arsenic acid and its salts 
- 
JAMP-SN0009 
- 
その他のヒ素化合物 
Arsenic compounds 
- 
JAMP-SN0010 
- 
(3) Principal uses for substances 
Part 
Purpose 
Clothing or accessories such as bags, textiles, footwear Pigments, germicides, biocides 
 
Table 2-I-32 Phenol, Isopropylated Phosphate (3:1) 
 (1) Details 
No. I-32 
Substance Group: Phenol, Isopropylated Phosphate (3:1) (PIP 3:1) 
Prohibition 
Level 
Date of ban 
on delivery*2 
Applications 
Control Value  
Note 
Level 1 
Immediate 
･All applications, excluding adhesives and 
sealants 
-Intentional inclusion 
prohibited 
*1 
Level 2 
July 6, 2024 
･Adhesives and sealants 
-Intentional inclusion 
prohibited 
*1 
Exemption 
«FDA-registered medical devices» 
The following Official Journal is applicable. 
TSCA: CHAPTER 53—TOXIC SUBSTANCES CONTROL SUBCHAPTER I—CONTROL OF TOXIC 
SUBSTANCES Sec. 2602. Definitions. (2)(vi) 
(https://www.govinfo.gov/content/pkg/USCODE-2018-title15/pdf/USCODE-2018-title15-chap53.pdf) 
(Note) FDA-registered medical devices are not subject to TSCA but Olympus may require suppliers to 
report the contents of these substances so that Olympus can confirm the exemptions are applied. 
«Exceptions to US TSCA PBT Rules » 
・ Regulated substances, products or articles containing regulated substances, which have already 
been sold to end-consumers (such as secondhand articles and donations to charity) 
・ Disposal of regulated substances, products or articles containing regulated substances 
・ Production, treatment, distribution in commerce and use of regulated substances, products or 
articles containing regulated substances for research and development purposes 
・ Processing and distribution in commerce of “hydraulic fluids that meet specifications and 
requirements of the Defense Department”, “lubricants and greases”, “new and replacement parts 
for aerospace vehicles and automobiles”, etc.; plastic containing recycled PIP(3:1); and products 
and articles using plastic that contains recycled PIP(3:1), etc. 
(Note) Only the exceptions related with Olympus Group products are listed above. 
(Note) Items other than “FDA-registered medical devices” described above. 
Note 
*1 US TSCA PBT Rules 
*2 The date of ban on delivery is set as the date six months before the effective date of an 
applicable  regulation. 
(2) Regulated substances 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No or 
JAMP-SN 
188

Ver. 15 
45/57 
[Control Rules for Environment-related Substances Used in Product] 
リン酸トリス(イソプロピルフェニル) 
PIP (3:1) 
Phenol, Isopropylated Phosphate (3:1) 
(PIP 3:1) 
Unspecified  68937-41-7 
(3) Principal uses for substances 
Part 
Purpose 
Polyvinyl chloride (PVC) 
Flame-retardant plasticizers 
 
Table 2-I-33 2,4,6-tris(tert-butyl)phenol (2,4,6-TTBP) 
(1) Details 
No. I-33 
Substance Group: 2,4,6-tris(tert-butyl)phenol (2,4,6-TTBP) 
Prohibition 
Level 
Date of ban 
on delivery 
Applications 
Control Value  
Note 
Level 1 
Immediate 
･All applications, excluding articles 
-Intentional inclusion 
prohibited 
*1 
Exemption 
«FDA-registered medical devices» 
The following Official Journal is applicable. 
TSCA: CHAPTER 53—TOXIC SUBSTANCES CONTROL SUBCHAPTER I—CONTROL OF TOXIC 
SUBSTANCES Sec. 2602. Definitions. (2)(vi) 
(https://www.govinfo.gov/content/pkg/USCODE-2018-title15/pdf/USCODE-2018-title15-chap53.pdf) 
(Note) FDA-registered medical devices are not subject to TSCA but Olympus may require suppliers to 
report the contents of these substances so that Olympus can confirm the exemptions are applied. 
«Exceptions to US TSCA PBT Rules » 
・ Regulated substances, products or articles containing regulated substances, which have already 
been sold to end-consumers (such as secondhand articles and donations to charity) 
・ Disposal of regulated substances, products or articles containing regulated substances 
・ Production, treatment, distribution in commerce and use of regulated substances, products or 
articles containing regulated substances for research and development purposes 
(Note) Items other than “FDA-registered medical devices” described above 
Note 
*1 Class I Specified Chemical Substances designated by Japanese Chemical Substances 
Control Act. US TSCA PBT Rules 
(2) Regulated substances 
Substance (Japanese) 
Substance (English) 
Chemical 
formula 
CAS No or 
JAMP-SN 
2,4,6- トリ-tert-ブチルフェノール
(2,4,6-TTBP) 
2,4,6-tris(tert-butyl)phenol (2,4,6-TTBP) C18H30O 
732-26-3 
(3) Principal uses for substances 
Part 
Purpose 
Lubricants 
Additives 
 
 
189

Ver. 15 
46/57 
[Control Rules for Environment-related Substances Used in Product] 
Table 3 Criteria for managing controlled substances 
Table 3-II-1 Candidate List of Substances of Very High Concern in REACH (SVHC) 
No. II-1 
Substance Group: Candidate List of Substances of Very High Concern in REACH (SVHC) 
Applications 
Control Values 
Note 
・All applications 
- 1000ppm 
*1 
Note 
*1 The candidate list of substances of very high concern in REACH (SVHC) will be 
periodically updated. 
Please refer to the website of the European Chemicals Agency (ECHA). 
(https://www.echa.europa.eu/candidate-list-table) 
 
Table 3-II-2 Substances subject to the European Union’s Medical Device Regulation (EU-MDR) or 
In Vitro Diagnostic Medical Device Regulation (EU-IVDR) 
No. II-2 
Substance group: Substances subject to the European Union’s Medical Device Regulation 
(EU-MDR) or In Vitro Diagnostic Medical Device Regulation (EU-IVDR) 
Applicable regulation 
Applications 
Control Values 
Note 
The European Union’s Medical 
Device Regulation (EU-MDR) 
Devices, or those parts thereof or those 
materials used therein that: 
- Are invasive and come into direct 
contact with the human body, 
- (re)administer medicines, body fluids 
or other substances, including gases, 
to or from the body, or, 
- transport or store such medicines, 
body fluids or substances, including 
gases, to be (re)administered to the 
body. 
- 1000ppm *2 
*1 
The European Union’s In Vitro 
Diagnostic Medical Device 
Regulation (EU-IVDR) 
Components and subsidiary materials 
that come into direct or indirect contact 
with the patient 
Note 
*1: The substances subject to EU-MDR or EU-IVDR are defined in items (1) and (2) below. 
Substances in item (3) may be added to this substance group in the future. Please refer to 
EU 2017/745 at Annex I, 10.4.1 (b) for details.  
 
(1) Category 1A/1B substances that are carcinogenic, mutagenic or toxic to 
reproduction, listed in Table 3.1 of Annex VI to the CLP regulation, List of harmonized 
classification and labelling of hazardous substances. 
Please refer to the following website for the table. 
(https://echa.europa.eu/information-on-chemicals/annex-vi-to-clp) 
 
(2) Substances that are on the candidate list of Substances of Very High Concern in 
REACH (SVHC), and have endocrine disrupting effects on humans. 
The candidate list of SVHC will be periodically updated. Please refer to the website of the 
European Chemicals Agency (ECHA). 
(https://www.echa.europa.eu/candidate-list-table) 
 
(3) BPR substances BPR Regulation (Regulation (EU) No 528/2012 o)  
(https://echa.europa.eu/guidance-documents/guidance-on-biocides-legislation) 
 
*2: Regarding surface treatment coatings, the concentration of a substance in an article (not 
in the coating) may be used as its control value. 
 
 
 
190

Ver. 15 
47/57 
[Control Rules for Environment-related Substances Used in Product] 
5. Major Revisions 
Ver. 
Date 
Article 
Contents and reason for revisions 
15 
2021.06.30 
All pages 
・The structure of articles and tables were reviewed. 
 
 
3 
・“Homogeneous materials” was added under “Terms 
and Definitions”. “Control content” was incorporated 
into “Control value”. 
・“CMR substances” and “Effective date of an 
applicable law or regulation” were deleted. 
 
 
4 
・The structure of this section was reviewed. The 
contents of the section were revised so as to best 
reflect the changes made to the terms and the 
definitions. 
 
 
Table 2-I-1 
・“Intentional inclusion prohibited” and “The following 
applications, other than *1 and *2” were deleted 
・“Less than 100 ppm” according to RoHS Directive 
was replaced with “100 ppm or less”. 
 
 
Table 2-I-2 
・“Intentional inclusion prohibited” and “The following 
applications, other than *1, *2 and *3” were deleted 
・“Less than 1000 ppm” according to RoHS Directive 
was replaced with “1000 ppm or less”. 
 
 
Table 2-I-3 
・“Intentional inclusion prohibited” and “The following 
applications, other than *1, *2 and *3” were deleted 
・“Less than 1000 ppm” according to RoHS Directive 
was replaced with “1000 ppm or less”. 
 
 
Table 2-I-4 
・“Intentional inclusion prohibited” and “The following 
applications, other than *1, *2 and *3” were deleted 
・“Less than 1000 ppm” according to RoHS Directive 
was replaced with “1000 ppm or less”. 
 
 
Table 2-I-9 
・“Intentional inclusion prohibited” and “The following 
applications, other than *1, *2 and *3” were deleted 
・“Less than 1000 ppm” according to RoHS Directive 
was replaced with “1000 ppm or less”. 
 
 
Table 2-I-10 
・“Intentional inclusion prohibited” and “The following 
applications, other than *1, *2 and *3” were deleted 
・“Less than 1000ppm” according to RoHS Directive 
was replaced with “1000 ppm or less”. 
・“US TSCA PBT Rules” was added to note *3, and *4 
Exemption was also added to the table. 
 
 
Table 2-I-17 
・Pentachlorothiophenol (PCTP) was added. 
 
 
Table 2-I-18 
・Hexachlorobutadiene (HCBD) was added. 
 
 
Table 2-I-21 
・The substances in this substance group were 
reviewed. 
 
 
Table 2-I-27 
“Less than 1000 ppm” according to RoHS Directive was 
replaced with “1000 ppm or less”. 
 
 
Table 2-I-28 
・“certain Long-Chain Perfluoroalkyl Carboxylates 
(LCPFAC)” was added. 
・Regarding PFOA, changes were made in response to 
the publication of Official Journals about “Class I 
Specified 
Chemical 
Substances 
designated 
by 
Japanese Chemical Substances Control Act.” and “EU 
POPs regulation”. 
・“Implantable medical devices*2, *5” was deleted from  
191

Ver. 15 
48/57 
[Control Rules for Environment-related Substances Used in Product] 
“Exemption”. 
・Notes *6 and *7 were added. 
 
 
Table 2-I-30 
・“EU POPs regulation” was added to note *1. 
 
 
Table 2-I-32 
・Phenol, Isopropylated Phosphate (3:1) (PIP 3:1) was 
added. 
 
 
Table 2-I-33 
・2,4,6-tris(tert-butyl)phenol (2,4,6-TTBP) was added. 
 
 
Table 3-II-2 
・BPR substances was added to note *1. Explanation 
of the control value of surface coatings was added to 
note *2. 
14 
2020.05.01 
4.1 
Table 1 Environment-related Substances 
“II-2: Substances subject to the European Union’s 
Medical Device Regulation (EU-MDR) or In Vitro 
Diagnostic Medical Device Regulation (EU-IVDR)” was 
added. 
4.2.3 
Table 2-I-1 Cadmium and its compounds 
Table 2-I-2 Hexavalent chromium compounds 
Table 2-I-3 Lead and its compounds 
Table 2-I-4 Mercury and its compounds 
Table 2-I-9 Polybrominated biphenyl (PBBs) 
・The applications that had been classified according 
to the RoHS Directive categories were unified as 
“Electric and electronic equipment subject to RoHS 
Directive (2011/65/EU)” because the RoHS Directive 
entered into force in all the categories on its effective 
date. 
・“Electric and electronic equipment as provided by 
Article 2-2 of RoHS Directive (2011/65/EU)” was 
deleted to reflect the removal of Article 2-2 from the 
RoHS Directive. 
 
Table 2-I-10 Polybrominated diphenyl ethers (PBDEs) 
・The applications were divided into “PBDEs 
excluding DecaBDE” and “DecaBDE only” because 
while PBDEs are regulated by the EU POPs 
regulation, only DecaBDE is controlled by Japanese 
Chemical Substances Control Act. 
 
Table 2-I-14 Substance Group: Short-chained 
chlorinated paraffin (having the chain length of 10 
- 13) 
・The control value is “Intentional inclusion 
prohibited” ,it is controlled by Japanese Chemical 
Substances Control Act. 
 
Table 4-I-24 Fluorinated Greenhouse Gases (PFC, 
SF6, HFC) 
・Regarding the control on these substances, “EC 
No.842/2006” was repealed with the revision of “(EU) 
No. 517/2014”. Accordingly, Table 4-I-24 was updated 
with the addition of several substances. 
 
Table 2-I-26 Perfluorooctanoic acid (PFOA) and its 
salts and esters 
・Level 1: “Norwegian Product Regulations” was 
192

Ver. 15 
49/57 
[Control Rules for Environment-related Substances Used in Product] 
deleted because the same level of control can be 
guaranteed by complying with other applicable laws 
and regulations. 
・Level 2: The control by the REACH was replaced 
with the proposed control by the EU POPs regulation, 
which is set to be published. 
4.2.4 
Table 5-II-2 
“Substances subject to the European Union’s Medical 
Device Regulation (EU-MDR) or In Vitro Diagnostic 
Medical Device Regulation (EU-IVDR)” was added. 
5 
Perfluorooctanoic acid (PFOA) and its salts and esters 
・Some information in Table 2-I-26 was moved to Table 
6-I-26 (where it is now provided as information on 
examples belonging to this substance group). 
・“JAMP-SN0102” and “JAMP-SN0103” were added as 
substances belonging to this substance group. 
 
Short-chained chlorinated paraffin (having the carbon 
chain length of 10 - 13) 
・Some information in Table 2-I-14 was moved to Table 
6-I-14 (where it is now provided as information on 
examples belonging to this substance group). 
・To reflect regulatory information, some substances 
belonging to this substance group were added. 
Pentachlorophenol and its salts and esters 
・To reflect regulatory information, some substances 
belonging to this substance group were added. 
 
Table 6-I-2 Hexavalent chromium compounds 
・Copper chromite (CAS NO.12053-18-8) was deleted 
because it’s a trivalent chromium. 
13 
2018.03.31 
3 
3. Terms and Definitions 
・“CMR substances” was added to explain the new 
prohibited substances. 
・“RoHS2 Directive” was replaced with “RoHS 
Directive (2011/65/EU)” to clearly indicate the 
applicable regulation. 
4.1 
Table 1 Environment-related Substances 
・In keeping with the new regulation, “I-29 Certain 
CMR substances” was added. A note was also added 
to the table, in order to clearly indicate the 
applications of “I-29 Certain CMR substances.” 
4.2.3 
Table 2-I 
･With regard to cadmium, hexavalent chromium, 
lead, mercury, PBB, PBDE and phthalate esters, 
the timing of the application of RoHS Directive was 
incorporated. Accordingly, cadmium, hexavalent 
chromium, lead, mercury, PBB, PBDE are 
categorized as Level 1, and phthalate esters as 
Level 2. 
･With regard to cadmium, hexavalent chromium, 
lead, mercury, PBB, PBDE and phthalate esters, 
“RoHS2 Directive” was replaced with “RoHS 
Directive (2011/65/EU)” to clearly indicate the 
applicable regulation. 
193

Ver. 15 
50/57 
[Control Rules for Environment-related Substances Used in Product] 
・In Europe, all the information contained in Annex 
B, except for “Date of ban on delivery,” is public 
information. Therefore, regarding cadmium, 
hexavalent chromium, lead and mercury, “Annex B” 
was deleted from the “Exemption,” and “Exclusions 
from RoHS Directive: 6 months prior to expiration” 
was added to “Date of ban on delivery.” 
Table 2-I-2 (Hexavalent chromium compounds) 
･The timing of the application of the REACH 
regulation to Level-2 substances was incorporated, 
and the prohibition level was changed to Level 1. 
Table 2-I-25 (Phthalate esters) 
･Regarding “the restriction of plasticized material 
that includes DEHP, BBP, DBP and/or DIBP,” 
which are four substances newly added to Annex 
XVII to REACH (restriction), their effective dates 
of REACH regulation, dates of ban on delivery, 
applications and control values were added to the 
Level-2 boxes. Additional information was also 
provided in “Exemption” and “Note.” 
・Table 2-I-29 (Certain CMR substances) 
This new table was created in keeping with the 
addition of “Certain CMR substances” to Annex 
XVII to REACH (restriction). 
5 
“Table 6-I-29 Certain CMR substances” was added to 
provide examples of arsenic compounds among 
certain CMR substances. 
The sentence of “The table below does not cover all 
the substances in this substance group” was added to 
Tables 6-I-1 - 6-I-29 to clearly indicate that these 
examples are provided for illustrative purposes only. 
12 
2018.06.01 
4.1 
Table 1 (Environment-related Substances) 
・Table 1 I-28: “Benzenamine, N-phenyl-, Reaction 
Products with Styrene and 2,4,4-Trimethylpentene 
(BNST)” was deleted because these substances 
became exempt from the “Prohibition of Certain 
Toxic Substances Regulations, 2012” of Canada. 
4.2.3 
Table 2-I 
･With regard to cadmium, hexavalent chromium, lead, 
mercury, PBB and PBDE, the timing of the 
application of RoHS2 Directive was incorporated. 
Table 2-I-2 (Hexavalent chromium compounds) 
･“Intentional inclusion prohibited” was deleted from 
the Control Value column for Level-1 electric and 
electronic equipment subject to RoHS2 Directive. 
･Regarding the four Level-2 substances that will 
become subject to applicable regulations on 
January 22, 2019 (Annex XIV to REACH), their 
control value was changed to “Intentional inclusion 
prohibited.” 
Table 2-I-10 (PBDEs) 
･“Annex XVII to REACH (restriction)” was added. 
Table 2-I-12 (PCTs) 
･“Intentional inclusion prohibited” was deleted from 
the Control Value column, and “mixture” was 
replaced with “mixture or finished product.” 
194

Ver. 15 
51/57 
[Control Rules for Environment-related Substances Used in Product] 
Table 2-I-20 (PFOS and PFOS analogs) 
･The Exemption row was deleted to reflect the 
review of exemption from “Class I Specified 
Chemical Substances designated by Japanese 
Chemical Substances Control Act.” 
Table 2-I-26 (PFOA and its salts and esters) 
･“Annex XVII to REACH (restriction)” was added. 
Table 2-I-28 (BNST) was deleted. 
Table 6-I-5 (Trisubstituted organotin compounds) 
･“JAMP-SN0024” was added in the CAS No. or 
JAMP-SN column. 
Table 6-I-6 (Dibutyltin compounds) 
･“JAMP-SN0072” was added in the CAS No. or 
JAMP-SN column. 
Table 6-I-7 (Dioctyltin compounds) 
･“JAMP-SN0073” was added in the CAS No. or 
JAMP-SN column. 
Table 6-I-10 (PBDEs) 
･In the Substance (Japanese) column, “PBDE 類” 
was spelled out as “ポリ臭化ジフェニルエーテル類” 
in keeping with the use of unabbreviated names for 
PBBs. 
Tabl 6-I-17 (Asbestos) 
･“JAMP-SN0056” was added in the CAS No. or 
JAMP-SN column. 
Table 6-I-28 (BNST) was deleted because these 
substances became exempt from the “Prohibition of 
Certain Toxic Substances Regulations, 2012” of 
Canada. 
11 
2017.04.01 
4.2.3 
Table 2-I: With regard to cadmium, hexavalent 
chromium, lead, mercury, PBB and PBDE, 
incorporated the timing of the application of 
RoHS2 Directive. 
Table 2-I-2 (Hexavalent chromium compounds): The 
prohibition level of nine hexavalent chromium 
compounds was changed from 2 to 1. 
Table 
2-I-13 
(Polychlorinated 
naphthalene): 
The 
information on “2 chlorine atoms” was integrated with 
that on “3 or more chlorine atoms”. 
10 
2016.04.04 
4.1 
・The number of chlorine atoms of polychlorinated 
naphthalene was changed from 3 or more to 2 or more. 
・“and 
its 
salts 
and 
esters” 
was 
added 
to 
perfluorooctanoic acid (PFOA), which was also added 
to the relevant parts in other pages. 
・I-29: “Pentachlorophenol and its salts and esters” 
was added. 
4.3 
In Table 2-I-13 (Polychlorinated naphthalene) , 
・The number of chlorine atoms of polychlorinated 
naphthalene was changed from 3 or more to 2 or more. 
In Table 2-I-14 (Short-chained chlorinated paraffin), 
・*1: (EC)No.850/2004 was added to EU POPs 
regulation 
・*2: Norwegian Product Regulations was deleted. 
195

Ver. 15 
52/57 
[Control Rules for Environment-related Substances Used in Product] 
・From the examples of substances listed in Table 6-1-
14, only chlorinated paraffins (short chain) (number of 
carbon from 10 to 13) was added. 
In Table 2-I-16 (hexabromocyclododecane), 
・EU POPs regulation (EC)No.850/2004 was added to 
Note *1. 
In Table 2-I-25 (Phthalate esters), 
・Categories” was deleted from the RoHS directive 
categories for level 2 applications. 
・In Note *3, TBT notification was replaced with. 
(EU)2015/863. 
In Table 2-I-18 (BNST), 
・Under Applications, description was changed to 
incorporate the exemption. 
・In the note, the name of regulation was changed to 
Canadian Prohibition of Certain Toxic Substances 
Regulations, 2012. 
Table 2-I-29 (Pentachlorophenol) was added. 
In Table 3-I-19 (Ozone depleting substances), 
・Under Chemical formula, chemical formula was 
added to a blank field. 
In Table 6-1-9 (PBBs), 
・Under Chemical formula, chemical formula was 
added to a blank field. 
In Table 6-I-14 (Short-chained chlorinated paraffin), 
・The examples of substances were removed and were 
incorporated into Table 2-I-14 as reference. 
9 
2015.06.05 
3 
Definition of terms: “preparation” was replaced 
with “mixture”.  
4.1 
Table 1, I-28: “Benzenamine, N-phenyl-, Reaction 
Products with Styrene and 2,4,4-Trimethylpentene 
(BNST)” was added. 
4.2.3 
Table 2-I: With regard to cadmium, hexavalent 
chromium, lead, mercury, PBB, and PBDE, 
incorporated the timing of the adoption of 
RoHS2 Directive. 
Table 2-I-2: The regulation on leather products was 
added to hexavalent chromium.  
Table 2-I-6: The exemptions for dibutyltin 
compounds were removed. 
Table 2-I-25, Phthalate esters: Removed the 
Danish regulation, and addressed the official 
publication that has added prohibited substances to 
RoHS2. 
Table 2-I-28: “Benzenamine, N-phenyl-, Reaction 
Products with Styrene and 2,4,4-Trimethylpentene 
(BNST)” was added. 
REACH Regulation: Added SVHC as examples to 
the corresponding substance tables, and 
reviewed descriptions.  
8 
2014.02.20 
4.1 
Table 1: “I-26 Perfluorooctanoic acid (PFOA)” and “I-
196

Ver. 15 
53/57 
[Control Rules for Environment-related Substances Used in Product] 
27 Polycyclic aromatic hydrocarbon (PAH)” were 
added. 
4.2.3 
“In some cases, business units set their own dates on 
ban on delivery that are different from the ones 
herein. These dates set by business units take 
precedence over the ones herein” was added.  
Table 2: “Intentional use prohibited” was replaced 
with “intentional inclusion prohibited” in each table. 
“If the Control Value column lists “intentional 
inclusion prohibited” and the control value, both of 
these requirements must be fulfilled” was also added. 
“Intentional use prohibited” was deleted from Table 2 
for cadmium, lead, dioctyltin, nickel, and azo 
compounds. The denominators as the standard for the 
control values were defined. 
In Table 2-I-16, Level 1 was established in accordance 
with Japanese Chemical Substances Control Act., and 
applicable substances were added. 
In Table 2-I-24, the applications of PFC were defined. 
2, 6 
Tables 2 and 6 were revised in accordance with the 
JAMP－AIS format. 
7 
2013.09.05 
4.2.3 
In Table 2-I-6, “Intentional use prohibited” was 
deleted. 
In Table 2-I-18, date of ban on delivery at Level 2 was 
corrected. 
6 
2013.05.17 
2 
・The code for RoHS2 was corrected: 2010/65/EU ⇒ 
2011/65/EU 
・Substance names followed the spelling used by 
JAMP. 
・Regarding the control on phthalate esters in 
Demark, it was difficult to impose a ban on delivery 
six months before the deadline of December 2013. 
Therefore, a date three months before was set as 
the date of the ban on delivery. As for products 
subject to RoHS2, a date 12 months before was set 
as the date of ban on delivery, mainly because of the 
amount of inventory on the market. 
5 
2012.06.12 
3 
The explanations on the terms (a), (b) and (c) under 
(1) Environment-related substances were repeated in 
Section 4.2.1.  For this reason, these explanations 
were deleted from the Terms and Definitions section. 
3 
(14) Intentionally added, (15) Impurities, (16) 
Preparation and (17) Article were added. 
4.1 
Table 1 was reviewed and the following changes were 
made: 
(I) Prohibited substances 
TBTO was included into trisubstituted organotin 
compounds. 
Radioactive substances, acrylamide and musk xylene 
were deleted, and hexabromocyclododecane was 
added. 
(II) Controlled substances 
Antimony, arsenic, beryllium, bismuth, selenium, 
brominated flame retardants (except prohibited 
substances), perchlorates, phthalate esters (except 
197

Ver. 15 
54/57 
[Control Rules for Environment-related Substances Used in Product] 
prohibited substances) and PRTR substances were 
deleted. 
2.3 
In Section 4.2.3, “Detailed information about the 
control of prohibited substances,” a separate table was 
made for each prohibited substance group. 
“Intentionally added” was added to the control value 
column. Prohibited substances were reviewed and 
their substance groups were renumbered. 
4.2.3 
“I-19 Ozone depleting substances” were extracted 
from the examples and separately presented as Table 
3. 
4.2.3 
In Table 3, because the CAS number for 
Tribromodifluoroethane, 128903-21-9, was an error in 
writing, it was replaced with “-”. 
4.2.3 
“I-24 Fluorinated greenhouse gasses (PFC, SF6, 
HFC)” were extracted from the examples and 
separately presented as Table 4. 
4.2.4 
Section 4.2.4 on controlled substances was devoted to 
substances of very high concern in REACH (SVHC). 
5 
Examples and principal uses were listed for each 
substance. 
4 
2011.07.22 
All 
 
・REACH Regulation Annex 16: Addressed 6 
substances added to "Approved Substances" and 7 
substances added to the "List of Candidate 
Substances for Approval". 
・REACH Regulation Annex 17: Addressed additions 
to "Limited Substances", and confirmed/revised 
exemptions. 
・Incorporated the latest information from JIG (Joint 
Industry Guidelines) Ver4.0 and JAMP. 
・Revised description to make it easier to understand. 
Corrected table errors. 
3 
2011.03.04 
2 
Scope has been amended to “Olympus” and “These 
rules apply to domestic Olympus, OGZ, OSZ and OPI. 
Products manufactured and sold in other regions 
shall be subject to these rules” has been deleted. 
8 substances of Very High Concern have been added 
to Table 5 and Table 6. 
2 
2010.12.17 
2 
”Dibutyltin compounds (DBT), Dioctyltin compounds 
(DOT), Nickel, Dimethylfumarate (DMF), Fluorinated 
Greenhouse Gases (PFC, SF6, HFC), partial 
phthalate esters” have been added as “Prohibited 
substances”. 
“Perchlorates” has been added as “Controlled 
substances”. 
“Tributyltin (TBTs), Triphenyltin (TPTs)” has been 
amended to “Trisubstituted organotin compounds”. 
All 
"Products used for sales promotion" has been added in 
2.1 Applicable items. 
Exclusions from RoHS Directive was revised under 
Commission Decision 2009/425/EC. 
Table 6: Examples of environment-related substances 
was revised by reference to JIG-101Ed3.1 
Versions 
before 2 
December 2010: 
Revisions of REACH ANNEX 14 (candidate substances for approval) were 
accepted, "Hexabromocyclododecane (HBCDD)" and "Musk xylene" were newly added 
198

Ver. 15 
55/57 
[Control Rules for Environment-related Substances Used in Product] 
as "prohibited substances", and the prohibited usage and thresholds were reviewed 
for "Azo dyes and pigments (specific amines formed by degrading azo dies and 
pigments)" and "Phthalate esters". 
Revisions of REACH ANNEX 17 (limited substances) were accepted, and 
"Acrylamide" was made a "prohibited substance". 
August 2010: 
Examples of environment-related substances in Table 6 were revised by reference 
to JIG-101Ed3.1. This revision included the addition of substances and name 
changes. 
October 2009: 
“Formaldehyde” was classified as a “prohibited substance” according to the 
regulations of various countries as well as social needs. 
June 2009: 
Directive 76/769/EEC (on restrictions on the marketing and use of certain 
dangerous substances and preparations) was repealed with effect. Any amendment 
to the restrictions adopted under Directive 76/769/EEC from June 1, 2007 were 
incorporated in Annex XVII, EC 1907/2006. (Article 137, Article 139 of the REACH) 
October 2008: 
Following the publication of 15 Substances of Very High Concern that were added 
to the candidate list, additional substances were classified as “controlled substances.” 
June 2008: 
The 30th amendment directive (2006/122/EC) concerning Directive 76/769/EEC 
(PFOS and PFOS analogs) came into effect. 
November 2007: 
Specific benzotriazole was designated as a Class I designated chemical substance 
pursuant to a partial amendment of Japanese Chemical Substances Control Act. 
August 2007: 
The Joint Industry Guidelines (JIG) came into force. Therefore, regarding the five 
substances that had been designated under the JGPSS, their designation was 
cancelled and deleted from the list of “prohibited substances.” 
June 2007: 
The REACH came into force. 
 
199

地球温暖化対策計画書
東京都の地球温暖化対策制度に基づき、技術開発センター石川の地球温暖化対策計画書を公開いたします。
地球温暖化対策計画書2020 （PDF形式: 313.1KB）
地球温暖化対策計画書2019 （PDF形式: 293.0KB）
地球温暖化対策計画書2018 （PDF形式: 219.3KB）
地球温暖化対策計画書2017 （PDF形式: 175.3KB）
地球温暖化対策計画書2016 （PDF形式: 170.7KB）
地球温暖化対策計画書2015 （PDF形式: 303.3KB）
200

年度
１　指定地球温暖化対策事業者の概要
 (1)　指定地球温暖化対策事業者及び特定テナント等事業者の氏名
 (2)　指定地球温暖化対策事業所の概要
令和2年4月版.
93,658.41
㎡
㎡
前年度末
前年度末
㎡
㎡
基準年度
㎡
㎡
93,647.50
93,647.50
基準年度
地球温暖化対策計画書
事業の
業　種
氏名（法人にあっては名称）
業務用機械器具製造業
オリンパス株式会社　技術開発センター石川
八王子市石川町２９５１番地
E_製造業
業務用機械器具製造業
E27
㎡
前年度末
前年度末
㎡
前年度末
㎡
基準年度
㎡
㎡
基準年度
㎡
基準年度
㎡
基準年度
オリンパス株式会社
前年度末
㎡
基準年度
93,658.41
㎡
前年度末
㎡
事務所
㎡
㎡
基準年度
㎡
基準年度
㎡
基準年度
㎡
㎡
医
療
文
化
物
流
駐
車
場
基準年度
顕微鏡、内視鏡、カメラの研究、開発事業所
1号棟から6号棟がある。従業員 4800人が就業
48,569.15
基準年度
前年度末
前年度末
工場その他上記以外
前年度末
㎡
前年度末
㎡
前年度末
㎡
事
業
の
概
要
敷
地
面
積
用
途
別
内
訳
事
業
所
の
名
称
事
業
所
の
所
在
地
分類番号
産業分類名
業
種
等
2020
指定地球温暖化対策事業者
又は特定テナント等事業者の別
事業所
の種類
主たる用途
建
物
の
延
べ
面
積
（熱供給事業所にあっては熱供給先面積）
事
務
所
情
報
通
信
放
送
局
商
業
宿
泊
教
育
指定地球温暖化対策事業者
201

１　指定地球温暖化対策事業者の概要
 (1-2)　指定地球温暖化対策事業者及び特定テナント等事業者の氏名
地球温暖化対策計画書
氏名（法人にあっては名称）
指定地球温暖化対策事業者
又は特定テナント等事業者の別
202

(3)　担当部署
 (4)　地球温暖化対策計画書の公表方法
 (5)　指定年度等
年
月
日
２　地球温暖化の対策の推進に関する基本方針
３　地球温暖化の対策の推進体制
計 画 の
担当部署
オリンパス㈱ 八王子事業場人事・総務
042-642-2157
公 表 の
担当部署
名
称
名
称
オリンパス㈱ 八王子事業場人事・総務
042-642-2157
電
話
番
号
等
電
話
番
号
等
年度
入手方法：
オリンパスグループは、経営理念に掲げている「世界の人々の健康と安心、心の豊かさの実現」をすべての活動の基本思想としています。
当社はこの基本思想のもと、人々の安全・健康とそれを支える自然のいとなみを尊重し、製品・サービス、あらゆる事業活動において環境
との調和と、経済を両立した取り組みを通じて、持続的発展が可能な社会と健全な環境の実現に貢献します。
1. 全員参加
従業員一人ひとりが環境活動に対する理解を深め、地域特性を考慮した環境活動に全員参加で取り組みます。
2. 環境経営の推進
グローバルでの体制と仕組みを維持し、環境活動を継続的に改善します。
3. 法規制・社会規範の遵守
環境に関する法令、ステークホルダーとの合意事項や自主基準を確実に遵守します。
4. 環境負荷の低減
汚染
予防
持続的な資源
利用
気候変動
緩和と適応
生物多様性
保護と
た環境課題
解決に向け
製品
サ
ビ
事業活
公表方法
https://www.olympus.co.jp/csr/effort/warming.html?p
アドレス：
1
ホームページで公表
2009
アドレス：
閲覧可能時間
冊子名：
所在地：
窓
口
で
閲
覧
指定地球温暖化対策事業所
年度
特定地球温暖化対策事業所
閲覧場所：
2009
冊
子
そ
の
他
事業所の使用開始年月日
1963
8
203

４　温室効果ガス排出量の削減目標（自動車に係るものを除く。）
 (1)　現在の削減計画期間の削減目標
 (2)　次の削減計画期間以降の削減目標
５　温室効果ガス排出量（自動車に係るものを除く。）
 (1)　温室効果ガス排出量の推移
単位：ｔ（二酸化炭素換算）
(2)　建物の延べ面積当たりの特定温室効果ガス年度排出量の状況
単位：kg（二酸化炭素換算）/㎡・年
計画
期間
削減
目標
削減
義務
の
概要
特
定
温
室
効
果
ガ
ス
40
35
メ
タ
ン
（
CH4
）
一酸化二窒素
（
N2O
）
ﾊｲﾄﾞﾛﾌﾙｵﾛｶｰﾎﾞﾝ
（
HFC
）
特定温室効果ガス
（エネルギー起源CO2）
計画
期間
特
定
温
室
効
果
ガ
ス
削減
目標
設備の効率的運転およびこまめな省エネ活動を実施する。また、エネルギー
部会の各部門推進委員を巻込んで日々の運用実施することにより、削減義務
以上の削減を目指す。
年度
8,319
年度
2016
88.8
97.3
2015
六ふっ化いおう
（
SF6
）
上
水
・
下
水
37
合
計
延べ面積当たり
特定温室効果ガス
年
度
排
出
量
8,357
そ
の
他
ガ
ス
38
ﾊﾟｰﾌﾙｵﾛｶｰﾎﾞﾝ
（
PFC
）
非エネルギー起源
二酸化炭素（CO2）
三ふっ化窒素
（
NF3
）
98.0
9,150
9,335
9,235
98.2
年度
年度
99.3
年度
2017
2018
2019
9,216
51,685
年度まで
27%
Ⅰ－１
ｔ（二酸化炭素
換算）/年
14,159
排出上限量
(削減義務期間合計)
削減義務
率の区分
平均削減
義務率
9,200
年度
年度
2015
2016
2017
9,298
9,113
特定温室効果
ガス以外の
温室効果ガス
2024
2025
2029
年度から
年度から
設備の効率的運転およびこまめな省エネ活動を実施する。また、エネルギー
部会の各部門推進委員を巻込んで日々の運用実施することにより、削減義務
（27％）以上の削減を目指す。
2020
年度まで
ｔ（二酸化炭素
換算）
基準排出量
特定温室効果
ガス以外の
温室効果ガス
37
年度
2018
2019
年度
年度
9,176
204

６　総量削減義務に係る状況（特定地球温暖化対策事業所に該当する場合のみ記載）
 (1)　基準排出量の算定方法
）
）
 (2)　基準排出量の変更
 (3)　削減義務率の区分
 (4)　削減義務期間
 (5)　優良特定地球温暖化対策事業所の認定
 (6)　年度ごとの状況
単位：ｔ（二酸化炭素換算）
 (7)　前年度と比較したときの特定温室効果ガスの排出量に係る増減要因の分析
排出削減量
（F＝A - E）
実
績
4,959
特定温室効果
ガス排出量(E)
4,117
4,861
8,319
9,113
9,298
9,200
具体的な増減要因
・7号棟の1階～4階までの蛍光灯をLED照明に変更(2019年12月～）
・実験増で動力用電気増
・2号棟の厨房設備更新工事で上水、下水、電気、ガス減（2019年2月～3月）
増
減
要
因
削
減
対
策
床
面
積
の
増
減
用
途
変
更
設
備
の
増
減
そ
の
他
削減義務
期間合計
2018 年度
2019 年度
年度
21,975
4,983
3,055
45,106
9,176
14,159
17.00%
67,081
17.00%
14,159
14,159
年度
2017 年度
2018
17.00%
年度
17.00%
2015
年度
過去の実績排出量の
平
均
値
排出標準原単位を
用
い
る
方
法
そ
の
他
特
に
優
れ
た
事業所への認定
年度から
極めて優れた
事業所への認定
削減義務率の区分
基準年度：（
2015
2016
2015
年度まで
55,678
基準排出量
(A)
削減義務率
(B)
2016
2019
2017 年度
Ⅰ－１
算定方法：（
変
更
年
度
年度
決
定
及
び
予
定
の
量
11,374
13,230
17.00%
2019 年度
削減義務量
(D ＝Σ (A × B))
排出上限量
（C＝ΣA-D）
2002年度、2003年度、2004年度
2019 年度
前削減計画期間
2018 年度
○
○
2015 年度
2016 年度
2017 年度
11,403
205

７　温室効果ガス排出量の削減等の措置の計画及び実施状況（自動車に係るものを除く。）
区 分
番 号
区 分 名 称
【特定温室効果ガス排出量の削減の計画及び実施の状況】
1 130200 13_空気調和設備の効率管
理
加湿方式の変更
2015年度
電気蒸気発生器による、空調加湿から滴下式加湿器に変更（14台）7
号棟 169.7Kw×0.1稼働率×8ｈ×60日/日/1000×9.97×0.0258
2 140100 14_給湯設備の管理
給湯設備局所対応
2015年度
2号棟給湯設備局所対応。セントラル方式から局所方式に変更（シャ
ワー室と厨房のみ）　ガス　16,000㎥（32,000/2）
3 150200 15_照明設備の運用管理
照明器具更新
2016年度
ＬＥＤ照明器具へ更新対象設備　：　2号棟全館基本照明器具
1600台×50W×12h×240日＝230,400Kwh
4 150200 15_照明設備の運用管理
照明器具採用
2016年度
新設の6号棟の照明器具は、ＬＥＤを採用
1358台×68.2W×12h×240日=226,733Kwh
5 130300 13_換気設備の運転管理
サーバー室の12台の24時間運転の運転周波
数変更
2018年度
2019.3より実施で実測で2,300kwh/月　削減
6 150200 15_照明設備の運用管理
照明器具更新
2019年度
7号棟の蛍光灯をLED照明に更新した。2020年1月より1,400kwh/月程
削減
7 140100 14_給湯設備の管理
給湯設備局所対応
2019年度
1号棟給湯設備局所対応。セントラル方式から局所式に変更
2020.1より稼働。16t-CO2/年　削減を見込む。
8 329900
32_ボイラー・工業炉・蒸
気系統・熱交換器等に係る
その他の削減対策
セントラルから分離し、専用ボイラー設置
2019年度
第6実験棟用ボイラー設置。配管からの放熱ロス削減を見込む。
2020.1より稼働。 267t-CO2/年　削減を見込む。
9
10
11
12
13
14
15
16
備 考
対策
Ｎｏ
対策の区分
対 策 の 名 称
実 施 時 期
206

７　温室効果ガス排出量の削減等の措置の計画及び実施状況（自動車に係るものを除く。）
区 分
番 号
区 分 名 称
備 考
対策
Ｎｏ
対策の区分
対 策 の 名 称
実 施 時 期
17
18
19
20
　　（再生可能エネルギーの設備導入及び利用の状況）
71
72
73
【その他ガス排出量の削減の計画及び実施の状況（その他ガス削減量を特定温室効果ガスの削減義務に充当する場合のみ記載）】
81
82
83
【排出量取引の計画及び実施の状況】
91
92
93
207

８　事業者として実施した対策の内容及び対策実施状況に関する自己評価（自動車に係るものを除く。）
　従業員の環境に対する意識を向上させるため、以下に取組んでいます。
　　◆　新入社員や、転入者に対する環境教育の実施
　　◆　環境に関するメールニュース(EHSニュース）の発信（12回/年）
　　◆　環境(節電)パトロールの実施（1月）
再エネの導入・利用に関する取組みについて： 今後検討
208

Status of Acquiring ISO14001 Certification in Olympus Group
Since 1998, the Olympus Group has acquired ISO14001 Certification at its main manufacturing facilities and at its distribution and sales subsidiaries on a
site-by-site basis. We started a unified environmental management system for 12 subsidiaries in Japan and Asia in 2018, aiming to strengthen environmental
governance and improve environmental management efficiency, and obtained ISO14001 multi-site certification* in August 2020.
* Integrating multiple ISO 14001 certification at several sites into a single scope of certification.
ISO14001 Multisite Certification
ISO14001:2015
JP19/071613
Olympus Group
Design, development, manufacture, sales and incidental services (repair, maintenance and customer
training) for gastrointestinal endoscopes, surgical endoscopes, endoscopic instruments, ultrasonic
endoscopes and accessories
Design, development, manufacture, sales and incidental services (repair, maintenance and customer
training) for biological microscopes, industrial microscopes, industrial endoscopes, non-destructive
inspection equipment and accessories
Design, development and manufacture of artificial bone, artificial skin and accessories
Sites/Office
Date of Certification
Japan
Olympus Corporation
Headquarters (Shinjuku) *1
August 2020
Sasazuka Facility *2
August 2020
Technology Research Center (Ishikawa)
March 2000
Technology Research Center (Utsugi)
March 2000
Technology Research Center (Takakura)
February 2018
Nagano Facility (Tatsuno)
February 1998
Nagano Facility (Ina)
May 2014
Shirakawa Facility
October 1998
Olympus Medical Systems Corporation
Technology Research Center (Ishikawa)
March 2000 *3
Technology Research Center (Utsugi)
March 2000 *3
Hinode Plant
July 1998
Nagano Olympus Co., Ltd.
February 1998
Aizu Olympus Co., Ltd.
October 1998
Shirakawa Olympus Co., Ltd.
October 1998
Aomori Olympus Co., Ltd.
November 1998
Olympus Terumo Biomaterials Corp.
Mishima Plant
August 2020
ISO standard number
:
Certificate number
:
Company name
:
Scope of registration
: Medical business
:
Science business
:
Biomaterials
business
:
209

R&D Center
Olympus Logitex Co., Ltd.
Distribution Center in Sagamihara
November 2003
Olympus Medical Science Sales Corp.
March 2004
Asia
Olympus (GuangZhou) Industrial Co., Ltd.
October 2004
Olympus Trading (Shanghai) Limited
February 2012
Olympus Vietnam Co.,Ltd.
April 2013
*1 The scope of registration includes the EHS division for Olympus Group and headquarters, and its medical business management functions.
*2 The scope of registration includes the administrative functions at Sasazuka Facility in Tokyo and the customer support for the medical products.
*3 It had been included in the scope of the ISO 14001 certification of Olympus Corporation until March, 2020.
ISO14001 Certification
Sites/Office
Date of Certification
Americas
Olympus Surgical Technologies America National Service Center
December 2005
Olympus Scientific Solutions Americas Corp.
July 2010
Olympus Scientific Solutions Technologies Inc.
July 2010
Olympus NDT Canada Inc.
July 2010
Olympus Corporation of the America
September 2019
Olympus Surgical Technologies America
September 2019
Olympus Respiratory America
September 2019
Europe/Middle East
Olympus Winter & Ibe GmbH
May 2001
KeyMed (Medical & Industrial Equipment) Ltd.
March 2002
KeyMed (Ireland) Ltd.
March 2002
Algram Group Ltd
January 2007
Medical Physics International Limited
October 2012
Olympus Iberia S.A.U.
September 2018
Oceania
Olympus Australia Pty Ltd
August 2017
Olympus New Zealand Limited
August 2017
* For inquiries about certificates, please contact each company.
As of July, 2021
Center Valley Pennsylvania Regional Headquarters
Breinigsville Pennsylvania Distribution Center
Bartlett Tennessee Manufacturing Facility
Brooklyn Park Minnesota Manufacturing Facility
Norwalk Ohio Manufacturing Facility
Redmond Washington Manufacturing Facility
210

Green Procurement
Olympus published its approach to environmental activities as the Olympus Group Green Procurement Standard and distributed the Standard to all
suppliers. We also continuously improve the environmental initiative contents working together with our suppliers through surveys covering their
environmental management systems and activities.
Olympus Group Green Procurement Standard (Japanese, English, Simplified
Chinese)
Green Procurement Standard Ver.6.0
Japanese (PDF: 176.2KB)
English (PDF: 143.2KB)
Simplified Chinese (PDF: 216.6KB)
Control of Chemical Substances Used in Products
211

Olympus Group 
Green Procurement Standard 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
September 1, 2021   Ver. 6.0 
 
 
212

Index 
1.  Introduction                  …………………………………………  2 
2.  Purpose                   …………………………………………  3 
3.  Scope of Application              …………………………………………   3 
4.  Olympus Group Green Procurement Standard ………………………………………  3 
1)  Selection of suppliers 
2)  Mutual cooperation 
5.  Requests to Suppliers             ………………………………………………  4 
5.1 Management of Environment-related Substances 
1)  Compliance with Olympus Group Management Rule on  
environment-related substances 
2)  Maintenance of system for managing environment-related substances 
3)  Submission of data for environment-related substances 
5.2 Compliance with Laws and Regulations Relating to Energy Conservation,  
Resource Conservation and Recycling 
5.3 Cooperation concerning reduction activities of CO2 emissions and water use 
6.  Contact for Enquiry on This Standard   ………………………………………………  5 
 
 
 
 
 
 
 
 
 
 
213

1.  Introduction 
In Olympus Group, we established “Olympus Group Environment Policy” in August, 1992 (which 
was revised in July, 2018) to clearly state the basic stance on environmental issues as a corporate 
citizen, thus leading it to specific activities. This Environment Policy was then converted into the 
Environmental Health and Safety Policy in April 2021, by incorporating environmental health and safety 
policies to comprehensively manage our EHS activities, and we have been promoting business 
activities considering the environment health and safety related issues. 
 
＜Environmental Health and Safety Policy ＞ 
All our activities are based on our corporate philosophy, "Making people's lives healthier, safer and 
more fulfilling." Following this philosophy, the Olympus Group respects people’s security and health 
and the natural mechanisms that realize this. We will contribute to the realization of a sustainable 
society by working to harmony with the environment and keep employees’ security and health. 
 
1.  Continual Improvement of Environmental Health and Safety Activities 
We will maintain the environmental health and safety management system and 
mechanism on a global scale and monitor the progress of environmental health 
and safety activities regularly so that we can continuously improve our 
environmental health and safety performance. 
 
2.  Compliance with Laws, Regulations, and Social Norms 
We will fully comply with the laws and regulations, agreements with our 
stakeholders, and our voluntary standards in respect to the environment, health 
and safety. 
 
3.  Reduction of Environmental Impact 
Toward the solution of environmental issues, prevention of pollution, sustainable 
resource use, climate change mitigation and adaptation, and protection of 
biodiversity, we will reduce environmental impact through all business activities 
from research, development, design, procurement, production, logistics, sales and 
repair. 
 
4.  Keeping safety and health 
We will keep a safe and hygienic work environment by taking measures to eliminate 
and reduce safety and health risk factors based on the risk assessments. 
 
5.  Attributing Importance to Communication 
We will ensure transparency and reliability in dispatch of information about 
environmental safety and health activities, deepen mutual understanding with our 
stakeholders, and promote activities for solving environmental safety and health 
214

issues in cooperation with each other. 
 
In recent years, the concern about the earth environment has become increasingly stronger. With 
an aim of resolving the global environmental issues such as climate change, resource depletion, 
control of environment-related substances, etc., we strengthened our environmental activities in the 
total product life cycle from manufacturing of raw materials to parts production, product production, 
distribution, use of products and further to disposal of products. 
 
In order to reduce the environmental burdens in the total product life cycle in Olympus Group, it is 
indispensable to have understanding and cooperation of suppliers.  We would like to contribute to 
realization of the society where sustainable development is possible by creating the products with 
reduced environmental burdens together with suppliers, for which we rely on your cooperation.  
                   Environment Health Safety, Global 
                 Olympus Corporation 
 
2.  Purpose  
This standard has been established to promote, in collaboration with environmentally conscious 
suppliers, activities that use materials that have a minimal environmental impact in an effort to 
promote environmentally responsible production and to contribute to the creation of a sustainable 
society 
 
3.  Scope of Application  
This standard applies to green procurement activities by the Olympus Group with   respect to 
product-related materials. The following items are collectively referred to as product-related 
materials:  
(1)  Raw materials, auxiliary materials, components and subassemblies to be used for the 
manufacturing of products; 
(2)  The products themselves, as well as their packaging materials and related accessories;  
(3)  Dies, machinery, jigs and tools, which could cause environment-related substances to attach, 
travel, scatter or fall onto any of the items listed in (1) and (2) above;   
(4)  Dies, machinery, jigs and tools for production which are exported from Japan to Europe; and, 
(5)  Jigs and tools to be used for repairs and servicing.   
 
4.  Olympus Group Green Procurement Standard 
1)  Selection of suppliers 
In selecting suppliers, in addition to quality, price, delivery time, service, technical capabilities 
and legislation/social norms, the transaction with suppliers who are working enthusiastically on 
the following environment protection activities is given priority.  In this connection, we 
recommend suppliers that the environment management system (EMS) such as ISO14001 is 
obtained.  
215

(1) Suppliers which have put in place environment protection policies and a control structure   
that ensures the appropriate management thereof;   
(2) Suppliers which disseminate information and administer education on the topic of 
environmental protection to employees;  
(3) Suppliers which have a good grasp of the applicable environment-related laws and regulations 
of the countries and regions in which they do business; 
(4) Suppliers which have a quantitative grasp on their CO2 emissions and water use, and have 
rolled out actions to achieve reductions in them;  
(5) Suppliers which have a quantitative grasp on the amount of waste material they discard and 
have rolled out actions to achieve reductions in this amount; 
(6) Suppliers which have established standards and rules for the management of chemical 
substances in line with the Olympus Group Control Rules for Environment-related Substances 
Used in Product and the relevant national laws and regulations, and have a management 
system in place to maintain these standards and rules. 
2)  Mutual cooperation 
In Olympus Group, while we request suppliers to comply with the green procurement standard, 
we will also take actions which will bring advantages to both by supporting suppliers upon 
request and strengthening mutual cooperation.   
 
5.  Requests to Suppliers 
In Olympus Group, we ask suppliers to approach the following issues to observe the green 
procurement standard.  
 5.1 Management of Environment-related Substances 
1) Compliance with the Olympus Group Control Rules for Environment-related Substances Used in 
Product  
We would like to ask suppliers to observe the management standard of environment-related 
substances as specified in the Olympus Group Control Rules for Environment-related 
Substances Used in Product distributed separately.  
 
2) Maintenance of system for managing environment-related substances   
To ensure suppliers’ compliance with the Management Rule on Environment-related 
Substances in Products, suppliers are kindly requested to implement a mechanism for an 
environment-related chemical substance management structure, as set forth in JIS Z7201 
Management of Chemical Substances in Products – Principles and Guidelines. 
  
3) Submission of data for environment-related substances 
In Olympus Group, we are asking suppliers to provide the information on use/non-use of 
environment-related substances and its content, Certificate of Non-Use, etc., to ensure that the 
procured items conform to the Olympus Group Control Rules for Environment-related 
Substances Used in Product.  As details will be given from our contact window, submission 
216

within the time limit is cordially requested.  
5.2 Compliance with Laws and Regulations Relating to Energy Conservation, Resource Conservation 
and Recycling  
Olympus asks for its suppliers’ cooperation in reducing environmental impacts through their full 
compliance with the laws and regulations relating to energy and resource conservation and 
recycling, in addition to the requests made by Olympus. 
 
 5.3 Cooperation concerning reduction activities of CO2 emissions and water use 
We in Olympus Group would like to strive for reducing CO2 emission and water use in the total 
life cycle of products together with suppliers with an aim of realizing the society where sustainable 
development is possible. As we may ask for survey etc. to grasp the volume of CO2 emission and 
water use, please cooperate with us in such a case. 
 
6. Contact for Enquiry on This Standard 
Please contact the department in charge of distributing this standard.  
217

Human Rights Policy
At Olympus Group (hereinafter referred to as "Olympus"), we define "Our Purpose" as "Making people's lives healthier, safer and more fulfilling." In order to
achieve this, we seek to build this Purpose into all of our activities. This commitment is one that extends to all of our employees, and we encourage our third-
parties and whoever engages in activities on our behalf and whose services or products we use, including our suppliers and our clients and users of our
products and services, to abide by the same commitment as well. We believe that we need to be ever conscious of this commitment and to be transparent
about our efforts.
Since people's understanding and sense of values in relation to human rights and social norms evolve as society develops and changes, we seek to
understand and adapt our activities as needed. We will continue to support the well-being of the people around the world through our business and other
pursuits, continuously working to identify, prevent, mitigate and account for how we address any adverse human rights risks and impacts in our activities,
including in our supply chains, and to adapt ourselves appropriately to the evolution of standards and norms.
Olympus commitment to respect Human Rights
Olympus established a set of five core values* which shall guide us in "Making people's lives healthier, safer and more fulfilling." Known as "Our Core
Values," these values are shared and put into practice across the company. Among them, we consider the values of Integrity ("We are trustworthy and act in
good faith") and Empathy ("We care about all of our stakeholders") as integral to our company's responsibility to respect for human rights. We believe that
sharing and practicing these values at all levels of the company creates an environment of respect for human rights among all those associated with
Olympus.
* Integrity, Empathy, Long-term View, Agility, Unity
Olympus commits to respect all Human Rights and supports the following international human rights standards and promises unwavering respect for them in
managing our group and daily business.
Olympus commits to proactively avoid causing or contributing to adverse human rights impacts and to address such impacts when they occur. The company
also strives to identify, prevent or mitigate adverse human rights impacts directly linked with our operations and business activities.
Guided by the United Nations Guiding Principles on Business and Human Rights, Olympus will establish human rights due diligence systems and processes
designed to support ongoing identification and monitoring of potential impact of our business activities on human rights and appropriately address any
identified challenges. We will seek guidance from stakeholders and experts to support continuous improvement in alignment with the expectations for global
companies.
Olympus commits to continually update its human rights approach, and to use due diligence and monitoring for continuous improvement.
As a global business and as stated in our Global Code of Conduct, we promise to observe the human rights laws and regulations of the countries/regions
where we operate, and where there are inconsistencies between the local and the international norms or where local laws and regulations may be less
stringent than international human rights standards, the international norms, where stronger, will be followed.
Scope of application
Universal Declaration of Human Rights
International Covenant on Civil and Political Rights
International Covenant on Economic, Social and Cultural Rights
ILO Declaration on Fundamental Principles and Rights at Work
United Nations Guiding Principles on Business and Human Rights
The Ten Principles of the UN Global Compact
OECD Guidelines for Multinational Enterprises
218

This policy is applicable to all officers, executives and employees of the Olympus Group.
Third-parties associated with Olympus are also expected to follow the policy. We seek their understanding and support, as well their help to improve it.
Assessing, avoiding and mitigating negative impacts on human rights
We will work to regularly assess potential impacts on human rights in all of our business activities, identify areas of concern and act appropriately to prevent
or mitigate them. We will create and execute a plan in line with due diligence procedures suggested in the United Nations Guiding Principles on Business
and Human Rights.
Remediation, correction and prevention
Should we become aware of a situation where we believe appropriate standards are not being met, we will work to provide appropriate remediation for those
affected, in line with the United Nations Guiding Principles on Business and Human Rights. We will also work to determine the cause of the problem and take
action to support meaningful reforms.
Raising awareness and promoting behavior that respects human rights
To promote recognition and respect of human rights and human well-being we will work to continuously encourage awareness and correct behavior by all
officers and employees of all of Olympus. We believe our corporate philosophy, consisting of Our Purpose and Our Core Values, provides a strong
foundation for understanding and practicing genuine support of human rights values.
Because we recognize that consistent understanding plays a pivotal role in this process and supports implementation of our commitments, we will regularly
provide education and communication to our employees as well as to our third-parties that will serve to assure that expectations are clearly understood by
all.
Stakeholder engagement and dialogue
We will regularly communicate with external organizations, and engage in meaningful consultation with potentially affected groups and other relevant
stakeholders or their representative organizations, as well as independent experts with knowledge of human rights risks globally to ensure that we
understand rightsholders concerns and are aware of new trends and challenges so that we can anticipate and proactively address emergent risks that could
impact our business and third parties.
Information disclosure
We will periodically report on the results of our human rights risk mitigation efforts, through relevant channels such as our website.
Whistleblowing System
Olympus Global Code of Conduct
Global Standards: What Olympus Expects of Third Parties
219

Olympus Group Quality Policy
The Olympus Group will pursue value that is genuinely wanted by our customers, act with the utmost focus on quality and will
sustainably deliver safe products and services that are useful to society.
To this end, the Olympus Group will continue to maintain and improve the effectiveness of its quality management system in full
conformance with regulatory requirements.
Guiding principles for ensuring the utmost focus on quality
1. Customer-centric approach
We will keep our customers and patients in mind, fully focus on their safety and need, and act in a sincere manner.
2. Ensuring compliance with laws, regulations and social norms
We will strive to fully and correctly understand and comply with all relevant laws, regulations and social norms, as this understanding and
compliance forms the foundation for the delivery of safe, reliable products and services to our customers and patients.
3. Constant quest for quality
We will never be content with the status quo when it comes to the quality of all relevant business processes, which will boost the safety and quality
of our products and services.
4. Appropriate communication
We will provide useful and accurate information in an appropriate manner to our customers and patients in order to ensure their safety and peace of
mind.
220

Supply Chain Policy of Olympus Group
All activities of Olympus group (hereinafter referred to as Olympus) are based on our corporate philosophy, "Making people's lives healthier, safer
and more fulfilling". Following this philosophy, we contribute to the development of a sustainable society through our ESG (Environment, Society,
and Governance) initiatives. Also, this document stipulates the way in which we will procure the materials and services necessary for our business
activities.
1. Compliance with Laws, Regulations, Ethics and Social Norms
Olympus complies with applicable laws, regulations, ethics, and social norms (those concerning the respect for human rights including the prohibition of child
labor, forced labor, and anti-corruption). We take due care of labor environment, safety and health of workers, and Olympus carries out corporate activities in
a sound and fair manner. We ask that suppliers of the materials and services do the same.
2. Promotion of Business Activities in consideration of the Environment
Olympus recognizes the importance of various environmental issues such as climatic changes, and establishes "Olympus Group Environmental Policy" and
"Olympus Green Procurement Standard". In conducting its business activities, we endeavor to realize a human society that has a sound environment and
that is capable of sustainable development in consideration of the environment. We ask the suppliers to do the same.
3. Promotion of Fair and Impartial Trade:
Olympus opens its doors to current suppliers and future suppliers all over the world, and engages in fair and impartial trade in accordance with established
policies and procedures.
4. Selection of Suppliers and Management System:
Olympus selects suppliers based on the key elements of a comprehensive decision process which are the management compliance with laws, regulations,
ethics, and social norms, environmental considerations, quality & safety assurance and a stable supply, management stability, technical capabilities, security
of information, respect for the intellectual property of other parties, compliance with the designated delivery date and appropriate pricing. We also evaluate
periodically by management indexes, quality, price, and service, in addition accurately understanding of the importance and obeying compliance with the
laws, regulations, ethics and social norms that we added into our evaluation criteria definition.
5. Reinforcement of Partnership with Suppliers
Olympus endeavors to establish and maintain a relationship of trust with our suppliers based on mutual understanding.
6.	Prohibition on Accepting Personal Interests:
Olympus prohibits its employees from accepting any improper personal gifts, benefits or entertainment from suppliers.
221

Request to Suppliers
Olympus utilises various materials and services necessary for its production activities from corporations in many countries and regions around the world. We
would like all suppliers to Olympus to note and follow the important points described below.
1. Compliance with Laws, Regulations, and Social Norms
Olympus aims to provide its customers with products that fully meet or exceed their expectations. In doing so, we discipline ourselves to comply with the
laws, regulations, and social norms of the countries and regions of the world in which we operate (specifically including laws, standards, or conventions
concerning the prohibition of forced labor and child labor, prohibition of discrimination based on unreasonable grounds, anti-corruption, laws regarding
appropriate wages and working hours, and maintenance of safe and clean working environments), carry out sound corporate activities and behave in a
manner that is in accordance with laws, regulations, and social norms. As noted below, we would therefore expect our suppliers to do the same in those
countries and regions where you operate and to execute the appropriate management necessary to comply with this requirement.
2. Health & Safety
Suppliers are asked to ensure health and safety in the workplace (including equipment and facilities), work to track industrial accidents and illness, build a
system and framework for emergency response, and properly manage the health of their employees.
3. Fair and Impartial Trade
Olympus opens its doors wide to suppliers who can develop mutual understanding and trust. We carry out fair and appropriate procurement activities based
on our policies and procedures disclosed to the suppliers. Suppliers are also requested to follow our policies and procedures.
4. Ensuring Quality and Safety, Delivery, Fair Pricing, and Stable Supply
Products, parts, and raw materials provided by our suppliers have an enormous impact on Olympus. Suppliers are asked to provide products, parts, and raw
materials that meet Olympus specifications and quality standards, while complying with delivery dates and providing fair prices.
5. Environmental Considerations
Olympus takes the protection of the global environment as one of its critical management tasks, and strives to contribute to the development of a sustainable
society by delivering environmentally conscious products to consumers. To this end, suppliers must manage the parts and raw materials that constitute our
products at their source, including in their procurement activities and production processes. We would like you to promote the following biodiversity and other
environmental protection activities so that together, we can create products that are not harmful to the global environment.
6. Ensuring Information Security and the Appropriate Protection of Information
With respect to trade with Olympus, suppliers can access and obtain Olympus' corporate information, such as its know-how or classified information, as well
as the classified or private information Olympus has on others. You are requested to strictly safeguard the information you have accessed through your
business dealings with us to prevent any leak or disclosure to unauthorized personnel or outside parties. Suppliers are also asked to implement measures to
combat computer viruses, and to manage such measures so as to prevent causing harm either internally or to other companies.
222

7. Promoting Social Contributions
Companies must grow sustainably with society. To this end, we ask that our suppliers determine what is feasible for each of you, and be proactive in your
initiatives to contribute to both the global and your local communities. These initiatives may involve contributions using your primary business or
technologies, non-monetary contributions utilizing your facilities or personnel, monetary donations, and others.
8. Promoting CSR Activities Internally and Among Suppliers
We ask that our suppliers have a correct understanding of the importance of CSR, and work to promote CSR activities both internally and among your own
suppliers.
Request to Suppliers (English version) (PDF: 248.1KB)
Request to Suppliers (Chinese version) (PDF: 276.6KB)
223

作成日：2011/４1  
訂番：01 
 
 
 
 
 
Olympus Group 
 
Request to Suppliers 
 
 
 
224

作成日：2011/４1  
訂番：01 
- 1 -
１． 
Compliance 
with Laws,  
Regulations, 
and Social 
Norms 
Olympus aims to provide its customers with products that fully meet or exceed their 
expectations. In doing so, we discipline ourselves to comply with the laws, regulations, 
and social norms of the countries and regions of the world in which we operate 
(specifically including laws, standards, or conventions concerning the prohibition of 
forced labor and child labor, prohibition of discrimination based on unreasonable 
grounds, anti-corruption, laws regarding appropriate wages and working hours, and 
maintenance of safe and clean working environments), carry out sound corporate 
activities and behave in a manner that is in accordance with laws, regulations, and 
social norms. As noted below, we would therefore expect our suppliers to do the same 
in those countries and regions where you operate and to execute the appropriate 
management necessary to comply with this requirement. 
1) Prohibition of 
forced labor 
- All employees shall be employed of their own free will, and no 
employee shall be forced into labor. 
2) Prohibition of 
inhumane 
treatment 
- The human rights of employees shall be respected, and cruel and 
inhumane treatment, including all forms of abuse and harassment 
shall be prohibited. 
3) Prohibition of 
child labor 
 
- Children below minimum working age shall not be employed, nor 
shall children be forced into work which would impair their 
development. 
In general terms, child labor shall refer to employment of those 
below the minimum working age as set forth under the terms and 
recommendations of the International Labour Organization (ILO), 
or that neglects to protect the welfare of young workers. 
4) Prohibition of  
discrimination 
 
- Suppliers shall work to eliminate discrimination in recruiting and 
hiring, and to achieve fairness in providing equal opportunity and 
treatment. 
Discrimination refers to establishing differences in opportunities 
and treatment in hiring, promotion, compensation, training, and 
other areas based on other than legitimate factors such as an 
individual’s abilities, suitability, performance, etc.  
5) Adequate 
wages 
- Employees shall be paid at least the legally mandated minimum 
wage, and wages shall not be unfairly reduced. 
6) Working hours 
- Employee working hours, holidays, and breaks shall be 
appropriately managed to ensure hours do not exceed legally 
established limits. 
7) Employee right 
to organize 
- Employee right to organize shall be respected as a means of 
enabling labor/management consultation regarding the working 
environment, wage levels, and other issues.  
8) Exclusion of 
anti-social 
forces  
- Suppliers 
shall 
work 
to 
exclude 
anti-social 
forces 
and 
organizations that pose a threat to the order and security of civil 
society and sever all relations with such individuals and groups. 
225

作成日：2011/４1  
訂番：01 
- 2 -
２． 
Health & Safety 
Suppliers are asked to ensure health and safety in the workplace (including 
equipment and facilities), work to track industrial accidents and illness, build a system 
and framework for emergency response, and properly manage the health of their 
employees. 
1) Workplace 
health and 
safety 
- Assess risks associated with workplace safety, and ensure safety 
through appropriate design, technology, and management 
methods. 
- Track exposure in the workplace to substances and chemicals 
harmful to humans, as well as to unwanted noise, odors, etc., and 
take appropriate steps to deal with same. 
2) Equipment and 
machinery 
safety 
measures 
- Take appropriate safety measures for use of supplier’s own 
equipment and machinery to prevent workplace accidents and 
health problems  
3) Industrial 
accidents/ 
illness 
- Track the status of industrial accidents and illness, and take 
appropriate steps to deal with same. 
4) Emergency 
response 
- To protect the safety of life and limb, prepare an emergency 
response to all envisioned disasters, accidents, etc., and ensure 
they are thoroughly communicated in the workplace. 
5) Concern for 
physically 
demanding 
labor 
- Identify physically demanding tasks (to include, in addition to 
heavy labor, repetitive or continuous tasks carried out over a long 
period of time, such as assembly work, data entry, etc.), and 
manage same appropriately to ensure they do not lead to 
industrial accidents and/or illness. 
6) Facility health 
and safety 
- Ensure an appropriate level of health and safety in facilities 
provided for employees (including dormitories, cafeterias, toilets, 
etc.). 
7) Management of 
employee 
health 
- Provide appropriate health management for all employees, 
including medical examinations, disease prevention, and mental 
health care. 
３． 
Fair and 
Impartial Trade 
Olympus opens its doors wide to suppliers who can develop mutual understanding and 
trust. We carry out fair and appropriate procurement activities based on our policies and 
procedures disclosed to the suppliers. Suppliers are also requested to follow our policies 
and procedures. 
1) Prohibition of  
corruption and 
bribery 
- Suppliers shall maintain constructive, legitimate relationships with 
politics and government, and shall not engage in bribery, illegal 
political donations, or other such acts. 
2) Prohibition of 
abuse of 
dominant 
bargaining 
position 
- Suppliers shall not penalize their own suppliers through abuse of 
a dominant bargaining position. 
Abuse of a dominant bargaining position refers to use of one’s 
position as a purchaser or consignor to unilaterally decide or alter 
the terms of transactions with suppliers, etc., or to place on them 
unreasonable demands or obligations. 
226

作成日：2011/４1  
訂番：01 
- 3 -
3) Prohibition 
against making 
or accepting 
illegal payoffs 
- Suppliers shall neither make nor accept illegal payoffs in their 
relationships with stakeholders. 
Making or accepting illegal payoffs refers to giving or receiving 
from customers gifts, prizes, monetary awards, etc. beyond what 
is allowed by law, or providing or accepting monetary gifts or 
entertainment beyond social convention, or other acts of venality. 
4) Prohibition of 
anticompetitive 
behavior 
- Suppliers shall not act in ways that interfere with fair, transparent, 
and free competition. 
Acts that interfere with competition refer to agreements between 
competitors regarding prices, volumes, sales territories, etc. 
(cartels), working with other bidders to decide the winning bidder 
or price in a bid (collusive bidding), and other such acts. 
5) Provision of 
accurate 
product/service 
information 
- Suppliers shall provide consumers, customers, and others with 
accurate information about their products and services. 
6) Respect for 
intellectual 
property 
- Suppliers shall respect the intellectual property of others, and 
shall not misuse or infringe on same. 
7) Appropriate 
export controls 
- Suppliers shall have a clear structure for controlling the export of 
technologies and goods regulated by law, and shall carry out 
appropriate export procedures regarding same. 
8) Information 
disclosure 
- Regardless of whether or not such disclosure is required by law, 
suppliers shall be proactive in providing and disclosing 
information to stakeholders. 
Information to be provided and disclosed to stakeholders refers to 
descriptions of business activities, financial status, business 
performance, risk-related information (e.g. damage related to a 
major disaster, incidents having a negative impact on the 
environment or society, discovery of significant violations of the 
law, etc.).  
9) Prevention and 
early detection 
of illegal 
behavior 
- Suppliers shall act to prevent illegal behavior, and have in place a 
system for early detection of, and response to, such acts. 
227

作成日：2011/４1  
訂番：01 
- 4 -
４． 
Ensuring 
Quality and 
Safety, Delivery, 
Fair Pricing, 
and Stable 
Supply 
Products, parts, and raw materials provided by our suppliers have an enormous 
impact on Olympus. Suppliers are asked to provide products, parts, and raw materials 
that meet Olympus specifications and quality standards, while complying with delivery 
dates and providing fair prices. 
1) Ensuring 
quality and 
safety 
- Suppliers shall build and operate a quality management system, 
and to maintain and improve the quality of the products they 
deliver to customers, shall comply with the safety standards of the 
countries and regions in which they do business, to provide 
products, parts, and raw materials that meet the required 
specifications and quality standards. 
- Suppliers who design their own products shall ensure those 
products meet the safety standards prescribed by the laws, etc. of 
each country. 
A quality management system refers to an overall management 
framework for promoting quality assurance activities, and includes 
organizational structures, systematic activities, 
division of 
responsibility, practices, procedures, processes, and corporate 
resources. Quality assurance activities, in this context, refers to 
the creation of quality-related policies, the implementation of 
measures in accordance with those policies, and their 
achievement, reevaluation, and maintenance. In practice, this 
means running quality assurance through a PDCA cycle to ensure 
continuous improvement. 
2) Ensuring 
on-time 
delivery and 
stable supply 
- To enhance their responsiveness to change, suppliers shall work 
to appropriately manage delivery schedules through a close 
exchange of information with Olympus, and having in place a 
flexible supply structure.  
- Suppliers shall establish and disclose a business continuity plan 
(BCP), and even in times of disaster, shall work to continue 
business while placing first priority on saving lives. 
3) Ensuring fair 
pricing 
- To ensure customers are happy with product prices, as well, 
suppliers shall provide products, parts, and raw materials which 
are highly competitively priced, and shall maintain efforts to keep 
prices low. 
- To maintain a continuing relationship, it is essential that the 
parties involved have a healthy, stable management base, and to 
that end, suppliers shall disclose their management policies and 
business conditions (including financial status). 
５. 
Environmental 
Considerations 
Olympus takes the protection of the global environment as one of its critical management 
tasks, and strives to contribute to the development of a sustainable society by delivering 
environmentally conscious products to consumers. To this end, suppliers must manage 
the parts and raw materials that constitute our products at their source, including in their 
procurement activities and production processes. We would like you to promote the 
following biodiversity and other environmental protection activities so that together, we can 
create products that are not harmful to the global environment. 
1) Control of 
chemical 
substances in 
products 
- For all products, suppliers shall control those chemical 
substances 
designated 
under 
Olympus 
Group 
environment-related substance control standards and other laws 
and regulations. 
228

作成日：2011/４1  
訂番：01 
- 5 -
2) Control of 
chemical 
substances in 
the 
manufacturing 
process 
- Suppliers shall control chemical substances in the manufacturing 
process as designated under the laws and regulations of the 
country(ies) in which they are located. 
3) Environmental 
management 
system 
 
- Suppliers shall build and operate an environmental management 
system. (As described in “4. Requests to Suppliers” of Olympus Group 
Green Procurement Standard:   
http://www.olympus-global.com/en/corc/csr/environment/products/green-procurement/) 
Environmental 
management 
systems 
refer 
to 
a 
general 
management framework for the promotion of environmental 
activities, and includes organizational structures, systematic 
activities, 
division 
of 
responsibility, 
practices, 
procedures, 
processes, and corporate resources. Environmental activities, in 
this context, refers to the creation of environmental policies, the 
implementation of measures in accordance with those policies, 
and their achievement, reevaluation, and maintenance. In 
practice, this means running environmental protection through a 
PDCA cycle to ensure continuous improvement. 
Examples of this would include the creation of an environmental 
protection framework in compliance with ISO14001 or similar 
environmental management systems, and promotion of external 
certification. 
4) Minimizing 
environmental 
impact 
- Suppliers shall abide by the laws and regulations of the countries 
in which they are located with regards to waste water, sludge, 
exhaust, noise, and odors, and, where necessary, shall make 
further improvements based on self-imposed standards. 
- Suppliers shall respect the biodiversity guidelines of the countries 
in which they are located, and shall work to minimize their impact 
on biodiversity. 
5) Environmental 
permits/ 
government 
approvals 
- When so required, suppliers shall obtain government approvals in 
accordance with the laws and regulations of the countries in 
which they are located, and shall submit all management reports 
to government as requested. 
6) Efficient use of 
resources and 
energy (the 
3Rs) 
- Suppliers shall establish their own goals for resource and energy 
conservation, and shall work toward the continuous efficient use 
of resources and energy. 
7) Reduction of 
greenhouse 
gas emissions 
- Suppliers shall establish their own goals for the reduction of 
greenhouse gases, and shall work toward their continuous 
reduction. 
8) Waste 
reduction 
- Suppliers shall establish their own goals for the reduction of waste 
products, and shall work toward their continuous reduction. 
229

作成日：2011/４1  
訂番：01 
- 6 -
9) Disclosure of 
environmental 
protection 
activities. 
- Suppliers shall disclose, as needed, the results of their 
biodiversity and other environmental activities. 
- To regularly compile results, suppliers shall designate and 
organization and individual(s) responsible for environmental 
protection activities, and shall maintain a regular record of 
management indicators, level of attainment of goals, and other 
important environment-related items. 
６.  
Ensuring 
Information 
Security and 
the Appropriate 
Protection of 
Information 
With respect to trade with Olympus, suppliers can access and obtain Olympus' corporate 
information, such as its know-how or classified information, as well as the classified or 
private information Olympus has on others. You are requested to strictly safeguard the 
information you have accessed through your business dealings with us to prevent any leak 
or disclosure to unauthorized personnel or outside parties. 
Suppliers are also asked to implement measures to combat computer viruses, and to 
manage such measures so as to prevent causing harm either internally or to other 
companies.  
1) Preventing 
leaks of private 
information 
 
- Suppliers shall appropriately manage and protect the private 
information of their customers, third parties, and their own 
employees. 
Appropriate management refers to building and operating an 
overall system for managing private information, including the 
creation of rules and policies to be followed by employees, as well 
as the planning, implementation, supervision, and reevaluation of 
measures in accordance with those rules and policies.  
Appropriate protection refers to protecting private information from 
being illegally or wrongfully obtained, used, disclosed, or leaked.  
2) Defending 
against 
computer 
network threats 
- Suppliers shall undertake defensive measures against computer 
network threats, and shall manage such measures so as to 
prevent harm either internally or to other parties. 
3) Preventing 
leaks of 
confidential 
information of 
customer and 
other third 
parties 
 
 
- Suppliers shall appropriately manage and protect confidential 
information received from customers and other third parties. 
Appropriate management refers to building and operating an 
overall system for managing confidential information, including the 
creation of rules and policies to be followed by employees, as well 
as the planning, implementation, supervision, and reevaluation of 
measures in accordance with those rules and policies. 
Appropriate protection refers to protecting confidential information 
from being illegally or wrongfully obtained, used, disclosed, or 
leaked. 
７． 
Promoting 
Social 
Contributions 
Companies must grow sustainably with society. To this end, we ask that our suppliers 
determine what is feasible for each of you, and be proactive in your initiatives to 
contribute to both the global and your local communities. These initiatives may involve 
contributions using your primary business or technologies, non-monetary contributions 
utilizing your facilities or personnel, monetary donations, and others. 
230

作成日：2011/４1  
訂番：01 
- 7 -
８． 
Promoting CSR 
Activities 
Internally and 
Among 
Suppliers 
We ask that our suppliers have a correct understanding of the importance of CSR, 
and work to promote CSR activities both internally and among your own suppliers. 
1) Promoting CSR 
activities 
internally 
- Suppliers shall build an overall framework encompassing the 
organization, division of responsibilities, processes, etc. needed 
for the promotion of CSR activities, and shall continuously 
improve its CSR policies through a PDCA cycle of creation, 
execution, achievement, reevaluation, and maintenance.  
2) Promoting CSR 
activities among 
suppliers 
- Internally, suppliers shall track the status of CSR activities among 
their own suppliers, and shall work to spread and disseminate 
CSR activities among suppliers by building a system and 
designating individuals responsible for educating them. 
 
 
231

General Employer Action Plan based on the Act on Promotion of
Women's Participation and Advancement in the Workplace
The Olympus Group believes that the active participation of diverse human resources is indispensable for the sustainable development of the company and
therefore promotes Work-Life Integration (WLI) to enable our employees to achieve the optimum balance. 
Olympus Corporation recognizes promoting the advancement of women as a priority issue to achieve WLI and have created the following action plan.
1. Plan duration
April 1, 2019 to March 31, 2024.
2. Current status
3. Approach
Based on an understanding of the current situation, we are adopting the following approaches in the education and promotion of
professionals/experts and managers.
4. Goals, concrete actions, and start date
Goal 1: Increase the number of female managers to twice that compared to FY2021 by the beginning of FY2025.
(Concrete actions and start date)
From April 2019.
The percentage of female managers is 2.4% as of the end of FY2019, which is low compared with the overall percentage of female full-time employees
(approx. 14%).
The percentage of women among new graduate employees in FY2020 was 23.5%.
We provide management skills training programs and a mentor system to nurture female managers. We also provide leader training programs and
mentoring for manager candidates.
It is difficult for female employees to find a female role model and design a career path as the number of female managers and opportunities to get to
know them are few.
The education and promotion of professionals and experts is insufficient.
In FY2018, the scope of workers eligible for teleworking was expanded from those in childcare to include those engaged in elderly care or nursing care.
Since then we have been expanding the trial for target employees in each business site.
To help female workers to return smoothly to work after childcare leave, we provide the means to view work-related information during their leave and a
return-to-work career design training programs.
Although we are promoting WLI awareness among managers, understanding and active utilization of the WLI schemes is still insufficient.
Despite difficulties in achieving WLI for sales personnel, there is no support system for female employees to remain in the job.
Reinforce systematic education for female manager candidates.
Reinforce establishment of a working environment that enables a sound work-life balance.
Reinforce female employment.
232

Goal 2: Reinforce the working environment to enable a sound work-life balance
(Concrete actions and start date)
From April 2019.
Goal 3: Increase the percentage of female new graduates to 25% or higher in our employment as of April 2024.
(Concrete actions and start date)
From April 2019.
Provide genderless manager training programs.
Educate managers on nurturing subordinates.
Introduce a mentor system with female managers as role models.
Provide training programs per job level for promoted employees incorporating their career path planning.
Establish a scheme that enables work continuation during illness treatment (including fertility treatment and breast cancer).
Support smooth returning to work by opening childcare centers and providing a return-to-work briefing together with the employee's child.
Support returning to work through a partnership with a housekeeping agency.
Achieve WLI by making teleworking available to all employees and introducing hourly usage of annual leave.
Toward achieving WLI in the workplace, reform WLI awareness through training improvement and booklet renewal.
Offer financial assistance to obtain qualifications during childcare leave.
Introduce a half-day childcare leave system to enhance working opportunities while on childcare leave.
Actively publish information on female employment and appoint a female employee as a recruiter to increase job applications from women.
Promote targeted recruitment of female students in the STEM field (where the ratio of female students is low) as the number of students from this field
hired by our company is high.
Introduce location-specific employment for sales personnel.
233

General Employer Action Plan based on the Act on Advancement of
Measures to Support Raising Next-Generation Children
The Olympus Group promotes Work-Life Integration (WLI), through which we aim to create a positive interaction between work and life that fulfills the
aspirations of our employees.
As a company committed to the sustainable development of society, we value Nurturing the Next Generation, aiming to care for the children who will bear the
future and valuing their healthy growth.
Based on these ideas, Olympus Corporation will implement the following action plan to establish a working environment that enables our employees to fulfill
both their work and child caring commitments, exerting their capabilities to the full.
1. Plan duration
April 1, 2021 to March 31, 2024 (three years).
2. Plan details
Goal 1: Implement the WLI schemes and raise understanding of them to encourage usage of the schemes according to employees' life plans
regardless of gender.
<Measures>
Goal 2: Implement measures to revise working styles as a part of WLI promotion.
<Measures>
(1) Establish a working environment that supports balancing work and life for employees engaged in
childcare
Introduce teleworking
Jointly with the labor union, introduce teleworking utilizing telecommunication devices at a permitted location other than the office. (From FY2022)
Introduce hourly-based leave
Allow employees to use their annual leave on an hourly basis to enable flexible and autonomous ways of working. (From FY2022)
Introduce options for taking summer holidays
Promote autonomous and flexible working according to the individual employee's life plans. (From FY2022)
Consider a support system during and after childcare leave
Consider a career development system for employees engaged in childcare by supporting career progress during childcare leave and offering a
housekeeping service after they return to work. (From FY2022)
Introduce a personnel evaluation system that takes account of diverse working styles
To expand the working opportunities of employees who have to work during limited hours or locations due to child or elderly care etc., we are
considering widening the scope of the personnel evaluation system, currently in use for assessing employees in the job classification system. (From
FY2022)
(2) Revise working styles and diversify the working environment and culture
Provide WLI information and training sessions for managers
234

Provide managers with continuing training programs on appropriate workplace management to support employees' balance between work and child
or elderly care, as well as promoting understanding of the aims of WLI. (From FY2022)
Encourage men to participate in childcare
Create a corporate culture in which male employees can freely participate in childcare and provide related information. (From FY2022)
Contracts with corporate childcare centers
Consider making contracts with corporate childcare centers (employer-sponsored childcare centers) operated by other companies. (From FY2022)
Provide information about the nurseries in Shirakawa Facility (opened in September 2018) and Hachioji Facility (opened in June 2020), to ensure
they are used effectively and support WLI. (From FY2022)
235

Promoting Work-Life Integration
Olympus has been promoting "Work-Life Integration" tohelp employees keep their work-life balance and generatework-life synergies, believing that they will
maximize theirabilities and proactively continue their careers even duringperiods when they need to take care of their children orother family members.
Support Systems and Measures
We have introduced work at home, reentry, task flex, and reduction of working hours systems as a way to give more support to employees who are taking
care of their children or other family members.
Use of the Work-Life Integration-Related Systems
FY2018
FY2019
FY2020
Work at home system (persons)
282
595
828
Reentry system (persons)
4
0
4
Task flex system (persons)
1
0
0
Reduction of working hours system (persons)
254
250
246
Leave Systems and Leave Utilization Situation
Refresh Leave
7th year of employment
Paid holidays: 5 days
Bonus: 55,000 yen
20th year of employment
Paid holidays: 10 days
Bonus: 330,000 yen
At the age of 55
Paid holidays: 5 days
Participation in the PLP Seminar
Utilization of Refresh Leave
FY2018
FY2019
FY2020
7th year of employment
250
204
130
20th year of employment
142
187
164
At the age of 55
185
206
224
Annual Paid Leave
236

No. of annual paid holidays (for full-time workers)
20 days a year, starting the first year of employment (for employees who join Olympus b
etween April and June). Unused paid holidays can be carried over to the next year only.
Consecutive leave promotion scheme (Creative Holi
day)
Employees are encouraged to take 5 consecutive leave days. (These can be combined
with ordinary holidays.)
Expired annual paid holiday saving scheme (Special
Sick Leave)
Saving of up to 50 days allowed for medical treatment and family care (paid holidays).
Utilization of Annual Paid Leave
FY2018
FY2019
FY2020
Average days available
19.8
19.2
19.7
Average days used
13.0
10.8
10.9
Utilization ratio (%)
65.4
56.3
55.6
Leaves of Absence for Voluntary Activities
Number of people used since 1995: 6 persons
Utilization of Childcare & Family Care Leave and Leaves of Absence
FY2018
FY2019
FY2020
Number of employees taking maternity leave
134
131
156
Subtotal: Males
8
13
23
Number of employees taking leaves of absence for f
amily care
3
4
4
237

Corporate Citizenship Policy
At the Olympus Group (hereinafter, "Olympus"), our corporate activity is based on Olympus' corporate philosophy and the Olympus Global Code of Conduct.
Olympus implements appropriate corporate citizenship activities as a leading global medtech company, while taking a long-term view in an effort to achieve
Our Purpose of "Making people's lives healthier, safer and more fulfilling."
Olympus is committed to fulfilling its responsibilities to society and its stakeholders by proactively carrying out the activities that benefit global and local
communities.
1. Three Priority Areas
As a leading global medtech company, Olympus conducts its citizenship activities in healthcare. In an effort to leverage the spirit of monozukuri (excellence
in manufacturing fostered by Olympus for over a century), our activities also focus on fostering scientific and technological progress, as well as
environmental sustainability. These three areas have been selected as priorities in which our corporate citizenship activities will be rolled out globally.
"Healthcare": An area in which we can take advantage of the insights we have gained from our Medical business
"Science and Technology": An area in which we can take advantage of the insights we have gained from our Scientific Solutions business
"Environment": Activities that future generations would be able to enjoy a rich natural environment
In addition to the priority areas listed above, we are engaging in humanitarian and charitable activities to nourish the world, to combat poverty, emergency
disaster relief assistance as well as local community involvement programs.
2. Approach to Activities
(1) Respect for local cultures and customs
While society expects a multinational company like Olympus to take action to address shared challenges on the globe, we still need to respect local cultures
and customs and take into account local needs when launching local voluntary activities.
(2) Meaningful partnership
238

We work in partnership with NGOs, NPOs, local and national governments and international organizations, etc., as appropriate for each area of activity, to
achieve greater speed and efficiency in addressing social issues. We utilize the findings, experiences, know-how that we gain in order to improve our future
actions, which leads to our continuous growth.
(3) Developing the next generation of leaders
We foster people who will support the sustainable growth of society in the future by imparting the insight and know-how we have gained during our corporate
activity over the past century to future leaders through providing learning opportunities and conducting awareness-raising activities.
(4) Enhancing employee participation
Olympus believes that its employees should become more connected with the world around them through volunteer activities, which not only have positive
effects on society, but also help employees broaden their horizons and improve their sensitivity. Olympus encourages its employees to get involved in society
on their own initiative by providing them with opportunities to volunteer.
3. Information Disclosure
To fulfill our responsibilities to society and our stakeholders, we proactively disclose information on the corporate citizenship activities we have implemented
in the past in a timely and appropriate manner.
4. Continuous Improvement
By reflecting on the outcomes of past corporate citizenship activities and listening to feedback from society and our stakeholders, we will strive to improve
our activities.
239

Charitable Donations and Grants Policy
Based on our corporate philosophy of "Making people's lives healthier, safer and more fulfilling" that provides the basis for all corporate activities, the
Olympus Group (hereinafter, "Olympus") is committed to gain trust from society, in addition to creating social values through our business operations.
Through charitable donations and grants, we live up to our commitment and responsibility to address social issues.
1. Priority Areas and Activities
Our charitable donations and grants efforts are focused on following areas: "Medicine and Health", "Culture and the Arts", "Global Environment" and
"Science and Technology". Also, our contributions shall be socially just and shall follow ethical norms.
2. Compliance with Legal Regulations and Social Norms
We will fully comply with both Japanese and non-Japanese law and industry guidelines in respect to charitable donations and grants.
3. Rules and Organizational Systems
We clearly separate charitable donations and grants from any Olympus commercial activities, and establish guidelines and operational structures to ensure
transparency.
4. Information Disclosure
We will fully comply with Japanese and non-Japanese law and industry guidelines, will assuredly record charitable donations and grants activities, and will
commit to disclose information in a timely and appropriate manner. Furthermore, through information disclosure and active communication, we will commit to
deepen mutual understanding with stakeholders.
Charitable Donations
We provide monetary aid and/or in-kind donations to philanthropic activities, and contribution activity for local community based on CSR for
humanitarian aid. Aid and donations provided for disaster relief will also be considered charitable donations.
1.
Grants
We provide monetary aid and/or in-kind donations to education as well as research activities, conducted by organizations for public welfare, that relate
to four priority areas: "Medicine and Health", "Culture and the Arts", "Global Environment", and "Science and Technology".
2.
240

Charitable Donation Initiatives
Year
Monetary and In-kind Charitable Donations
Total Amount
FY2018
24
13,280,226 yen
FY2019
18
16,028,224 yen
FY2020
18
10,977,619 yen
FY2021
900
172,013,216 yen
* Only Olympus is included in the data from the FY2018 to the FY2020, and the Olympus Group (excluding some areas) from the FY2021.
Charitable Donations and Grants Policy
Monetary and In-kind Charitable Donations
Charitable Donation Results
June 4, 2020
July 21, 2020
Olympus Increases Support for COVID-19 Measures to 100 Million Yen
Emergency Assistance for Children Impacted by the Spread of COVID-19 (COVID-19 Response)
241

242

243

244

245

246

247

Because What We Do Matters:
Olympus Global Code of Conduct
What we do matters and how we act at work matters. Through these actions, we intend to maintain the trust of our stakeholders. Our Global Code of
Conduct explains our unwavering commitment to integrity, our passion for what we do, and our shared standard of excellence. Our Code is designed to help
put Our Purpose and Core Values into practice. It serves as our guide to ethical and responsible business conduct, along with local policies and procedures.
Our Code is available in the following languages here:
Global Code of Conduct
Chinese (Simplified) | 中文（简体） (PDF: 2.5MB)
Chinese (Traditional) | 中文（繁体） (PDF: 2.4MB)
Czech | čeština (PDF: 2.1MB)
English (PDF: 2.2MB)
French (Canadian) | Français (Canadien) (PDF: 2.1MB)
French (European) | Français (Européen) (PDF: 2.1MB)
German | Deutsch (PDF: 2.1MB)
Italian | Italiano (PDF: 2.1MB)
Japanese | 日本語 (PDF: 2.4MB)
Korean | 한국어 (PDF: 2.2MB)
Polish | Polskie (PDF: 2.1MB)
Portuguese (Brazilian) | Português (Brasileiro) (PDF: 2.1MB)
Portuguese (European) | Português (Europeu) (PDF: 2.0MB)
Russian | русский (PDF: 2.1MB)
Spanish (European) | Espanol (Europeo) (PDF: 2.1MB)
Spanish (Mexican) | Espanol (Mexicano) (PDF: 2.1MB)
Thai | ภาษาไทย (PDF: 2.2MB)
Vietnamese | Tiếng việt nam (PDF: 2.2MB)
248

Whistleblowing System
Whistleblowing System
Olympus Corporation and all Olympus Group companies abide by the laws, regulations and ethics standards in each industry. In April 2019, Olympus
launched Global Whistleblowing Desk "Integrity Line" on top of current External Reception Desk and Internal Reception Desk. Please make use of these 3
reception desks when you get to know the inappropriate actions or questionable conducts.
Integrity Line (Global Operation Desk)
Integrity Line is operated by an independent company. This global desk is designed for all employees and Olympus business partners, who can
report in confidence. Anyone may report anonymously, except where specifically prohibited by local laws. Special technology incorporated in the
system guarantees no traceability in both web reporting and telephone.
24 hours/day, 365 days/year
http://olympus.ethicspoint.com (multi-languages) 
free dial 0120-929-973 (select 1 for Japanese, select 2 for English or others)
*Other dial numbers outside Japan can be found at Olympus regional homepages.
External Reception Desk (Independent law firm in Japan)
9:30-17:30 of business day
yohamabe@ybb.ne.jp
03-5272-8156 (switchboard)
03-5272-8163
1-1-7 Nishi-Waseda, Shinjuku-ku, 169-0051
Waseda Univ. Legal Clinic
Attention: Yoichiro Hamabe, Esq
Internal Reception Desk (OT Group Compliance Japan)
8:45-17:30 of business day
JP-Compliance-Helpline@olympus.com
Operation time
:
Web reporting
:
Telephone
:
Operation time
:
Email
:
Telephone
:
Fax
:
Post
:
Operation time
:
Email
:
249

Global Standards:
What Olympus Expects of Third Parties
These Global Standards ("Global Standards") have been designed to provide guidance to our third parties on the fundamental values, principles, and
standards of behavior which Olympus expects whenever a third party is engaged by or on behalf of the Olympus Group. We consider our third parties to be
our partners in business and we expect the same high standard of integrity from them that we expect from our employees and managers.
Third Party: A third party is any external company, organization or individual, not owned, controlled, or employed by an Olympus Group company that
Olympus has hired or intends to contract to provide goods or services or engage in business activities with or on behalf of an Olympus Group company.
The Global Standards are available through the following links:
Arabic (PDF: 7.4MB)
Chinese (Simplified) | 中文（简体） (PDF: 3.9MB)
Chinese (Traditional) | 中文（繁体） (PDF: 7.5MB)
Czech | čeština (PDF: 7.4MB)
English (PDF: 4.8MB)
French (Canadian) | Français (Canadien) (PDF: 3.8MB)
French (European) | Français (Européen) (PDF: 3.8MB)
German | Deutsch (PDF: 7.3MB)
Italian | Italiano (PDF: 3.8MB)
Japanese | 日本語 (PDF: 7.5MB)
Korean | 한국어 (PDF: 7.4MB)
Polish | Polskie (PDF: 7.3MB)
Portuguese (Brazilian) | Português (Brasileiro) (PDF: 21.5MB)
Portuguese (European) | Português (Europeu) (PDF: 7.4MB)
Russian | русский (PDF: 7.4MB)
Spanish (European) | Espanol (Europeo) (PDF: 7.3MB)
Spanish (Mexican) | Espanol (Mexicano) (PDF: 7.3MB)
Thai | ภาษาไทย (PDF: 3.9MB)
Vietnamese | Tiếng việt nam (PDF: 7.4MB)
250

Olympus Group Tax Policy
Introduction
Our Corporate Philosophy and Global Code of Conduct set out the legal and ethical principles that we apply to our business and defines our relationships
with all of our stakeholders, which includes tax authorities. Our Corporate Philosophy, “Our Core Values”, includes Empathy and Integrity. We earn trust and
empathy with patients, customers, healthcare professionals, authorities and the communities with integrity in all aspects of our operations, and “Our Core
Values” governs the way we operate our business.
Group Tax Policy
This Group Tax Policy outlines the principles of how Olympus people are expected to operate with respect to tax matters. The Policy is set out in detail
below.
1. Compliance with laws, rules and regulations
Olympus is committed to observing all applicable tax laws, rules, regulations, and reporting and disclosure requirements, wherever there is a requirement to
do so as a result of our business presence and transactions, in line with “Our Core Values”, “Integrity”, as described in the Corporate Philosophy and Global
Code of Conduct.
A dedicated tax function (Group Tax) collaborates with the Group’s businesses to provide advice and guidance necessary to ensure compliance, obtaining
external advice where necessary. There are clear management responsibilities, backed up by regular monitoring and review, carried out by members of
Group Tax with the necessary experience and skill set and where necessary support is provided by external professional advisors.
2. Consistency with Group strategy
Tax decisions are made at all times in a manner which is consistent with and complements the Group’s overall business strategy. Key business decisions are
made cognisant of the tax consequences. Group Tax partners with the businesses to ensure there is consistency.
3. Governance, Assurance and Tax Risk Management
Responsibility and accountability for the Group’s tax affairs is clearly defined in accordance with a Tax Responsibility Matrix, and decisions are taken at an
appropriate level, determined by formal Group Delegation of Authority.
Diligent professional care and judgement are employed to assess tax risks in order to arrive at well-reasoned conclusions on how the risks should be
managed. Olympus has a conservative approach to tax risks and seeks to mitigate tax risks as far as possible. Where there is uncertainty as to the
application or interpretation of tax law, appropriate written advice evidencing the facts, risks and conclusions may be taken from third party advisers to
support the decision-making process.
In reviewing the risks of a tax action or decision, the following would be considered
The legal and fiduciary duties of directors,
The requirements of our Group compliance and ethics policies,
The maintenance of corporate reputation, having particular regard to the principles regarding the way we interact with the stakeholders around us,
embodied in the Group’s approach to the stakeholders as described in the Corporate Philosophy of Olympus, “Empathy”,
The tax benefits and impact on the Group’s reported result comparative to the potential financial costs involved, including the risk of penalties and
interest,
251

Group Tax employs various risk management processes and systems to provide assurance that the requirements of the Group Tax Policy are being met.
This includes compliance and risk monitoring systems and internal audit reviews of tax compliance activity across the Group.
4. Relationships with tax authorities
Olympus is committed to the principles of openness and transparency in its approach to dealing with tax authorities wherever we operate around the world.
Where there is uncertainty as to the application or interpretation of tax law, we secure certainty by consultation with advance information disclosure. All
dealings with the tax authorities and other relevant bodies are conducted in a collaborative, courteous and timely manner. The aim would be to strive for
early agreement on disputed matters, and to achieve certainty wherever possible.
5. Tax Planning
Olympus pays its fair share of taxes in the countries where it operates, and considers this a part of its contribution to community. Olympus does not
undertake aggressive tax planning or artificial tax arrangements.
Olympus maintains and follows a transfer pricing policy that is based on OECD Transfer
Pricing Guidelines and the Base Erosion and Profit Shifting (“BEPS”) Action Plan which is the international framework to prevent cross-border tax avoidance
activities.
In particular, Olympus adhere to the principle that profits should accrue where economic value is created and that tax follows business reality and
is underpinned by business substance.
6. Incentives and reliefs
Olympus believes that it should pay the amounts of tax legally due in any territory. There will, however, be circumstances where this amount may not be
clearly defined, or where alternative approaches may result in differing tax outcomes. The Group uses its best judgement in determining the appropriate
course of action, using available reliefs and incentives where possible for tax cost optimization.
The wider consequences, as a double taxation where a specific income is taxed by multiple countries, of potential disagreement with tax authorities,
and any possible impact on relationships with them.
252

Olympus Group guidelines covering the prevention of bribery
The Olympus Group does business throughout the world and seeks to earn and maintain the respect and trust of all of our stakeholders - patients,
physicians, customers, governments and shareholders. Olympus expects that each and every one of our employees act in a manner that is
consistent with law, Olympus policies and our values. We also expect and require that third parties who act on Olympus' behalf operate in the same
manner.
Olympus has developed policies, procedures and training on key issues, such as the prevention of bribery and the support of fair competition to
help assure that we provide our employees with the tools to meet these expectations. We encourage all our employees to speak up and share any
concerns they might have. We will continue to hold ourselves to high standards but are always working to improve, so that we can meet or exceed
high expectations. The Guideline below summarizes our approach. We invite you to support these efforts, and let us know if we have areas in which
we can improve.
Olympus welcomes any reporting of concerns about unethical or unlawful conduct directly to Olympus Compliance Department, which can be
reached directly via email at compliance@olympus.com. Company policy prohibits retaliation against any individual for reporting concerns to the
above mentioned email in good faith.
Eva Gardyan-Eisenlohr
Chief Compliance Officer
Olympus Corporation
1. Background
At Olympus, all our activities are based on our corporate philosophy of "Making people's lives healthier, safer and more fulfilling." Following this philosophy,
Olympus affirms its commitment to carrying out responsible actions underpinned by a strong sense of ethics, in addition to strict compliance with laws.
Olympus does not tolerate bribery for the purpose of obtaining illicit benefits or unfair business advantages. In addition, Olympus does not engage in any
actions that could be perceived as bribery of any of its business partners, including public officials.
As a signatory to the United Nations Global Compact, Olympus is significantly increasing its efforts to ensure that the Compact's ten principles, including the
introduction of practical anti-corruption measures, the protection of human rights, the elimination of unfair labour practices and the management of
environmental issues are met.
2. Objective
This guideline summarizes Olympus' approach to the prevention of bribery and corruption. We ask that you familiarize yourself with this approach, which
takes into account various anti-bribery laws and regulations both in and outside of Japan, and conduct your business activities accordingly to ensure that all
actions that constitute or could be suspected to constitute bribery or corruption are prevented.
Please note that the anti-bribery laws and regulations referred to herein include the following statutes, international conventions, ministerial orders and
regulations from both in and outside of Japan. As the laws of some non-Japanese jurisdictions, including those of the United States and the United Kingdom,
have extraterritorial ramifications, a number of Japan-based companies doing business globally are required to comply with them as well.
1. Japan: Unfair Competition Prevention Act (Article 18)
2. U.S.: Foreign Corrupt Practices Act (FCPA)
3. U.K.: UK Bribery Act 2010
4. Equivalent statutes that are based on or concern for the OECD Convention on Combating Bribery of Foreign Public Officials in International Business
Transactions
253

3. Olympus' Approach to the Prevention of Bribery and Corruption
Olympus has set forth internal rules applicable to its Group companies in order to ensure compliance with all anti-bribery laws and regulations.
Prohibition of any acts considered to be bribery with regards to:
The provision, acceptance or promises of and demands for money or other undue favours, and the proposal or authorization of the provision or acceptance
thereof to or from public officials or any persons equivalent thereto ("Public Officials") with the intention of influencing their actions or decisions taken or made
as part of their duties for the purpose of obtaining illicit benefits are prohibited. Public Officials include domestic or foreign public officials, international public
organizations, political parties and members thereof, candidates for any public office and all persons who are potentially regarded as public officials.
The provision, acceptance or promises of and demands for money or other undue favours and proposals and the authorization of the provision or
acceptance thereof with the intention of influencing the recipient's actions or decisions for the purpose of obtaining illicit benefits are prohibited.
Money or other undue favours given with the intention of inappropriately influencing corporate or business decisions or business execution of Olympus are
not given, accepted, promised, demanded, proposed or authorized.
Definition of Bribery
Bribery refers to the offering, giving, soliciting, or receiving of any item of value as a means of influencing the actions of an individual holding a public or legal
duty, in other words, the giving of something of value to someone with the intent of obtaining undue favourable treatment from the recipient.
Forms of Bribery
Money and other undue favours including all cash and cash equivalents, gifts, services, employment, loans, travel expense payments, food and beverages,
entertainment and hospitality, including invitations to athletic events, political and charitable contributions, subsidies, per diem allowances, sponsorships,
rewards and all other favours or forms of value given under any pretext that benefits the recipient. Note that money and other undue favours, however
negligible the amount may be considered bribes and are therefore regulated.
The indirect provision of money or other undue favours through your business partners, customers, agents and intermediaries ("Third Parties") is also
prohibited.
Public Officials
"Public Officials" are, whether foreign or domestic, any government employee; a political candidate or party official; a representative of a government-
owned/majority-controlled organization; a representative carrying out public services; an employee of a public international organization. This term also
refers to immediate family members of the public official, such as spouse, dependent child, or dependent household member, of the above-mentioned
individuals.
4. Our Request to You:
We at Olympus vigilantly enforce our anti-bribery policy. We hereby request that you develop a full understanding of the Olympus Approach to the Prevention
of Bribery presented above and adhere to the same principles when dealing with Third Parties. To fully ensure that this objective is met, we ask you to take
the following steps when contracting or dealing with a Third Party in connection with the performance of your contractual obligations to Olympus.
(1) Public Officials
(2) Non "Public Officials"
Prohibition of bribe acceptance
Definitions:
254

(1) Due diligence on Third Parties:
When contracting with your business partners, you are requested to conduct a preliminary review on your business partners to preclude any possibility of
bribes being exchanged or any similar acts to be committed through such Third Parties.
(2) Anti-bribery provisions in contracts:
Your contracts with Third Parties must include anti-bribery provisions in clauses addressing representations, record-keeping, the right to audit, record control
and maintenance, and contract termination, etc.
(3) In-house education:
Please educate all directors and employees of your organization about anti-bribery and corruption regulations to ensure that they will not commit any action
that constitutes bribery or be suspected of giving or receiving bribes in any situation. In particular, your directors and employees should be aware that a
violation can lead to serious consequences for your organization, including termination of business contracts, fines, and even criminal or civil charges
pressed against the individuals responsible.
(4) Monitoring and audits:
We request that you keep track of the progress made in your efforts to prevent Third Parties from offering or accepting bribes and monitor the state of
compliance by your organization with regard to your internal rules. Additionally, periodic audits must be conducted to verify the effectiveness and
appropriateness of such efforts.
(5) Record keeping:
Please maintain accurate books and records for all your business transaction related to Olympus.
Established on April 1, 2015
255

Disclosure Policy
Olympus’s corporate philosophy states “making people's lives healthier, safer and more fulfilling,” and serves as the fundamental idea for all its corporate
activities. To this end and in order to gain proper understanding and confidence of all the stakeholders, Olympus shall disclose its management policies,
business activities, non-financial and other corporate information in a fair, timely, appropriate and proactive manner.
1.Information Disclosure Standards
In disclosing its information, Olympus shall comply with the laws and the Financial Instruments Exchange rules, and shall disclose information in compliance
therewith. Olympus shall also proactively disclose those information which may have a material impact on its corporate value evaluation in accordance with
the Article 27-36 of the Financial Instruments and Exchange Act (so-called “Fair Disclosure Rules”) and the Internal Information Disclosure Criteria
regardless whether such disclosure is not required by the laws or the rules.
2.Method for Information Disclosure
Olympus shall disclosure information, as required by the Timely Disclosure Rules of the Tokyo Stock Exchange, will be disclosed through the Timely
Disclosure network (TDnet) of the Tokyo Stock Exchange in general. Such information will then immediately be posted on our website. Furthermore, any
information not required by the laws or the rules will be disclosed through a press release or via the website.
3.Handling of Undisclosed Material Information
If any non-public material information is disclosed only to certain third parties and is considered that may have a significant impact on the corporate value
evaluation of Olympus, Olympus shall immediately disclose such information.
4.Quiet Period
In order to prevent any divulgation of financial closing information, the period from the end date of financial closing until the date of announcement of
financial results shall be set as a "quiet period," during which officers and employees shall refrain from making comments or answering questions that relates
to financial results. Provided, however, the same shall not apply in the case where any event subject to Timely Disclosure occurs or if the actual financial
results materially diverges from the forecast, Olympus Shall disclosure such information as required by the Timely Disclosure Rules of the Tokyo Stock
Exchange.
Applicable Scope
The Information Disclosure Policy of Olympus is applicable to all Olympus group companies.
256

The Ethics Committee
In conducting medical research targeting human beings, we check the ethical and scientific appropriateness of the research through the Ethics Committee,
which is composed of experts. To enhance the transparency of the Committee, we disclose its rules, membership list and the minutes of its meetings to the
public.
257

Payments to Healthcare Professionals and Healthcare Organizations
Japan
Americas
Transparency Guidelines
Payments to Healthcare Professionals and Healthcare Organizations (Only in Japanese) 
Visit here for inquiries related to our Transparency Guidelines.
Payments to Healthcare Professionals and Healthcare Organizations 
258

Transparency Guidelines
Olympus Group "Transparency Guideline for the Relation between Corporate
Activities and Medical Institutions and Other Organizations"
1. Basic Policy
The Olympus Group hereby declares compliance with the statutory laws and regulations and pledges to uphold high ethical standards to assure that all
executive officers and employees observe "what is right" and behave responsibly. 
Olympus is committed to complying with all laws, regulations and company policies, and we expect a similarly high standard of integrity from our employees,
managers, and our partners in business. We do not tolerate corruption or bribery in our company. To ensure that society at large is aware that we conduct
corporate activities in accordance with these ethical values in the context of our relationships with medical institutions, etc., Olympus has adopted these
guidelines and discloses information about payments to healthcare organizations, etc., in accordance with legal requirements, including the "Transparency
Guidelines for the Medical Device Industry and its Relationships with Medical Institutions and Other Organizations," as compiled by the Japan Federation of
Medical Devices Associations (JFMDA), of which is a corporate member.
* These guidelines apply to Olympus and its Japan subsidiaries that are members of the Japan Federation of Medical Devices Associations (JFMDA).
2. Scope of Application
Olympus and its Japan subsidiaries that are members of the Japan Federation of Medical Devices Associations (JFMDA)
Scientific societies, medical schools (their affiliated hospitals), hospitals and clinics, associations of paramedical staff, research institutes, research groups,
other facilities that provide medical care or conduct research, development or clinical trials, and healthcare professionals
3. Disclosure Methods
Related information for the previous fiscal year will be disclosed on the Olympus website.
4. Timing of Disclosure
Information about payments to healthcare organizations etc. in each fiscal year will be disclosed after the announcement of financial results for that fiscal
year.
5. Scope of Disclosure
The scope for information disclosure of the payment by Olympus to healthcare organizations and healthcare professionals covers in the categories of
research and development expenses, academic research grants, manuscript writing fees, etc., expenses related to information provision, and other
expenses.
Olympus
Medical institutions and other organizations
For more details on the "Scope of Disclosure" please visit the website of the Japan Federation of Medical Devices Associations (JFMDA) 
259

Olympus Group Information Security Policy
All our activities are based on our corporate philosophy, "Making people's lives healthier, safer and more fulfilling". Following this philosophy, The Olympus
Group appropriately protects and manages all the information and our information systems we handle ("Information assets"), as well as customer information
on our products and services while making proactive use of them and will continuously review and improve these activities.
1. Compliance with Laws and Regulations
We will comply with the laws, regulations, and contractual duties related to information security in all countries and regions where we operate.
2. Management and Protection of Information
We will manage and protect the information assets (customer and internal) appropriately in our business activities. We will also implement measures to
prevent the inappropriate use (e.g., violation of laws and regulations related information security) of these assets detrimental to Olympus and any acts that
might decrease the value of the assets, such as falsification, destruction, leakage and abuse.
3. Establishment of an Information Security Organization Structure
To ensure the appropriate management and protection of our information security related the Olympus Group business, we will establish an information
security organization structure led by Chief Information Security Officer (CISO) and clarify the related responsibilities.
We will make effort to manage and establish information security under the global governance structure that should comprehensively covers Olympus every
regions and functions (product, IT, data protection, and so on) initiated by CISO, and fulfill accountability to our stakeholders.
4. Establishment of Rules
We will establish the in-house rules to clarify the measures to be implemented to ensure information security. We will also revise these rules, processes and
controls continuously.
5. Education
We will increase information security awareness among all affiliates and provide them with necessary education and training on information security.
6. Emergency Responses
We will work to prevent information security-related incidents. If an information security incident occurs, we will make prompt responses to it and implement
measures to prevent the reoccurrence of similar problems.
We will implement countermeasures promptly, not to spread the impact of accidents, such as information sharing with authorities or information disclosure for
customers.
260

Internal Control System
Basic Policy on the Internal Control System
Our basic policy on the internal control system is as follows:
Revised date : July 30, 2020 (PDF: 76.7KB)
261

1 
 
Basic Policy on the Internal Control System, ver. 17 
 
All our activities are based on our corporate philosophy, "Making people's lives 
healthier, safer and more fulfilling". 
The Company, based on this basic concept, shall prepare and operate a framework 
which ensures the effectiveness and efficiency of operations and appropriateness and 
reliability of financial reporting of the Company and its subsidiaries (hereinafter, “the 
Olympus Group”), and make continuous improvements. 
 
1. 
Framework to ensure the compliance by Executive Officers and employees of the 
Company and Directors and employees of the its subsidiaries, in performance of 
duties, to applicable laws and regulations as well as the Articles of Incorporation 
(1) 
In order to ensure a system in which Executive Officers and employees of the 
Olympus Group perform their duties in compliance with applicable laws and 
regulations as well as the Articles of Incorporation, the Company shall establish 
“Management Basic Policy”, basic policy the Board of Directors relies on when 
the Board supervises the execution of duties of Directors and Executive Officers.  
Furthermore, it shall establish the Olympus Global Code of Conduct and 
internal corporate regulations, based on the corporate philosophy, and shall 
instill the policies and facilitate initiatives to raise awareness of compliance in 
Olympus Group through continuing education and other measures. 
(2) 
The Company shall also establish a compliance promotion system by appointing 
an officer in charge of compliance (“Chief Compliance Officer”) and establishing 
a function in charge of group-wide compliance. The function in charge of group-
wide compliance shall be responsible for activities toward the improvement of 
the group compliance system based on the Global Compliance Management 
System. Furthermore, it shall continuously conduct education of employees and 
measures relating to assessment. It shall establish a global contact desk which 
can be available 24 hours a day in multiple languages so that any employee and 
external stakeholders, when suspecting there is or may be a violation of laws 
and regulations, etc., may make a report in addition to a local hotline contact 
desk in each region 
(3) 
The CEO  shall be the person responsible for CSR at the Company, and shall 
determine the content, set objectives and conduct evaluations for CSR activities. 
Furthermore, beginning with instilling a strong sense of ethics, the Company 
shall drive initiatives to be in line with the Olympus Global Code of Conduct. 
(4) 
The Company shall set up an internal audit function reporting directly to the 
CEO. Based on the Internal Audit Charter, the internal audit function shall 
conduct audits to verify the effectiveness of the various processes for risk 
management, control and governance. The internal audit function shall report 
the results of internal audits to the CEO of the Company, and the Audit 
Committee. 
(5) 
In order to ensure the fairness of operations of subsidiaries, the Company shall 
dispatch Directors and Audit Committee to major subsidiaries and request them 
to obtain the Company’s approval for significant matters of subsidiaries based 
on the Job Authority Rules and any other related rules. 
(6) 
In order to ensure the appropriateness and reliability of financial reporting of 
the Olympus Group, the Internal Audit function shall continue to conduct 
improvement activities by regularly evaluating its efforts and operations to 
ensure that control activities relating to financial reporting function effectively 
under the internal control system. 
 
262

2 
 
(7) 
The Company shall be responsible for working with lawyers, the police and 
other parties to systematically stand firm against anti-social forces and 
organizations which threaten societal order and safety. The Olympus Group 
continuously shall conduct measures for excluding anti-social forces and 
prepare relevant rules and regulations in order to maintain its social 
responsibility to exclude anti-social forces. 
 
 
2. 
Framework regarding the maintenance of records and management of information 
in relation to performance of duties by Executive Officers of the Company 
(1) 
Pursuant to laws and regulations and the internal rules on document 
management, the Company shall maintain and manage documents or electronic 
data. 
(2) 
Directors may access important documents such as the minutes of a meeting of 
the Board of Directors and documentary approvals at any time based on the 
internal rules on document management. 
 
 
3. 
Regulations and other framework relating to managing risks of loss of the Olympus 
Group 
(1) 
The Company shall manage its business risks of the Olympus Group based on 
due deliberations held at meetings of the Board of Directors and the Group 
Executive Committee, among other meetings, and appropriate operation of the 
internal approval procedure.  
The Board of Directors shall determine basic management policy, matters 
related to the internal control system, other important matters and important 
matters related to business execution, as well as deciding matters to delegate to 
executive officers. Also, for important matters not decided by the Board of 
Directors, executive officers shall make a decision, and make a report to the 
Board of Directors. 
(2) 
The Company shall manage risks such as those relating to quality, product 
safety, export control, information security, health and safety, the environment 
and disasters by designating functions in charge, establishing internal 
corporate regulations, working for preventive risk management as the Olympus 
Group, and implementing education and training. 
(3) 
Based on the Internal Control Rules and other related rules, the Company shall 
prevent the emergence of serious risks resulting from the business activities of 
the Olympus Group, and shall create, operate appropriately, and manage a risk 
management system to minimize damage in the event of such risks emerging. 
Moreover, pursuant to the Risk Management Operation Rules, each function in 
charge in the Olympus Group shall be aware of risks and take preventative 
measures, and the Company has a framework which enables prompt actions in 
the event of an emergency. In the event of a violation of corporate ethics, or an 
earthquake, fire or accident, the function in charge shall make immediate 
reports to the executive officers and relevant people. The final determination in 
such circumstance shall be made by the CEO. 
 
 
 
 
263

3 
 
4. 
Framework to ensure the effective performance of duties by Executive Officers of 
the Company and Directors of its subsidiaries 
(1) 
The Board of Directors shall approve medium- and long-term Corporate 
Strategic Plans in which the business objectives of the Olympus Group are set 
forth, and action plans for these, which are called annual business plans. The 
Board of Directors shall decide on other important matters, and delegate except 
matters that should be resolved by the Board of Directors to executive officers 
in order to enhance efficient and agile decision-making on the execution of 
business. In addition, the Board of Directors shall receive reports, at least once 
a quarter, on business performance in order to evaluate the status of the 
Company’s annual business plan, and supervise executive officers’ performance 
of duties. 
(2) 
The Board of Directors shall determine the assignment of duties among the 
Executive Officers. In addition, the Board of Directors shall receive, at least once 
a quarter, reports on their duties as performed. 
(3) 
Based on the Job Authority Rules, Organization Rules, and other related rules, 
the Board of Directors shall approve the responsibilities and authorities of 
major job ranks. Based on internal corporate regulations including the internal 
rules on approval procedures and organizational matters, the Board of Directors 
shall approve the management organization and the separation of duties as well 
as the responsibility and authority of each of the Representative Director, other 
Operating Directors and Executive Officers, and receive reports from major 
management organizations on their duties as performed. 
(4) 
With the establishment of Treasury Control Framework, which regulate 
financial policies as a base for financial operations of the Olympus Group, the 
Company strengthens the governance of the Olympus Group from a financial 
aspect, and oversees and manages funding, foreign exchange, and transactions 
with financial institutions for the Olympus Group including the subsidiaries. 
 
 
5. 
Framework for reporting to the Company on matters concerning execution of duties 
by the Directors and employees of the subsidiaries  
(1) 
After the Company has clarified the management criteria of subsidiaries by 
means of the Affiliated Company Management Rules and other related rules, 
the presidents of the regional headquarters shall conduct reviews of the 
situation faced by management, and periodically report the results of the 
reviews to the president of the Company. 
(2) 
The Company shall ensure receiving reports as appropriate and in a timely 
manner from the subsidiaries in accordance with the Global Consolidated 
Accounting Control Framework to ensure that the Company will remain 
accurately informed of financial position and results of operation of the Olympus 
Group, and appropriately maintain and manage the consolidated accounting 
policies. 
 
 
6. Framework for matters related to employees whose assignment is to assist in the 
duties of Audit Committee of the Company, and matters related to the independence 
of those employees from the executive officers of the Company, and matters related to 
ensuring the effectiveness of instructions from Audit Committee of the Company to 
those employees 
 
 
264

4 
 
 
The Company shall allocate a dedicated employee who will assist with the Audit 
Committee’ duties. In addition, the Company shall set forth internal corporate 
regulations to ensure independence from execution as stated below, and ensure 
effectiveness of directions from the Audit Committee to such employees. 
(1) 
While employees who have been assigned to assist in the duties of the Audit 
Committee assist in those duties, directors (excluding Audit Committee 
members), executive officers and employees, etc. shall not give them commands 
or instructions. 
(2) 
The appointment, dismissal, transfer, wage or personnel evaluation of employees 
who are assisting the Audit Committee with their duties shall be decided only 
after obtaining the approval of the Audit Committee. 
 
 
7. 
Framework regarding reports by Directors (except those who are members of the 
Audit Committee),  executive officers and employees of the Company to the Audit 
Committee of the company, and reports by Directors and employees of the 
subsidiaries of the Company or personnel who have received reports from them to 
the Audit Committee of the Company 
(1) 
Directors (except those who are members of the Audit Committee), executive 
officers and employees of the Company, as well as directors, Audit and 
Supervisory Board members and employees of subsidiaries shall promptly, and 
either directly or via the relevant function, submit a report to the Audit 
Committee of the Company in cases where it becomes known that there has 
been a significant violation of laws or regulations or of the Articles of 
Incorporation; or when it becomes known that there has been wrongdoing; or 
when it becomes known that there is risk of substantial harm to the Company. 
In other cases where the Audit Committee requests a report from an executive 
officer or employee, etc. of the Olympus Group, in accordance with laws and 
regulations, or Audit Committee Rules etc., the executive officer or employee in 
question shall promptly report to the Audit Committee. 
(2) 
In case any material compliance issue arises in the Olympus Group, the Chief 
Compliance Officer shall make reports on details and other matters to the Board 
of Directors in accordance with the Compliance Management System Rule. 
Reports on details of issues reported and results of investigations shall also be 
made regularly to the Audit Committee. 
(3) 
The Internal Audit function of the Company shall regularly report the status of 
internal audit in the Olympus Group to the Audit Committee of the Company. 
In addition, the Chief Compliance Officer shall report the status concerning 
compliance to the Audit Committee regularly.  
 
8. 
Framework to ensure that any personnel who have made a report to the Audit 
Committee of the Company will not be subjected to any unfair treatment due to the 
report made 
The Company shall set forth internal corporate regulations and shall not impose any 
unfair treatment (including de-facto measures such as restricting the personnel to 
engage in duties, or assigning the personnel solely to work on chores, in addition to 
measures of personnel affairs such as dismissal, demotion, pay cut and other 
disciplinary actions and disadvantageous transfer) to any personnel who have made 
a report on the grounds of having made a report to the Audit Committee. 
 
 
265

5 
 
9. 
Matters regarding procedures for advance payment of expenses incurred in 
connection with execution of duties by the Audit Committee members of the 
Company and their reimbursement, and treatment of other expenses or liabilities 
incurred in connection with execution of the duties 
The Company shall set forth internal corporate regulations. When an advance 
payment or reimbursement of expenses is requested for execution of duties of Audit 
Committee members, the Company shall promptly process disbursement except for 
such case that the expense is obviously deemed unnecessary for execution of duties 
by Audit Committee members. 
 
 
10. Other systems to ensure the effectiveness of audit by the Audit Committee of the 
Company 
(1) 
Directors, executive officers and employees of the Company and Directors and 
employees of the subsidiaries shall ensure effectiveness of the audit by 
cooperating with the Audit Committee for investigations by interviews and on-
site inspections. 
(2) 
The Company shall ensure that it provides the Audit Committee with 
opportunities to sufficiently exchange opinions with Directors, Executive 
Officers, Accounting Auditors and any other personnel necessary. 
(3) 
The Company shall ensure that the Audit Committee is permitted to have its 
members attend important meetings, and that they have an opportunity to state 
their opinion. 
(4) 
The Audit Committee and an internal audit function shall work closely, and the 
Audit Committee are allowed to exercise authority to give instructions and 
make commands to the internal audit function as necessary. 
(5) 
The Company shall ensure that it provides the Audit Committee with, upon 
their request, opportunities of collaboration between the Audit Committee and 
Audit Committee of the subsidiaries and collecting information from employees 
of the subsidiaries. 
 
266

Olympus Group Risk Management and Crisis Response Policy
All our activities are based on our corporate philosophy, "Making people's lives healthier, safer and more fulfilling." Following this philosophy, the Olympus
Group will conduct global risk management activities to obviate and mitigate the risks that might prevent the achievement of its group management
objectives. In the event that a risk materializes, the Olympus Group will promptly and appropriately take actions to minimize any crisis and damage.
1. Basic Purpose
2. Action Guidelines
3. Establishment of a Risk Management System
We will establish a risk management system and a crisis response system, and clarify the related responsibilities in order to ensure conducting risk mitigation
activities and making appropriate management and responses in case of emergencies.
4. Establishment of Rules
We will establish the in-house rules to clarify the measures to be implemented, in order to ensure conducting appropriate risk mitigation activities and making
appropriate responses in case of emergencies.
5. Education
We will provide necessary education and training so that each organization and all personnel in the Group will be able to act appropriately in line with the
Action Guidelines to meet the Basic Purpose as described in this policy.
To secure the safety of customers, regional residents, officers, employees and their families
To keep the managerial resources intact and ensure the continuity of business
To improve the quality of business management and increase the corporate value
We respond to stakeholders' expectation by managing risks integrally on a company-wide basis, and through responses implemented with sufficient
consideration for social demand and/or change.
We incorporate risk management into our day-to-day global business activities.
We integrate risk management consciousness throughout our organizations and members, and continuously increase our risk response ability, through
global risk management activities.
We take prompt, responsible actions prioritizing human life and safety in case of emergency.
267

Global Privacy Notice
Effective Date: January 1, 2020
Last Updated: November 30, 2020
I.	Introduction
Appropriately managing and safeguarding personal data is fundamental to Olympus Corporation and its family of companies’ (“We” or “Olympus”), core
values and commitment to patients, healthcare professionals(“HCP”), external business partners, employees, and customers. This Privacy Notice explains
how we collect, use and share information, including your personal data, when it’s collected through this website and/or mobile application, linked products,
applications, services, websites, sub-sites, widgets, interactive features, forms, mobile site(s) and social media pages offered, owned, or operated by
Olympus (the “Site(s)”).
If we make changes to this Privacy Notice, we will notify you by revising the Effective Date above and, in some cases, we may provide you with more
prominent notice (such as sending you a notification or providing you with other disclosures within or in connection with the provision of the Sites). Your
access to and use of the Site(s) means you agree to the terms in this Privacy Notice. We encourage you to refer to this Privacy Notice periodically so that
you understand our current privacy practices.
This Privacy Notice Explains:
II. Who You Should Contact
If you have any questions about this Privacy Notice, please contact us by using the following information:
Contact us within the Americas:
Attn: Data Protection
Olympus Corporation of the Americas
3500 Corporate Parkway Center Valley, PA 18034
DataProtection.Americas@olympus.com
Introduction
I.
Who You Should Contact
II.
Types Of Information We Collect And Use
III.
Why We Collect And Use Information
IV.
Additional Ways We May Collect and Share Your Information
V.
How Long We Will Keep Your Personal Data
VI.
Our Use Of Information Technology
VII.
Security
VIII.
International Transfers Of Personal Data
IX.
Promotional Emails
X.
Information Applicable To Residents Of the United States
XI.
Personal Data Subject To European Privacy Laws
XII.
Personal Data Subject To Japanese Privacy Laws
XIII.
268

Contact us within Europe, Middle East and Africa:
Attn: Data Protection
Olympus Europa SE & CO. KG
Amsinckstraße 63 20097 Hamburg, Germany
DataProtection.EMEA@olympus.com
Contact us in Asia:
Attn: Data Protection
Olympus Corporation
Shinjuku Monolith, 3-1 Nishi-Shinjuku 2-chrome Shinjuku-ku, Tokyo 163-0914, Japan
Dataprotection_japan@ot.olympus.co.jp
Or, follow the instructions in the “contact us” section within the Site(s), if applicable.
III. Types Of Information We Collect And Use
Olympus collects certain information, including personal data, from you and about you. The term “personal data” means any information that identifies,
relates to, describes, is capable of being associated with, or could reasonably be linked, directly or indirectly, to a natural person (you). Olympus’ goal is to
limit the information we collect to the information needed to support our business. Not all categories may be collected about every individual.
Below is a summary of the categories of personal data we may collect, where we get it, why we collect it, and with whom we may share it:
Category of Personal
Data Collected
Source of Information
Purpose for Collection
Categories of Recipients
Identifying Information, such
as salutation, first/last name,
address, telephone number,
email address, fax number,
images posted by you, certificate
or license number, birth date,
title, and company name,
department and/or title
From you, when you create a
profile, place an order, register
for an event, register a product,
contact us for inquiries, enter
contests, request information
about our products, to make a
general inquiry and/or make a
complaint.
Olympus trainers and/or sales
and marketing representatives
may ask your permission to enter
your information into their
customer book.
Product and service fulfillment;
marketing, promotions &
advertising; internal operations;
and fraud prevention, security
and compliance.
Information provided to Olympus
trainers and/or sales and
marketing representatives is
used to communicate with you
on a one-to-one basis about our
products, services, and
promotions that may be of
interest to you or fulfill orders at
your requests.
Our current or future parent
company and corporate affiliates
and subsidiaries; our service
providers, sub processors,
and/or consultants (such as
advertising and marketing
vendors, shipping and fulfilment
service providers and/or third
party payment services); third
party marketers; our business
partners (including third parties
that provide products and
services related to our business,
such as contract-based
distributors of Olympus
products); and any other person
at your consent or direction
Login information, such as
usernames and passwords used
to access your account
From you
To enable you to access our
services
This information is not shared
outside Olympus
269

Category of Personal
Data Collected
Source of Information
Purpose for Collection
Categories of Recipients
Payment Information, such as
credit card number, bank account
number and/or billing address
From you. We collect this
information when you make
purchases.
Product and service fulfillment;
internal operations; fraud
prevention, and security and
compliance; payment processing
Our card processor stores all
credit card information. They
conduct the credit card
transactions using commercially
reasonable security precautions,
controls, policies, and
procedures, consistent with
generally accepted data
processing standards in the
financial services industry. We
only store a record that the
transaction took place and the
amount you paid in connection
with your account information.
Information you post in a
public space on the Site(s),
such as comments, images (from
Facebook, Instagram, etc.),
blogs, reviews, ratings, etc.
From you
Marketing, promotions &
advertising; and internal
operations
Our sites (we may display
information you post on reviews
or comments with various social
media platforms); our current or
future parent company and
corporate affiliates and
subsidiaries; our service
providers, sub processors,
and/or consultants (such as
advertising and marketing
vendors); third party marketers;
our business partners (including
third parties that provide
products and services related to
our business, such as contract-
based distributors of Olympus
products); and any other person
at your consent or direction
Event Information, such as
contact information, title,
company and/or mailing address
From you, when you sign up for
our events and trainings
Marketing, promotions &
advertising; internal operations;
and fraud prevention, security
and compliance
Our current or future parent
company and corporate affiliates
and subsidiaries; our service
providers, sub processors,
and/or consultants (such as
advertising and marketing
vendors or shipping and
fulfilment service providers); third
party marketers; our business
partners (including third parties
that provide products and
services related to our business,
such as contract-based
distributors of Olympus
products); and any other person
at your consent or direction
270

Category of Personal
Data Collected
Source of Information
Purpose for Collection
Categories of Recipients
Demographic Information,
such as your age, gender and zip
code
From you, when you create
profiles, participate in contests,
sweepstakes, promotions,
surveys, etc.
Marketing, promotions &
advertising; internal operations
Our current or future parent
company and corporate affiliates
and subsidiaries; our service
providers, sub processors,
and/or consultants (such as
advertising and marketing
vendors); third party marketers;
our business partners (including
third parties that provide
products and services related to
our business, such as contract-
based distributors of Olympus
products); and any other person
at your consent or direction
Device Information, such as the
type of device you use to access
the Site(s), your device
identification number, IP address
or mobile operating system
From you, automatically when
you visit the Site(s)
Product and service fulfillment;
marketing, promotions &
advertising; internal operations;
and fraud prevention, security
and compliance
Our current or future parent
company and corporate affiliates
and subsidiaries; our service
providers, sub processors,
and/or consultants (such as
advertising and marketing
vendors, shipping and fulfilment
service providers and/or third
party payment services); third
party marketers; our business
partners (including third parties
that provide products and
services related to our business,
such as contract-based
distributors of Olympus
products); and any other person
at your consent or direction
271

Category of Personal
Data Collected
Source of Information
Purpose for Collection
Categories of Recipients
Location information, such as
the physical location of your
device based on, for example,
satellite, cell phone tower or Wi-
Fi signals
From you, automatically when
your device is set to provide
location information
Product and service fulfillment;
marketing, promotions &
advertising; internal operations;
fraud prevention, security and
compliance; and to provide you
with personalized location-based
services and content
Our current or future parent
company and corporate affiliates
and subsidiaries; our service
providers, sub processors,
and/or consultants (such as
advertising and marketing
vendors, shipping and fulfilment
service providers and/or third
party payment services); third
party marketers; our business
partners (including third parties
that provide products and
services related to our business,
such as contract-based
distributors of Olympus
products); and any other person
at your consent or direction.
We may also share your device’s
physical location, combined with
information we collect, with our
marketing partners to enable
them to provide you with more
personalized content and to
study the effectiveness of
advertising campaigns. In some
instances, you may be permitted
to allow or deny such uses
and/or sharing of your device’s
location, but if you do, we and/or
our marketing partners may not
be able to provide you with the
applicable personalized services
and content.
Internet or Other Network
Activity Information, such as
your browsing history, search
history and other information
regarding your interactions with
our Site(s) or advertisements
From you, as initiated by you or
automatically when you visit the
Site(s), through the use of our
own and/or third-party
technologies such as cookies
and mobile device identifiers as
further discussed in Section VII
Product and service fulfillment;
marketing, promotions &
advertising; internal operations;
and fraud prevention, security
and compliance
Our current or future parent
company and corporate affiliates
and subsidiaries; our service
providers, sub processors,
and/or consultants (such as
advertising and marketing
vendors, shipping and fulfilment
service providers and/or third
party payment services); third
party marketers; our business
partners (including third parties
that provide products and
services related to our business,
such as contract-based
distributors of Olympus
products); and any other person
at your consent or direction
272

Category of Personal
Data Collected
Source of Information
Purpose for Collection
Categories of Recipients
Browser or App Information,
such as what site you came from
and what site you visit when you
leave the Site(s) or how often
you use the app and where you
downloaded it
From you, automatically when
you visit the Site(s)
Product and service fulfillment;
marketing, promotions &
advertising; internal operations;
and fraud prevention, security
and compliance
Our current or future parent
company and corporate affiliates
and subsidiaries; our service
providers, sub processors,
and/or consultants (such as
advertising and marketing
vendors, shipping and fulfilment
service providers and/or third
party payment services); third
party marketers; our business
partners (including third parties
that provide products and
services related to our business,
such as contract-based
distributors of Olympus
products); and any other person
at your consent or direction
Other information you provide,
such as recordings of calls when
you call our customer service
team or Technical Assistance
Center or when you contact us
through one of our internet
marketing channels or via social
media
From you
For quality assurance and
operational optimization
purposes; product and service
fulfillment; marketing, promotions
& advertising; internal
operations; and fraud prevention,
security and compliance
Our current or future parent
company and corporate affiliates
and subsidiaries; our service
providers, sub processors,
and/or consultants; our business
partners (including third parties
that provide products and
services related to our business,
such as contract-based
distributors of Olympus
products); and any other person
at your consent or direction
Legal information, such as
fraud checks or flags raised
about your transactions, the
payment card you want to use,
payment card refusals,
suspected crimes, complaints,
claims and accidents
From you, the police, crime and
fraud prevention agencies,
payment card providers, the
public, regulators, and your and
our professional advisors and
representatives
To protect you, other customers
and our business against
criminal activities and risks; if
required by law, governmental
request or court order or based
on our good faith belief that it is
necessary to conform or comply
with such law, request or court
order or to protect the users of
our website or the public
Our current or future parent
company and corporate affiliates
and subsidiaries; our service
providers who help us with fraud
protection and credit risk
reduction; law enforcement and
other governmental authorities in
accordance with applicable law
IV. Why We Collect And Use Information
Below are examples of ways we use your information collected for product and service fulfillment; marketing, promotions, and advertising; internal
operations; fraud prevention, security and compliance; and payment processing, as referenced above:
(a)	Product and Service Fulfillment
(b)	Marketing, Promotions & Advertising
To complete, fulfill, manage, and communicate with you about your transactions;
To establish and service your online profile/account on the Site(s);
To provide you with customer service and alert you to product or shipping information;
To enable the provision of services, such as training events, repair of products, and other events or services;
To administer loyalty programs; and
Respond to inquiries, requests, complaints, questions, comments.
273

(c)	Internal Operations
(d)	Fraud Prevention, Security and Compliance
(e)	Payment Processing
Olympus does not rent, lease, or otherwise sell your Personal Data.
V. Additional Ways We May Collect And Share Your Information
In addition to the methods enumerated above, Olympus may collect and share information, including your personal data, through the following methods:
(a)	Information From Other Sources
(b)	Business Transfers
To deliver information about our products, services, and promotions (e.g., email, third-party sites or applications, and mobile devices);
To provide interactive features on the Site(s) (e.g. product ratings and reviews, comments, blogs, real-time offers and location-based offers);
To identify product preferences and shopping preferences (e.g. services and promotions of possible interest) and;
To administer contests, sweepstakes, promotions, and surveys.
To improve the effectiveness of the Site(s), services, merchandise assortment, and customer service;
Quality control and training;
To confirm contractual requirements;
To conduct research and analytics related to our operations; and
To perform other logistics and operations activities as needed.
To protect our assets and prevent fraudulent transactions;
To validate credentials and authenticate customers, HCP’s and other users when logging into your online profile, and/or applications;
To protect the security and integrity of our services and our data; and
To assist law enforcement and respond to legal regulatory inquiries.
To process your payments and address your order inquiries and requests.
We may receive your updated shipping information from a third-party provider.
We engage with current and prospective customers through multiple internet marketing channels and social media services (e.g., Facebook, Instagram,
Twitter, Tiktok, Wechat, Weibo). If you contact us on one of our internet marketing channels, request customer service via social media or otherwise direct
us to communicate with you via social media, we may contact you via direct message or use other internal or social media tools to interact with you. In
these instances, your interactions with us are governed by this Privacy Notice as well as the privacy notice of the social media platform you use. If you
choose to access, link to, or log-in to our Sites or internet marketing channels or otherwise communicate with us through a third-party social media
service, you are granting us permission to access and use the information that you post or store on the applicable social media service in accordance with
the privacy notice of that service and the privacy settings that are applicable to your account, and to store the user name and password you use to log-in
to the applicable social media service. By accessing or logging into our Sites or internet marketing channels via a social media service, any information
you provide to us may also become accessible to that service, subject to that service’s privacy notice. For additional information and more details on how
you can manage the information provided to us by these social media services, please review the privacy settings applicable to your account with the
applicable social media service. We do not control, and are not responsible for, the privacy practices of such services. Please consult the privacy notice of
such services for additional information.
We may also share aggregated or anonymize information, which cannot reasonably be used to identify you.
We participate in consortiums to share information or match customer data. When shared, this information is de-identified or anonymized.
We may receive various types of information, including identification information, contact information, and transactional information, from our service
providers, vendors, and family of companies. We may combine the personal data and non-personal data collected online and offline, including information
collected from third parties to provide you with advertisements we think you will find interesting.
Unless otherwise prohibited by law, if Olympus merges with, acquires or is acquired by another business entity, it may share your information with any
successors to all or part of its business. This may include an asset sale, corporate reorganization or other change of control. If Olympus or any of its
274

(c)	Third Party Marketing
VI. How Long We Will Keep Your Personal Data
We will retain your Personal Data only as long as necessary to provide you with the products, services and programs you request, our essential business
purposes, such as maintaining the performance of the services and programs, making data-driven business decisions about new features and offerings,
complying with our legal obligations and resolving disputes. When we have no justifiable business need to process your Personal Data, we will either delete
or anonymize it.
The criteria, used to determine our retention periods include:
VII.	Our Use Of Information Technology
This section describes the various types of technologies we may use when you interact with our Site(s), and your choices regarding those technologies:
(a)	Cookies, Pixel Tags, and Flash Cookies
(b)	Website Optimization Services
(c)	Interest-Based or Online Behavioral Advertising
(d)	Social Network & New Tech Advertising Programs
(e)	Do Not Track
subsidiaries sold to or are otherwise acquired by a third party, all Olympus’ data assets will become the property of the acquiring party. Such a party will
be subject to the consent(s), opt-outs or other customer conditions on data. A change in data ownership may or may not include a notice on the Site(s).
Unless prohibited by law, including the European Privacy laws, as defined in Section XII, we may share your information with third parties that provide
products or services we believe may interest you. These third parties may also share your information with others. These third parties may use your
information for their own marketing purposes or the marketing purposes of others. This may include the delivery of internet-based advertising.
The length of time we have an ongoing relationship with you and provide services or programs to you (for example, for as long as you have a
profile/account with us or keep using the services/programs);
Whether there is a legal obligation to which we are subject; or
Whether retention is advisable in light of our legal position (such as in regard to applicable statues of limitations, litigation or regulatory investigations).
We collect certain information, including personal data, by automated means, using technologies such as cookies, pixel tags, browser analysis tools,
server logs, and web beacons. Cookies are small text files that websites send to your computer or other connected device to uniquely identify your
browser or to store information or settings in your browser. Cookies allow us to recognize when you return to the Site(s). They also help us provide a
customized experience and enable us to detect certain kinds of fraud. The types of technology used by Olympus may change over time as technology
evolves. Some of these technologies are essential for the provision of the Site(s), such as account access/authentication.
Olympus shares information with Google Analytics and other optimization services to understand and optimize website performance and enhance site
usability for users. These tools run in the background of our sites analyzing site usage information and then return reports to us through an encrypted
connection. They are required to maintain data securely and confidentially and are not permitted to share data collected with parties other than Olympus.
Credit card, passwords or other sensitive information is not collected through these optimization services. In addition, these services may associate and
group session visits to our website from various browsers and devices. To learn more about Google Analytics, including options for opting out and/or
managing the ads you may see online please visit: www.google.com/policies/privacy/partners.
Olympus uses third-party advertising companies to serve interest-based advertisements. These companies compile information from various online
sources to match user profiles with ads we believe will be most relevant, interesting and timely based on that users profile.
Olympus has relationships with several social networks. These companies have specific interest-based ads programs that match people that have
shown an interest in Olympus through our Site(s) or other services within their profiles (such as on Facebook) and platforms (such as Facebook and
Google). This matching allows us to deliver relevant, interest-based ads on those companies’ networks.
Olympus does not currently recognize and process Do Not Track signals from different web browsers. For more information on Do Not Track please visit
http://www.allaboutdnt.org/ 
.
275

VIII. Security
Olympus is committed to maintaining appropriate organizational, technical, and physical controls to protect the personal data entrusted to us. These controls
protect personal data from anticipated threats and hazards as well as unauthorized access and use. Olympus will strive to provide security that is
proportional to the sensitivity of the personal data being protected, with the greatest effort being focused on protecting sensitive personal data, like financial
or medical data, that could result in substantial harm or inconvenience if it got into the wrong hands.
IX. International Transfers Of Personal Data
Your information, including your personal data, will be submitted to servers managed by Olympus and/or its service providers/sub processor(s). By accessing
or using the Site(s) or otherwise providing information to us, you consent to the processing and transfer of information, including your personal data, to the
European Union, Japan, United States and/or any other location where the Olympus group operates which are described at https://www.olympus-
global.com/company/base/?page=company.
X.	Promotional Emails
If we send you any promotional emails, and you no longer would like to receive such emails, please follow the “unsubscribe” instructions on those emails, if
available. Your email address will be removed from our marketing list. Please allow us a reasonable period of time in order to satisfy your request.
XI. Information Applicable To Residents Of the United States
(a) Information about Minors
Olympus is strongly committed to preserving online privacy for all of our Site(s) visitors, including children. Olympus’ policy is not to collect any personal data
about children under 13 years old. Olympus’ services are offered to customers who are the age of 13 years and above. No programs, services or offerings
are intended for children under the age of 13. Furthermore, we may restrict entries to any contests, sweepstakes or promotions to entrants who are at least
18 years of age.
Minors under 18 years of age may have the Personal Information that they provide to us through the Site deleted by sending an email requesting deletion to
DataProtection.Americas@olympus.com. Please note that, while we make reasonable efforts to comply with such requests, deletion of your personal data
does not ensure complete and comprehensive removal of that data from all systems.
(b) California Residents
California residents have certain additional rights regarding our use and disclosure of personal information. For purposes of this section XI only, the term
“personal information” means information that identifies, relates to, describes, is reasonably capable of being associated with, or could reasonably be linked,
directly or indirectly, with a particular consumer or household, as further defined by the California Consumer Privacy Act of 2018.
You may request a copy of the following: (1) The categories of personal information we collected about you; (2) The categories of sources from which
the personal information is collected; (3) The business or commercial purpose for collecting or selling (if applicable) the personal information; (4) The
categories of third parties with whom we share personal information; and (5) The specific pieces of personal information we have collected about you.
To submit a request for this information, you may email us at DataProtection.Americas@olympus.com.
1.
You may request that we (and our service providers) delete your personal information. Note that deletion requests are subject to certain limitations, for
example, we may retain personal information as permitted by law, such as for tax or other record keeping purposes, to maintain an active account, to
process transactions and facilitate customer requests, and for certain other internal business purposes described in this Privacy Notice. To submit a
request for deletion, you may email us at DataProtection.Americas@olympus.com.
2.
276

Olympus may require proof of California residence before responding to any request made under this section. You may authorize another person (your
“agent”) to submit a request on your behalf by emailing DataProtection.Americas@olympus.com. Shortly after you (or your agent) submit a request, we will
contact you (via email at the email address provided during submission of your request) with instructions on how to verify the request before we fulfill it. We
will verify your identity by asking you to log in to your account if you have one with us. Or if you do not, we may ask for your email address, the order number
of a recent order you placed with us or the last four digits of a credit or debit card used on our Site(s). We will aim to complete your requests as soon as
reasonably practicable and consistent with any applicable laws.
If you have an account with us, you may also see certain personal information (such as certain profile and transaction information) directly through your
account profile page after logging in to a Site. Please note that changes you make on your account profile page through one of our Sites may not always be
reflected on other Sites operated by us.
(c) Shine the Light Law - Direct Marketing
You have the right to request information from Olympus once per calendar year regarding the manner in which Olympus shares certain categories of your
personal information with third parties, for the third parties' direct marketing purposes. California Civil Code § 1798.83 provides you with the right to submit a
request to Olympus at its designated address and receive the following information:
You are entitled to receive a copy of this information in a standardized format and the information will not be specific to you individually. Olympus’ designated
email address for such a request is DataProtection.Americas@olympus.com 
.
To learn more about managing your privacy and to know your choices concerning interest-based ads, you may visit the Network Advertising Initiative's opt-
out page at http://www.networkadvertising.org/managing/opt_out.asp or www.aboutads.info/choices 
.
XII.	Personal Data Subject To European Privacy Laws
If you are located in the European Union, the United Kingdom, Switzerland and/or your personal data is otherwise subject to the General Data Protection
Regulation or comparable European Data Protection Legislation (collectively referred to as “European Privacy Laws”), this section provides additional
You may request to opt-out of the sale of your personal information by emailing mailto:DataProtection.Americas@olympus.com. Please see below for
the categories of personal information we may have sold about you in the preceding 12 months.
3.
We will not discriminate against you for exercising your rights under this section.
4.
As set forth above, California law requires us to identify, for the prior to the collection of your personal data, what information Olympus has “sold” about
you. Please be assured that Olympus does not sell or rent your information to third parties purely for our profit, to data brokers, or in any way other than
those intended to improve your online experiences and the relevance of offers made to you through Olympus and elsewhere. Instead, there are
instances where Olympus has shared personal information in order to provide our customers with personalized services or customized offers to
improve your online experiences through our services or elsewhere. We do this in ways that are intended to extend the Olympus experience to our
customers in a variety of environments. Depending on the circumstances and the contractual obligations in place, this sharing may be a “sale” under
applicable law and you may have the right to request that we stop such sharing as more fully set forth below. This sharing includes:
5.
identifiers such as a real name, alias, postal address, unique personal identifier (such as a device identifier; cookies, beacons, pixel tags, mobile ad
identifiers and similar technology; customer number, unique pseudonym, or user alias; telephone number and other forms of persistent or
probabilistic identifiers), online identifier, Internet Protocol address, email address, account name, and other similar identifiers;
・
commercial information, including records of services purchased, obtained, or considered, and other purchasing or consuming histories or
tendencies;
・
Internet and other electronic network activity information, including, but not limited to, browsing history, search history, and information regarding
your interaction with websites, applications or advertisements; and
・
inferences drawn from any of the information identified above to create a profile about you reflecting your preferences, characteristics,
psychological trends, predispositions, behavior, attitudes, intelligence, abilities, and aptitudes.
・
The categories of personal information Olympus’ disclosed to third parties for the third parties' direct marketing purposes during the preceding calendar
year;
1.
The names and addresses of third parties that received such information; and
2.
If the nature of a third party's business cannot be reasonably determined from the third party's name, examples of the products or services marketed.
3.
277

information about your rights and how Olympus processes your personal data.
Olympus is the controller of personal data submitted by you or otherwise collected when you use the Site(s). Please note, however, that Olympus is not the
controller of third-party data you may submit to the Site(s). We process such information within the Site(s) solely in the processor’s role and, depending on
the scope of your activity, you may be the data controller.
(a)	Rights to Control Your Personal Data
(b)	Sharing your personal data
(c)	Tracking Tools (“Cookies”)
(d)	Contact us
(e)	Submit a Complaint to a Supervisory Authority
(f)	Legal Basis
Olympus has the following legal basis for processing your Personal Data:
Type of Personal
Data
Legal Basis
Information you
provide to us
Information we c
ollect automatic
ally
If you have questions about or need further information concerning the legal basis on which we collect and use your Personal Data, please contact us at
DataProtection.EMEA@olympus.com.
XIII. Personal Data Subject To Japanese Privacy Laws
You may request, pursuant to the Act on the Protection of Personal Information (Japanese Law), the disclosure correction, deletion or other measures
regarding the personal data provided hereby. Please see “Personal Information Inquiry” for matters concerning procedures for consenting to “requests for
disclosure” on the service desk. 
https://www.olympus-global.com/products/contact/privacy.html
You may have certain rights with regard to your personal data under European Privacy Laws. If you would like to request a copy of your personal data
being held by us, request that your personal data is deleted, request to update and/or correct your personal data, or request that we provide a copy of
your personal data to another data controller, please contact us. We will aim to respond to your request within one calendar month of receipt of your
request. Where we are unable to do so within the calendar month, we will notify you of the soonest practicable time within which we can respond to your
request (and within three months from the date of your request). There are certain exemptions and restrictions of these rights under the European
Privacy Laws that enable personal data to be retained, processed or withheld from access and we will inform you of these restrictions if they apply. We
use your Personal Data as described in the chart above.
We share your personal data with third parties to help us use your personal data, as described in the Privacy Notice.
We use cookies as described in our Cookie Notice. You may choose to block or delete cookies, but doing so will cause the Site(s) to not operate
correctly.
You may access, download, change, or modify your personal data by contacting us. You may also exercise your right to prevent us from sharing your
personal data at any time by contacting us as described above in the “Who You Should Contact” section.
You have the right at all times to submit a complaint to a data protection supervisory authority, in case you feel that the processing of your personal data,
as described in this Notice, infringes with the law. You may find a list of the supervisory data protection authorities in Europe here:
https://edpb.europa.eu/about-edpb/board/members_en 
.
Olympus exercising its rights and performing its obligations in connection with any contract we make with Controller (Article
6 (1) (b) General Data Protection Regulation).
Compliance with Olympus’ legal obligations (Article 6 (1) (c) General Data Protection Regulation).
Legitimate interests pursued by Olympus (Article 6 (1) (f) General Data Protection Regulation). Olympus has assessed that t
hese legitimate interests are not overridden by the data protection interests or fundamental rights of any individuals.
Compliance with Olympus’ legal obligations (Article 6 (1) (c) General Data Protection Regulation).
278

History of revision
Date
Content of revision
Reason
Oct. 2 2020
Revise Mail address of “Contact us in Asia” in II
Correction of typos
Oct. 2 2020
Add XIII newly
Legal response to Japanese privacy law
279

The Olympus Group Personal Information Protection Policy 
(Translation)
Note: This Personal Information Protection Policy is based on a Japanese law, and thus is applicable only to Olympus Group Companies in Japan (excluding
companies with their own personal information protection policy in place).
The Olympus Group recognizes the importance of protecting personal information in the network society and believes that it is the Olympus Group's social
responsibility to properly handle and protect personal information. Accordingly, the Olympus Group shall implement the following measures.
Established Mar. 11, 2005
Updated Oct. 1, 2015
See Handling of Personal Information for information on how the Olympus Group handles personal information.
Personal Information Protection Policy
1. Implementation of an Internal System
The Olympus Group shall implement its internal system for the protection of personal information and educate all of its Directors, Auditors and employees to
enable proper handling of personal information. In addition, in order to ensure that initiatives to protect personal information are being accurately
implemented, the Olympus Group shall periodically hold audits.
2. Proper Handling of Information
The collection of personal information shall be limited to the appropriate scope and amount and may only occur after the person who provides his or her
personal information (the "Information Provider") has been clearly informed of the intended purpose and use of such information. In addition, the Olympus
Group shall not handle any personal information outside the appropriate scope and shall accommodate an Information Provider's requests for disclosure,
correction, deletion or discontinued of use of his or her personal information within a reasonable period following such request.
Furthermore, the Olympus
Group shall handle specific personal information only within the scope of purpose of use prescribed by law.
3. Limitation of Provision and Disclosure of Personal Information to Third Parties
Unless consent of the relevant Information Provider is obtained or otherwise required by law, the Olympus Group shall not disclose or otherwise provide
personal information to third parties.
Furthermore, unless required by law, the Olympus Group shall not disclose or provide any specific personal information the Olympus Group hold to any third
party, regardless of whether the relevant Information Provider consents to the disclosure.
If the Olympus Group engages a third party on a matter that involves disclosure of personal information (maintained by the Olympus Group) to the third
party, the Olympus Group shall cause such third party to enter into a contract that obligates such party to properly maintain and manage personal
information.
Further, in such situations, the Olympus Group shall supervise and provide directions to such third party in connection to the protection of personal
information.
4. Ensuring of Accuracy and Safety
The Olympus Group shall make efforts to maintain accurate and up-to-date personal information, and take appropriate security measures against risks such
as unauthorized access to personal information, loss, destruction and falsification of personal information, and unauthorized disclosure of personal
information.
280

5. Compliance with Laws and Regulations, and Continuous Improvements
The Olympus Group shall comply with laws, regulations and standards applicable to the protection of personal information and review and make continuous
improvements to the above-mentioned measures.
Related Links
Handling of Personal Information
Personal Information Inquiry
281

External Evaluation
External Evaluation Regarding ESG *As of June 2021
Selected for Inclusion in ESG Indexes
Dow Jones Sustainability Asia Pacific Indices
FTSE4Good Index Series
FTSE Blossom Japan Index
External Evaluation Regarding ESG
Obtained an A- rating in the climate change survey and the water security survey by CDP Worldwide, an international NGO that aims at the realization of
a sustainable economy.
Listed in White 500, the Certified Health & Productivity Management Organization Recognition Program (five consecutive years since 2017 for Olympus,
and 2021 for Olympus Medical Science Sales).
Listed in the Certified Health and Productivity Management Organization Recognition Program (2021 for Aizu Olympus).
Certified as a Sports Yell Company (2021 for Olympus Terumo Biomaterials, and Olympus Medical Science Sales).
Received Kurumin accreditation from the Ministry of Health, Labour and Welfare as a company well-equipped with supports for raising children (2016 and
2019 for Olympus, 2018 for Olympus Terumo Biomaterials, and 2020 for Olympus Medical Science Sales).
Received Eruboshi certification from the Minister of Health, Labour and Welfare as a company that actively promotes female workers (Eruboshi Grade 3
for Olympus in 2019).
Received the Bronze rating under the PRIDE Index 2020, a Japanese index to evaluate a corporation's performance in LGBTQ inclusion.
282

Participating in External Initiatives
Commitment to External Initiatives
UN Global Compact
In October 2004, Olympus joined the UN Global Compact, agreeing to uphold its 10 principles.
The Global Compact (GC) is a voluntary initiative to create a global framework within which companies can contribute to
good corporate citizenship and sustainable growth through responsible and creative leadership. The 10 principles of the
Global Compact are incorporated into our Corporate Conduct Charter and related policies, and are reflected in our business
activities.
Olympus has supported initiatives on climate change as a signatory to the Global Compact "Caring for Climate" since 2009,
and announced its support for Global Compact Network Japan's "Tokyo Principles for Strengthening Anti-Corruption
Initiatives" in April 2018. Also, we participate in the Disaster Risk Reduction (DRR) Subcommittee of Global Compact
Network Japan.
Task Force on Climate-related Financial Disclosures
The Financial Stability Board created the Task Force on Climate-related Financial Disclosures (TCFD) to
improve and increase reporting of climate-related financial information including risks and opportunities. In
April 2021, Olympus announced that it would endorse the final recommendations issued in June 2017 by
TCFD.
283

Page 1 of 2
LR Independent Assurance Statement 
Relating to Olympus Corporation’s Environmental and Social Data 
within its Sustainability Report 2021 for the fiscal year 2020 
This Assurance Statement has been prepared for Olympus Corporation in accordance with our contract but is 
intended for the readers of this report. 
Terms of engagement 
Lloyd’s Register Quality Assurance Limited (LR) was commissioned by Olympus Corporation (“the Company”) to 
provide independent assurance on its environmental and social data within its Sustainability Report 2021 (“the 
report”) for the fiscal year 2020, that is, from 1 April 2020 to 31 March 2021, against the assurance criteria below 
to a limited level of assurance and at the materiality of the professional judgement of the verifier using ISAE 3000 
and ISO 14064 - 3:2006 for greenhouse gas  (“GHG”) data. 
Our assurance engagement covered the Company’s and its consolidated subsidiaries’ operations and activities in 
Japan and overseas and specifically the following requirements: 
•
Verifying conformance with the Company’s reporting methodologies 
•
Evaluating the accuracy and reliability of data for the selected indicators listed below: 1
Environmental data2
•
Energy consumption 3 (MWh equivalent) 
•
Scope 1 GHG emissions (tonnes CO2e)
•
Scope 2 GHG emissions (Location-based and Market-based)  (tonnes CO2)
•
Scope 3 GHG emissions (Category 2-8, 12, 15) (tonnes CO2e) 
•
Water consumption volume (Piped water and Ground water) (m3) 3 
•
Waste generated (tonnes) 3 
Social data 
•
LTIFR 3 
•
OIFR 3 
•
Number of Occupational Incidents 3
•
Fatalities 3 
Our assurance engagement excluded the data and information of the Company’s suppliers, contractors and any 
third-parties mentioned in the report. 
LR’s responsibility is only to the Company.  LR disclaims any liability or responsibility to others as explained in the 
end footnote. The Company’s responsibility is for collecting, aggregating, analysing and presenting all the data 
and information within the report and for maintaining effective internal controls over the systems from which the 
report is derived.  Ultimately, the report has been approved by, and remains the responsibility of the Company. 
LR’s Opinion 
Based on LR’s approach nothing has come to our attention that would cause us to believe that Company has not, 
in all material respects: 
•
Met the requirements above 
•
Disclosed accurate and reliable environmental and social data
The opinion expressed is formed on the basis of a limited level of assurance and at the materiality of the
professional judgement of the verifier. 
1 LR undertook a limited assurance engagement of the environmental data marked with ★ within the Sustainability Report 2021. 
2 GHG quantification is subject to inherent uncertainty.  
3 The scope is covered the breakdown of each selected indicators. 
284

Page 2 of 2
Note: The extent of evidence-gathering for a limited assurance engagement is less than for a reasonable assurance engagement.  Limited 
assurance engagements focus on aggregated data rather than physically checking source data at sites.  Consequently, the level of assurance 
obtained in a limited assurance engagement is substantially lower than the assurance that would have been obtained had a reasonable 
assurance engagement been performed. 
LR’s approach 
LR’s assurance engagements are carried out in accordance with ISAE 3000 and ISO 14064 - 3 for GHG data. The 
following tasks though were undertaken as part of the evidence gathering process for this assurance engagement: 
•
Auditing the Company’s data management systems to confirm that there were no significant errors,
omissions or mis-statements in the report.  We did this by reviewing the effectiveness of data handling
procedures, instructions and systems, including those for internal verification; 
•
Interviewing with key people responsible for compiling the data and drafting the report;
•
Sampling datasets and tracing activity data back to aggregated levels; 
•
Verifying the historical environmental / social data and records for the fiscal year 2020; and 
•
By implementing the Company’s “No Visitor” Policy due to the global infection spread of COVID-19,
conducting the remote verification of Hinode Plant of Olympus Medical Systems Co., Ltd., Aomori Olympus
Co., Ltd., and the headquarter of Olympus Corporation to assess whether the data management systems
have been effectively implemented via e-mail and Microsoft Teams.
Observations  
The Company should further demonstrate the completeness, accuracy and reliability of its future environmental 
and social data reporting. This is particular to establish robust internal data control systems at consolidated 
subsidiary levels. 
LR’s standards, competence and independence 
LR implements and maintains a comprehensive management system that meets accreditation requirements for 
ISO 14065 Greenhouse gases – Requirements for greenhouse gas validation and verification bodies for use in 
accreditation or other forms of recognition and ISO/IEC 17021-1 Conformity assessment – Requirements for bodies 
providing audit and certification of management systems – Part 1: Requirements that are at least as demanding as 
the requirements of the International Standard on Quality Control 1 and comply with the Code of Ethics for 
Professional Accountants issued by the International Ethics Standards Board for Accountants. 
LR ensures the selection of appropriately qualified individuals based on their qualifications, training and 
experience. The outcome of all verification and certification assessments is then internally reviewed by senior 
management to ensure that the approach applied is rigorous and transparent. 
This is the only work undertaken by LR for Company and as such does not compromise our independence or 
impartiality. 
Signed 
Dated: 23 June 2021 
Norihiko Kinoshita 
LR Lead Verifier 
On behalf of Lloyd’s Register Quality Assurance Limited 
10th Floor, Queen's Tower A, 2-3-1 Minatomirai, Nishi-ku, Yokohama, JAPAN  
LR reference: YKA4005278 
Lloyd's Register Group Limited, its affiliates and subsidiaries, including Lloyd’s Register Quality Assurance Limited (LRQA), and their respective 
officers, employees or agents are, individually and collectively, referred to in this clause as 'Lloyd's Register'. Lloyd's Register assumes no 
responsibility and shall not be liable to any person for any loss, damage or expense caused by reliance on the information or advice in this 
document or howsoever provided, unless that person has signed a contract with the relevant Lloyd's Register entity for the provision of this 
information or advice and in that case any responsibility or liability is exclusively on the terms and conditions set out in that contract. 
The English version of this Assurance Statement is the only valid version. Lloyd’s Register Group Limited assumes no responsibility for versions 
translated into other languages.  
This Assurance Statement is only valid when published with the report to which it refers. It may only be reproduced in its entirety.
Copyright © Lloyd's Register Quality Assurance Limited, 2021.  A member of the Lloyd’s Register Group.
285

GRI Content Index
The information contained within the Sustainability Report (target period April 1, 2020 to March 31, 2021) and some of the information on our Website
conform to the Global Reporting Initiative (GRI) Sustainability Reporting Standards.
This report refers to the GRI Sustainability Reporting Standards below.
Indicator
Item
102 GENERAL DISCLOSURES
GRI 102: General Disclosures 2016
1 Organizational profile
102-1
Name of the organization
102-2
Activities, brands, products, and services
102-3
Location of headquarters
102-4
Location of operations
102-5
Ownership and legal form
102-6
Markets served
102-7
Scale of the organization


102-8
Information on employees and other workers
102-9
Supply chain
102-10
Significant changes to the organization and its supply chain
-
102-11
Precautionary Principle or approach
102-12
External initiatives



102-13
Membership of associations
2 Strategy
102-14
Statement from senior decision- maker
102-15
Key impacts, risks, and opportunities

3 Ethics and integrity
102-16
Values, principles, standards, and norms of behavior

102-17
Mechanisms for advice and concerns about ethics
Consolidated Company Outline
Our Business Fields
Consolidated Company Outline
Worldwide Office Locations
Consolidated Company Outline (Company Name)
Consolidated Company Outline > Revenue by Region
Consolidated Company Outline (Consolidated Headcount)
Worldwide Office Locations
Financial Results (Fiscal Year Ended Mar. 31, 2021)
Employment > Number of employees
Procurement
Environmental Policy and Strategy
Environmental Policy and Strategy > Response to Climate Change
Communication with Stakeholders > Basic Approach and Policy
Human Rights > Basic Approach and Policy
Participating in External Initiatives
Procurement > System, Mechanisms and Initiatives > Response to
Conflict Minerals
Reduce Environmental Impact > Energy/Atmospheric Release
Message from Chief Strategy Officer
Olympus Group ESG
Environmental Policy and Strategy
Risk Management System
Olympus Group Corporate Philosophy
Olympus Global Code of Conduct
Compliance > Promotion Structure
286

4 Governance
102-18
Governance structure
102-19
Delegating authority

102-20
Executive-level responsibility for economic,
environmental,and social topics
102-21
Consulting stakeholders on economic, environmental,and
social topics
-
102-22
Composition of the highest governance body and its
committees

102-23
Chair of the highest governance body
102-24
Nominating and selecting the highest governance body

102-25
Conflicts of interest

102-26
Role of highest governance body in setting purpose,
values,and strategy

102-27
Collective knowledge of highest governance body
102-28
Evaluating the highest governance body's performance
102-29
Identifying and managing economic, environmental, and
social impacts



102-30
Effectiveness of risk management processes


102-31
Review of economic, environmental, and social topics

102-32
Highest governance body's role in sustainability reporting
102-33
Communicating critical concerns

102-34
Nature and total number of critical concerns
102-35
Remuneration policies


Corporate Governance Structure
Olympus Group ESG
Environmental Policy and Strategy > Environmental Management
Structure
Corporate Governance Structure
Olympus Group ESG
Corporate Governance Structure
CORPORATE GOVERNANCE REPORT (PDF: 1.4MB)
Corporate Governance > Corporate Governance Structure
Board of Directors
Basic Policy	on Corporate Governance (PDF: 82.8KB)
CORPORATE GOVERNANCE REPORT (PDF: 1.4MB)
Notice Regarding the Convocation of the General Meeting of
Shareholders For the Fiscal Year Ended March 31, 2021 (PDF:
1.5MB)
Basic Policy on Corporate Governance (PDF: 82.8KB)
CORPORATE GOVERNANCE REPORT (PDF: 1.4MB)
Olympus Group ESG
CORPORATE GOVERNANCE REPORT OLYMPUS (PDF: 1.4MB)
Board of directors > Board of Directors Effectiveness Evaluation
(PDF: 128.2KB)
Olympus Group ESG > Promotion Structure
Environmental Policy and Strategy > Systems, Mechanisms and
Initiatives
Environmental Policy and Strategy > Environmental Management
Risk Management System
CORPORATE GOVERNANCE REPORT (PDF: 1.4MB)
Risk Management Structure
Basic Policy on Corporate Governance (PDF: 82.8KB)
Board of Directors > Evaluation of effectiveness of the Board of
Directors
Olympus Group ESG > Basic Approach and Policy
Basic Approach and Policy > Systems, Mechanisms and Initiatives
> Response to Climate Change
Olympus Group ESG > Basic Approach and Policy
Risk Management System
Corporate Governance Structure
Risk Management System
CORPORATE GOVERNANCE REPORT OLYMPUS (PDF: 1.4MB)
Olympus Group ESG > Promotion Structure
Environment > Environmental Policy and Strategy
287

102-36
Process for determining remuneration
102-37
Stakeholders' involvement in remuneration
-
102-38
Annual total compensation ratio
-
102-39
Percentage increase in annual total compensation ratio
-
5 Stakeholder engagement
102-40
List of stakeholder groups
102-41
Collective bargaining agreements
102-42
Identifying and selecting stakeholders
-
102-43
Approach to stakeholder engagement
102-44
Key topics and concerns raised
6 Reporting practice
102-45
Entities included in the consolidated financial statements

102-46
Defining report content and topic Boundaries

102-47
List of material topics

102-48
Restatements of information
102-49
Changes in reporting
102-50
Reporting period
102-51
Date of most recent report
102-52
Reporting cycle
102-53
Contact point for questions regarding the report
102-54
Claims of reporting in accordance with the GRI Standards
102-55
GRI content index
102-56
External assurance
GRI 103: Management Approach 2016
103-1
Explanation of the material topic and its Boundary

103-2
The management approach and its components





CORPORATE GOVERNANCE REPORT OLYMPUS (PDF: 1.4MB)
Communication with Stakeholders
Labor Relations > Initiatives > Labor-Management Consultations
(Japan)
Communication with Stakeholders
Communication with Stakeholders
Financial Results (Fiscal Year Ended Mar. 31, 2021)
Editorial Policy
Olympus Group ESG
Editorial Policy
Olympus Group ESG
Editorial Policy
Editorial Policy
Editorial Policy
Editorial Policy
Editorial Policy
Editorial Policy
Editorial Policy
GRI Content Index
Independent Assurance Statement Related to Environmental Data
(PDF: 609.1KB)
Independent Assurance Statement related to the occupational
health and safety (PDF: 609.1KB)
External Evaluation
Olympus Group ESG
Olympus Group ESG
Environmental Health and Safety Policy
Environment > Environmental Policy and Strategy
Environment > Environmental Policy and Strategy > Mechanisms
and Initiatives > Major Environmental Activity Results in Fiscal 2021
Environment > Environmental Policy and Strategy > Environmental
Management
Environment > Reduce Environmental Impact
Compliance > Basic Approach and Policy
288

103-3
Evaluation of the management approach

200 Economic
Economic Performance
GRI 201: Economic Performance 2016
201-1
Direct economic value generated and distributed
201-2
Financial implications and other risks and opportunities due
to climate change
201-3
Defined benefit plan obligations and other retirement plans
-
201-4
Financial assistance received from government
-
Market Presence
GRI 202: Market Presence 2016
202-1
Ratios of standard entry level wage by gender compared to
local minimum wage
-
202-2
Proportion of senior management hired from the local
community
-
Tax > Olympus Group Tax Policy
Disclosure Policy
Transparency Guidelines > Olympus Group "Transparency
Guideline for the Relation between Corporate Activities and Medical
Institutions and Other Organizations"
Olympus Group Information Security Policy
The Olympus Group Personal Information Protection Policy
(Translation)
Risk Management System > Basic Approach and Policy,Promotion
Structure
Olympus Group Quality Policy
Product Responsibility > Basic Approach and Policy
Olympus Group Procurement Policy
Procurement > Basic Approach and Policy
Human Rights Policy
Human Rights > Basic Approach and Policy
Employment > Promotion Structure > Organization of Human
Resource Strategy Promotion (Olympus and its Japan subsidiaries)
Training and Education > Promotion Structure and Systems
Occupational Safety and Health > Promotion Structure and
Initiatives,Global Safety and Health Organization
Occupational Safety and Health, Health Management > Basic
Approach and Policy
Charitable Donations and Grants Policy
Corporate Citizenship Policy
Olympus Group ESG
Environmental Policy and Strategy > Mechanisms and Initiatives >
Major Environmental Activity Results in Fiscal 2021
Environmental Policy and Strategy > Environmental Management >
Status of Acquiring ISO14001 Certification in Olympus Group
Reduce Environmental Impact > Basic Approach > Internal (Scope
1, 2) Results, Water Use/Wastewater Results
Independent Assurance Statement Related to Environmental Data
(PDF: 609.1KB)
Occupational Safety and Health > Promotion Structure and
Initiatives > Shirakawa Facility Transition from OHSAS 18001 to ISO
45001
Product Responsibility > Basic Approach and Policy > Quality
Management System
External Evaluation
Financial Results (Fiscal Year Ended Mar. 31, 2021)
Environmental Policy and Strategy > Mechanisms and Initiatives
289

Indirect Economic Impacts
GRI 203: Indirect Economic Impacts 2016
203-1
Infrastructure investments and services supported
-
203-2
Significant indirect economic impacts
-
Procurement Practices
GRI 204: Procurement Practices 2016
204-1
Proportion of spending on local suppliers
-
Anti-corruption
GRI 205: Anti-corruption 2016
205-1
Operations assessed for risks related to corruption
-
205-2
Communication and training about anti-corruption policies
and procedures
205-3
Confirmed incidents of corruption and actions taken
Anti-competitive Behavior
GRI 206: Anti-competitive Behavior 2016
206-1
Legal actions for anti- competitive behavior, anti- trust,and
monopoly practices
Tax
GRI 207: Tax 2019
207-1
Approach to tax
207-2
Tax governance, control, and risk management
207-3
Stakeholder engagement and management of concerns
related to tax
207-4
Country-by-country reporting
-
300　Environmental
Materials
GRI 301: Materials 2016
301-1
Materials used by weight or volume
301-2
Recycled input materials used
-
301-3
Reclaimed products and their packaging materials
-
Energy
GRI 302: Energy 2016
302-1
Energy consumption within the organization
302-2
Energy consumption outside of the organization
302-3
Energy intensity
302-4
Reduction of energy consumption
302-5
Reductions in energy requirements of products and services
Water
Anti-Corruption
Compliance > Initiatives > Compliance with Laws and Regulations
Compliance > Initiatives > Compliance with Laws and Regulations
Tax
Tax > Olympus Group Tax Policy
Tax > Olympus Group Tax Policy
Environmental Data > Material Balance
Reduce Environmental Impact > Basic Approach >
Energy/Atmospheric Release > Internal (Scope 1, 2)
Reduce Environmental Impact > Basic Approach >
Energy/Atmospheric Release > External (Scope 3 [Category 4
Upstream transportation and distribution]) Results
Reduce Environmental Impact > Basic Approach >
Energy/Atmospheric Release > Internal (Scope 1, 2) Results
Reduce Environmental Impact > Basic Approach >
Energy/Atmospheric Release
Reduce Environmental Impact > Basic Approach >
Energy/Atmospheric Release
290

GRI 303: Water 2018
303-1
Interactions with water as a shared resource
303-2
Management of water discharge- related impacts
303-3
Water withdrawal
303-4
Water discharge
303-5
Water consumption
Biodiversity
GRI 304: Biodiversity 2016
304-1
Operational sites owned, leased, managed in, or adjacent to,
protected areas and areas of high biodiversity value outside
protected areas
-
304-2
Significant impacts of activities, products, and services on
biodiversity
-
304-3
Habitats protected or restored
-
304-4
IUCN Red List species and national conservation list species
with habitats in areas affected by operations
-
Emissions
GRI 305: Emissions 2016
305-1
Direct (Scope1) GHG emissions
305-2
Energy indirect (Scope2) GHG emissions
305-3
Other indirect (Scope3) GHG emissions
305-4
GHG emissions intensity
305-5
Reduction of GHG emissions
305-6
Emissions of ozone-depleting substances (ODS)
-
305-7
Nitrogen oxides (NOx), sulfur oxides (SOx), and other
significant air emissions
Effluents and Waste
GRI 306: Effluents and Waste 2016
306-1
Water discharge by quality and destination
306-2
Waste by type and disposal method
Environmental Policy and Strategy > Response to Water Risk
Reduce Environmental Impact > Basic Approach > Water/Emission
Reduce Environmental Impact > Basic Approach > Water/Emission
Environmental Data
Reduce Environmental Impact > Basic Approach > Water/Emission
Environmental Data
Reduce Environmental Impact > Basic Approach > Water/Emission
Environmental Data
Reduce Environmental Impact > Basic Approach >
Energy/Atmospheric Release > Internal (Scope 1, 2) Results
Environmental Data
Reduce Environmental Impact > Basic Approach >
Energy/Atmospheric Release > Internal (Scope 1, 2) Results
Environmental Data
Reduce Environmental Impact > Basic Approach >
Energy/Atmospheric Release > External (Scope 3 [Category 4
Upstream transportation and distribution]) Results
Environmental Data
Reduce Environmental Impact > Basic Approach >
Energy/Atmospheric Release
Environmental Data
Reduce Environmental Impact > Basic Approach >
Energy/Atmospheric Release
Environmental Data
Reduce Environmental Impact > Basic Approach >
Energy/Atmospheric Release
Environmental Data
Reduce Environmental Impact > Basic Approach > Water
Use/Wastewater Results
291

306-3
Significant spills
306-4
Transport of hazardous waste
-
306-5
Water bodies affected by water discharges and/or runoff
-
Environmental Compliance
GRI 307: Environmental Compliance 2016
307-1
Non-compliance with environmental laws and regulations
Supplier Environmental Assessment
GRI 308: Supplier Environmental Assessment 2016
308-1
New suppliers that were screened using environmental
criteria
-
308-2
Negative environmental impacts in the supply chain and
actions taken

400　Social
Employment
GRI 401: Employment 2016
401-1
New employee hires and employee turnover
401-2
Benefits provided to full-time employees that are not
provided to temporary or part-time employees
-
401-3
Parental leave
Labor/Management Relations
GRI 402: Labor/Management Relations 2016
402-1
Minimum notice periods regarding operational changes
-
Occupational Health and Safety
GRI 403: Occupational Health and Safety 2018
403-1
Occupational health and safety management system
403-2
Hazard identification, risk assessment, and incident
investigation
403-3
Occupational health services
403-4
Worker participation, consultation, and communication on
occupational health and safety
-
403-5
Worker training on occupational health and safety
403-6
Promotion of worker health
403-7
Prevention and mitigation of occupational health and safety
impacts directly linked by business relationships
-
403-8
Workers covered by an occupational health and safety
management system
Reduce Environmental Impact > Basic Approach > Water
Use/Wastewater Results
Reduce Environmental Impact > Basic Approach > Emission
Results
Environmental Policy and Strategy > Environmental Management >
Major Environmental Activity Results in Fiscal 2021
Procurement > System, Mechanisms and Initiatives
Environmental Policy and Strategy > Mechanisms and Initiatives >
Long-term targets and measures > Green Procurement
Employment > Employee-Related Data > Employee composition >
Job retention rate and Number of staff leaving
Employment > Employee-Related Data > Employee composition >
Work-Life Integration
Occupational Safety and Health > Promotion Structure and
Initiatives > Regional Activities
Occupational Safety and Health > Promotion Structure and
Initiatives > Industral Accident Data
Occupational Safety and Health > Promotion Structure and
Initiatives > Industral Accident Data
Occupational Safety and Health > Promotion Structure and
Initiatives > Industral Accident Data > Employee Training,Regional
Activities
Occupational Safety and Health, Health Management
Occupational Safety and Health > Promotion Structure and
Initiatives > Global Safety and Health Organization
292

403-9
Work-related injuries
403-10
Work-related ill health
Training and Education
GRI 404: Training and Education 2016
404-1
Average hours of training per year per employee
-
404-2
Programs for upgrading employee skills and transition
assistance programs
404-3
Percentage of employees receiving regular performance and
career development reviews
Diversity and Equal Opportunity
GRI 405: Diversity and Equal Opportunity 2016
405-1
Diversity of governance bodies and employees

405-2
Ratio of basic salary and remuneration of women to men
Non-discrimination
GRI 406: Non-discrimination 2016
406-1
Incidents of discrimination and corrective actions taken
Freedom of Association and Collective Bargaining
GRI 407: Freedom of Association and Collective Bargaining 2016
407-1
Operations and suppliers in which the right to freedom of
association and collective bargaining may be at risk
Child Labor
GRI 408: Child Labor 2016
408-1
Operations and suppliers at significant risk for incidents of
child labor
Forced or Compulsory Labor
GRI 409: Forced or Compulsory Labor 2016
409-1
Operations and suppliers at significant risk for incidents of
forced or compulsory labor
Security Practices
GRI 410: Security Practices 2016
410-1
Security personnel trained in human rights policies or
procedures
-
Rights of Indigenous Peoples
GRI 411: Rights of Indigenous Peoples 2016
411-1
Incidents of violations involving rights of indigenous peoples
-
Human Rights Assessment
Occupational Safety and Health > Promotion Structure and
Initiatives > Industral Accident Data
Occupational Safety and Health > Promotion Structure and
Initiatives > Industral Accident Data
Training and Education > Promotion Structure and Systems >
Promotional Structure in Human Resources Development
Diversity and Equal Opportunity > Personnel Evaluation System
Employment > Employee-Related Data
Human Rights > Initiatives > Preventing Harassing Behavior and
Promoting DEI
Diversity and Inclusion
Diversity and Equal Opportunity > Promoting the Advancement of
Women
Human Rights > Initiatives > Preventing Harassing Behavior and
Promoting DEI
Human Rights > Initiatives > Initiatives with Suppliers > Key
Evaluation Items in Supplier Survey for Initiatives with Suppliers
Human Rights > Initiatives > Initiatives with Suppliers
Human Rights > Initiatives > Initiatives with Suppliers > Key
Evaluation Items in Supplier Survey for Initiatives with Suppliers
Human Rights > Initiatives > Initiatives with Suppliers
Human Rights > Initiatives > Initiatives with Suppliers > Key
Evaluation Items in Supplier Survey for Initiatives with Suppliers
Human Rights > Initiatives > Initiatives with Suppliers
293

GRI 412: Human Rights Assessment 2016
412-1
Operations that have been subject to human rights reviews
or impact assessments
-
412-2
Employee training on human rights policies or procedures
412-3
Significant investment agreements and contracts that include
human rights clauses or that underwent human rights
screening
-
Local Communities
GRI 413: Local Communities 2016
413-1
Operations with local community engagement, impact
assessments, and development programs
-
413-2
Operations with significant actual and potential negative
impacts on local communities
-
Supplier Social Assessment
GRI 414: Supplier Social Assessment 2016
414-1
New suppliers that were screened using social criteria
-
414-2
Negative social impacts in the supply chain and actions
taken
Public Policy
GRI 415: Public Policy 2016
415-1
Political contributions
-
Customer Health and Safety
GRI 416: Customer Health and Safety 2016
416-1
Assessment of the health and safety impacts of product and
service categories
-
416-2
Incidents of non-compliance concerning the health and
safety impacts of products and services
-
Marketing and Labeling
GRI 417: Marketing and Labeling 2016
417-1
Requirements for product and service information and
labeling
-
417-2
Incidents of non-compliance concerning product and service
information and labeling
-
417-3
Incidents of non-compliance concerning marketing
communications
-
Customer Privacy
GRI 418: Customer Privacy 2016
418-1
Substantiated complaints concerning breaches of customer
privacy and losses of customer data
Socioeconomic Compliance
GRI 419: Socioeconomic Compliance 2016
419-1
Non-compliance with laws and regulations in the social and
economic area
Human Rights > Initiatives > Preventing Harassing Behavior and
Promoting DEI
Procurement > System, Mechanisms and Initiatives > Sharing
Business Strategies and Supply Chain Policy
Information Security
Compliance > Initiatives > Compliance with Laws and Regulations
294